Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27943222,protein binding,Cediranib binds to serum albumin and α1-acid glycoprotein; protein binding in human plasma is approximately 95%.,Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27943222/),%,95,597,DB01045,Rifampicin
,27943222,terminal half-life,The apparent oral clearance is moderate and the mean terminal half-life is 22 h.,Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27943222/),h,22,598,DB01045,Rifampicin
,2530933,MICs,"The MICs for 90% of strains tested were 4 micrograms/ml for clarithromycin, 64 micrograms/ml for erythromycin, 32 micrograms/ml for difloxacin, 8 micrograms/ml for temafloxacin, 4 micrograms/ml for ciprofloxacin, 4 micrograms/ml for rifampin, 32 micrograms/ml for amikacin, and 32 micrograms/ml for ethambutol.",In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],4,1008,DB01045,Rifampicin
,2530933,MICs,"The MICs for 90% of strains tested were 4 micrograms/ml for clarithromycin, 64 micrograms/ml for erythromycin, 32 micrograms/ml for difloxacin, 8 micrograms/ml for temafloxacin, 4 micrograms/ml for ciprofloxacin, 4 micrograms/ml for rifampin, 32 micrograms/ml for amikacin, and 32 micrograms/ml for ethambutol.",In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],64,1009,DB01045,Rifampicin
,2530933,MICs,"The MICs for 90% of strains tested were 4 micrograms/ml for clarithromycin, 64 micrograms/ml for erythromycin, 32 micrograms/ml for difloxacin, 8 micrograms/ml for temafloxacin, 4 micrograms/ml for ciprofloxacin, 4 micrograms/ml for rifampin, 32 micrograms/ml for amikacin, and 32 micrograms/ml for ethambutol.",In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],32,1010,DB01045,Rifampicin
,2530933,MICs,"The MICs for 90% of strains tested were 4 micrograms/ml for clarithromycin, 64 micrograms/ml for erythromycin, 32 micrograms/ml for difloxacin, 8 micrograms/ml for temafloxacin, 4 micrograms/ml for ciprofloxacin, 4 micrograms/ml for rifampin, 32 micrograms/ml for amikacin, and 32 micrograms/ml for ethambutol.",In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],8,1011,DB01045,Rifampicin
,2530933,peak concentration,The peak concentration in serum at which clarithromycin was active was approximately 1.0 microgram/ml.,In vitro and in vivo activities of clarithromycin against Mycobacterium avium. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530933/),[μg] / [ml],1.0,1012,DB01045,Rifampicin
,28719501,Cmax,"The median (interquartile range) Cmax was 5.9 (4.5-7.7) µg/mL for isoniazid, 6.5 (4.9-8.8) µg/mL for rifampin, 26.0 (21.2-33.4) µg/mL for pyrazinamide and 1.7 (0.9-2.7) µg/mL for ethambutol.",Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28719501/),[μg] / [ml],5.9,1903,DB01045,Rifampicin
,28719501,Cmax,"The median (interquartile range) Cmax was 5.9 (4.5-7.7) µg/mL for isoniazid, 6.5 (4.9-8.8) µg/mL for rifampin, 26.0 (21.2-33.4) µg/mL for pyrazinamide and 1.7 (0.9-2.7) µg/mL for ethambutol.",Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28719501/),[μg] / [ml],6.5,1904,DB01045,Rifampicin
,28719501,Cmax,"The median (interquartile range) Cmax was 5.9 (4.5-7.7) µg/mL for isoniazid, 6.5 (4.9-8.8) µg/mL for rifampin, 26.0 (21.2-33.4) µg/mL for pyrazinamide and 1.7 (0.9-2.7) µg/mL for ethambutol.",Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28719501/),[μg] / [ml],26.0,1905,DB01045,Rifampicin
,28719501,Cmax,"The median (interquartile range) Cmax was 5.9 (4.5-7.7) µg/mL for isoniazid, 6.5 (4.9-8.8) µg/mL for rifampin, 26.0 (21.2-33.4) µg/mL for pyrazinamide and 1.7 (0.9-2.7) µg/mL for ethambutol.",Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28719501/),[μg] / [ml],1.7,1906,DB01045,Rifampicin
<,28719501,Cmax,"In addition, 75/97 (77.3%) children had pyrazinamide Cmax < 35 µg/mL.",Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28719501/),[μg] / [ml],35,1907,DB01045,Rifampicin
,20197489,plasma half-life,"By incorporating the long plasma half-life of 4βHC (~17 days) into the model, the inductive effect of 2 known inducers (carbamazepine and rifampicin) reported in the literature was adequately described.",Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197489/),d,17,1989,DB01045,Rifampicin
,25673441,peak plasma concentration (C max ),"Mean pharmacokinetic parameter values of RFP obtained for formulations A, B, C, and D products were 11.42 ± 3.41 μg/ml, 7.86 ± 5.78 μg/ml, 13.05 ± 6.80 μg/ml, and 16.18 ± 3.87 μg/ml, respectively, for peak plasma concentration (C max ), 91.43 ± 30.82 μg·h-1·ml-1 , 55.49 ± 37.58 μg·h-1·ml-1 , 96.50 ± 47.24 μg·h-1·ml-1 , 101.47 ± 33.07 μg·h-1·ml-1 , respectively, for area under the concentration-time curve (AUC 0-24 h ).",Relative bioavailability of rifampicin in four Chinese fixed-dose combinations compared with rifampicin in free combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25673441/),[μg] / [h·ml],91.43,2070,DB01045,Rifampicin
,25673441,peak plasma concentration (C max ),"Mean pharmacokinetic parameter values of RFP obtained for formulations A, B, C, and D products were 11.42 ± 3.41 μg/ml, 7.86 ± 5.78 μg/ml, 13.05 ± 6.80 μg/ml, and 16.18 ± 3.87 μg/ml, respectively, for peak plasma concentration (C max ), 91.43 ± 30.82 μg·h-1·ml-1 , 55.49 ± 37.58 μg·h-1·ml-1 , 96.50 ± 47.24 μg·h-1·ml-1 , 101.47 ± 33.07 μg·h-1·ml-1 , respectively, for area under the concentration-time curve (AUC 0-24 h ).",Relative bioavailability of rifampicin in four Chinese fixed-dose combinations compared with rifampicin in free combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25673441/),[μg] / [h·ml],96.50,2071,DB01045,Rifampicin
,25673441,peak plasma concentration (C max ),"Mean pharmacokinetic parameter values of RFP obtained for formulations A, B, C, and D products were 11.42 ± 3.41 μg/ml, 7.86 ± 5.78 μg/ml, 13.05 ± 6.80 μg/ml, and 16.18 ± 3.87 μg/ml, respectively, for peak plasma concentration (C max ), 91.43 ± 30.82 μg·h-1·ml-1 , 55.49 ± 37.58 μg·h-1·ml-1 , 96.50 ± 47.24 μg·h-1·ml-1 , 101.47 ± 33.07 μg·h-1·ml-1 , respectively, for area under the concentration-time curve (AUC 0-24 h ).",Relative bioavailability of rifampicin in four Chinese fixed-dose combinations compared with rifampicin in free combinations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25673441/),[μg] / [h·ml],101.47,2072,DB01045,Rifampicin
,25759035,Cmax,"The median (IQR) Cmax was 2.90 (2.08-3.43), 3.37 (2.55-4.59), 34.60 (32.30-40.90) and 1.20 (0.85-1.68) mg/L while the median (IQR) AUC0-∞ was 16.92 (11.10-22.74), 11.48 (7.35-18.93), 333.50 (279.50-487.2) and 8.65 (5.96-11.47) mg·h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively.",Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759035/),[mg] / [l],2.90,2315,DB01045,Rifampicin
,25759035,Cmax,"The median (IQR) Cmax was 2.90 (2.08-3.43), 3.37 (2.55-4.59), 34.60 (32.30-40.90) and 1.20 (0.85-1.68) mg/L while the median (IQR) AUC0-∞ was 16.92 (11.10-22.74), 11.48 (7.35-18.93), 333.50 (279.50-487.2) and 8.65 (5.96-11.47) mg·h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively.",Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759035/),[mg] / [l],3.37,2316,DB01045,Rifampicin
,25759035,Cmax,"The median (IQR) Cmax was 2.90 (2.08-3.43), 3.37 (2.55-4.59), 34.60 (32.30-40.90) and 1.20 (0.85-1.68) mg/L while the median (IQR) AUC0-∞ was 16.92 (11.10-22.74), 11.48 (7.35-18.93), 333.50 (279.50-487.2) and 8.65 (5.96-11.47) mg·h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively.",Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759035/),[mg] / [l],34.60,2317,DB01045,Rifampicin
,25759035,Cmax,"The median (IQR) Cmax was 2.90 (2.08-3.43), 3.37 (2.55-4.59), 34.60 (32.30-40.90) and 1.20 (0.85-1.68) mg/L while the median (IQR) AUC0-∞ was 16.92 (11.10-22.74), 11.48 (7.35-18.93), 333.50 (279.50-487.2) and 8.65 (5.96-11.47) mg·h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively.",Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759035/),[mg] / [l],1.20,2318,DB01045,Rifampicin
,25759035,AUC0-∞,"The median (IQR) Cmax was 2.90 (2.08-3.43), 3.37 (2.55-4.59), 34.60 (32.30-40.90) and 1.20 (0.85-1.68) mg/L while the median (IQR) AUC0-∞ was 16.92 (11.10-22.74), 11.48 (7.35-18.93), 333.50 (279.50-487.2) and 8.65 (5.96-11.47) mg·h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively.",Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759035/),[h·mg] / [l],16.92,2319,DB01045,Rifampicin
,25759035,AUC0-∞,"The median (IQR) Cmax was 2.90 (2.08-3.43), 3.37 (2.55-4.59), 34.60 (32.30-40.90) and 1.20 (0.85-1.68) mg/L while the median (IQR) AUC0-∞ was 16.92 (11.10-22.74), 11.48 (7.35-18.93), 333.50 (279.50-487.2) and 8.65 (5.96-11.47) mg·h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively.",Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759035/),[h·mg] / [l],11.48,2320,DB01045,Rifampicin
,25759035,AUC0-∞,"The median (IQR) Cmax was 2.90 (2.08-3.43), 3.37 (2.55-4.59), 34.60 (32.30-40.90) and 1.20 (0.85-1.68) mg/L while the median (IQR) AUC0-∞ was 16.92 (11.10-22.74), 11.48 (7.35-18.93), 333.50 (279.50-487.2) and 8.65 (5.96-11.47) mg·h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively.",Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759035/),[h·mg] / [l],333.50,2321,DB01045,Rifampicin
,25759035,AUC0-∞,"The median (IQR) Cmax was 2.90 (2.08-3.43), 3.37 (2.55-4.59), 34.60 (32.30-40.90) and 1.20 (0.85-1.68) mg/L while the median (IQR) AUC0-∞ was 16.92 (11.10-22.74), 11.48 (7.35-18.93), 333.50 (279.50-487.2) and 8.65 (5.96-11.47) mg·h/L for rifampicin, isoniazid, pyrazinamide and ethambutol, respectively.",Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25759035/),[h·mg] / [l],8.65,2322,DB01045,Rifampicin
,6639842,oral clearance,"Rifampicin (600 mg/day) caused a large increase in propranolol's oral clearance (35.7 +/- 16.3 vs 96.1 +/- 26.9 ml min-1 kg-1, mean +/- s.d.), but neither the elimination half-life nor extent of plasma binding were affected.",Induction of propranolol metabolism by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639842/),[ml] / [kg·min],35.7,2502,DB01045,Rifampicin
,6639842,oral clearance,"Rifampicin (600 mg/day) caused a large increase in propranolol's oral clearance (35.7 +/- 16.3 vs 96.1 +/- 26.9 ml min-1 kg-1, mean +/- s.d.), but neither the elimination half-life nor extent of plasma binding were affected.",Induction of propranolol metabolism by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639842/),[ml] / [kg·min],96.1,2503,DB01045,Rifampicin
,25239466,Concentrations at steady-state,Concentrations at steady-state were 4111 ng/mL at week 12 versus 6095 ng/mL at week 48 (P < 0.0001).,Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25239466/),[ng] / [ml],4111,2965,DB01045,Rifampicin
,25239466,Concentrations at steady-state,Concentrations at steady-state were 4111 ng/mL at week 12 versus 6095 ng/mL at week 48 (P < 0.0001).,Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25239466/),[ng] / [ml],6095,2966,DB01045,Rifampicin
,25239466,concentrations,"Efavirenz concentrations were higher on than off tuberculosis treatment (2700 versus 2450 ng/mL, P < 0.0001).",Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25239466/),[ng] / [ml],2700,2967,DB01045,Rifampicin
,25239466,concentrations,"Efavirenz concentrations were higher on than off tuberculosis treatment (2700 versus 2450 ng/mL, P < 0.0001).",Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25239466/),[ng] / [ml],2450,2968,DB01045,Rifampicin
,3947503,half-life,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),h,13.2,3495,DB01045,Rifampicin
,3947503,half-life,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),h,7.7,3496,DB01045,Rifampicin
,3947503,total body clearance,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),[ml] / [min],41.8,3497,DB01045,Rifampicin
,3947503,total body clearance,Administration of rifapentine (600 mg 48 h-1) for 10 days resulted in a significant reduction in antipyrine half-life (from 13.2 +/- 1.0 h to 7.7 +/- 0.4 h) and a corresponding increase in its total body clearance (from 41.8 +/- 5.5 ml min-1 to 67.4 +/- 5.6 ml min-1).,"Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3947503/),[ml] / [min],67.4,3498,DB01045,Rifampicin
,8169802,peak plasma drug concentration,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),[μg] / [ml],0.16,4061,DB01045,Rifampicin
,8169802,peak plasma drug concentration,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),[μg] / [ml],0.18,4062,DB01045,Rifampicin
,8169802,area under the plasma drug concentration-time curve from time zero to infinity,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),[h·μg] / [ml],4.56,4063,DB01045,Rifampicin
,8169802,area under the plasma drug concentration-time curve from time zero to infinity,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),[h·μg] / [ml],4.22,4064,DB01045,Rifampicin
,8169802,time to the peak plasma drug concentration,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),h,10.3,4065,DB01045,Rifampicin
,8169802,time to the peak plasma drug concentration,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),h,10.2,4066,DB01045,Rifampicin
,8169802,lag time,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),h,3.7,4067,DB01045,Rifampicin
,8169802,lag time,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),h,3.8,4068,DB01045,Rifampicin
,8169802,terminal elimination half-life,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),h,17.8,4069,DB01045,Rifampicin
,8169802,terminal elimination half-life,"Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),h,15.0,4070,DB01045,Rifampicin
,8169802,peak plasma drug concentration,"In contrast, the mean peak plasma drug concentration (2.01 micrograms/mL) and area under the curve from time zero to infinity (57.35 micrograms.h/mL) for the capsule formulation with food were enhanced approximately 11- and 14-fold, respectively, when compared with that without food.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),[μg] / [ml],2.01,4071,DB01045,Rifampicin
,8169802,area under the curve from time zero to infinity,"In contrast, the mean peak plasma drug concentration (2.01 micrograms/mL) and area under the curve from time zero to infinity (57.35 micrograms.h/mL) for the capsule formulation with food were enhanced approximately 11- and 14-fold, respectively, when compared with that without food.",Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),[h·μg] / [ml],57.35,4072,DB01045,Rifampicin
,8169802,lag time,The corresponding mean lag time (2.1 h) was decreased approximately 50%.,Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8169802/),h,2.1,4073,DB01045,Rifampicin
,12709345,MIC,"The infecting strain (MRSA strain 32) was susceptible to daptomycin (MIC = 1 micro g/ml), vancomycin (MIC = 0.5 micro g/ml), and rifampin (MIC = 0.5 micro g/ml).",Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709345/),[μg] / [ml],1,4312,DB01045,Rifampicin
,12709345,MIC,"The infecting strain (MRSA strain 32) was susceptible to daptomycin (MIC = 1 micro g/ml), vancomycin (MIC = 0.5 micro g/ml), and rifampin (MIC = 0.5 micro g/ml).",Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709345/),[μg] / [ml],0.5,4313,DB01045,Rifampicin
,12709345,peak daptomycin levels,"The mean peak daptomycin levels in serum at 2 h after subcutaneous administration of 25 and 40 mg/kg were 64 and 91 micro g/ml, respectively.",Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709345/),[μg] / [ml],64,4314,DB01045,Rifampicin
,12709345,peak daptomycin levels,"The mean peak daptomycin levels in serum at 2 h after subcutaneous administration of 25 and 40 mg/kg were 64 and 91 micro g/ml, respectively.",Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709345/),[μg] / [ml],91,4315,DB01045,Rifampicin
<,18672531,plasma concentration at 12 h (C12),"There were more patients with NVP plasma concentration at 12 h (C12) <3.1 mg/l at week 2 in NVP400 than in NVP600 (79% versus 19%, respectively; P=0.002).",Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672531/),[mg] / [l],3.1,5191,DB01045,Rifampicin
,30170758,Tmax,"After administration of ertugliflozin 15mg alone or with rifampin, the Tmax was 1hour.",Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30170758/),h,1,5659,DB01045,Rifampicin
,30170758,t½,The mean t½ was 12.3hours for ertugliflozin alone and 9.2hours with steady-state rifampin.,Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30170758/),h,12.3,5660,DB01045,Rifampicin
,30170758,t½,The mean t½ was 12.3hours for ertugliflozin alone and 9.2hours with steady-state rifampin.,Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30170758/),h,9.2,5661,DB01045,Rifampicin
,17517835,AUC(0-24),"Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC(0-24), 1.29 versus 2.79 mug.h/ml).",Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517835/),[h·μg] / [ml],1.29,5662,DB01045,Rifampicin
,17517835,AUC(0-24),"Concentrations of the sulfate conjugate metabolite of moxifloxacin were increased twofold following rifampin coadministration (AUC(0-24), 1.29 versus 2.79 mug.h/ml).",Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17517835/),[h·μg] / [ml],2.79,5663,DB01045,Rifampicin
,2729952,Total clearance,Total clearance of ciprofloxacin increased from 0.96 +/- 0.32 (standard deviation) to 1.57 +/- 0.63 liters/h per kg (P less than 0.05).,Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729952/),[l] / [h·kg],0.96,5721,DB01045,Rifampicin
,2729952,Total clearance,Total clearance of ciprofloxacin increased from 0.96 +/- 0.32 (standard deviation) to 1.57 +/- 0.63 liters/h per kg (P less than 0.05).,Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729952/),[l] / [h·kg],1.57,5722,DB01045,Rifampicin
less,21986820,half-lives,All four agents distributed rapidly from plasma to tissue with equilibration half-lives of less than 1 min to an hour.,Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21986820/),min,1,6330,DB01045,Rifampicin
,29430306,area under the concentration-versus-time curve,"The median rifampin area under the concentration-versus-time curve during the 8-hour observation period was 42.8 mg·hr/L (range: 21.2 to 57.6), with a median peak concentration of 10.1 mg/L (range: 5.3 to 12.5).",A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29430306/),[h·mg] / [l],42.8,6727,DB01045,Rifampicin
,29430306,peak concentration,"The median rifampin area under the concentration-versus-time curve during the 8-hour observation period was 42.8 mg·hr/L (range: 21.2 to 57.6), with a median peak concentration of 10.1 mg/L (range: 5.3 to 12.5).",A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29430306/),[mg] / [l],10.1,6728,DB01045,Rifampicin
greater,29430306,time to maximum concentration,"We observed delayed rifampin absorption, with a time to maximum concentration greater than 2 hours, in 2 of 6 participants.",A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29430306/),h,2,6729,DB01045,Rifampicin
,17032686,concentration,"The geometric mean efavirenz concentration was 1730 ng/mL (range 354-27,179) on and 1377 ng/mL (range 572-3975) off rifampicin (P = 0.55).",Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17032686/),[ng] / [ml],1730,7004,DB01045,Rifampicin
,17032686,concentration,"The geometric mean efavirenz concentration was 1730 ng/mL (range 354-27,179) on and 1377 ng/mL (range 572-3975) off rifampicin (P = 0.55).",Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17032686/),[ng] / [ml],1377,7005,DB01045,Rifampicin
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],1.64,7058,DB01045,Rifampicin
,9578186,total area under the plasma buspirone concentration-time curve,"The total area under the plasma buspirone concentration-time curve after rifampicin was 10.4% (95% CI, 6.3-14.5%) of that after placebo (1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P< 0.01).",Concentrations and effects of buspirone are considerably reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[h·ng] / [ml],22.0,7059,DB01045,Rifampicin
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],6.6,7060,DB01045,Rifampicin
,9578186,peak plasma concentration,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),[ng] / [ml],0.84,7061,DB01045,Rifampicin
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,2.8,7062,DB01045,Rifampicin
,9578186,half-life,Rifampicin decreased the peak plasma concentration of buspirone from 6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P< 0.01) and the half-life from 2.8+/-0.7 h to 1.3+/-0.5 h (P< 0.01).,Concentrations and effects of buspirone are considerably reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578186/),h,1.3,7063,DB01045,Rifampicin
,1409366,flow rate,Radial Pak cartridge in conjunction with a binary linear gradient system at a flow rate of 3 ml/min.,"Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409366/),[ml] / [min],3,7895,DB01045,Rifampicin
,1409366,retention times,"Under these conditions, no interference in the analysis was observed, and the retention times of AINH, INH, IS, DARIF, and RIF were 3.95, 4.89, 15.82, 17.25, and 19.34 min, respectively.","Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409366/),min,3.95,7896,DB01045,Rifampicin
,1409366,retention times,"Under these conditions, no interference in the analysis was observed, and the retention times of AINH, INH, IS, DARIF, and RIF were 3.95, 4.89, 15.82, 17.25, and 19.34 min, respectively.","Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409366/),min,4.89,7897,DB01045,Rifampicin
,1409366,retention times,"Under these conditions, no interference in the analysis was observed, and the retention times of AINH, INH, IS, DARIF, and RIF were 3.95, 4.89, 15.82, 17.25, and 19.34 min, respectively.","Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409366/),min,15.82,7898,DB01045,Rifampicin
,1409366,retention times,"Under these conditions, no interference in the analysis was observed, and the retention times of AINH, INH, IS, DARIF, and RIF were 3.95, 4.89, 15.82, 17.25, and 19.34 min, respectively.","Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409366/),min,17.25,7899,DB01045,Rifampicin
,1409366,retention times,"Under these conditions, no interference in the analysis was observed, and the retention times of AINH, INH, IS, DARIF, and RIF were 3.95, 4.89, 15.82, 17.25, and 19.34 min, respectively.","Simultaneous microdetermination of rifampin, deacetylrifampin, isoniazid, and acetylisoniazid in plasma by liquid chromatography with dual electrochemical and spectrophotometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409366/),min,19.34,7900,DB01045,Rifampicin
,9542475,area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]),Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005).,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542475/),,349,8099,DB01045,Rifampicin
,9542475,area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]),Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005).,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542475/),,225,8100,DB01045,Rifampicin
,9542475,AUC(0-24),Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005).,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542475/),,1336,8101,DB01045,Rifampicin
,9542475,AUC(0-24),Rifampin decreased the area under the concentration-time curve from time zero to 24 hours after the dose (AUC[0-24]) of losartan by 35% (349 +/- 246 versus 225 +/- 130; p = 0.0001) and decreased the AUC(0-24) of E3174 by 40% (1336 +/- 445 versus 792 +/- 302; p < 0.005).,Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542475/),,792,8102,DB01045,Rifampicin
,22339279,AUC(0-48),"The AUC(0-48) of RIF in both reference and test tablets were 304.77 ± 42.27 and 353.79 ± 31.63 µg·h·mL(-1), respectively.",Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339279/),[h·μg] / [ml],304.77,8774,DB01045,Rifampicin
,22339279,AUC(0-48),"The AUC(0-48) of RIF in both reference and test tablets were 304.77 ± 42.27 and 353.79 ± 31.63 µg·h·mL(-1), respectively.",Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339279/),[h·μg] / [ml],353.79,8775,DB01045,Rifampicin
,22339279,AUC(0-48),"The AUC(0-48) of INH in both reference and test tablets were 17.14 ± 8.59 and 19.62 ± 10.57 µg·h·mL(-1), respectively.",Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339279/),[h·μg] / [ml],17.14,8776,DB01045,Rifampicin
,22339279,AUC(0-48),"The AUC(0-48) of INH in both reference and test tablets were 17.14 ± 8.59 and 19.62 ± 10.57 µg·h·mL(-1), respectively.",Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339279/),[h·μg] / [ml],19.62,8777,DB01045,Rifampicin
,14768975,AUC(0-1),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[h·ng] / [ml],4531.28,9469,DB01045,Rifampicin
,14768975,AUC(0-1),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[h·ng] / [ml],1629.1,9470,DB01045,Rifampicin
,14768975,AUC(0-infinity),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[h·ng] / [ml],4632.42,9471,DB01045,Rifampicin
,14768975,AUC(0-infinity),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[h·ng] / [ml],1629.46,9472,DB01045,Rifampicin
,14768975,Cmax,"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[ng] / [ml],544.89,9473,DB01045,Rifampicin
,14768975,Cmax,"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[ng] / [ml],238.61,9474,DB01045,Rifampicin
,14768975,t(1/2),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),h,9.3,9475,DB01045,Rifampicin
,14768975,t(1/2),"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),h,4.0,9476,DB01045,Rifampicin
,14768975,Cl/f,"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[l] / [h],43.14,9477,DB01045,Rifampicin
,14768975,Cl/f,"A significant difference was observed in AUC(0-1) (4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p < 0.0001), AUC(0-infinity) (4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006), Cmax (544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04), t(1/2) (9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317) and Cl/f (43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p < 0.0001) of celecoxib administered before and after rifampicin pretreatment.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[l] / [h],122.85,9478,DB01045,Rifampicin
,14768975,"time to reach peak concentration, tmax","However, time to reach peak concentration, tmax (4 +/- 0.88 vs 4 +/- 0.83 h) and volume of distribution Vd/f (583 +/- 251 vs 710 +/- 690 l/kg) were not affected significantly.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),h,4,9479,DB01045,Rifampicin
,14768975,"time to reach peak concentration, tmax","However, time to reach peak concentration, tmax (4 +/- 0.88 vs 4 +/- 0.83 h) and volume of distribution Vd/f (583 +/- 251 vs 710 +/- 690 l/kg) were not affected significantly.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),h,4,9480,DB01045,Rifampicin
,14768975,volume of distribution Vd/f,"However, time to reach peak concentration, tmax (4 +/- 0.88 vs 4 +/- 0.83 h) and volume of distribution Vd/f (583 +/- 251 vs 710 +/- 690 l/kg) were not affected significantly.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[l] / [kg],583,9481,DB01045,Rifampicin
,14768975,volume of distribution Vd/f,"However, time to reach peak concentration, tmax (4 +/- 0.88 vs 4 +/- 0.83 h) and volume of distribution Vd/f (583 +/- 251 vs 710 +/- 690 l/kg) were not affected significantly.",Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14768975/),[l] / [kg],710,9482,DB01045,Rifampicin
,33975336,fAUC/MIC,The minocycline fAUC/MIC for 24 h static effect and -1 log drop in bacterial load were 12.5 ± 7.1 and 23.3 ± 12.4.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,12.5,11415,DB01045,Rifampicin
,33975336,fAUC/MIC,The minocycline fAUC/MIC for 24 h static effect and -1 log drop in bacterial load were 12.5 ± 7.1 and 23.3 ± 12.4.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,23.3,11416,DB01045,Rifampicin
,33975336,fAUC/MIC,An fAUC/MIC minocycline target of 12-36 is appropriate for S. aureus.,The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33975336/),,12-36,11417,DB01045,Rifampicin
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],219.2,12007,DB01045,Rifampicin
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],976.7,12008,DB01045,Rifampicin
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],75.0,12009,DB01045,Rifampicin
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],289.8,12010,DB01045,Rifampicin
,2439789,absolute bioavailability,Bisoprolol exhibits a high absolute bioavailability (90%) because of its nearly complete absorption (greater than 90%) and small first-pass effect (10%).,Balanced pharmacokinetics and metabolism of bisoprolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439789/),%,90,13263,DB01045,Rifampicin
,2439789,plasma-elimination half-life,A long plasma-elimination half-life (10-11h) allows a once-a-day dose regimen.,Balanced pharmacokinetics and metabolism of bisoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439789/),h,10-11,13264,DB01045,Rifampicin
below,21709081,peak plasma concentrations (C(max)),Simulations showed that increasing the daily rifampin dose by 150 mg in patients with the polymorphism would result in plasma concentrations similar to those of wild-type individuals and reduce the percentage of patients with peak plasma concentrations (C(max)) below 8 mg/liter from 63% to 31%.,The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709081/),[mg] / [l],8,13613,DB01045,Rifampicin
,23880168,MIC,The MIC of dalbavancin was 0.078 mg/L; MBC(log) and MBC(stat) were both >128× MIC.,"Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23880168/),[mg] / [l],0.078,13987,DB01045,Rifampicin
,23880168,half-life,The half-life of dalbavancin in cage fluid was 35.8-45.4 h and the concentration remained above the MIC of MRSA during 7 days after a single dose.,"Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23880168/),h,35.8-45.4,13988,DB01045,Rifampicin
,22546991,peak concentration,"Median predose concentration of nevirapine was 2.93 mg/l (range: 1.06-11.4), and peak concentration was 6.33 mg/l (range: 2.61-14.5).",Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546991/),[mg] / [l],6.33,14040,DB01045,Rifampicin
,22546991,AUC up to 12 h,The nevirapine AUC up to 12 h was estimated as 52.0 mg.h/l (range: 22.6-159.7) compared with 90.9 mg.h/l (range: 40.4-232.1) in children without tuberculosis (P < 0.001).,Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546991/),[h·mg] / [l],52.0,14041,DB01045,Rifampicin
,22546991,AUC up to 12 h,The nevirapine AUC up to 12 h was estimated as 52.0 mg.h/l (range: 22.6-159.7) compared with 90.9 mg.h/l (range: 40.4-232.1) in children without tuberculosis (P < 0.001).,Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22546991/),[h·mg] / [l],90.9,14042,DB01045,Rifampicin
,26342028,apparent clearance,"The apparent clearance of rifampicin and 25-deacetyl-rifampicin was estimated at 10.3 [relative standard error (RSE) 5.6%] and 95.8 (RSE 10%) L/h, respectively, for 70 kg adults.",Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342028/),[l] / [h],10.3,14631,DB01045,Rifampicin
,26342028,apparent clearance,"The apparent clearance of rifampicin and 25-deacetyl-rifampicin was estimated at 10.3 [relative standard error (RSE) 5.6%] and 95.8 (RSE 10%) L/h, respectively, for 70 kg adults.",Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342028/),[l] / [h],95.8,14632,DB01045,Rifampicin
,2975827,EC50,The value found for the EC50 was 3.8 micrograms/l and the mean maximal effect was a log ratio of 5.03 (SEM 0.33).,The efficacy of rifampicin against Staphylococcus aureus in vitro and in an experimental infection in normal and granulocytopenic mice. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2975827/),[μg] / [l],3.8,15512,DB01045,Rifampicin
,2975827,plasma concentrations,"The corresponding mean plasma concentrations of non-protein-bound drug were 28 and 24 mg/l, respectively.",The efficacy of rifampicin against Staphylococcus aureus in vitro and in an experimental infection in normal and granulocytopenic mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2975827/),[mg] / [l],28,15513,DB01045,Rifampicin
,2975827,plasma concentrations,"The corresponding mean plasma concentrations of non-protein-bound drug were 28 and 24 mg/l, respectively.",The efficacy of rifampicin against Staphylococcus aureus in vitro and in an experimental infection in normal and granulocytopenic mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2975827/),[mg] / [l],24,15514,DB01045,Rifampicin
,9124833,CL/F,"CL/F and V/F were 1.83 liters/h and 69.6 liters, respectively, for patients not taking rifampin.",Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124833/),[l] / [h],1.83,16315,DB01045,Rifampicin
,9124833,V/F,"CL/F and V/F were 1.83 liters/h and 69.6 liters, respectively, for patients not taking rifampin.",Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124833/),l,69.6,16316,DB01045,Rifampicin
,9124833,Ka,The value of Ka was 0.957 h-1 for a patient with a bilirubin level of 0.7 mg/dl.,Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124833/),1/[h],0.957,16317,DB01045,Rifampicin
,25803093,peak plasma concentration (C(max),"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[ng] / [ml],112,17469,DB01045,Rifampicin
,25803093,peak plasma concentration (C(max),"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[ng] / [ml],16.0,17470,DB01045,Rifampicin
,25803093,total area under the concentration-time curve (AUC,"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[h·ng] / [ml],2740,17471,DB01045,Rifampicin
,25803093,total area under the concentration-time curve (AUC,"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[h·ng] / [ml],207,17472,DB01045,Rifampicin
,25803093,AUC to the last measurable concentration at time T,"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[h·ng] / [ml],2440,17473,DB01045,Rifampicin
,25803093,AUC to the last measurable concentration at time T,"Bosutinib exposures were reduced following concomitant administration of rifampin vs. bosutinib alone, measured by peak plasma concentration (C(max); 112 vs. 16.0 ng/mL; 86% reduction), total area under the concentration-time curve (AUC; 2740 vs. 207 ng·h/mL; 92% reduction), and AUC to the last measurable concentration at time T (2440 vs. 158 ng·h/mL; 94% reduction).","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),[h·ng] / [ml],158,17474,DB01045,Rifampicin
,25803093,volume of distribution,"Oral clearance increased approximately 13-fold; the volume of distribution increased from 9560 to 72,900 L.","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),l,9560,17475,DB01045,Rifampicin
,25803093,volume of distribution,"Oral clearance increased approximately 13-fold; the volume of distribution increased from 9560 to 72,900 L.","Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25803093/),l,"72,900",17476,DB01045,Rifampicin
,23525933,Maximum tolerated dosage,Maximum tolerated dosage of rifampin in the murine TB was 160 mg/kg/d.,Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23525933/),mg,160,17982,DB01045,Rifampicin
,23525933,C(max),"Pharmacokinetic measurement in HR(10)Z and HR(160)Z therapy regimens showed for rifampin a C(max) of 16.2 and 157.3 mg/L, an AUC(0-24h) of 132 and 1,782 h·mg/L, and AUC(0-24h)/minimum inhibitory concentration ratios of 528 and 7129, respectively.",Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23525933/),[mg] / [l],16.2,17983,DB01045,Rifampicin
,23525933,C(max),"Pharmacokinetic measurement in HR(10)Z and HR(160)Z therapy regimens showed for rifampin a C(max) of 16.2 and 157.3 mg/L, an AUC(0-24h) of 132 and 1,782 h·mg/L, and AUC(0-24h)/minimum inhibitory concentration ratios of 528 and 7129, respectively.",Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23525933/),[mg] / [l],157.3,17984,DB01045,Rifampicin
,23525933,AUC(0-24h),"Pharmacokinetic measurement in HR(10)Z and HR(160)Z therapy regimens showed for rifampin a C(max) of 16.2 and 157.3 mg/L, an AUC(0-24h) of 132 and 1,782 h·mg/L, and AUC(0-24h)/minimum inhibitory concentration ratios of 528 and 7129, respectively.",Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23525933/),[h·mg] / [l],132,17985,DB01045,Rifampicin
,23525933,AUC(0-24h),"Pharmacokinetic measurement in HR(10)Z and HR(160)Z therapy regimens showed for rifampin a C(max) of 16.2 and 157.3 mg/L, an AUC(0-24h) of 132 and 1,782 h·mg/L, and AUC(0-24h)/minimum inhibitory concentration ratios of 528 and 7129, respectively.",Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23525933/),[h·mg] / [l],"1,782",17986,DB01045,Rifampicin
,23525933,AUC(0-24h)/minimum inhibitory concentration ratios,"Pharmacokinetic measurement in HR(10)Z and HR(160)Z therapy regimens showed for rifampin a C(max) of 16.2 and 157.3 mg/L, an AUC(0-24h) of 132 and 1,782 h·mg/L, and AUC(0-24h)/minimum inhibitory concentration ratios of 528 and 7129, respectively.",Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23525933/),,528,17987,DB01045,Rifampicin
,23525933,AUC(0-24h)/minimum inhibitory concentration ratios,"Pharmacokinetic measurement in HR(10)Z and HR(160)Z therapy regimens showed for rifampin a C(max) of 16.2 and 157.3 mg/L, an AUC(0-24h) of 132 and 1,782 h·mg/L, and AUC(0-24h)/minimum inhibitory concentration ratios of 528 and 7129, respectively.",Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23525933/),,7129,17988,DB01045,Rifampicin
,2371759,peak concentrations,"The salivary concentrations of rifampicin were much lower than those in serum, the mean peak concentrations being 0.9 and 8.5 microgram/ml, respectively.",Salivary levels of isoniazid and rifampicin in tuberculous patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371759/),[μg] / [ml],0.9,18486,DB01045,Rifampicin
,2371759,peak concentrations,"The salivary concentrations of rifampicin were much lower than those in serum, the mean peak concentrations being 0.9 and 8.5 microgram/ml, respectively.",Salivary levels of isoniazid and rifampicin in tuberculous patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2371759/),[μg] / [ml],8.5,18487,DB01045,Rifampicin
,24734521,MIC,More importantly the plasma concentration of RIF with the nanoparticles was significantly greater than the MIC of RIF (0.25 microng/mL) over 24 h.,"Comparative evaluation of polymeric nanoparticles of rifampicin comprising Gantrez and poly(ethylene sebacate) on pharmacokinetics, biodistribution and lung uptake following oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24734521/),[μng] / [ml],0.25,18652,DB01045,Rifampicin
,37091,A.U.C.,Rifampicin caused a significant reduction in the A.U.C. of a single dose of 1 mg norethisterone from 37.8 +/- 13.1 to 21.9 +/- 5.9 ng/ml X h (p less than 0.01).,The effect of rifampicin on norethisterone pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),[ng] / [h·ml],37.8,19017,DB01045,Rifampicin
,37091,A.U.C.,Rifampicin caused a significant reduction in the A.U.C. of a single dose of 1 mg norethisterone from 37.8 +/- 13.1 to 21.9 +/- 5.9 ng/ml X h (p less than 0.01).,The effect of rifampicin on norethisterone pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),[ng] / [h·ml],21.9,19018,DB01045,Rifampicin
,37091,half life (beta-phase),The plasma norethisterone half life (beta-phase) was also reduced from 6.2 +/- 1.7 to 3.2 +/- 1.0 h (p less than 0.0025).,The effect of rifampicin on norethisterone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),h,6.2,19019,DB01045,Rifampicin
,37091,half life (beta-phase),The plasma norethisterone half life (beta-phase) was also reduced from 6.2 +/- 1.7 to 3.2 +/- 1.0 h (p less than 0.0025).,The effect of rifampicin on norethisterone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),h,3.2,19020,DB01045,Rifampicin
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],86.1,20158,DB01045,Rifampicin
,9159561,total area under the plasma z,The total area under the plasma zopiclone concentration-time curve after rifampicin was 18.0% (95% CI 13.5-22.5%) of that after placebo (86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P<0.001).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[h·ng] / [ml],473,20159,DB01045,Rifampicin
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],76.9,20160,DB01045,Rifampicin
,9159561,peak plasma concentration,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),[ng] / [ml],22.5,20161,DB01045,Rifampicin
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,3.8,20162,DB01045,Rifampicin
,9159561,half-life,Rifampicin decreased the peak plasma concentration of zopiclone from 76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P<0.001) and the half-life from 3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P<0.005).,Concentrations and effects of zopiclone are greatly reduced by rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9159561/),h,2.3,20163,DB01045,Rifampicin
,22224832,peak plasma concentration,"The peak plasma concentration of RMP at 2 h was subtherapeutic, i.e. 3.76 ± 1.23 mg/l (range 1.80-6.62), in all of our patients.",Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224832/),[mg] / [l],3.76,20921,DB01045,Rifampicin
below,22224832,2-h,"Out of 20 patients, 13 (65%), had 2-h plasma concentrations below 4 mg/l.",Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224832/),[mg] / [l],4,20922,DB01045,Rifampicin
below,22224832,plasma concentrations,"Out of 20 patients, 13 (65%), had 2-h plasma concentrations below 4 mg/l.",Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224832/),[mg] / [l],4,20923,DB01045,Rifampicin
,3322752,peak serum level,The peak serum level of ciprofloxacin at the oral dose of 20 mg/kg was 0.43 mg/l which was well above the MIC values for E. coli but not for Bact. fragilis.,Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3322752/),[mg] / [l],0.43,21332,DB01045,Rifampicin
,27795624,Drug requirement,Drug requirement increased from 4.5 ± 3.6 to 8.5 ± 6.4 units (P < 0.0001).,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),,4.5,21462,DB01045,Rifampicin
,27795624,Drug requirement,Drug requirement increased from 4.5 ± 3.6 to 8.5 ± 6.4 units (P < 0.0001).,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),,8.5,21463,DB01045,Rifampicin
,27795624,time to first increase in dose,Mean time to first increase in dose was 6.5 ± 3.6 days.,Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27795624/),d,6.5,21464,DB01045,Rifampicin
≤,30025351,MIC,The preliminary results indicated that all mono-isatin-ciprofloxacin hybrids exhibited excellent antibacterial activities with MIC ranging from ≤0.03 to 0.5 μg/mL against most of the tested strains.,"Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0,21477,DB01045,Rifampicin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.10,21478,DB01045,Rifampicin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.5,21479,DB01045,Rifampicin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.78,21480,DB01045,Rifampicin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],0.39,21481,DB01045,Rifampicin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],2.0,21482,DB01045,Rifampicin
,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],32,21483,DB01045,Rifampicin
>,30025351,MIC,"Whereas, conjugate 3b (MIC: 0.10 and 0.5 μg/mL) was 4- and 8-fold more active than ciprofloxacin (MIC: 0.78 μg/mL) and rifampicin (MIC: 0.39 μg/mL) against MTB H37Rv, and 4->256 times more potent than the three references ciprofloxacin (MIC: 2.0 μg/mL), rifampicin (MIC: 32 μg/mL) and isoniazid (>128 μg/mL) against MDR-TB.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],128,21484,DB01045,Rifampicin
,30025351,CC50,"Both hybrid 3b and 3d with low cytotoxicity (CC50: 64 and 256 μg/mL) also showed acceptable metabolic stability and in vivo PK properties, could act as leads for further optimization.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],64,21485,DB01045,Rifampicin
,30025351,CC50,"Both hybrid 3b and 3d with low cytotoxicity (CC50: 64 and 256 μg/mL) also showed acceptable metabolic stability and in vivo PK properties, could act as leads for further optimization.","Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30025351/),[μg] / [ml],256,21486,DB01045,Rifampicin
,15001966,elimination half-life,"h/mL, P <.001) and the mean elimination half-life from 3.9 to 1.5 hours (P <.001).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),h,3.9 to 1.5,21692,DB01045,Rifampicin
,15001966,peak plasma concentration,"The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P <.01).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),[ng] / [ml],537.7,21693,DB01045,Rifampicin
,15001966,peak plasma concentration,"The peak plasma concentration of rosiglitazone was significantly decreased by rifampin (537.7 ng/mL versus 362.3 ng/mL, P <.01).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),[ng] / [ml],362.3,21694,DB01045,Rifampicin
,15001966,apparent oral clearance,"The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P <.001).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),[l] / [h],2.8,21695,DB01045,Rifampicin
,15001966,apparent oral clearance,"The apparent oral clearance of rosiglitazone increased about 3-fold after rifampin treatment (2.8 L/h versus 8.5 L/h, P <.001).",Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15001966/),[l] / [h],8.5,21696,DB01045,Rifampicin
<,9164416,steady,"In the rifampin group, delavirdine oral clearance increased by about 27-fold (p = 0.022), resulting in virtually negligible (< 0.09 mumol/L) steady-state through drug concentrations in all patients after 2 weeks of concurrent dosing of delavirdine mesylate and rifampin.",Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),,0,21792,DB01045,Rifampicin
,9164416,elimination half-life,The ratio of metabolite formation to elimination clearance for desalkyldelavirdine was significantly higher (3.9 +/- 1.2 versus 0.23 +/- 0.10) and delavirdine elimination half-life was significantly shorter (1.7 +/- 1.4 versus 4.3 +/- 1.3 hours) when delavirdine mesylate was taken with rifampin.,Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),h,1.7,21793,DB01045,Rifampicin
,9164416,elimination half-life,The ratio of metabolite formation to elimination clearance for desalkyldelavirdine was significantly higher (3.9 +/- 1.2 versus 0.23 +/- 0.10) and delavirdine elimination half-life was significantly shorter (1.7 +/- 1.4 versus 4.3 +/- 1.3 hours) when delavirdine mesylate was taken with rifampin.,Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164416/),h,4.3,21794,DB01045,Rifampicin
,21682979,minimum inhibitory concentration [MIC],"Phenotypically, low-level rifampicin (RMP) resistance (minimum inhibitory concentration [MIC] 1-2 mg/l) was observed.",Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21682979/),[mg] / [l],1-2,21985,DB01045,Rifampicin
up to,21682979,MICs,"We retrospectively performed pharmacokinetic calculations to assess the potential for RMP treatment, from which we conclude that MICs for RMP up to 1 μg/ml may be safely overcome by applying 20 mg/kg RMP doses in treatment regimens.",Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21682979/),[μg] / [ml],1,21986,DB01045,Rifampicin
,10591535,bioavailability,"However, bioavailability of propafenone dropped from 30 +/- 15% to 10 +/- 8% in extensive metabolizers (P < 0.01) and from 81 +/- 6% to 48 +/- 8% in poor metabolizers (P < 0.001).",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),%,30,22338,DB01045,Rifampicin
,10591535,bioavailability,"However, bioavailability of propafenone dropped from 30 +/- 15% to 10 +/- 8% in extensive metabolizers (P < 0.01) and from 81 +/- 6% to 48 +/- 8% in poor metabolizers (P < 0.001).",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),%,10,22339,DB01045,Rifampicin
,10591535,bioavailability,"However, bioavailability of propafenone dropped from 30 +/- 15% to 10 +/- 8% in extensive metabolizers (P < 0.01) and from 81 +/- 6% to 48 +/- 8% in poor metabolizers (P < 0.001).",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),%,81,22340,DB01045,Rifampicin
,10591535,bioavailability,"However, bioavailability of propafenone dropped from 30 +/- 15% to 10 +/- 8% in extensive metabolizers (P < 0.01) and from 81 +/- 6% to 48 +/- 8% in poor metabolizers (P < 0.001).",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),%,48,22341,DB01045,Rifampicin
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],4.1,22342,DB01045,Rifampicin
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],23.5,22343,DB01045,Rifampicin
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],3.4,22344,DB01045,Rifampicin
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],16.0,22345,DB01045,Rifampicin
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],123,22346,DB01045,Rifampicin
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],457,22347,DB01045,Rifampicin
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],43,22348,DB01045,Rifampicin
,10591535,clearances,"Following propafenone p.o. clearances through N-dealkylation (4.1 +/- 2.1 ml/min versus 23.5 +/- 12.6 ml/min in extensive metabolizers, P < 0.01; 3.4 +/- 1.3 ml/min versus 16.0 +/- 5.5 ml/min in poor metabolizers, P < 0.001) and glucuronidation (123 +/- 48 ml/min versus 457 +/- 267 ml/min in extensive metabolizers, P < 0.05; 43 +/- 9 ml/min versus 112 +/- 34 ml/min in poor metabolizers, P < 0.01), but not 5-hydroxylation increased regardless of phenotype indicating substantial enzyme induction.",Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10591535/),[ml] / [min],112,22349,DB01045,Rifampicin
,11851646,AUC,"The treatment with rifampicin reduced the mean (+/- s.d.) AUC of nilvadipine from 17.4 +/- 8.4 to 0.6 +/- 0.4 microg l-1 h (mean difference -16.8 microg l-1 h, 95% CI -9.4, 24.2 microg l-1 h).",The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851646/),[h·μg] / [l],17.4,23022,DB01045,Rifampicin
,11851646,AUC,"The treatment with rifampicin reduced the mean (+/- s.d.) AUC of nilvadipine from 17.4 +/- 8.4 to 0.6 +/- 0.4 microg l-1 h (mean difference -16.8 microg l-1 h, 95% CI -9.4, 24.2 microg l-1 h).",The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851646/),[h·μg] / [l],0.6,23023,DB01045,Rifampicin
,7736687,oral bioavailability,Rifabutin has relatively low oral bioavailability; about 20% after single dose administration.,Clinical pharmacokinetics of rifabutin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736687/),%,20,23123,DB01045,Rifampicin
,7736687,elimination half-life,"The elimination half-life of rifabutin is long (45 hours) but, as a result of a very large volume of distribution (> 9 L/kg), average plasma concentrations remain relatively low after repeated administration of standard doses.",Clinical pharmacokinetics of rifabutin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736687/),h,45,23124,DB01045,Rifampicin
>,7736687,volume of distribution,"The elimination half-life of rifabutin is long (45 hours) but, as a result of a very large volume of distribution (> 9 L/kg), average plasma concentrations remain relatively low after repeated administration of standard doses.",Clinical pharmacokinetics of rifabutin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736687/),[l] / [kg],9,23125,DB01045,Rifampicin
,31404235,apparent volume of distribution (V/F),"The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively.",Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404235/),l,12.7,23268,DB01045,Rifampicin
,31404235,apparent clearance (CL/F),"The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively.",Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404235/),[l] / [h],1.12,23269,DB01045,Rifampicin
,9855317,Cmax,"Both fasting conditions produced similar results: mean PZA Cmax 53.4+/-10.4 microg/ml, Tmax 1.43+/-1.06 hours, and AUC(0-infinity) 673+/-79.7 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[μg] / [ml],53.4,23533,DB01045,Rifampicin
,9855317,Tmax,"Both fasting conditions produced similar results: mean PZA Cmax 53.4+/-10.4 microg/ml, Tmax 1.43+/-1.06 hours, and AUC(0-infinity) 673+/-79.7 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),h,1.43,23534,DB01045,Rifampicin
,9855317,AUC(0-infinity),"Both fasting conditions produced similar results: mean PZA Cmax 53.4+/-10.4 microg/ml, Tmax 1.43+/-1.06 hours, and AUC(0-infinity) 673+/-79.7 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[h·μg] / [ml],673,23535,DB01045,Rifampicin
,9855317,Cmax,"In the presence of antacids, subjects had a mean Cmax of 55.6+/-9.0 microg/ml, Tmax of 1.43+/-1.23 hours, and AUC(0-infinity) of 628+/-88.4 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[μg] / [ml],55.6,23536,DB01045,Rifampicin
,9855317,Tmax,"In the presence of antacids, subjects had a mean Cmax of 55.6+/-9.0 microg/ml, Tmax of 1.43+/-1.23 hours, and AUC(0-infinity) of 628+/-88.4 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),h,1.43,23537,DB01045,Rifampicin
,9855317,AUC(0-infinity),"In the presence of antacids, subjects had a mean Cmax of 55.6+/-9.0 microg/ml, Tmax of 1.43+/-1.23 hours, and AUC(0-infinity) of 628+/-88.4 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[h·μg] / [ml],628,23538,DB01045,Rifampicin
,9855317,Cmax,"In the presence of the high-fat meal, mean Cmax was 45.6+/-9.44 pg/ml, Tmax 3.09+/-1.74 hours, and AUC(0-infinity) 687+/-116 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[pg] / [ml],45.6,23539,DB01045,Rifampicin
,9855317,Tmax,"In the presence of the high-fat meal, mean Cmax was 45.6+/-9.44 pg/ml, Tmax 3.09+/-1.74 hours, and AUC(0-infinity) 687+/-116 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),h,3.09,23540,DB01045,Rifampicin
,9855317,AUC(0-infinity),"In the presence of the high-fat meal, mean Cmax was 45.6+/-9.44 pg/ml, Tmax 3.09+/-1.74 hours, and AUC(0-infinity) 687+/-116 microg x hr/ml.","Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855317/),[h·μg] / [ml],687,23541,DB01045,Rifampicin
,16624533,drug,"The average size of alginate nanoparticles was found to be 235.5+/-0.0 nm with a polydispersity index of 0.44; drug encapsulation was 70-90% for INH and PZA, 80-90% for RIF and 88-95% for EMB.",Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16624533/),%,70-90,23713,DB01045,Rifampicin
,16624533,encapsulation,"The average size of alginate nanoparticles was found to be 235.5+/-0.0 nm with a polydispersity index of 0.44; drug encapsulation was 70-90% for INH and PZA, 80-90% for RIF and 88-95% for EMB.",Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16624533/),%,70-90,23714,DB01045,Rifampicin
,16624533,encapsulation,"The average size of alginate nanoparticles was found to be 235.5+/-0.0 nm with a polydispersity index of 0.44; drug encapsulation was 70-90% for INH and PZA, 80-90% for RIF and 88-95% for EMB.",Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16624533/),%,80-90,23715,DB01045,Rifampicin
,16624533,encapsulation,"The average size of alginate nanoparticles was found to be 235.5+/-0.0 nm with a polydispersity index of 0.44; drug encapsulation was 70-90% for INH and PZA, 80-90% for RIF and 88-95% for EMB.",Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16624533/),%,88-95,23716,DB01045,Rifampicin
,21690284,oral clearance,"Typical oral clearance in this analysis (39.9 liters/h for a 50-kg individual) was lower than that previously reported, a finding partly explained by the differences in body weight between the studied populations.",Population pharmacokinetics of ethambutol in South African tuberculosis patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690284/),[l] / [h],39.9,24020,DB01045,Rifampicin
,12968844,peak plasma concentrations,"Average peak plasma concentrations of isoniazid, rifampin, and pyrazinamide were 3.3 mg/L, 6.5 mg/L, and 30.9 mg/L, respectively, all of which much exceed the minimum inhibitory concentration (MIC) for Mycobacterium tuberculosis.","Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968844/),[mg] / [l],3.3,24066,DB01045,Rifampicin
,12968844,peak plasma concentrations,"Average peak plasma concentrations of isoniazid, rifampin, and pyrazinamide were 3.3 mg/L, 6.5 mg/L, and 30.9 mg/L, respectively, all of which much exceed the minimum inhibitory concentration (MIC) for Mycobacterium tuberculosis.","Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968844/),[mg] / [l],6.5,24067,DB01045,Rifampicin
,12968844,peak plasma concentrations,"Average peak plasma concentrations of isoniazid, rifampin, and pyrazinamide were 3.3 mg/L, 6.5 mg/L, and 30.9 mg/L, respectively, all of which much exceed the minimum inhibitory concentration (MIC) for Mycobacterium tuberculosis.","Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968844/),[mg] / [l],30.9,24068,DB01045,Rifampicin
,2661102,absorption half-life,Peak plasma drug concentration is reached at about 4 hours; absorption half-life is 1.1 hours; elimination half-life is about 30 hours.,Clinical pharmacokinetic considerations in the treatment of patients with leprosy. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2661102/),h,1.1,24211,DB01045,Rifampicin
,2661102,elimination half-life,Peak plasma drug concentration is reached at about 4 hours; absorption half-life is 1.1 hours; elimination half-life is about 30 hours.,Clinical pharmacokinetic considerations in the treatment of patients with leprosy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2661102/),h,30,24212,DB01045,Rifampicin
,2661102,Oral availability,Oral availability is around 90%.,Clinical pharmacokinetic considerations in the treatment of patients with leprosy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2661102/),%,90,24213,DB01045,Rifampicin
,2661102,plasma half-life,Single- and multiple-dose studies have shown a plasma half-life of around 10 days.,Clinical pharmacokinetic considerations in the treatment of patients with leprosy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2661102/),d,10,24214,DB01045,Rifampicin
,10695183,Cmax,"There was a significant difference in the Cmax between free and RIF combined with INH (6.1 and 7.6 mg/l respectively) and no significant difference in the other parameters measured, of the local products.",Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10695183/),[mg] / [l],6.1,24707,DB01045,Rifampicin
,10695183,Cmax,"There was a significant difference in the Cmax between free and RIF combined with INH (6.1 and 7.6 mg/l respectively) and no significant difference in the other parameters measured, of the local products.",Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10695183/),[mg] / [l],7.6,24708,DB01045,Rifampicin
,11408210,half-life,"Rifalazil, also known as KRM-1648 or benzoxazinorifamycin, is a new semisynthetic rifamycin with a long half-life of approximately 60 h.",Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11408210/),h,60,24824,DB01045,Rifampicin
,9024169,area under the plasma triazolam concentration-time curve,The area under the plasma triazolam concentration-time curve in the rifampin phase was only 5.1% of that in the placebo phase (0.74 +/- 0.14 versus 14.8 +/- 1.0 ng.hr/ml [mean +/- SEM; p < 0.001]).,Triazolam is ineffective in patients taking rifampin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[h·ng] / [ml],0.74,24933,DB01045,Rifampicin
,9024169,area under the plasma triazolam concentration-time curve,The area under the plasma triazolam concentration-time curve in the rifampin phase was only 5.1% of that in the placebo phase (0.74 +/- 0.14 versus 14.8 +/- 1.0 ng.hr/ml [mean +/- SEM; p < 0.001]).,Triazolam is ineffective in patients taking rifampin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[h·ng] / [ml],14.8,24934,DB01045,Rifampicin
,9024169,maximum plasma concentration,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[ng] / [ml],2.9,24935,DB01045,Rifampicin
,9024169,maximum plasma concentration,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),[ng] / [ml],0.36,24936,DB01045,Rifampicin
,9024169,elimination half-life,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),h,2.8,24937,DB01045,Rifampicin
,9024169,elimination half-life,"Rifampin pretreatment decreased the maximum plasma concentration of triazolam to 12.4% of the control value (i.e., from 2.9 +/- 0.2 to 0.36 +/- 0.06 ng/ml [p < 0.001]) and the elimination half-life from 2.8 +/- 0.1 to 1.3 +/- 0.1 hours (p < 0.001).",Triazolam is ineffective in patients taking rifampin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024169/),h,1.3,24938,DB01045,Rifampicin
,27028459,metabolic rate,The rat liver microsome incubation experiment indicated that moxifloxacin could increase the metabolic rate of rifampicin from 23.7 to 38.7 min.,Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028459/),min,23.7,25110,DB01045,Rifampicin
,27028459,metabolic rate,The rat liver microsome incubation experiment indicated that moxifloxacin could increase the metabolic rate of rifampicin from 23.7 to 38.7 min.,Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27028459/),min,38.7,25111,DB01045,Rifampicin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],41.1,25631,DB01045,Rifampicin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],15.2,25632,DB01045,Rifampicin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],380,25633,DB01045,Rifampicin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],25.5,25634,DB01045,Rifampicin
,24985091,AUC₀₋₂₄,"Geometric mean AUC₀₋₂₄ values for rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin were 41.1, 15.2, 380, 25.5 and 33.6 hmg/L, respectively.",Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985091/),[hmg] / [l],33.6,25635,DB01045,Rifampicin
,28510480,mass median aerodynamic diameter (MMAD),The mass median aerodynamic diameter (MMAD) was in the range of 4.3-5.8 μm with the maximum fine particle fraction of 28.9%.,Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510480/),μm,4.3-5.8,25693,DB01045,Rifampicin
<,27742636,peak concentration,The main predictors of therapy failure or death were a pyrazinamide peak concentration <38.10 mg/L and rifampin peak concentration <3.01 mg/L.,Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742636/),[mg] / [l],38.10,25716,DB01045,Rifampicin
<,27742636,peak concentration,The main predictors of therapy failure or death were a pyrazinamide peak concentration <38.10 mg/L and rifampin peak concentration <3.01 mg/L.,Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742636/),[mg] / [l],3.01,25717,DB01045,Rifampicin
<,27742636,0- to 24-hour,"In children <3 years old, isoniazid 0- to 24-hour area under the concentration-time curve <11.95 mg/L × hour and/or rifampin peak <3.10 mg/L were the best predictors of therapy failure, with relative risk of 3.43 (95% CI, .99-11.82).",Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742636/),[mg] / [h·l],11.95,25718,DB01045,Rifampicin
<,27742636,area under the concentration-time curve,"In children <3 years old, isoniazid 0- to 24-hour area under the concentration-time curve <11.95 mg/L × hour and/or rifampin peak <3.10 mg/L were the best predictors of therapy failure, with relative risk of 3.43 (95% CI, .99-11.82).",Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742636/),[mg] / [h·l],11.95,25719,DB01045,Rifampicin
<,27742636,peak,"In children <3 years old, isoniazid 0- to 24-hour area under the concentration-time curve <11.95 mg/L × hour and/or rifampin peak <3.10 mg/L were the best predictors of therapy failure, with relative risk of 3.43 (95% CI, .99-11.82).",Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27742636/),[mg] / [l],3.10,25720,DB01045,Rifampicin
>,34330719,hepatic extraction ratio,"After the first dose, all statins were rapidly cleared from the circulation (hepatic extraction ratio > 0.7) and excreted into the bile.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,0.7,26059,DB01045,Rifampicin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,7.2,26060,DB01045,Rifampicin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,3.1,26061,DB01045,Rifampicin
,34330719,AUC ratio,"A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data.",Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34330719/),,2.6,26062,DB01045,Rifampicin
,32482623,half-life,"CPI-d8 has a half-life and bioavailability of 7.6 hours and 3.2%, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h,7.6,26063,DB01045,Rifampicin
,32482623,bioavailability,"CPI-d8 has a half-life and bioavailability of 7.6 hours and 3.2%, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),%,3.2,26064,DB01045,Rifampicin
,32482623,maximum blood concentrations (C max),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,0.19,26065,DB01045,Rifampicin
,32482623,maximum blood concentrations (C max),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,2.5,26066,DB01045,Rifampicin
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,3.8,26067,DB01045,Rifampicin
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,2.7,26068,DB01045,Rifampicin
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,10.5,26069,DB01045,Rifampicin
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,26.6,26070,DB01045,Rifampicin
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1.8,26071,DB01045,Rifampicin
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,6.2,26072,DB01045,Rifampicin
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,10.5,26073,DB01045,Rifampicin
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1,26074,DB01045,Rifampicin
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1.4,26075,DB01045,Rifampicin
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,4.4,26076,DB01045,Rifampicin
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,4.6,26077,DB01045,Rifampicin
,3455371,steady state concentrations,"Infusion of aldosterone at a constant rate of 0.17 mg/h over 4.5 h produced steady state concentrations after 2 h, with no difference before and after rifampicin treatment (mean +/- SD, 1649 +/- 144 vs 1586 +/- 80 pg/ml, respectively).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[pg] / [ml],1649,26474,DB01045,Rifampicin
,3455371,steady state concentrations,"Infusion of aldosterone at a constant rate of 0.17 mg/h over 4.5 h produced steady state concentrations after 2 h, with no difference before and after rifampicin treatment (mean +/- SD, 1649 +/- 144 vs 1586 +/- 80 pg/ml, respectively).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[pg] / [ml],1586,26475,DB01045,Rifampicin
,3455371,alpha-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,29,26476,DB01045,Rifampicin
,3455371,alpha-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,30,26477,DB01045,Rifampicin
,3455371,beta-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,129,26478,DB01045,Rifampicin
,3455371,beta-phase,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),min,126,26479,DB01045,Rifampicin
,3455371,MCR,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[l] / [h·kg],1.47,26480,DB01045,Rifampicin
,3455371,MCR,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[l] / [h·kg],1.46,26481,DB01045,Rifampicin
,3455371,volume of distribution,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),l,9.9,26482,DB01045,Rifampicin
,3455371,volume of distribution,"No change could be observed in the plasma half-lives (alpha-phase 29 +/- 1.9 min vs 30 +/- 1.5 min, beta-phase 129 +/- 3.2 min vs 126 +/- 4.3 min), the MCR (1.47 +/- 0.1 l/h/kg vs 1.46 +/- 0.1 l/h/kg), and the volume of distribution (9.9 +/- 1.9 vs 10.2 +/- 0.3 l).",Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),l,10.2,26483,DB01045,Rifampicin
,3455371,half-life,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),h,12.2,26484,DB01045,Rifampicin
,3455371,half-life,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),h,7.6,26485,DB01045,Rifampicin
,3455371,clearance,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[ml] / [kg·min],0.38,26486,DB01045,Rifampicin
,3455371,clearance,The antipyrine half-life decreased significantly from 12.2 +/- 2.6 h to 7.6 +/- 0.9 h (P less than 0.05) with a rise in antipyrine clearance from 0.38 +/- 0.07 to 0.80 +/- 0.23 ml/min/kg (P less than 0.05) and no change in the volume of distribution.,Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3455371/),[ml] / [kg·min],0.80,26487,DB01045,Rifampicin
,9698286,total recovery of radioactive dose,"The total recovery of radioactive dose was 86.8%, with the majority of the radioactive dose recovered in feces (70.2%).",Disposition and metabolism of 14C-rifapentine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698286/),%,86.8,26649,DB01045,Rifampicin
,32077827,Tmax,"The Tmax decreased from 5.67 h to 3.3 h, and the plasma concentration of RIF remained above its MIC (8 μg/ml) at all the tested time points starting with 15 min, when administered as RIF-SLNs in combination with INH.",Encapsulating Rifampicin into SLNs: A Viable Option for Managing its Bioavailability Issues Upon Co-Delivery with Isoniazid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32077827/),h,5.67,26775,DB01045,Rifampicin
,32077827,Tmax,"The Tmax decreased from 5.67 h to 3.3 h, and the plasma concentration of RIF remained above its MIC (8 μg/ml) at all the tested time points starting with 15 min, when administered as RIF-SLNs in combination with INH.",Encapsulating Rifampicin into SLNs: A Viable Option for Managing its Bioavailability Issues Upon Co-Delivery with Isoniazid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32077827/),h,3.3,26776,DB01045,Rifampicin
,32077827,MIC,"The Tmax decreased from 5.67 h to 3.3 h, and the plasma concentration of RIF remained above its MIC (8 μg/ml) at all the tested time points starting with 15 min, when administered as RIF-SLNs in combination with INH.",Encapsulating Rifampicin into SLNs: A Viable Option for Managing its Bioavailability Issues Upon Co-Delivery with Isoniazid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32077827/),[μg] / [ml],8,26777,DB01045,Rifampicin
,27287644,bioavailability,"While one formulation achieved 2 h concentrations in the range of those observed in adults (median 6.54 mg/l, interquartile range [IQR] 4.47-8.84), the other attained a median bioavailability of only 25% of this, with a median 2 h concentration of 1.59 mg/l (IQR 0.89-2.38).",Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27287644/),%,25,26909,DB01045,Rifampicin
,1981019,maximum plasma concentrations,"On treatment with tertatolol alone, maximum plasma concentrations were 123.7 +/- 32.4 ng/ml (mean +/- SD) and were reached after 1.95 +/- 1.77 hours.",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),[ng] / [ml],123.7,27380,DB01045,Rifampicin
,1981019,elimination half-life,The tertatolol elimination half-life was 9.0 +/- 7.1 hours.,Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),h,9.0,27381,DB01045,Rifampicin
,1981019,maximum plasma levels,"Rifampicin, however, decreased the maximum plasma levels of tertatolol to 80.6 +/- 18.5 ng/ml and markedly shortened the elimination half-life to 3.4 +/- 2.6 hours (p less than 0.01 compared with tertatolol alone).",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),[ng] / [ml],80.6,27382,DB01045,Rifampicin
,1981019,elimination half-life,"Rifampicin, however, decreased the maximum plasma levels of tertatolol to 80.6 +/- 18.5 ng/ml and markedly shortened the elimination half-life to 3.4 +/- 2.6 hours (p less than 0.01 compared with tertatolol alone).",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),h,3.4,27383,DB01045,Rifampicin
,1981019,heart rate,"Twenty-four hours after administration, the heart rate in those patients on tertatolol alone (68 +/- 6 beats/min) was lower than in those on tertatolol plus rifampicin (74 +/- 7 beats/min).",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),[beats] / [min],68,27384,DB01045,Rifampicin
,1981019,heart rate,"Twenty-four hours after administration, the heart rate in those patients on tertatolol alone (68 +/- 6 beats/min) was lower than in those on tertatolol plus rifampicin (74 +/- 7 beats/min).",Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981019/),[beats] / [min],74,27385,DB01045,Rifampicin
<,27510252,peak concentration (Cmax),RMP peak concentration (Cmax) was sub-therapeutic (<8 μg/ml) in 88% of the patients.,"Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27510252/),[μg] / [ml],8,27525,DB01045,Rifampicin
,15483198,metabolic clearance,The metabolic clearance estimated from microsomes was 4.59 +/- 0.69 ml/min/kg.,Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15483198/),[ml] / [kg·min],4.59,27593,DB01045,Rifampicin
,15483198,metabolic clearance,"However, the metabolic clearance estimated from hepatocytes was 15.9 +/- 3.0 ml/min/kg.",Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15483198/),[ml] / [kg·min],15.9,27594,DB01045,Rifampicin
,15483198,clearance,The former did not correlate with in vivo clearance (12.9 ml/min/kg) for digoxin.,Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15483198/),[ml] / [kg·min],12.9,27595,DB01045,Rifampicin
,15483198,area under the curve (AUC),"Concentration-time course studies further demonstrated that, compared with the area under the curve (AUC) of control (15.6 +/- 0.1 microM . min), an increase of AUC (20.1 +/- 0.5 microM . min, p < 0.005) was observed when digoxin was coincubated with rifampin and a decrease of AUC (14.1 +/- 0.1 microM . min, p < 0.01) when GG918 was also present.",Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15483198/),min·μM,15.6,27596,DB01045,Rifampicin
,15483198,AUC,"Concentration-time course studies further demonstrated that, compared with the area under the curve (AUC) of control (15.6 +/- 0.1 microM . min), an increase of AUC (20.1 +/- 0.5 microM . min, p < 0.005) was observed when digoxin was coincubated with rifampin and a decrease of AUC (14.1 +/- 0.1 microM . min, p < 0.01) when GG918 was also present.",Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15483198/),min·μM,20.1,27597,DB01045,Rifampicin
,15483198,AUC,"Concentration-time course studies further demonstrated that, compared with the area under the curve (AUC) of control (15.6 +/- 0.1 microM . min), an increase of AUC (20.1 +/- 0.5 microM . min, p < 0.005) was observed when digoxin was coincubated with rifampin and a decrease of AUC (14.1 +/- 0.1 microM . min, p < 0.01) when GG918 was also present.",Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15483198/),min·μM,14.1,27598,DB01045,Rifampicin
,12894568,peak concentrations,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [ml],274.2,28183,DB01045,Rifampicin
,12894568,peak concentrations,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [ml],458,28184,DB01045,Rifampicin
,12894568,areas under the serum concentration-time curve,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[min·ng] / [ml],"8,344",28185,DB01045,Rifampicin
,12894568,areas under the serum concentration-time curve,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [min·ml],"14,093",28186,DB01045,Rifampicin
,12894568,total clearances,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[l] / [min],1.146,28187,DB01045,Rifampicin
,12894568,total clearances,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[l] / [min],1.003,28188,DB01045,Rifampicin
,11218826,entrapment efficiencies,Niosomes and liposomes exhibited mean diameter of 9.73 and 11.87 microns with entrapment efficiencies of 30.5 and 34.2% respectively.,Prolonged release biodegradable vesicular carriers for rifampicin--formulation and kinetics of release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11218826/),%,30.5,28382,DB01045,Rifampicin
,11218826,entrapment efficiencies,Niosomes and liposomes exhibited mean diameter of 9.73 and 11.87 microns with entrapment efficiencies of 30.5 and 34.2% respectively.,Prolonged release biodegradable vesicular carriers for rifampicin--formulation and kinetics of release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11218826/),%,34.2,28383,DB01045,Rifampicin
up to,11218826,zero order drug release kinetics,Both the products exhibited sustained release characteristics in vitro with zero order drug release kinetics up to initial 10 hr.,Prolonged release biodegradable vesicular carriers for rifampicin--formulation and kinetics of release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11218826/),h,10,28384,DB01045,Rifampicin
,25801554,total AUC0-24,"Females had significantly higher total AUC0-24 (geometric mean, 59.2 versus 48.2 h · mg/liter; P = 0.02) and higher unbound AUC0-24 (geometric mean, 6.2 versus 4.8 h · mg/liter; P = 0.02) than males.",Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801554/),[h·mg] / [l],59.2,28878,DB01045,Rifampicin
,25801554,total AUC0-24,"Females had significantly higher total AUC0-24 (geometric mean, 59.2 versus 48.2 h · mg/liter; P = 0.02) and higher unbound AUC0-24 (geometric mean, 6.2 versus 4.8 h · mg/liter; P = 0.02) than males.",Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801554/),[h·mg] / [l],48.2,28879,DB01045,Rifampicin
,25801554,unbound AUC0-24,"Females had significantly higher total AUC0-24 (geometric mean, 59.2 versus 48.2 h · mg/liter; P = 0.02) and higher unbound AUC0-24 (geometric mean, 6.2 versus 4.8 h · mg/liter; P = 0.02) than males.",Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801554/),[h·mg] / [l],6.2,28880,DB01045,Rifampicin
,25801554,unbound AUC0-24,"Females had significantly higher total AUC0-24 (geometric mean, 59.2 versus 48.2 h · mg/liter; P = 0.02) and higher unbound AUC0-24 (geometric mean, 6.2 versus 4.8 h · mg/liter; P = 0.02) than males.",Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25801554/),[h·mg] / [l],4.8,28881,DB01045,Rifampicin
,11744833,area under the curve (AUC) 0-12h,"The median area under the curve (AUC) 0-12h of nevirapine before and after rifampicin was 56.2 and 32.8 microg/ml per hour, respectively ( p =.04).",Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744833/),[μg] / [h·ml],56.2,29186,DB01045,Rifampicin
,11744833,area under the curve (AUC) 0-12h,"The median area under the curve (AUC) 0-12h of nevirapine before and after rifampicin was 56.2 and 32.8 microg/ml per hour, respectively ( p =.04).",Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744833/),[μg] / [h·ml],32.8,29187,DB01045,Rifampicin
,11744833,C(max),"The C(max) decreased from 5.6 to 4.5 microg/ml ( p =.04), which represented a 36% reduction.",Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744833/),[μg] / [ml],5.6,29188,DB01045,Rifampicin
,11744833,C(max),"The C(max) decreased from 5.6 to 4.5 microg/ml ( p =.04), which represented a 36% reduction.",Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11744833/),[μg] / [ml],4.5,29189,DB01045,Rifampicin
,346286,peak serum concentration,"With a single 600mg dose, peak serum concentration of the order of 10microgram/ml generally occur 2 hours after administration.",Clinical pharmacokinetics of rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346286/),[μg] / [ml],10,29442,DB01045,Rifampicin
,346286,half-life,The half-life of rifampicin for this dose level is of the order of 2.5 hours.,Clinical pharmacokinetics of rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346286/),h,2.5,29443,DB01045,Rifampicin
,32304015,elimination half-life,Median maximum concentration was reached 2-6 h following single and repeat dosing of gilteritinib; mean elimination half-life was 113 h.,Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32304015/),h,113,29795,DB01045,Rifampicin
,9987705,clearance,Coadministration of rifampin significantly increased tacrolimus clearance (36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03) and decreased tacrolimus bioavailability (14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03).,Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987705/),[ml] / [h·kg],36.0,29878,DB01045,Rifampicin
,9987705,clearance,Coadministration of rifampin significantly increased tacrolimus clearance (36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03) and decreased tacrolimus bioavailability (14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03).,Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987705/),[ml] / [h·kg],52.8,29879,DB01045,Rifampicin
,9987705,bioavailability,Coadministration of rifampin significantly increased tacrolimus clearance (36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03) and decreased tacrolimus bioavailability (14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03).,Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987705/),%,14.4,29880,DB01045,Rifampicin
,9987705,bioavailability,Coadministration of rifampin significantly increased tacrolimus clearance (36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03) and decreased tacrolimus bioavailability (14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03).,Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987705/),%,7.0,29881,DB01045,Rifampicin
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],7.8,29991,DB01045,Rifampicin
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],13.3,29992,DB01045,Rifampicin
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],5.8,29993,DB01045,Rifampicin
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],19.3,29994,DB01045,Rifampicin
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],14.3,29995,DB01045,Rifampicin
,7341283,Clearance,"Clearance to 3-hydroxymethylantipyrine was increased from 7.8 +/- 0.9 ml/min to 13.3 +/- 1.3 ml/min, to norphenazone from 5.8 +/- 0.6 ml/min to 19.3 +/- 2.1 ml/min and to 4-hydroxyantipyrine from 14.3 +/- 2.2 ml/min to 21.9 +/- 3.9 ml/min.",Differential induction of antipyrine metabolism by rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7341283/),[ml] / [min],21.9,29996,DB01045,Rifampicin
,31202922,AUC0-24),The geometric mean plasma PZA exposure (AUC0-24) and peak concentration (Cmax) on Day 2 were 709 h·mg/L and 59 mg/L following a median dose of 33.3 mg/kg/day; AUC0-24 on Day 10 (523 h·mg/L) was lower (P < 0.001).,Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202922/),[h·mg] / [l],709,30341,DB01045,Rifampicin
,31202922,peak concentration (Cmax),The geometric mean plasma PZA exposure (AUC0-24) and peak concentration (Cmax) on Day 2 were 709 h·mg/L and 59 mg/L following a median dose of 33.3 mg/kg/day; AUC0-24 on Day 10 (523 h·mg/L) was lower (P < 0.001).,Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202922/),[mg] / [l],59,30342,DB01045,Rifampicin
,31202922,AUC0-24,The geometric mean plasma PZA exposure (AUC0-24) and peak concentration (Cmax) on Day 2 were 709 h·mg/L and 59 mg/L following a median dose of 33.3 mg/kg/day; AUC0-24 on Day 10 (523 h·mg/L) was lower (P < 0.001).,Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202922/),[h·mg] / [l],523,30343,DB01045,Rifampicin
,31202922,CSF concentration,The CSF concentration at 3-6 h was 42 mg/L and the CSF-to-plasma ratio was 90%.,Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202922/),[mg] / [l],42,30344,DB01045,Rifampicin
,31202922,CSF-to-plasma ratio,The CSF concentration at 3-6 h was 42 mg/L and the CSF-to-plasma ratio was 90%.,Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31202922/),%,90,30345,DB01045,Rifampicin
,26407268,AUC0-8h,"The median (interquartile range) AUC0-8h for isoniazid was 17.7 (10.2-23.4) µg·h mL-1, rifampin was 26.0 (15.3-36.1) µg·h mL-1, pyrazinamide was 144.6 (111.5-201.2) µg·h mL-1, and ethambutol was 6.7 (3.8-10.4) µg·h mL-1.",Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26407268/),[h·μg] / [ml],17.7,31255,DB01045,Rifampicin
,26407268,AUC0-8h,"The median (interquartile range) AUC0-8h for isoniazid was 17.7 (10.2-23.4) µg·h mL-1, rifampin was 26.0 (15.3-36.1) µg·h mL-1, pyrazinamide was 144.6 (111.5-201.2) µg·h mL-1, and ethambutol was 6.7 (3.8-10.4) µg·h mL-1.",Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26407268/),[h·μg] / [ml],26.0,31256,DB01045,Rifampicin
,26407268,AUC0-8h,"The median (interquartile range) AUC0-8h for isoniazid was 17.7 (10.2-23.4) µg·h mL-1, rifampin was 26.0 (15.3-36.1) µg·h mL-1, pyrazinamide was 144.6 (111.5-201.2) µg·h mL-1, and ethambutol was 6.7 (3.8-10.4) µg·h mL-1.",Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26407268/),[h·μg] / [ml],144.6,31257,DB01045,Rifampicin
,26407268,AUC0-8h,"The median (interquartile range) AUC0-8h for isoniazid was 17.7 (10.2-23.4) µg·h mL-1, rifampin was 26.0 (15.3-36.1) µg·h mL-1, pyrazinamide was 144.6 (111.5-201.2) µg·h mL-1, and ethambutol was 6.7 (3.8-10.4) µg·h mL-1.",Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26407268/),[h·μg] / [ml],6.7,31258,DB01045,Rifampicin
,32816220,time to maximum plasma concentration,"Following oral administration, doravirine is rapidly absorbed (median time to maximum plasma concentration, 1-4 h) and undergoes cytochrome P450 (CYP)3A-mediated oxidative metabolism.",Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816220/),h,1-4,31275,DB01045,Rifampicin
,32816220,AUC0-24,"Steady-state geometric means for AUC0-24, C24, and Cmax in individuals with HIV-1 following administration of doravirine 100 mg once daily are 37.8 μM·h, 930 nM, and 2260 nM, respectively.",Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816220/),h·μM,37.8,31276,DB01045,Rifampicin
,32816220,C24,"Steady-state geometric means for AUC0-24, C24, and Cmax in individuals with HIV-1 following administration of doravirine 100 mg once daily are 37.8 μM·h, 930 nM, and 2260 nM, respectively.",Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816220/),nM,930,31277,DB01045,Rifampicin
,32816220,Cmax,"Steady-state geometric means for AUC0-24, C24, and Cmax in individuals with HIV-1 following administration of doravirine 100 mg once daily are 37.8 μM·h, 930 nM, and 2260 nM, respectively.",Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816220/),nM,2260,31278,DB01045,Rifampicin
up to,25853075,entrapment,The entrapment of rifampicin in microparticles was up to 72%.,"Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853075/),%,72,32535,DB01045,Rifampicin
,25853075,elimination rate,The in vivo pulmonary absorption of the chitosan microparticles suggested a sustained drug release profile up to 72 hrs with an elimination rate of 0.010 per hr.,"Preparation, in vitro characterization, and in vivo pharmacokinetic evaluation of respirable porous microparticles containing rifampicin. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25853075/),1/[h],0.010,32536,DB01045,Rifampicin
,30670438,clearance,"In a typical patient (body weight, 56 kg; fat-free mass, 45 kg), the values of clearance and volume of distribution were 1.33 liters/h and 25 liters, respectively.",A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30670438/),[l] / [h],1.33,32680,DB01045,Rifampicin
,30670438,volume of distribution,"In a typical patient (body weight, 56 kg; fat-free mass, 45 kg), the values of clearance and volume of distribution were 1.33 liters/h and 25 liters, respectively.",A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30670438/),l,25,32681,DB01045,Rifampicin
,30670438,bioavailability,HIV-infected patients had a 21.9% lower bioavailability.,A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30670438/),%,21,32682,DB01045,Rifampicin
,30670438,Bioavailability,Bioavailability was 23.3% lower among patients participating in the Daily RPE study than in those participating in the RIFAQUIN study.,A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30670438/),%,23.3,32683,DB01045,Rifampicin
,3348603,half-life,"After a single intravenous administration of 10 mg of DHMP A per kg, its half-life in serum in mice was about 0.5 h and in dogs it was 5.5 h.",Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348603/),h,0.5,32762,DB01045,Rifampicin
,3348603,half-life,"After a single intravenous administration of 10 mg of DHMP A per kg, its half-life in serum in mice was about 0.5 h and in dogs it was 5.5 h.",Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348603/),h,5.5,32763,DB01045,Rifampicin
,3348603,peak,A single oral administration to dogs of 12.5 mg/kg gave a peak of 5.0 micrograms/ml at 3 h.,Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348603/),[μg] / [ml],5.0,32764,DB01045,Rifampicin
,3348603,urinary recoveries,"In these experiments, urinary recoveries within 48 h were 21.0% in mice and 25.2% in dogs.",Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348603/),%,21.0,32765,DB01045,Rifampicin
,3348603,urinary recoveries,"In these experiments, urinary recoveries within 48 h were 21.0% in mice and 25.2% in dogs.",Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348603/),%,25.2,32766,DB01045,Rifampicin
,30335192,Cmax ratios,The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1.01-2.05 and AUC ratio 1.04-2.23).,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.01-2.05,33112,DB01045,Rifampicin
,30335192,AUC ratio,The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1.01-2.05 and AUC ratio 1.04-2.23).,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.04-2.23,33113,DB01045,Rifampicin
,30335192,Cmax ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.20,33114,DB01045,Rifampicin
,30335192,AUC ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.20,33115,DB01045,Rifampicin
,30335192,AUC ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.41,33116,DB01045,Rifampicin
,29845664,MIC,"From these isolates, two MS isolates (RFP MIC of 0.003 and 0.008 μg/mL, respectively) and two MR isolates (RFP MIC of 0.003 and 0.012 μg/mL, respectively) were subjected to time-kill studies.",Minimum inhibitory concentration and killing properties of rifampicin against canine Staphylococcus pseudintermedius isolates from dogs in the southeast USA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29845664/),[μg] / [ml],0.003,34229,DB01045,Rifampicin
,29845664,MIC,"From these isolates, two MS isolates (RFP MIC of 0.003 and 0.008 μg/mL, respectively) and two MR isolates (RFP MIC of 0.003 and 0.012 μg/mL, respectively) were subjected to time-kill studies.",Minimum inhibitory concentration and killing properties of rifampicin against canine Staphylococcus pseudintermedius isolates from dogs in the southeast USA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29845664/),[μg] / [ml],0.008,34230,DB01045,Rifampicin
,29845664,MIC,"From these isolates, two MS isolates (RFP MIC of 0.003 and 0.008 μg/mL, respectively) and two MR isolates (RFP MIC of 0.003 and 0.012 μg/mL, respectively) were subjected to time-kill studies.",Minimum inhibitory concentration and killing properties of rifampicin against canine Staphylococcus pseudintermedius isolates from dogs in the southeast USA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29845664/),[μg] / [ml],0.012,34231,DB01045,Rifampicin
,29845664,MIC50,"The MIC50 and MIC90 were the same for MS and MR isolates, at 0.004 μg/mL and 0.008 μg/mL, respectively.",Minimum inhibitory concentration and killing properties of rifampicin against canine Staphylococcus pseudintermedius isolates from dogs in the southeast USA. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29845664/),[μg] / [ml],0.004,34232,DB01045,Rifampicin
,29845664,MIC90,"The MIC50 and MIC90 were the same for MS and MR isolates, at 0.004 μg/mL and 0.008 μg/mL, respectively.",Minimum inhibitory concentration and killing properties of rifampicin against canine Staphylococcus pseudintermedius isolates from dogs in the southeast USA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29845664/),[μg] / [ml],0.008,34233,DB01045,Rifampicin
,32810723,lag time,Sequential process includes a typical lag time of 0.25 h prior to absorption start with a Ka of 1.24 h-1 and a zero-order absorption of 0.62 h to characterize the gradual increase in RMP plasma concentrations.,A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32810723/),h,0.25,34751,DB01045,Rifampicin
,32810723,Ka,Sequential process includes a typical lag time of 0.25 h prior to absorption start with a Ka of 1.24 h-1 and a zero-order absorption of 0.62 h to characterize the gradual increase in RMP plasma concentrations.,A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32810723/),1/[h],1.24,34752,DB01045,Rifampicin
,32810723,zero-order absorption,Sequential process includes a typical lag time of 0.25 h prior to absorption start with a Ka of 1.24 h-1 and a zero-order absorption of 0.62 h to characterize the gradual increase in RMP plasma concentrations.,A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32810723/),h,0.62,34753,DB01045,Rifampicin
,32810723,total clearance,"Final model includes total body weight in volume of distribution (0.7 L/kg, CV = 26.8%) and a total clearance of 5.96 L/h (CV = 38.5%).",A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32810723/),[l] / [h],5.96,34754,DB01045,Rifampicin
,8863056,elimination half-life,"Oral administration of activated charcoal (50 grams) and sodium sulphate (20 grams) after gastric lavage resulted in an elimination half-life in plasma of 11.1 and 10.8 h for dapsone and its main metabolite, monoacetyldapsone, respectively.",Combined dapsone and clofazimine intoxication. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863056/),h,11.1,34905,DB01045,Rifampicin
,8863056,elimination half-life,"Oral administration of activated charcoal (50 grams) and sodium sulphate (20 grams) after gastric lavage resulted in an elimination half-life in plasma of 11.1 and 10.8 h for dapsone and its main metabolite, monoacetyldapsone, respectively.",Combined dapsone and clofazimine intoxication. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863056/),h,10.8,34906,DB01045,Rifampicin
,8983939,Cmax,"The pharmacokinetic parameters, Cmax, Tmax, AUC0-10h (mean +/- SD), were 6.06 +/- 2.95 micrograms/ml, 2.33 +/- 1.60 h, 25.57 +/- 12.6 micrograms.",Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983939/),[μg] / [ml],6.06,35943,DB01045,Rifampicin
,8983939,Tmax,"The pharmacokinetic parameters, Cmax, Tmax, AUC0-10h (mean +/- SD), were 6.06 +/- 2.95 micrograms/ml, 2.33 +/- 1.60 h, 25.57 +/- 12.6 micrograms.",Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983939/),h,2.33,35944,DB01045,Rifampicin
,8983939,AUC0-10h,"The pharmacokinetic parameters, Cmax, Tmax, AUC0-10h (mean +/- SD), were 6.06 +/- 2.95 micrograms/ml, 2.33 +/- 1.60 h, 25.57 +/- 12.6 micrograms.",Bioequivalence study of two pharmaceutical forms of rifampicin capsules in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983939/),μg,25.57,35945,DB01045,Rifampicin
,9420037,peak concentrations in plasma (C[max]),"Fast and slow acetylators of INH had median peak concentrations in plasma (C[max]) of 2.44 and 3.64 microg/ml, respectively, both of which occurred at 1.0 h postdose (time of maximum concentrations of drugs in plasma [T(max)]), with median elimination half-lives (t1/2) of 1.2 and 3.3 h, respectively (by the NPEM method).","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),[μg] / [ml],2.44,36232,DB01045,Rifampicin
,9420037,peak concentrations in plasma (C[max]),"Fast and slow acetylators of INH had median peak concentrations in plasma (C[max]) of 2.44 and 3.64 microg/ml, respectively, both of which occurred at 1.0 h postdose (time of maximum concentrations of drugs in plasma [T(max)]), with median elimination half-lives (t1/2) of 1.2 and 3.3 h, respectively (by the NPEM method).","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),[μg] / [ml],3.64,36233,DB01045,Rifampicin
,9420037,time of maximum concentrations of drugs in plasma [T(max)],"Fast and slow acetylators of INH had median peak concentrations in plasma (C[max]) of 2.44 and 3.64 microg/ml, respectively, both of which occurred at 1.0 h postdose (time of maximum concentrations of drugs in plasma [T(max)]), with median elimination half-lives (t1/2) of 1.2 and 3.3 h, respectively (by the NPEM method).","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),h,1.0,36234,DB01045,Rifampicin
,9420037,elimination half-lives (t1/2),"Fast and slow acetylators of INH had median peak concentrations in plasma (C[max]) of 2.44 and 3.64 microg/ml, respectively, both of which occurred at 1.0 h postdose (time of maximum concentrations of drugs in plasma [T(max)]), with median elimination half-lives (t1/2) of 1.2 and 3.3 h, respectively (by the NPEM method).","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),h,1.2,36235,DB01045,Rifampicin
,9420037,elimination half-lives (t1/2),"Fast and slow acetylators of INH had median peak concentrations in plasma (C[max]) of 2.44 and 3.64 microg/ml, respectively, both of which occurred at 1.0 h postdose (time of maximum concentrations of drugs in plasma [T(max)]), with median elimination half-lives (t1/2) of 1.2 and 3.3 h, respectively (by the NPEM method).","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),h,3.3,36236,DB01045,Rifampicin
,9420037,C(max),"RIF produced a median C(max) of 11.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 3.4 h.","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),[μg] / [ml],11.80,36237,DB01045,Rifampicin
,9420037,T(max),"RIF produced a median C(max) of 11.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 3.4 h.","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),h,1.0,36238,DB01045,Rifampicin
,9420037,t1/2,"RIF produced a median C(max) of 11.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 3.4 h.","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),h,3.4,36239,DB01045,Rifampicin
,9420037,C(max),"PZA produced a median C(max) of 28.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 10.0 h.","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),[μg] / [ml],28.80,36240,DB01045,Rifampicin
,9420037,T(max),"PZA produced a median C(max) of 28.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 10.0 h.","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),h,1.0,36241,DB01045,Rifampicin
,9420037,t1/2,"PZA produced a median C(max) of 28.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 10.0 h.","Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420037/),h,10.0,36242,DB01045,Rifampicin
,12022896,half-life,"Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours.",Effect of rifampin on apparent clearance of everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022896/),h,32,36262,DB01045,Rifampicin
,12022896,half-life,"Everolimus half-life was reduced significantly, from an average of 32 hours to 24 hours.",Effect of rifampin on apparent clearance of everolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12022896/),h,24,36263,DB01045,Rifampicin
,27490210,CmaxCF/CmaxEF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,4.41,36577,DB01045,Rifampicin
,27490210,CmaxCF/CmaxEF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,0,36578,DB01045,Rifampicin
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,3.69,36579,DB01045,Rifampicin
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,1.84,36580,DB01045,Rifampicin
,27490210,AUC0-t-CF/AUC0-t-EF ratio,"In RIF-treated, BNF-treated and control groups, the value of the CmaxCF/CmaxEF ratio was 4.41, 0.81 and 0.95, and the corresponding value of the AUC0-t-CF/AUC0-t-EF ratio was 3.69, 1.84 and 1.76, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),,1.76,36581,DB01045,Rifampicin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,26.57,36582,DB01045,Rifampicin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,27.45,36583,DB01045,Rifampicin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,30.88,36584,DB01045,Rifampicin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,5.79,36585,DB01045,Rifampicin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,35.18,36586,DB01045,Rifampicin
,27490210,MRT,"In the RIF-treated, BNF-treated and control groups, the MRT values of EF were 26.57, 27.45 and 30.88h, and the corresponding values for CF were 5.79, 35.18 and 38.11h, respectively.",Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27490210/),h,38.11,36587,DB01045,Rifampicin
,32690646,area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,5.85,37069,DB01045,Rifampicin
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,5.77,37070,DB01045,Rifampicin
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,2.4,37071,DB01045,Rifampicin
,32690646,AUC0-24/MIC,"As monotherapy, tedizolid at an observed area under the concentration-time curve from 0 to 24 h (AUC0-24)/MIC of 5.85 and minocycline at an AUC0-24/MIC of 5.77 failed to kill the bacteria below day 0 (stasis), clarithromycin at an AUC0-24/MIC of 2.4 held the bacterial burden at stasis, but rifapentine at an AUC0-24/MIC of 140 killed 2 log10 CFU/ml below stasis.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),,140,37072,DB01045,Rifampicin
,32690646,combination kill slope,"The rifapentine-tedizolid-minocycline combination kill slope was -0.119 ± 0.031 CFU/ml/day, superior to that of the ATS regimen and comparable to that of the BTS regimen.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),[cfu] / [d·ml],-,37073,DB01045,Rifampicin
,32690646,combination kill slope,"The rifapentine-tedizolid-minocycline combination kill slope was -0.119 ± 0.031 CFU/ml/day, superior to that of the ATS regimen and comparable to that of the BTS regimen.","Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32690646/),[cfu] / [d·ml],0.119,37074,DB01045,Rifampicin
<,24554646,trough concentrations,"Among patients receiving 200 mg of voriconazole twice daily, predicted trough concentrations on day 7 were <2 mg/L for oral and intravenous regimens for 72% and 63% of patients without CYP2C19 LoF alleles, respectively, with 49% and 35% below this threshold with 300 mg twice daily dosing.",Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554646/),[mg] / [l],2,37709,DB01045,Rifampicin
≥,24554646,trough concentrations,"Conversely, these regimens resulted in 29%, 39%, 57% and 77% of patients with CYP2C19 LoF alleles with voriconazole trough concentrations ≥5 mg/L.",Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554646/),[mg] / [l],5,37710,DB01045,Rifampicin
,33177323,oral bioavailability,"The maximum concentration of oral hydromorphone was reduced by 37% (ratio to control: 0.63, 90% CI, 0.55-0.72), and oral bioavailability decreased from 33% to 26% (ratio to control: 0.78, 90% CI, 0.67-0.91) in the rifampin phase compared with placebo.",Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33177323/),%,33,38402,DB01045,Rifampicin
,33177323,oral bioavailability,"The maximum concentration of oral hydromorphone was reduced by 37% (ratio to control: 0.63, 90% CI, 0.55-0.72), and oral bioavailability decreased from 33% to 26% (ratio to control: 0.78, 90% CI, 0.67-0.91) in the rifampin phase compared with placebo.",Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33177323/),%,26,38403,DB01045,Rifampicin
,15086276,Plasma concentrations,Plasma concentrations (mean +/- SD) of rifampicin at 2 hours (9.15 +/- 5.4 mg/L) were not significantly different (p > 0.05) from those at 4 hours (9.10 +/- 5.6 mg/L) following the last dose.,Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15086276/),[mg] / [l],9.15,38747,DB01045,Rifampicin
,15086276,Plasma concentrations,Plasma concentrations (mean +/- SD) of rifampicin at 2 hours (9.15 +/- 5.4 mg/L) were not significantly different (p > 0.05) from those at 4 hours (9.10 +/- 5.6 mg/L) following the last dose.,Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15086276/),[mg] / [l],9.10,38748,DB01045,Rifampicin
,15086276,concentration,The ELF concentration was 2.0 +/- 1.6 mg/L with a range of 0-7.3 mg/L and the ELF/plasma ratio at 4 hours was 0.2 +/- 0.2.,Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15086276/),[mg] / [l],2.0,38749,DB01045,Rifampicin
,15086276,ELF/plasma ratio,The ELF concentration was 2.0 +/- 1.6 mg/L with a range of 0-7.3 mg/L and the ELF/plasma ratio at 4 hours was 0.2 +/- 0.2.,Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15086276/),,0.2,38750,DB01045,Rifampicin
,15086276,Alveolar cell concentrations,Alveolar cell concentrations of rifampicin were significantly greater in women (13.9 +/- 6.7 mg/L) than in men (6.6 +/- 4.1 mg/L) [p = 0.0003].,Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15086276/),[mg] / [l],13.9,38751,DB01045,Rifampicin
,15086276,Alveolar cell concentrations,Alveolar cell concentrations of rifampicin were significantly greater in women (13.9 +/- 6.7 mg/L) than in men (6.6 +/- 4.1 mg/L) [p = 0.0003].,Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15086276/),[mg] / [l],6.6,38752,DB01045,Rifampicin
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],1707,39239,DB01045,Rifampicin
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],695,39240,DB01045,Rifampicin
,9591931,dose-corrected,"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],277,39241,DB01045,Rifampicin
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],1707,39242,DB01045,Rifampicin
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],695,39243,DB01045,Rifampicin
,9591931,area under the plasma midazolam concentration time curve (AUC0-infinity),"During itraconazole treatment, or 4 days after, alpha-hydroxymetabolite the dose-corrected area under the plasma midazolam concentration time curve (AUC0-infinity) was 8- or 2.6-fold larger than that before itraconazole (i.e. 1707 or 695 versus 277 ng x h x ml(-1)), respectively.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],277,39244,DB01045,Rifampicin
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],4.4,39245,DB01045,Rifampicin
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),%,13,39246,DB01045,Rifampicin
,9591931,AUC0-infinity,"One day after rifampicin treatment, the AUC0-infinity of midazolam was 2.3% (i.e. 4.4 ng x h x ml(-1)) of the before-treatment value and only 0.26% of its value during itraconazole treatment; 4 days after rifampicin, the AUC0-infinity was still only 13% (i.e. 27.1 ng x h x ml(-1)) of the before-treatment value.",The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9591931/),[h·ng] / [ml],27.1,39247,DB01045,Rifampicin
less,2613393,metabolic ratio (MR),"In PM on rifampicin, the debrisoquine metabolic ratio (MR) was significantly reduced, even reaching a value less than 12.6 in 2 subjects but on phenobarbital and cimetidine, the MR was not significantly modified.","Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613393/),,12,39596,DB01045,Rifampicin
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],140,40634,DB01045,Rifampicin
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],100,40635,DB01045,Rifampicin
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],136,40636,DB01045,Rifampicin
,8843295,area under the concentration-time curve (AUC),"Compared with the baseline, the mean area under the concentration-time curve (AUC) (+/- standard deviation) for theophylline declined significantly following rifampin treatment (from 140 +/- 37 to 100 +/- 24 micrograms . h/ml, P <0.001); there was no significant change following rifabutin treatment (136 +/- 48 to 128 +/- 45 micrograms.h/ml).",Induction of theophylline clearance by rifampin and rifabutin in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843295/),[h·μg] / [ml],128,40637,DB01045,Rifampicin
,14605865,excretion,All subjects demonstrated a marked induction of hepatic microsomal CYP3A analyzed by the excretion ratio of 6beta-hydroxycortisol to cortisol from a mean baseline concentration of 5.6 U to 50.5 U.,"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14605865/),,50,40758,DB01045,Rifampicin
,25116663,C2.5 h,"In 57 patients, median (IQR) C2.5 hr was 3.6 (2.8-5.0) µg/mL.",Low rifampicin concentrations in tuberculosis patients with HIV infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116663/),[μg] / [ml],3.6,41497,DB01045,Rifampicin
,25116663,C2.5,"Polymorphism frequency in the SLCO1B1 (rs4149032) drug transporter gene was high (0.76) and was associated with low median rifampicin C2.5 hr, 3.7 (2.8-5.0) µg/mL in the heterozygous and 3.4 (2.7-4.7) µg/mL in the homozygous variant carriers.",Low rifampicin concentrations in tuberculosis patients with HIV infection. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116663/),[μg] / [ml],3.7,41498,DB01045,Rifampicin
,25116663,C2.5,"Polymorphism frequency in the SLCO1B1 (rs4149032) drug transporter gene was high (0.76) and was associated with low median rifampicin C2.5 hr, 3.7 (2.8-5.0) µg/mL in the heterozygous and 3.4 (2.7-4.7) µg/mL in the homozygous variant carriers.",Low rifampicin concentrations in tuberculosis patients with HIV infection. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116663/),[μg] / [ml],3.4,41499,DB01045,Rifampicin
below,25116663,peak rifampicin concentrations,Approximated peak rifampicin concentrations were well below the recommended target range of 8 to 24 µg/mL in this patient population with its high frequency of the SLCO1B1 (rs4149032) polymorphism.,Low rifampicin concentrations in tuberculosis patients with HIV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25116663/),[μg] / [ml],8 to 24,41500,DB01045,Rifampicin
,17502404,MIC,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.001,41685,DB01045,Rifampicin
,17502404,log,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.001,41686,DB01045,Rifampicin
,17502404,log,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.008,41687,DB01045,Rifampicin
,17502404,log,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.016,41688,DB01045,Rifampicin
,17502404,stationary-growth-phase minimal bactericidal concentration,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.25,41689,DB01045,Rifampicin
,17502404,stationary-growth-phase minimal bactericidal concentration,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.016,41690,DB01045,Rifampicin
,17502404,stationary-growth-phase minimal bactericidal concentration,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.8,41691,DB01045,Rifampicin
,17502404,stationary-growth-phase minimal bactericidal concentration,"The MIC, logarithmic-growth-phase minimal bactericidal concentration, and stationary-growth-phase minimal bactericidal concentration of ABI-0043 were 0.001, 0.008, and 0.25 microg/ml, respectively; the corresponding concentrations of rifampin were 0.016, 0.8, and 3.6 microg/ml, respectively.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],3.6,41692,DB01045,Rifampicin
,17502404,peak concentration,"After a single intraperitoneal dose of 12.5 mg/kg of body weight, the peak concentration in cage fluid was 1.13 micarog/ml of ABI-0043 and 0.98 microg/ml of rifampin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[micarog] / [ml],1.13,41693,DB01045,Rifampicin
,17502404,peak concentration,"After a single intraperitoneal dose of 12.5 mg/kg of body weight, the peak concentration in cage fluid was 1.13 micarog/ml of ABI-0043 and 0.98 microg/ml of rifampin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),[μg] / [ml],0.98,41694,DB01045,Rifampicin
,17502404,cure rates,"The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),%,46,41695,DB01045,Rifampicin
,17502404,cure rates,"The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),%,58,41696,DB01045,Rifampicin
,17502404,cure rates,"The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),%,88,41697,DB01045,Rifampicin
,17502404,cure rates,"The cure rates of cage-associated infections with rifampin and ABI-0043 administered alone were 46% and 58%, respectively, and increased to 88% and 92% in combination with levofloxacin.","Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502404/),,92,41698,DB01045,Rifampicin
,12698988,clearance,"The final model confirmed the appropriateness of separate clearance terms for single and multiple dose administration (2.65 versus 10.2 l/h, respectively).",Population pharmacokinetic meta-analysis with efavirenz. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698988/),[l] / [h],2.65,42958,DB01045,Rifampicin
,12698988,clearance,"The final model confirmed the appropriateness of separate clearance terms for single and multiple dose administration (2.65 versus 10.2 l/h, respectively).",Population pharmacokinetic meta-analysis with efavirenz. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698988/),[l] / [h],10.2,42959,DB01045,Rifampicin
,12698988,clearance,"A slightly lower clearance was observed in females relative to males (9.08 compared to 10.2 l/h in males) and interactions on clearance due to co-administration of fluconazole, ritonavir, rifampin, indinavir and azithromycin were identified.",Population pharmacokinetic meta-analysis with efavirenz. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698988/),[l] / [h],9.08,42960,DB01045,Rifampicin
,12698988,clearance,"A slightly lower clearance was observed in females relative to males (9.08 compared to 10.2 l/h in males) and interactions on clearance due to co-administration of fluconazole, ritonavir, rifampin, indinavir and azithromycin were identified.",Population pharmacokinetic meta-analysis with efavirenz. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698988/),[l] / [h],10.2,42961,DB01045,Rifampicin
,26282412,clearance,"The INH clearance in fast eliminators was 1.9- and 7.7-fold higher than in intermediate and slow eliminators, respectively (65 versus 35 and 8 liters/h).","Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26282412/),[l] / [h],65,44162,DB01045,Rifampicin
,26282412,clearance,"The INH clearance in fast eliminators was 1.9- and 7.7-fold higher than in intermediate and slow eliminators, respectively (65 versus 35 and 8 liters/h).","Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26282412/),[l] / [h],35,44163,DB01045,Rifampicin
,26282412,clearance,"The INH clearance in fast eliminators was 1.9- and 7.7-fold higher than in intermediate and slow eliminators, respectively (65 versus 35 and 8 liters/h).","Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26282412/),[l] / [h],8,44164,DB01045,Rifampicin
≤,26282412,Cmax,Simulations suggested that the current dosing guidelines (200 mg for 30 to 45 kg and 300 mg for >45 kg) may be suboptimal (3 mg/liter ≤ Cmax ≤ 6 mg/liter) irrespective of the acetylator class.,"Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26282412/),[mg] / [l],6,44165,DB01045,Rifampicin
,20584745,first-pass extraction ratio,"When administered intravenously and orally to cynomolgus monkeys, APZ had moderate clearance; its first-pass extraction ratio after oral dosing was estimated to be 0.09 in the liver and 0.45 in the intestine.",Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20584745/),,0.09,44231,DB01045,Rifampicin
,20584745,first-pass extraction ratio,"When administered intravenously and orally to cynomolgus monkeys, APZ had moderate clearance; its first-pass extraction ratio after oral dosing was estimated to be 0.09 in the liver and 0.45 in the intestine.",Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20584745/),,0.45,44232,DB01045,Rifampicin
,20584745,first-pass extraction ratios,"Pretreatment with multiple doses of rifampicin (20 mg/kg p.o. for 5 days), a known CYP3A inducer, significantly decreased plasma concentrations of APZ after intravenous and oral administrations (0.5 mg/kg), and first-pass extraction ratios were increased to 0.39 in the liver and 0.63 in the intestine.",Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20584745/),,0.39,44233,DB01045,Rifampicin
,20584745,first-pass extraction ratios,"Pretreatment with multiple doses of rifampicin (20 mg/kg p.o. for 5 days), a known CYP3A inducer, significantly decreased plasma concentrations of APZ after intravenous and oral administrations (0.5 mg/kg), and first-pass extraction ratios were increased to 0.39 in the liver and 0.63 in the intestine.",Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20584745/),,0.63,44234,DB01045,Rifampicin
,24420746,peak concentration (Cmax),"Of 11 evaluable subjects, the median interquartile range, rifampin peak concentration (Cmax) , area under the concentration-time curve (AUC0-24 hour ), and weight-normalized clearance were 8.9 (7.3-13.8) μg/ml, 48.8 (29.6-67.4) μg·h/ml, and 0.19 (0.11-0.29) L/h/kg, respectively.",Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24420746/),[μg] / [ml],8.9,44336,DB01045,Rifampicin
,24420746,area under the concentration-time curve (AUC0-24 hour ),"Of 11 evaluable subjects, the median interquartile range, rifampin peak concentration (Cmax) , area under the concentration-time curve (AUC0-24 hour ), and weight-normalized clearance were 8.9 (7.3-13.8) μg/ml, 48.8 (29.6-67.4) μg·h/ml, and 0.19 (0.11-0.29) L/h/kg, respectively.",Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24420746/),[h·μg] / [ml],48.8,44337,DB01045,Rifampicin
,24420746,weight-normalized clearance,"Of 11 evaluable subjects, the median interquartile range, rifampin peak concentration (Cmax) , area under the concentration-time curve (AUC0-24 hour ), and weight-normalized clearance were 8.9 (7.3-13.8) μg/ml, 48.8 (29.6-67.4) μg·h/ml, and 0.19 (0.11-0.29) L/h/kg, respectively.",Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24420746/),[l] / [h·kg],0.19,44338,DB01045,Rifampicin
less,24420746,Cmax,All four volunteers with rifampin Cmax less than 8 μg/ml (lower end of the normal range) had c.463CA genotype.,Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24420746/),[μg] / [ml],8,44339,DB01045,Rifampicin
,27052517,IC50,"In vitro experiments suggested the inhibitory effect of EGCG on CYP enzymes (IC50: 18.37 ± 1.36 μM, 26.08 ± 1.51 μM for simvastatin and simvastatin acid, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,18.37,45135,DB01045,Rifampicin
,27052517,IC50,"In vitro experiments suggested the inhibitory effect of EGCG on CYP enzymes (IC50: 18.37 ± 1.36 μM, 26.08 ± 1.51 μM for simvastatin and simvastatin acid, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,26.08,45136,DB01045,Rifampicin
,27052517,IC50,"Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 ± 1.27 μM and 22.67 ± 1.42 μM, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,8.68,45137,DB01045,Rifampicin
,27052517,IC50,"Simvastatin transport by OATP1B1 and OATP1B3 was also inhibited by EGCG (IC50: 8.68 ± 1.27 μM and 22.67 ± 1.42 μM, respectively).",Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052517/),μM,22.67,45138,DB01045,Rifampicin
,22491238,MIC,"Among 13 chromogenic agents that show antibacterial activity against S. aureus (MIC = 0.02 to 19 μg/mL), rifampicin had a therapeutic effect.",Evaluation of therapeutic effects and pharmacokinetics of antibacterial chromogenic agents in a silkworm model of Staphylococcus aureus infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22491238/),[μg] / [ml],0.02 to 19,45360,DB01045,Rifampicin
,2504254,er,"The erythrocyte sedimentation rate fell from a mean pretherapy value of 81 mm/h (range, 41 to 138 mm/h) to 18 mm/h (range, 3 to 45 mm/h) after the completion of antibiotic therapy.",Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504254/),[mm] / [h],81,46599,DB01045,Rifampicin
,20086150,critical concentration,"The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5.0 mg/liter, and that of fluoroquinolones is 1.0 mg/liter.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],0.2,47024,DB01045,Rifampicin
,20086150,critical concentration,"The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5.0 mg/liter, and that of fluoroquinolones is 1.0 mg/liter.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],1.0,47025,DB01045,Rifampicin
,20086150,critical concentration,"The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5.0 mg/liter, and that of fluoroquinolones is 1.0 mg/liter.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],100,47026,DB01045,Rifampicin
,20086150,critical concentration,"The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5.0 mg/liter, and that of fluoroquinolones is 1.0 mg/liter.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],5.0,47027,DB01045,Rifampicin
,20086150,critical concentration,"The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg/liter was identified for pyrazinamide, 0.0312 mg/liter and 0.125 mg/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg/liter was defined for rifampin.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],50,47028,DB01045,Rifampicin
,20086150,critical concentration,"The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg/liter was identified for pyrazinamide, 0.0312 mg/liter and 0.125 mg/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg/liter was defined for rifampin.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],0.0312,47029,DB01045,Rifampicin
,20086150,critical concentration,"The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg/liter was identified for pyrazinamide, 0.0312 mg/liter and 0.125 mg/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg/liter was defined for rifampin.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],0.125,47030,DB01045,Rifampicin
,20086150,critical concentration,"The critical concentrations of moxifloxacin and ethambutol remained unchanged, but a critical concentration of 50 mg/liter was identified for pyrazinamide, 0.0312 mg/liter and 0.125 mg/liter were defined for low- and high-level isoniazid resistance, respectively, and 0.0625 mg/liter was defined for rifampin.",New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20086150/),[mg] / [l],0.0625,47031,DB01045,Rifampicin
,25851638,absolute bioavailability,"Tasimelteon is rapidly absorbed, with a mean absolute bioavailability of approximately 38%, and is extensively metabolized primarily by oxidation at multiple sites, mainly by cytochrome P450 (CYP) 1A2 and CYP3A4/5, as initially demonstrated by in vitro studies and confirmed by the results of clinical drug-drug interactions presented here.","Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25851638/),%,38,47044,DB01045,Rifampicin
,33538008,drug clearance,"The mean drug clearance and exposure were 13.6 L/h and 57.9 mg h/L, respectively.","Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538008/),[l] / [h],13.6,47435,DB01045,Rifampicin
,33538008,exposure,"The mean drug clearance and exposure were 13.6 L/h and 57.9 mg h/L, respectively.","Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538008/),[h·mg] / [l],57.9,47436,DB01045,Rifampicin
,34420049,AUC24,"AUC24 for rifampicin, isoniazid, pyrazinamide and ethambutol were 32.5 (20.1-45.1), 16.7 (9.2 - 25.9), 317 (263 - 399) and 9.5 (7.5 - 11.5) mg.h/L, respectively, and lower in children compared to adults for rifampicin in 4.0-7.9 kg, 8-11.9kg and ≥25kg weight-bands, isoniazid in 4.0-7.9kg and ≥25kg, and ethambutol in all five weight-bands.",Pharmacokinetics of first-line drugs in children with tuberculosis using WHO-recommended weight band doses and formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34420049/),[h·mg] / [l],32.5,47519,DB01045,Rifampicin
,34420049,AUC24,"AUC24 for rifampicin, isoniazid, pyrazinamide and ethambutol were 32.5 (20.1-45.1), 16.7 (9.2 - 25.9), 317 (263 - 399) and 9.5 (7.5 - 11.5) mg.h/L, respectively, and lower in children compared to adults for rifampicin in 4.0-7.9 kg, 8-11.9kg and ≥25kg weight-bands, isoniazid in 4.0-7.9kg and ≥25kg, and ethambutol in all five weight-bands.",Pharmacokinetics of first-line drugs in children with tuberculosis using WHO-recommended weight band doses and formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34420049/),[h·mg] / [l],16.7,47520,DB01045,Rifampicin
,34420049,AUC24,"AUC24 for rifampicin, isoniazid, pyrazinamide and ethambutol were 32.5 (20.1-45.1), 16.7 (9.2 - 25.9), 317 (263 - 399) and 9.5 (7.5 - 11.5) mg.h/L, respectively, and lower in children compared to adults for rifampicin in 4.0-7.9 kg, 8-11.9kg and ≥25kg weight-bands, isoniazid in 4.0-7.9kg and ≥25kg, and ethambutol in all five weight-bands.",Pharmacokinetics of first-line drugs in children with tuberculosis using WHO-recommended weight band doses and formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34420049/),[h·mg] / [l],317,47521,DB01045,Rifampicin
,34420049,AUC24,"AUC24 for rifampicin, isoniazid, pyrazinamide and ethambutol were 32.5 (20.1-45.1), 16.7 (9.2 - 25.9), 317 (263 - 399) and 9.5 (7.5 - 11.5) mg.h/L, respectively, and lower in children compared to adults for rifampicin in 4.0-7.9 kg, 8-11.9kg and ≥25kg weight-bands, isoniazid in 4.0-7.9kg and ≥25kg, and ethambutol in all five weight-bands.",Pharmacokinetics of first-line drugs in children with tuberculosis using WHO-recommended weight band doses and formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34420049/),[h·mg] / [l],9.5,47522,DB01045,Rifampicin
,21537021,concentrations (C(0)),"The median [interquartile range (IQR)] predose LPV concentrations (C(0)) were 8.1 (6.2 to 9.8) mg/liter at baseline, 1.7 (0.3 to 3.0) mg/liter after 7 days of rifampin, 5.9 (2.1 to 9.9) mg/liter with 1.5 times the dose of LPV/r, and 10.8 (7.0 to 13.1) mg/liter with double-dose LPV/r.",Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21537021/),[mg] / [l],8.1,47758,DB01045,Rifampicin
,21537021,concentrations (C(0)),"The median [interquartile range (IQR)] predose LPV concentrations (C(0)) were 8.1 (6.2 to 9.8) mg/liter at baseline, 1.7 (0.3 to 3.0) mg/liter after 7 days of rifampin, 5.9 (2.1 to 9.9) mg/liter with 1.5 times the dose of LPV/r, and 10.8 (7.0 to 13.1) mg/liter with double-dose LPV/r.",Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21537021/),[mg] / [l],1.7,47759,DB01045,Rifampicin
,21537021,concentrations (C(0)),"The median [interquartile range (IQR)] predose LPV concentrations (C(0)) were 8.1 (6.2 to 9.8) mg/liter at baseline, 1.7 (0.3 to 3.0) mg/liter after 7 days of rifampin, 5.9 (2.1 to 9.9) mg/liter with 1.5 times the dose of LPV/r, and 10.8 (7.0 to 13.1) mg/liter with double-dose LPV/r.",Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21537021/),[mg] / [l],5.9,47760,DB01045,Rifampicin
,21537021,concentrations (C(0)),"The median [interquartile range (IQR)] predose LPV concentrations (C(0)) were 8.1 (6.2 to 9.8) mg/liter at baseline, 1.7 (0.3 to 3.0) mg/liter after 7 days of rifampin, 5.9 (2.1 to 9.9) mg/liter with 1.5 times the dose of LPV/r, and 10.8 (7.0 to 13.1) mg/liter with double-dose LPV/r.",Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21537021/),[mg] / [l],10.8,47761,DB01045,Rifampicin
,25942002,content,RIF content in the resulting particles was 91.8±0.1%.,Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25942002/),,91,47884,DB01045,Rifampicin
,24973908,cfu/,"In vivo: linezolid and its combination with rifampicin reduced bacterial concentrations at 24 h, median cfu/mL 4.85 vs 3.87 (p < 0.05) for linezolid and 5.02 vs 4.21 (p < 0.05) for linezolid + rifampicin, against the glycopeptide intermediate S. aureus (GISA) strain and improved inflammatory parameters.",Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24973908/),,4.85,48034,DB01045,Rifampicin
,24973908,cfu/,"In vivo: linezolid and its combination with rifampicin reduced bacterial concentrations at 24 h, median cfu/mL 4.85 vs 3.87 (p < 0.05) for linezolid and 5.02 vs 4.21 (p < 0.05) for linezolid + rifampicin, against the glycopeptide intermediate S. aureus (GISA) strain and improved inflammatory parameters.",Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24973908/),,3.87,48035,DB01045,Rifampicin
,24973908,cfu/,"In vivo: linezolid and its combination with rifampicin reduced bacterial concentrations at 24 h, median cfu/mL 4.85 vs 3.87 (p < 0.05) for linezolid and 5.02 vs 4.21 (p < 0.05) for linezolid + rifampicin, against the glycopeptide intermediate S. aureus (GISA) strain and improved inflammatory parameters.",Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24973908/),,5.02,48036,DB01045,Rifampicin
,24973908,cfu/,"In vivo: linezolid and its combination with rifampicin reduced bacterial concentrations at 24 h, median cfu/mL 4.85 vs 3.87 (p < 0.05) for linezolid and 5.02 vs 4.21 (p < 0.05) for linezolid + rifampicin, against the glycopeptide intermediate S. aureus (GISA) strain and improved inflammatory parameters.",Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24973908/),,4.21,48037,DB01045,Rifampicin
,28385543,AUC0-48,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [h·ml],92.5,48581,DB01045,Rifampicin
,28385543,AUC0-48,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [h·ml],83.5,48582,DB01045,Rifampicin
,28385543,Cmax,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [ml],10.0,48583,DB01045,Rifampicin
,28385543,Cmax,"For single rosuvastatin doses, AUC0-48 were 92.5 (±36.2) and 83.5 (±32.2) ng/mL × h and Cmax were 10.0 (±4.1) and 7.6 (±3.0) ng/mL for Asians and Whites, respectively.",Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28385543/),[ng] / [ml],7.6,48584,DB01045,Rifampicin
,25769294,entrapment efficiency,Novel microemulsification method with high drug loading (50%) and entrapment efficiency (∼67%) was developed (Indian Patent Application 3356/DEL/2013).,"Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769294/),%,∼67,48951,DB01045,Rifampicin
,25769294,zeta -,"Near neutral SLNs (zeta -3.5 ± 0.8), with average particle size of 130.0 ± 22.6 nm showed 70.12% release in phosphate buffer pH 6.8 in 9 days.","Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769294/),,3.5,48952,DB01045,Rifampicin
,25769294,TMIC,"Pharmacodynamic parameters viz. TMIC (120 h; time for which plasma levels were above MIC of 0.2 μg/ml), AUC0-∞/MIC (1868.9h) and Cmax/MIC (75.6) for RIF-SLNs were greater than free RIF by 2.5, 8.2 and 6.6 times, respectively.","Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769294/),h,120,48953,DB01045,Rifampicin
,25769294,MIC,"Pharmacodynamic parameters viz. TMIC (120 h; time for which plasma levels were above MIC of 0.2 μg/ml), AUC0-∞/MIC (1868.9h) and Cmax/MIC (75.6) for RIF-SLNs were greater than free RIF by 2.5, 8.2 and 6.6 times, respectively.","Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769294/),[μg] / [ml],0.2,48954,DB01045,Rifampicin
,25769294,AUC0-∞/MIC,"Pharmacodynamic parameters viz. TMIC (120 h; time for which plasma levels were above MIC of 0.2 μg/ml), AUC0-∞/MIC (1868.9h) and Cmax/MIC (75.6) for RIF-SLNs were greater than free RIF by 2.5, 8.2 and 6.6 times, respectively.","Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769294/),h,1868.9,48955,DB01045,Rifampicin
,25769294,Cmax/MIC,"Pharmacodynamic parameters viz. TMIC (120 h; time for which plasma levels were above MIC of 0.2 μg/ml), AUC0-∞/MIC (1868.9h) and Cmax/MIC (75.6) for RIF-SLNs were greater than free RIF by 2.5, 8.2 and 6.6 times, respectively.","Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769294/),,75.6,48956,DB01045,Rifampicin
,25769294,LD,Similar LD50 (1570 mg/kg) and absence (or reversal in satellite group) of adverse events in repeat dose (three doses; highest dose was up to 50 times the human therapeutic dose) toxicity studies confirmed safety of RIF-SLNs.,"Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769294/),[mg] / [kg],1570,48957,DB01045,Rifampicin
,26661397,Absolute bioavailability,"Absolute bioavailability in the fasted state and the fed state was 93% and 78% for isoniazid, 87% and 71% for rifampicin and 87% and 82% for ethambutol.",Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661397/),%,93,49083,DB01045,Rifampicin
,26661397,Absolute bioavailability,"Absolute bioavailability in the fasted state and the fed state was 93% and 78% for isoniazid, 87% and 71% for rifampicin and 87% and 82% for ethambutol.",Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661397/),%,78,49084,DB01045,Rifampicin
,26661397,Absolute bioavailability,"Absolute bioavailability in the fasted state and the fed state was 93% and 78% for isoniazid, 87% and 71% for rifampicin and 87% and 82% for ethambutol.",Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661397/),%,87,49085,DB01045,Rifampicin
,26661397,Absolute bioavailability,"Absolute bioavailability in the fasted state and the fed state was 93% and 78% for isoniazid, 87% and 71% for rifampicin and 87% and 82% for ethambutol.",Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661397/),%,71,49086,DB01045,Rifampicin
,26661397,Absolute bioavailability,"Absolute bioavailability in the fasted state and the fed state was 93% and 78% for isoniazid, 87% and 71% for rifampicin and 87% and 82% for ethambutol.",Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661397/),%,82,49087,DB01045,Rifampicin
,26661397,AUC0-24,Pyrazinamide AUC0-24 was comparable for the fasted state (481 mg·h/L) and the fed state (468 mg·h/L).,Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661397/),[h·mg] / [l],481,49088,DB01045,Rifampicin
,26661397,AUC0-24,Pyrazinamide AUC0-24 was comparable for the fasted state (481 mg·h/L) and the fed state (468 mg·h/L).,Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661397/),[h·mg] / [l],468,49089,DB01045,Rifampicin
,1956209,maximum concentration (Cmax),After the first dose the maximum concentration (Cmax) for HYD was significantly higher (p less than 0.05) in the elderly (0.4 +/- 0.07 microgram/ml) than in the young (0.24 +/- 0.08 microgram/ml).,The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1956209/),[μg] / [ml],0.4,49319,DB01045,Rifampicin
,1956209,maximum concentration (Cmax),After the first dose the maximum concentration (Cmax) for HYD was significantly higher (p less than 0.05) in the elderly (0.4 +/- 0.07 microgram/ml) than in the young (0.24 +/- 0.08 microgram/ml).,The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1956209/),[μg] / [ml],0.24,49320,DB01045,Rifampicin
,22146740,area under the concentration versus time curve from 0 to 12 hours,"The nevirapine area under the concentration versus time curve from 0 to 12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure.",Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22146740/),[h·mg] / [ml],85.3,49367,DB01045,Rifampicin
,22146740,trough concentration,"The nevirapine area under the concentration versus time curve from 0 to 12 hours and trough concentration with rifampicin were 85.3 (40.5-170.7) mg.h/mL and 6.4 (3.00-13.27) mg/mL, respectively, providing adequate exposure.",Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22146740/),[mg] / [ml],6.4,49368,DB01045,Rifampicin
,34310215,MIC,The median (range) MIC (n = 111) was 2.5 mg/liter (<0.3 to >40 mg/liter).,Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34310215/),[mg] / [l],2.5,49615,DB01045,Rifampicin
≥,34310215,"area under the concentration-time curve from 0 to 24 h for the free, unbound fraction of a drug (fAUC0-24)/MIC ratio","Simulations showed increased daily doses of ethionamide (1,250 mg, 1,500 mg, and 1,750 mg for patients weighing ≤45 kg, 46 to 70 kg, and >70 kg, respectively) resulted in the probability of attaining an area under the concentration-time curve from 0 to 24 h for the free, unbound fraction of a drug (fAUC0-24)/MIC ratio of ≥42 in more than 90% of patients only at the lowest MIC of 0.3 mg/liter.",Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34310215/),,42,49616,DB01045,Rifampicin
,34310215,MIC,"Simulations showed increased daily doses of ethionamide (1,250 mg, 1,500 mg, and 1,750 mg for patients weighing ≤45 kg, 46 to 70 kg, and >70 kg, respectively) resulted in the probability of attaining an area under the concentration-time curve from 0 to 24 h for the free, unbound fraction of a drug (fAUC0-24)/MIC ratio of ≥42 in more than 90% of patients only at the lowest MIC of 0.3 mg/liter.",Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34310215/),[mg] / [l],0.3,49617,DB01045,Rifampicin
,16106359,LC retention times,"The LC retention times for isoniazid and ethambutol were 2.46 and 2.27 min, respectively.",A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of isoniazid and ethambutol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16106359/),min,2.46,49783,DB01045,Rifampicin
,16106359,LC retention times,"The LC retention times for isoniazid and ethambutol were 2.46 and 2.27 min, respectively.",A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of isoniazid and ethambutol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16106359/),min,2.27,49784,DB01045,Rifampicin
,6501103,oral absorption,"In the rat, the overall evidence obtained was: the oral absorption of rifapentine into central compartment, due to its poor water solubility, appears to be dose-dependent with a satisfactory oral absorption (84%) after a dose of 3 mg/kg, lower (65%) after 10 mg/kg; the antibiotic undergoes rapid liver uptake while it diffuses into the tissue compartment more slowly, with particular affinity for the adrenals, pancreas and kidneys; concentrations higher than in plasma were also measured in the lungs; elimination of rifapentine from the blood and tissue compartments suggests a non linear capacity-limited kinetics where the terminal elimination phase has monoexponential course.","Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6501103/),%,84,50051,DB01045,Rifampicin
,6501103,oral absorption,"In the rat, the overall evidence obtained was: the oral absorption of rifapentine into central compartment, due to its poor water solubility, appears to be dose-dependent with a satisfactory oral absorption (84%) after a dose of 3 mg/kg, lower (65%) after 10 mg/kg; the antibiotic undergoes rapid liver uptake while it diffuses into the tissue compartment more slowly, with particular affinity for the adrenals, pancreas and kidneys; concentrations higher than in plasma were also measured in the lungs; elimination of rifapentine from the blood and tissue compartments suggests a non linear capacity-limited kinetics where the terminal elimination phase has monoexponential course.","Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6501103/),%,65,50052,DB01045,Rifampicin
,6501103,Terminal plasma half-life,Terminal plasma half-life ranged between 14 and 18 hours; the compound is eliminated mainly via the bile with the feces (92% of dose).,"Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6501103/),h,14 and 18,50053,DB01045,Rifampicin
,6501103,half-life,"In mice rifapentine shows a kinetic profile resembling that obtained in rats, whereas in rabbits is metabolized and/or eliminated much more rapidly with a half-life of only 1.8 hours.","Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6501103/),h,1.8,50054,DB01045,Rifampicin
,1768567,oral clearance,"2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],1.9,51649,DB01045,Rifampicin
,1768567,oral clearance,"2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],1.8,51650,DB01045,Rifampicin
,1768567,oral clearance,"2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],11.9,51651,DB01045,Rifampicin
,1768567,oral clearance,"2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],10.7,51652,DB01045,Rifampicin
,1768567,oral clearance,"3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],15.6,51653,DB01045,Rifampicin
,1768567,oral clearance,"3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],1146.7,51654,DB01045,Rifampicin
,1768567,oral clearance,"3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],10.3,51655,DB01045,Rifampicin
,1768567,oral clearance,"3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.",Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768567/),[ml] / [kg·min],199.9,51656,DB01045,Rifampicin
,10224335,serum peak value,The serum peak value was 7.82 microg/ml for rifametane and 4.04 microg/ml for rifampicin (p < 0.001); the elimination half-life was 10.58 h for rifametane and 1.89 h for rifampicin (p < 0.001); area under the serum concentration curve from 0 to infinity was 142.3 microg.h/ml for rifametane and 19.9 microg.h/ml for rifampicin (p < 0.001); the mean residence time was 18.05 h for rifametane and 3.93 h for rifampicin (p < 0.001).,Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224335/),[μg] / [ml],7.82,51659,DB01045,Rifampicin
,10224335,serum peak value,The serum peak value was 7.82 microg/ml for rifametane and 4.04 microg/ml for rifampicin (p < 0.001); the elimination half-life was 10.58 h for rifametane and 1.89 h for rifampicin (p < 0.001); area under the serum concentration curve from 0 to infinity was 142.3 microg.h/ml for rifametane and 19.9 microg.h/ml for rifampicin (p < 0.001); the mean residence time was 18.05 h for rifametane and 3.93 h for rifampicin (p < 0.001).,Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224335/),[μg] / [ml],4.04,51660,DB01045,Rifampicin
,10224335,elimination half-life,The serum peak value was 7.82 microg/ml for rifametane and 4.04 microg/ml for rifampicin (p < 0.001); the elimination half-life was 10.58 h for rifametane and 1.89 h for rifampicin (p < 0.001); area under the serum concentration curve from 0 to infinity was 142.3 microg.h/ml for rifametane and 19.9 microg.h/ml for rifampicin (p < 0.001); the mean residence time was 18.05 h for rifametane and 3.93 h for rifampicin (p < 0.001).,Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224335/),h,10.58,51661,DB01045,Rifampicin
,10224335,elimination half-life,The serum peak value was 7.82 microg/ml for rifametane and 4.04 microg/ml for rifampicin (p < 0.001); the elimination half-life was 10.58 h for rifametane and 1.89 h for rifampicin (p < 0.001); area under the serum concentration curve from 0 to infinity was 142.3 microg.h/ml for rifametane and 19.9 microg.h/ml for rifampicin (p < 0.001); the mean residence time was 18.05 h for rifametane and 3.93 h for rifampicin (p < 0.001).,Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224335/),h,1.89,51662,DB01045,Rifampicin
,10224335,area under the serum concentration curve from 0 to infinity,The serum peak value was 7.82 microg/ml for rifametane and 4.04 microg/ml for rifampicin (p < 0.001); the elimination half-life was 10.58 h for rifametane and 1.89 h for rifampicin (p < 0.001); area under the serum concentration curve from 0 to infinity was 142.3 microg.h/ml for rifametane and 19.9 microg.h/ml for rifampicin (p < 0.001); the mean residence time was 18.05 h for rifametane and 3.93 h for rifampicin (p < 0.001).,Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224335/),[h·μg] / [ml],142.3,51663,DB01045,Rifampicin
,10224335,area under the serum concentration curve from 0 to infinity,The serum peak value was 7.82 microg/ml for rifametane and 4.04 microg/ml for rifampicin (p < 0.001); the elimination half-life was 10.58 h for rifametane and 1.89 h for rifampicin (p < 0.001); area under the serum concentration curve from 0 to infinity was 142.3 microg.h/ml for rifametane and 19.9 microg.h/ml for rifampicin (p < 0.001); the mean residence time was 18.05 h for rifametane and 3.93 h for rifampicin (p < 0.001).,Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224335/),[h·μg] / [ml],19.9,51664,DB01045,Rifampicin
,10224335,mean residence time,The serum peak value was 7.82 microg/ml for rifametane and 4.04 microg/ml for rifampicin (p < 0.001); the elimination half-life was 10.58 h for rifametane and 1.89 h for rifampicin (p < 0.001); area under the serum concentration curve from 0 to infinity was 142.3 microg.h/ml for rifametane and 19.9 microg.h/ml for rifampicin (p < 0.001); the mean residence time was 18.05 h for rifametane and 3.93 h for rifampicin (p < 0.001).,Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224335/),h,18.05,51665,DB01045,Rifampicin
,10224335,mean residence time,The serum peak value was 7.82 microg/ml for rifametane and 4.04 microg/ml for rifampicin (p < 0.001); the elimination half-life was 10.58 h for rifametane and 1.89 h for rifampicin (p < 0.001); area under the serum concentration curve from 0 to infinity was 142.3 microg.h/ml for rifametane and 19.9 microg.h/ml for rifampicin (p < 0.001); the mean residence time was 18.05 h for rifametane and 3.93 h for rifampicin (p < 0.001).,Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224335/),h,3.93,51666,DB01045,Rifampicin
,9825270,maximum concentration (Cmax),"The mean maximum concentration (Cmax) of SPA-S-565 was 3.94 +/- 0.26 micrograms/ml, and resulted significantly higher as compared with the Cmax after rifampicin, which was 2.89 +/- 0.20 micrograms/ml.",Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9825270/),[μg] / [ml],3.94,51972,DB01045,Rifampicin
,9825270,Cmax,"The mean maximum concentration (Cmax) of SPA-S-565 was 3.94 +/- 0.26 micrograms/ml, and resulted significantly higher as compared with the Cmax after rifampicin, which was 2.89 +/- 0.20 micrograms/ml.",Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9825270/),[μg] / [ml],2.89,51973,DB01045,Rifampicin
,9825270,maximum time (tmax),"The mean maximum time (tmax) for SPA-S-565 was 2.1 +/- 0.3 h as compared with that of rifampicin, which was 1.6 +/- 0.3 h, the difference between these values not being statistically significant.",Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9825270/),h,2.1,51974,DB01045,Rifampicin
,9825270,maximum time (tmax),"The mean maximum time (tmax) for SPA-S-565 was 2.1 +/- 0.3 h as compared with that of rifampicin, which was 1.6 +/- 0.3 h, the difference between these values not being statistically significant.",Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9825270/),h,1.6,51975,DB01045,Rifampicin
,9825270,elimination half-life (t1/2),The elimination half-life (t1/2) of SPA-S-565 was 17.5 +/- 2.6 h in contrast to the half-life of 2.8 +/- 0.26 h seen with rifampicin; the difference was found to be highly significant.,Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9825270/),h,17.5,51976,DB01045,Rifampicin
,9825270,half-life,The elimination half-life (t1/2) of SPA-S-565 was 17.5 +/- 2.6 h in contrast to the half-life of 2.8 +/- 0.26 h seen with rifampicin; the difference was found to be highly significant.,Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9825270/),h,2.8,51977,DB01045,Rifampicin
,11938937,drug loading,The drug loading was 16.0% and encapsulation efficiency was 31.9%.,[Study on the rifampicin polylactic acid microspheres for lung targeting]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11938937/),%,16.0,51984,DB01045,Rifampicin
,11938937,encapsulation efficiency,The drug loading was 16.0% and encapsulation efficiency was 31.9%.,[Study on the rifampicin polylactic acid microspheres for lung targeting]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11938937/),%,31.9,51985,DB01045,Rifampicin
,1291477,time to reach peak concentration,The absorption rate constant was found to be lower and the time to reach peak concentration was longer after drug administration at 24.00 hr than at other dosing times.,Chronopharmacokinetics of rifampicin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1291477/),,24,52186,DB01045,Rifampicin
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,1,52327,DB01045,Rifampicin
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,2,52328,DB01045,Rifampicin
,32337660,terminal phase half-life,The terminal phase half-life ranged from 11 to 18 h and steady-state concentrations were achieved by 6 days after initiating once-daily dosing.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,11 to 18,52329,DB01045,Rifampicin
,32337660,absolute bioavailability,Ertugliflozin is categorized as a Biopharmaceutical Classification System Class I drug with an absolute bioavailability of ~ 100% under fasted conditions.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),%,100,52330,DB01045,Rifampicin
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],2.8,53268,DB01045,Rifampicin
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],5.3,53269,DB01045,Rifampicin
,11753266,clearances,"Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[ml] / [kg·min],0.42,53270,DB01045,Rifampicin
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,280,53271,DB01045,Rifampicin
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,120,53272,DB01045,Rifampicin
,11753266,AUEC(infinity),"AUEC(infinity) values after control, CYP3A4 induction, and inhibition were 280 +/- 150, 120 +/- 22, and 1030 +/- 240 mm x min, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min·mm,1030,53273,DB01045,Rifampicin
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],4.2,53274,DB01045,Rifampicin
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],8.8,53275,DB01045,Rifampicin
,11753266,Effect clearances (CL(miosis)),"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),[μg] / [min·mm],1.2,53276,DB01045,Rifampicin
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,62,53277,DB01045,Rifampicin
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,34,53278,DB01045,Rifampicin
,11753266,effect half-times,"Effect clearances (CL(miosis)) were 4.2 +/- 1.3, 8.8 +/- 2.4, and 1.2 +/- 0.8 microg/mm x min, respectively, and effect half-times were 62 +/- 23, 34 +/- 27, and 211 +/- 35 minutes, respectively (P <.05 versus control).",A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11753266/),min,211,53279,DB01045,Rifampicin
>,29133558,trough concentrations,"Most children (81% of children with MDR-TB, 88% of controls) achieved therapeutic lopinavir trough concentrations (>1 mg/liter).",Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29133558/),[mg] / [l],1,54608,DB01045,Rifampicin
,34370588,concentrations,Bedaquiline concentrations from month 1 to month 6 of treatment ranged from 94.7 - 2540 ng/mL in plasma and 16.2 - 5478 ng/mL in PBMCs and concentrations of M2 over the six-month treatment period ranged from 34.3 - 496 ng/mL in plasma and 109.2 - 16764 ng/mL in PBMCs.,Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370588/),[ng] / [ml],94.7 - 2540,55164,DB01045,Rifampicin
,34370588,concentrations,Bedaquiline concentrations from month 1 to month 6 of treatment ranged from 94.7 - 2540 ng/mL in plasma and 16.2 - 5478 ng/mL in PBMCs and concentrations of M2 over the six-month treatment period ranged from 34.3 - 496 ng/mL in plasma and 109.2 - 16764 ng/mL in PBMCs.,Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370588/),[ng] / [ml],16.2 - 5478,55165,DB01045,Rifampicin
,34370588,intracellular-plasma ratio,The typical intracellular-plasma ratio 1 and 2 months after start of treatment was 0.61 (95%CI: 0.42-0.92) and 1.10 (95%CI: 0.74-1.63) for bedaquiline and 12.4 (95%CI: 8.8-17.8) and 22.2 (95%CI: 15.6-32.3) for M2.,Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370588/),,0.61,55166,DB01045,Rifampicin
,34370588,intracellular-plasma ratio,The typical intracellular-plasma ratio 1 and 2 months after start of treatment was 0.61 (95%CI: 0.42-0.92) and 1.10 (95%CI: 0.74-1.63) for bedaquiline and 12.4 (95%CI: 8.8-17.8) and 22.2 (95%CI: 15.6-32.3) for M2.,Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370588/),,1.10,55167,DB01045,Rifampicin
,34370588,intracellular-plasma ratio,The typical intracellular-plasma ratio 1 and 2 months after start of treatment was 0.61 (95%CI: 0.42-0.92) and 1.10 (95%CI: 0.74-1.63) for bedaquiline and 12.4 (95%CI: 8.8-17.8) and 22.2 (95%CI: 15.6-32.3) for M2.,Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370588/),,12.4,55168,DB01045,Rifampicin
,34370588,intracellular-plasma ratio,The typical intracellular-plasma ratio 1 and 2 months after start of treatment was 0.61 (95%CI: 0.42-0.92) and 1.10 (95%CI: 0.74-1.63) for bedaquiline and 12.4 (95%CI: 8.8-17.8) and 22.2 (95%CI: 15.6-32.3) for M2.,Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34370588/),,22.2,55169,DB01045,Rifampicin
,2868864,t1/2,The second rate constant did not represent the accumulation or persistence of rifampin (t1/2 = 4.4 hr).,The kinetics of induction by rifampin of alpha 1-acid glycoprotein and antipyrine clearance in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2868864/),h,4.4,55477,DB01045,Rifampicin
,33693537,plasma AUC0-24hr,"On day 2, geometric mean plasma AUC0-24hr was 42.9·h mg/L with standard-of-care 10 mg/kg dosing, 249·h mg/L for IV-20 and 327·h mg/L for PO-35 (P < .001).",High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33693537/),[h·mg] / [l],42.9,56102,DB01045,Rifampicin
,33693537,plasma AUC0-24hr,"On day 2, geometric mean plasma AUC0-24hr was 42.9·h mg/L with standard-of-care 10 mg/kg dosing, 249·h mg/L for IV-20 and 327·h mg/L for PO-35 (P < .001).",High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33693537/),[h·mg] / [l],249,56103,DB01045,Rifampicin
,33693537,plasma AUC0-24hr,"On day 2, geometric mean plasma AUC0-24hr was 42.9·h mg/L with standard-of-care 10 mg/kg dosing, 249·h mg/L for IV-20 and 327·h mg/L for PO-35 (P < .001).",High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33693537/),[h·mg] / [l],327,56104,DB01045,Rifampicin
,33693537,AUC0-24hr,"In CSF, standard of care achieved undetectable rifampicin concentration in 56% of participants and geometric mean AUC0-24hr 0.27 mg/L, compared with 1.74 mg/L (95% confidence interval [CI] 1.2-2.5) for IV-20 and 2.17 mg/L (1.6-2.9) for PO-35 regimens (P < .001).",High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33693537/),[mg] / [l],0.27,56105,DB01045,Rifampicin
,33693537,AUC0-24hr,"In CSF, standard of care achieved undetectable rifampicin concentration in 56% of participants and geometric mean AUC0-24hr 0.27 mg/L, compared with 1.74 mg/L (95% confidence interval [CI] 1.2-2.5) for IV-20 and 2.17 mg/L (1.6-2.9) for PO-35 regimens (P < .001).",High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33693537/),[mg] / [l],1.74,56106,DB01045,Rifampicin
,33693537,AUC0-24hr,"In CSF, standard of care achieved undetectable rifampicin concentration in 56% of participants and geometric mean AUC0-24hr 0.27 mg/L, compared with 1.74 mg/L (95% confidence interval [CI] 1.2-2.5) for IV-20 and 2.17 mg/L (1.6-2.9) for PO-35 regimens (P < .001).",High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33693537/),[mg] / [l],2.17,56107,DB01045,Rifampicin
,25645830,kill rate,"We indexed the efficacy of the standard combination regimen, which was a kill rate of -0.08 ± 0.05 log10 CFU/ml/day (r(2) = 0.99).",Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[cfu] / [d·ml],-,56447,DB01045,Rifampicin
,25645830,kill rate,"We indexed the efficacy of the standard combination regimen, which was a kill rate of -0.08 ± 0.05 log10 CFU/ml/day (r(2) = 0.99).",Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[cfu] / [d·ml],0.08,56448,DB01045,Rifampicin
,25645830,half-life,We next performed moxifloxacin dose-effect and dose-scheduling studies at a half-life of 11.1 ± 6.47 h.,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),h,11.1,56449,DB01045,Rifampicin
,25645830,AUC0-24/MIC,The moxifloxacin exposure associated with 80% of maximal kill (EC80) was an AUC0-24/MIC of 317 (the non-protein-bound moxifloxacin AUC0-24/MIC was 158.5).,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),,317,56450,DB01045,Rifampicin
,25645830,AUC0-24/MIC,The moxifloxacin exposure associated with 80% of maximal kill (EC80) was an AUC0-24/MIC of 317 (the non-protein-bound moxifloxacin AUC0-24/MIC was 158.5).,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),,158.5,56451,DB01045,Rifampicin
,25645830,MIC susceptibility breakpoint,The MIC susceptibility breakpoint at this dose was 0.25 mg/liter.,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[mg] / [l],0.25,56452,DB01045,Rifampicin
,26066583,C max,"While rifampicin intracellular concentrations were similar to plasma values (median intra-PBMC C max = 7503 ng/mL versus median plasma C max = 6505 ng/mL), isoniazid and pyrazinamide intracellular concentrations were lower than plasma values (median intra-PBMC C max = 12 ng/mL versus median plasma C max = 3258 ng/mL for isoniazid and median intra-PBMC C max = 2364 ng/mL versus median plasma C max = 26 988 ng/mL for pyrazinamide) and ethambutol intracellular concentrations were significantly higher than plasma values (median intra-PBMC C max = 73 334 ng/mL versus median plasma C max = 2244 ng/mL).",A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066583/),[ng] / [ml],7503,56621,DB01045,Rifampicin
,26066583,plasma C max,"While rifampicin intracellular concentrations were similar to plasma values (median intra-PBMC C max = 7503 ng/mL versus median plasma C max = 6505 ng/mL), isoniazid and pyrazinamide intracellular concentrations were lower than plasma values (median intra-PBMC C max = 12 ng/mL versus median plasma C max = 3258 ng/mL for isoniazid and median intra-PBMC C max = 2364 ng/mL versus median plasma C max = 26 988 ng/mL for pyrazinamide) and ethambutol intracellular concentrations were significantly higher than plasma values (median intra-PBMC C max = 73 334 ng/mL versus median plasma C max = 2244 ng/mL).",A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066583/),[ng] / [ml],6505,56622,DB01045,Rifampicin
,26066583,C max,"While rifampicin intracellular concentrations were similar to plasma values (median intra-PBMC C max = 7503 ng/mL versus median plasma C max = 6505 ng/mL), isoniazid and pyrazinamide intracellular concentrations were lower than plasma values (median intra-PBMC C max = 12 ng/mL versus median plasma C max = 3258 ng/mL for isoniazid and median intra-PBMC C max = 2364 ng/mL versus median plasma C max = 26 988 ng/mL for pyrazinamide) and ethambutol intracellular concentrations were significantly higher than plasma values (median intra-PBMC C max = 73 334 ng/mL versus median plasma C max = 2244 ng/mL).",A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066583/),[ng] / [ml],12,56623,DB01045,Rifampicin
,26066583,plasma C max,"While rifampicin intracellular concentrations were similar to plasma values (median intra-PBMC C max = 7503 ng/mL versus median plasma C max = 6505 ng/mL), isoniazid and pyrazinamide intracellular concentrations were lower than plasma values (median intra-PBMC C max = 12 ng/mL versus median plasma C max = 3258 ng/mL for isoniazid and median intra-PBMC C max = 2364 ng/mL versus median plasma C max = 26 988 ng/mL for pyrazinamide) and ethambutol intracellular concentrations were significantly higher than plasma values (median intra-PBMC C max = 73 334 ng/mL versus median plasma C max = 2244 ng/mL).",A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066583/),[ng] / [ml],3258,56624,DB01045,Rifampicin
,26066583,C max,"While rifampicin intracellular concentrations were similar to plasma values (median intra-PBMC C max = 7503 ng/mL versus median plasma C max = 6505 ng/mL), isoniazid and pyrazinamide intracellular concentrations were lower than plasma values (median intra-PBMC C max = 12 ng/mL versus median plasma C max = 3258 ng/mL for isoniazid and median intra-PBMC C max = 2364 ng/mL versus median plasma C max = 26 988 ng/mL for pyrazinamide) and ethambutol intracellular concentrations were significantly higher than plasma values (median intra-PBMC C max = 73 334 ng/mL versus median plasma C max = 2244 ng/mL).",A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066583/),[ng] / [ml],2364,56625,DB01045,Rifampicin
,26066583,plasma C max,"While rifampicin intracellular concentrations were similar to plasma values (median intra-PBMC C max = 7503 ng/mL versus median plasma C max = 6505 ng/mL), isoniazid and pyrazinamide intracellular concentrations were lower than plasma values (median intra-PBMC C max = 12 ng/mL versus median plasma C max = 3258 ng/mL for isoniazid and median intra-PBMC C max = 2364 ng/mL versus median plasma C max = 26 988 ng/mL for pyrazinamide) and ethambutol intracellular concentrations were significantly higher than plasma values (median intra-PBMC C max = 73 334 ng/mL versus median plasma C max = 2244 ng/mL).",A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066583/),[ng] / [ml],26 988,56626,DB01045,Rifampicin
,26066583,C max,"While rifampicin intracellular concentrations were similar to plasma values (median intra-PBMC C max = 7503 ng/mL versus median plasma C max = 6505 ng/mL), isoniazid and pyrazinamide intracellular concentrations were lower than plasma values (median intra-PBMC C max = 12 ng/mL versus median plasma C max = 3258 ng/mL for isoniazid and median intra-PBMC C max = 2364 ng/mL versus median plasma C max = 26 988 ng/mL for pyrazinamide) and ethambutol intracellular concentrations were significantly higher than plasma values (median intra-PBMC C max = 73 334 ng/mL versus median plasma C max = 2244 ng/mL).",A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066583/),[ng] / [ml],73 334,56627,DB01045,Rifampicin
,26066583,plasma C max,"While rifampicin intracellular concentrations were similar to plasma values (median intra-PBMC C max = 7503 ng/mL versus median plasma C max = 6505 ng/mL), isoniazid and pyrazinamide intracellular concentrations were lower than plasma values (median intra-PBMC C max = 12 ng/mL versus median plasma C max = 3258 ng/mL for isoniazid and median intra-PBMC C max = 2364 ng/mL versus median plasma C max = 26 988 ng/mL for pyrazinamide) and ethambutol intracellular concentrations were significantly higher than plasma values (median intra-PBMC C max = 73 334 ng/mL versus median plasma C max = 2244 ng/mL).",A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26066583/),[ng] / [ml],2244,56628,DB01045,Rifampicin
,12405865,bioavailability,Methadone has a mean bioavailability of around 75% (range 36-100%).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,75,57243,DB01045,Rifampicin
,12405865,free fraction,"Its mean free fraction is around 13%, with a 4-fold interindividual variation.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),%,13,57244,DB01045,Rifampicin
,12405865,volume of distribution,Its volume of distribution is about 4 L/kg (range 2-13 L/kg).,Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [kg],4,57245,DB01045,Rifampicin
,12405865,Total body clearance,"Total body clearance is about 0.095 L/min, with wide interindividual variation (range 0.02-2 L/min).",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[l] / [min],0.095,57246,DB01045,Rifampicin
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,22,57247,DB01045,Rifampicin
,12405865,elimination half-life,"Plasma concentrations of methadone decrease in a biexponential manner, with a mean value of around 22 hours (range 5-130 hours) for elimination half-life.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),h,5,57248,DB01045,Rifampicin
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],400,57249,DB01045,Rifampicin
,12405865,trough plasma concentrations,"In the case of non-response trough plasma concentrations of 400 microg/L for (R,S)-methadone or 250 microg/L for (R)-methadone might be used as target values.",Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12405865/),[μg] / [l],250,57250,DB01045,Rifampicin
,11263520,Cmax,"Non-compartmental analysis indicated that the mean (coefficient of variation [%CV]) values for the tablet for Cmax, Tmax and AUC(0-infinity) were 8.59 (53.66) microg/ml, 1.58 h and 49.54 (61.79) microg x h/ml, respectively.",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),[μg] / [ml],8.59,57441,DB01045,Rifampicin
,11263520,Tmax,"Non-compartmental analysis indicated that the mean (coefficient of variation [%CV]) values for the tablet for Cmax, Tmax and AUC(0-infinity) were 8.59 (53.66) microg/ml, 1.58 h and 49.54 (61.79) microg x h/ml, respectively.",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),h,1.58,57442,DB01045,Rifampicin
,11263520,AUC(0-infinity),"Non-compartmental analysis indicated that the mean (coefficient of variation [%CV]) values for the tablet for Cmax, Tmax and AUC(0-infinity) were 8.59 (53.66) microg/ml, 1.58 h and 49.54 (61.79) microg x h/ml, respectively.",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),[h·μg] / [ml],49.54,57443,DB01045,Rifampicin
,11263520,Cl/F,"Two-compartment analysis indicated that the mean (%CV) values for Cl/F, beta and t(1/2beta) were respectively 197.51 (46.58) (ml/h)/kg, 0.2153 (32.01) h(-1) and 3.57 (34.85) h, at the 450 mg dose (tablet), and were significantly different from the respective 94.76 (33.96) (ml/h)/kg, 0.1210 (33.66) h(-1) and 5.44 (16.69) h at the 600 mg dose (suspension) (P < 0.05).",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),,197.51,57444,DB01045,Rifampicin
,11263520,beta,"Two-compartment analysis indicated that the mean (%CV) values for Cl/F, beta and t(1/2beta) were respectively 197.51 (46.58) (ml/h)/kg, 0.2153 (32.01) h(-1) and 3.57 (34.85) h, at the 450 mg dose (tablet), and were significantly different from the respective 94.76 (33.96) (ml/h)/kg, 0.1210 (33.66) h(-1) and 5.44 (16.69) h at the 600 mg dose (suspension) (P < 0.05).",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),1/[h],0.2153,57445,DB01045,Rifampicin
,11263520,beta,"Two-compartment analysis indicated that the mean (%CV) values for Cl/F, beta and t(1/2beta) were respectively 197.51 (46.58) (ml/h)/kg, 0.2153 (32.01) h(-1) and 3.57 (34.85) h, at the 450 mg dose (tablet), and were significantly different from the respective 94.76 (33.96) (ml/h)/kg, 0.1210 (33.66) h(-1) and 5.44 (16.69) h at the 600 mg dose (suspension) (P < 0.05).",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),[ml] / [h)·kg],94.76,57446,DB01045,Rifampicin
,11263520,t(1/2beta),"Two-compartment analysis indicated that the mean (%CV) values for Cl/F, beta and t(1/2beta) were respectively 197.51 (46.58) (ml/h)/kg, 0.2153 (32.01) h(-1) and 3.57 (34.85) h, at the 450 mg dose (tablet), and were significantly different from the respective 94.76 (33.96) (ml/h)/kg, 0.1210 (33.66) h(-1) and 5.44 (16.69) h at the 600 mg dose (suspension) (P < 0.05).",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),h,3.57,57447,DB01045,Rifampicin
,11263520,t(1/2beta),"Two-compartment analysis indicated that the mean (%CV) values for Cl/F, beta and t(1/2beta) were respectively 197.51 (46.58) (ml/h)/kg, 0.2153 (32.01) h(-1) and 3.57 (34.85) h, at the 450 mg dose (tablet), and were significantly different from the respective 94.76 (33.96) (ml/h)/kg, 0.1210 (33.66) h(-1) and 5.44 (16.69) h at the 600 mg dose (suspension) (P < 0.05).",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),[ml] / [h)·kg],94.76,57448,DB01045,Rifampicin
,11263520,t(1/2beta),"Two-compartment analysis indicated that the mean (%CV) values for Cl/F, beta and t(1/2beta) were respectively 197.51 (46.58) (ml/h)/kg, 0.2153 (32.01) h(-1) and 3.57 (34.85) h, at the 450 mg dose (tablet), and were significantly different from the respective 94.76 (33.96) (ml/h)/kg, 0.1210 (33.66) h(-1) and 5.44 (16.69) h at the 600 mg dose (suspension) (P < 0.05).",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),1/[h],0.1210,57449,DB01045,Rifampicin
,11263520,t(1/2beta),"Two-compartment analysis indicated that the mean (%CV) values for Cl/F, beta and t(1/2beta) were respectively 197.51 (46.58) (ml/h)/kg, 0.2153 (32.01) h(-1) and 3.57 (34.85) h, at the 450 mg dose (tablet), and were significantly different from the respective 94.76 (33.96) (ml/h)/kg, 0.1210 (33.66) h(-1) and 5.44 (16.69) h at the 600 mg dose (suspension) (P < 0.05).",Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263520/),h,5.44,57450,DB01045,Rifampicin
,29701775,Cmax,"Treatment duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L (SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mg·h/L (SEM 2.60) and 38.73 mg·h/L (SEM 4.33) after single and steady-state dosing, respectively.",Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29701775/),[mg] / [l],8.98,57609,DB01045,Rifampicin
,29701775,Cmax,"Treatment duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L (SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mg·h/L (SEM 2.60) and 38.73 mg·h/L (SEM 4.33) after single and steady-state dosing, respectively.",Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29701775/),[mg] / [l],5.79,57610,DB01045,Rifampicin
,29701775,AUC,"Treatment duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L (SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mg·h/L (SEM 2.60) and 38.73 mg·h/L (SEM 4.33) after single and steady-state dosing, respectively.",Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29701775/),[h·mg] / [l],72.56,57611,DB01045,Rifampicin
,29701775,AUC,"Treatment duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L (SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mg·h/L (SEM 2.60) and 38.73 mg·h/L (SEM 4.33) after single and steady-state dosing, respectively.",Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29701775/),[h·mg] / [l],38.73,57612,DB01045,Rifampicin
,29718967,maximal effect,"Single oral doses of bedaquiline produced readily detectable WBA ex vivo, reaching a maximal effect of -0.28 log/day, with negative values indicating bacterial killing.",Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[log] / [d],-,58488,DB01045,Rifampicin
,29718967,maximal effect,"Single oral doses of bedaquiline produced readily detectable WBA ex vivo, reaching a maximal effect of -0.28 log/day, with negative values indicating bacterial killing.",Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[log] / [d],0.28,58489,DB01045,Rifampicin
,29718967,Plasma concentrations,Plasma concentrations of 355 ng/ml were sufficient for intracellular mycobacteriostasis.,Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[ng] / [ml],355,58490,DB01045,Rifampicin
,29718967,maximal effects,"Combined dosing with rifampin or rifabutin produced maximal effects of -0.91 and -0.79 log/d, respectively.",Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[log] / [d],0.91,58491,DB01045,Rifampicin
,29718967,maximal effects,"Combined dosing with rifampin or rifabutin produced maximal effects of -0.91 and -0.79 log/d, respectively.",Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718967/),[log] / [d],0.79,58492,DB01045,Rifampicin
,34286843,Apparent clearance,Apparent clearance was 6.95 L/h for a typical 16 kg child.,"Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286843/),[l] / [h],6.95,58772,DB01045,Rifampicin
,34286843,maximum change,The median (range) maximum change in QTcF after moxifloxacin administration was 16.3 (-27.7 to 61.3) ms.,"Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286843/),ms,16.3,58773,DB01045,Rifampicin
,34286843,maximum drug effect (Emax),"The concentration-QTcF relationship was nonlinear, with a maximum drug effect (Emax) of 8.80 ms (inter-individual variability = 9.75 ms).","Moxifloxacin pharmacokinetics, cardiac safety, and dosing for the treatment of rifampicin-resistant tuberculosis in children. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34286843/),ms,8.80,58774,DB01045,Rifampicin
≤,29897466,fractional inhibitory concentration index,The combination had synergistic activity (fractional inhibitory concentration index ≤0.5) against all cfr-positive MRSA isolates.,Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897466/),,0.5,59176,DB01045,Rifampicin
,29897466,AUC ratio,Linezolid demonstrated excellent pulmonary penetration with an ELF/fplasma AUC ratio of 2.68 ± 0.17.,Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897466/),,2.68,59177,DB01045,Rifampicin
,29897466,fAUC/MIC targets,"The fAUC/MIC targets of linezolid associated with stasis, 1 log10 kill and 2 log10 kill were 15.9, 38.8 and 175 in plasma, and 43.5, 108 and 415 in ELF, respectively.",Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897466/),,15.9,59178,DB01045,Rifampicin
,29897466,fAUC/MIC targets,"The fAUC/MIC targets of linezolid associated with stasis, 1 log10 kill and 2 log10 kill were 15.9, 38.8 and 175 in plasma, and 43.5, 108 and 415 in ELF, respectively.",Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897466/),,38.8,59179,DB01045,Rifampicin
,29897466,fAUC/MIC targets,"The fAUC/MIC targets of linezolid associated with stasis, 1 log10 kill and 2 log10 kill were 15.9, 38.8 and 175 in plasma, and 43.5, 108 and 415 in ELF, respectively.",Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897466/),,175,59180,DB01045,Rifampicin
,29897466,fAUC/MIC targets,"The fAUC/MIC targets of linezolid associated with stasis, 1 log10 kill and 2 log10 kill were 15.9, 38.8 and 175 in plasma, and 43.5, 108 and 415 in ELF, respectively.",Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897466/),,43.5,59181,DB01045,Rifampicin
,29897466,fAUC/MIC targets,"The fAUC/MIC targets of linezolid associated with stasis, 1 log10 kill and 2 log10 kill were 15.9, 38.8 and 175 in plasma, and 43.5, 108 and 415 in ELF, respectively.",Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897466/),,108,59182,DB01045,Rifampicin
,29897466,fAUC/MIC targets,"The fAUC/MIC targets of linezolid associated with stasis, 1 log10 kill and 2 log10 kill were 15.9, 38.8 and 175 in plasma, and 43.5, 108 and 415 in ELF, respectively.",Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29897466/),,415,59183,DB01045,Rifampicin
<,33675664,serum AUC0-24,Subtarget exposures of levofloxacin were defined by serum AUC0-24 <80 mg·h/L.,Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675664/),[h·mg] / [l],80,59790,DB01045,Rifampicin
,33675664,AUC0-24,Median AUC0-24 in serum was 140 (IQR = 102.4-179.09) mg·h/L and median AUC0-24 in saliva was 97.10 (IQR = 74.80-121.10) mg·h/L.,Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675664/),[h·mg] / [l],140,59791,DB01045,Rifampicin
,33675664,AUC0-24,Median AUC0-24 in serum was 140 (IQR = 102.4-179.09) mg·h/L and median AUC0-24 in saliva was 97.10 (IQR = 74.80-121.10) mg·h/L.,Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675664/),[h·mg] / [l],97.10,59792,DB01045,Rifampicin
,33675664,AUC0-24,"Utilizing a saliva AUC0-24 cut-off of 91.6 mg·h/L, the assay was 88.9% sensitive and 69.4% specific in detecting subtarget serum AUC0-24 values, including identifying eight of nine patients below target.",Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33675664/),[h·mg] / [l],91.6,59793,DB01045,Rifampicin
,23592830,Cmin,Median Cmin was 1.96 µg/mL on-RIF versus 1.80 off-RIF (P = .067).,"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23592830/),[μg] / [ml],1.96,60209,DB01045,Rifampicin
,23592830,Cmin,Median Cmin was 1.96 µg/mL on-RIF versus 1.80 off-RIF (P = .067).,"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23592830/),,1.80,60210,DB01045,Rifampicin
,23592830,Cmin,"Cmin were significantly higher on-RIF versus off-RIF in blacks (2.08 vs 1.75, P = .005).","Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23592830/),,2.08,60211,DB01045,Rifampicin
,23592830,Cmin,"Cmin were significantly higher on-RIF versus off-RIF in blacks (2.08 vs 1.75, P = .005).","Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23592830/),,1.75,60212,DB01045,Rifampicin
,27813241,apparent clearance,"The apparent clearance and apparent central volume of distribution mean values [95% confidence interval (CI)] were 5.1 1 h-1 (1.2, 8.2 1 h-1 )/23.8 l (8.9, 38.7 l) and 13.7 1 h-1 (10.6, 18.0 1 h-1 )/61.1 1 (40.8, 129.0 1) for patients with and without administration of fusidic acid, respectively.",Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813241/),[1] / [h],5.1,61092,DB01045,Rifampicin
,27813241,apparent clearance,"The apparent clearance and apparent central volume of distribution mean values [95% confidence interval (CI)] were 5.1 1 h-1 (1.2, 8.2 1 h-1 )/23.8 l (8.9, 38.7 l) and 13.7 1 h-1 (10.6, 18.0 1 h-1 )/61.1 1 (40.8, 129.0 1) for patients with and without administration of fusidic acid, respectively.",Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813241/),[1] / [h],13.7,61093,DB01045,Rifampicin
,27813241,apparent central volume of distribution,"The apparent clearance and apparent central volume of distribution mean values [95% confidence interval (CI)] were 5.1 1 h-1 (1.2, 8.2 1 h-1 )/23.8 l (8.9, 38.7 l) and 13.7 1 h-1 (10.6, 18.0 1 h-1 )/61.1 1 (40.8, 129.0 1) for patients with and without administration of fusidic acid, respectively.",Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813241/),l,23.8,61094,DB01045,Rifampicin
,27813241,apparent central volume of distribution,"The apparent clearance and apparent central volume of distribution mean values [95% confidence interval (CI)] were 5.1 1 h-1 (1.2, 8.2 1 h-1 )/23.8 l (8.9, 38.7 l) and 13.7 1 h-1 (10.6, 18.0 1 h-1 )/61.1 1 (40.8, 129.0 1) for patients with and without administration of fusidic acid, respectively.",Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813241/),1,61.1,61095,DB01045,Rifampicin
,27813241,Residual variability,"Residual variability was 2.3 mg l-1 (1.6, 2.6 mg l-1 ).",Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813241/),[mg] / [l],2.3,61096,DB01045,Rifampicin
,15778422,C(max),"Mean dicloxacillin C(max) measurements were 30.5 +/- 13.5, 33.3 +/- 4.7, and 31.1 +/- 12.8 mug/mL in individuals with the CC, CT, and TT genotype at position 3435 in exon 26 of the MDR1 gene.",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),[μg] / [ml],30.5,62770,DB01045,Rifampicin
,15778422,C(max),"Mean dicloxacillin C(max) measurements were 30.5 +/- 13.5, 33.3 +/- 4.7, and 31.1 +/- 12.8 mug/mL in individuals with the CC, CT, and TT genotype at position 3435 in exon 26 of the MDR1 gene.",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),[μg] / [ml],33.3,62771,DB01045,Rifampicin
,15778422,C(max),"Mean dicloxacillin C(max) measurements were 30.5 +/- 13.5, 33.3 +/- 4.7, and 31.1 +/- 12.8 mug/mL in individuals with the CC, CT, and TT genotype at position 3435 in exon 26 of the MDR1 gene.",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),[μg] / [ml],31.1,62772,DB01045,Rifampicin
,15778422,C(max),"Following rifampin dosing, the mean dicloxacillin C(max) across genotypes decreased from 31.4 +/- 10.8 to 22.9 +/- 7.0 microg/mL (P < .05), whereas the mean oral clearance increased from 235 +/- 82 to 297 +/- 71 mL/min (P < .001), and the mean absorption time increased from 0.71 +/- 0.55 to 1.34 +/- 0.77 h (P < .05).",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),[μg] / [ml],31.4,62773,DB01045,Rifampicin
,15778422,C(max),"Following rifampin dosing, the mean dicloxacillin C(max) across genotypes decreased from 31.4 +/- 10.8 to 22.9 +/- 7.0 microg/mL (P < .05), whereas the mean oral clearance increased from 235 +/- 82 to 297 +/- 71 mL/min (P < .001), and the mean absorption time increased from 0.71 +/- 0.55 to 1.34 +/- 0.77 h (P < .05).",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),[μg] / [ml],22.9,62774,DB01045,Rifampicin
,15778422,oral clearance,"Following rifampin dosing, the mean dicloxacillin C(max) across genotypes decreased from 31.4 +/- 10.8 to 22.9 +/- 7.0 microg/mL (P < .05), whereas the mean oral clearance increased from 235 +/- 82 to 297 +/- 71 mL/min (P < .001), and the mean absorption time increased from 0.71 +/- 0.55 to 1.34 +/- 0.77 h (P < .05).",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),[ml] / [min],235,62775,DB01045,Rifampicin
,15778422,oral clearance,"Following rifampin dosing, the mean dicloxacillin C(max) across genotypes decreased from 31.4 +/- 10.8 to 22.9 +/- 7.0 microg/mL (P < .05), whereas the mean oral clearance increased from 235 +/- 82 to 297 +/- 71 mL/min (P < .001), and the mean absorption time increased from 0.71 +/- 0.55 to 1.34 +/- 0.77 h (P < .05).",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),[ml] / [min],297,62776,DB01045,Rifampicin
,15778422,mean absorption time,"Following rifampin dosing, the mean dicloxacillin C(max) across genotypes decreased from 31.4 +/- 10.8 to 22.9 +/- 7.0 microg/mL (P < .05), whereas the mean oral clearance increased from 235 +/- 82 to 297 +/- 71 mL/min (P < .001), and the mean absorption time increased from 0.71 +/- 0.55 to 1.34 +/- 0.77 h (P < .05).",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),h,0.71,62777,DB01045,Rifampicin
,15778422,mean absorption time,"Following rifampin dosing, the mean dicloxacillin C(max) across genotypes decreased from 31.4 +/- 10.8 to 22.9 +/- 7.0 microg/mL (P < .05), whereas the mean oral clearance increased from 235 +/- 82 to 297 +/- 71 mL/min (P < .001), and the mean absorption time increased from 0.71 +/- 0.55 to 1.34 +/- 0.77 h (P < .05).",Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778422/),h,1.34,62778,DB01045,Rifampicin
,19438397,C12,"At weeks 6 and 12, the mean C12 of efavirenz (+/- standard deviation) were 4.27+/-4.49 and 3.54+/-3.78 mg/L, respectively, and those for nevirapine were 5.59+/-3.48 and 5.6+/-2.65 mg/L, respectively.",A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438397/),[mg] / [l],4.27,63994,DB01045,Rifampicin
,19438397,C12,"At weeks 6 and 12, the mean C12 of efavirenz (+/- standard deviation) were 4.27+/-4.49 and 3.54+/-3.78 mg/L, respectively, and those for nevirapine were 5.59+/-3.48 and 5.6+/-2.65 mg/L, respectively.",A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438397/),[mg] / [l],3.54,63995,DB01045,Rifampicin
,19438397,C12,"At weeks 6 and 12, the mean C12 of efavirenz (+/- standard deviation) were 4.27+/-4.49 and 3.54+/-3.78 mg/L, respectively, and those for nevirapine were 5.59+/-3.48 and 5.6+/-2.65 mg/L, respectively.",A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438397/),[mg] / [l],5.59,63996,DB01045,Rifampicin
,19438397,C12,"At weeks 6 and 12, the mean C12 of efavirenz (+/- standard deviation) were 4.27+/-4.49 and 3.54+/-3.78 mg/L, respectively, and those for nevirapine were 5.59+/-3.48 and 5.6+/-2.65 mg/L, respectively.",A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19438397/),[mg] / [l],5.6,63997,DB01045,Rifampicin
,31519935,CMAX,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),[ng] / [ml],"1,200",64476,DB01045,Rifampicin
,31519935,TMAX,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),h,2.2,64477,DB01045,Rifampicin
,31519935,T1/2,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),h,4.7,64478,DB01045,Rifampicin
,31519935,CMAX,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),[ng] / [ml],"28,900",64479,DB01045,Rifampicin
,31519935,T1/2,"A monotherapy protocol mimicking isoniazid in lung lesion homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented in a hollow-fiber system.",Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31519935/),h,8.0,64480,DB01045,Rifampicin
,16154726,drug encapsulation efficiencies,"The nanoparticles were prepared by cation-induced gelification of alginate and were 235.5 +/- 0 nm in size, with drug encapsulation efficiencies of 70-90% for INH and PZA and 80-90% for RIF.",Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154726/),%,70-90,64653,DB01045,Rifampicin
,16154726,drug encapsulation efficiencies,"The nanoparticles were prepared by cation-induced gelification of alginate and were 235.5 +/- 0 nm in size, with drug encapsulation efficiencies of 70-90% for INH and PZA and 80-90% for RIF.",Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154726/),%,80-90,64654,DB01045,Rifampicin
,16154726,aerodynamic diameter,"The majority of particles (80.5%) were in the respirable range, with mass median aerodynamic diameter of 1.1 +/- 0.4 microm and geometric standard deviation of 1.71 +/- 0.1 microm.",Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16154726/),μ,1.1,64655,DB01045,Rifampicin
,26870790,total,The total rifampicin concentration pericardial-to-serum ratios in 16 paired samples were 0.19 ± 0.33.,Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26870790/),,0.19,64985,DB01045,Rifampicin
,26870790,pericardial-to-serum ratios,The total rifampicin concentration pericardial-to-serum ratios in 16 paired samples were 0.19 ± 0.33.,Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26870790/),,0.19,64986,DB01045,Rifampicin
,26870790,peak concentration,"The non-protein bound rifampicin concentrations in pericardial fluid were 4-fold lower than rifampicin MICs in the pilot study, and the peak concentration was 0.125 versus 0.208 mg/L in the second (p = 0.001).",Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26870790/),[mg] / [l],0.125,64987,DB01045,Rifampicin
,26870790,peak concentration,"The non-protein bound rifampicin concentrations in pericardial fluid were 4-fold lower than rifampicin MICs in the pilot study, and the peak concentration was 0.125 versus 0.208 mg/L in the second (p = 0.001).",Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26870790/),[mg] / [l],0.208,64988,DB01045,Rifampicin
,26870790,clearance,The rifampicin clearance from pericardial fluid was 9.45 L/h versus 7.82 L/h in plasma (p = 0.002).,Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26870790/),[l] / [h],9.45,64989,DB01045,Rifampicin
,26870790,clearance,The rifampicin clearance from pericardial fluid was 9.45 L/h versus 7.82 L/h in plasma (p = 0.002).,Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26870790/),[l] / [h],7.82,64990,DB01045,Rifampicin
,26870790,peak concentrations,The median pyrazinamide peak concentrations were 42.93 mg/L versus a median MIC of 800 mg/L at pH 7.34 (p < 0.0001).,Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26870790/),[mg] / [l],42.93,64991,DB01045,Rifampicin
,26870790,MIC,The median pyrazinamide peak concentrations were 42.93 mg/L versus a median MIC of 800 mg/L at pH 7.34 (p < 0.0001).,Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26870790/),[mg] / [l],800,64992,DB01045,Rifampicin
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],5.3,65594,DB01045,Rifampicin
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],14.6,65595,DB01045,Rifampicin
,9232132,noncompartmental clearance,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],1.1,65596,DB01045,Rifampicin
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,58,65597,DB01045,Rifampicin
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,35,65598,DB01045,Rifampicin
,9232132,elimination half-life,"Alfentanil noncompartmental clearance was 5.3 +/- 2.3, 14.6 +/- 3.8, and 1.1 +/- 0.5 ml.kg-1.min-1, and elimination half-life was 58 +/- 13, 35 +/- 7, and 630 +/- 374 min, respectively, in participants with normal (controls), high (rifampin), and low (troleandomycin) P450 3A4 activity (means +/- SD; P < 0.05 compared with controls).",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),min,630,65599,DB01045,Rifampicin
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],4.9,65600,DB01045,Rifampicin
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],13.2,65601,DB01045,Rifampicin
,9232132,clearance,"This clearance was 4.9 +/- 2.1, 13.2 +/- 3.6, and 1.5 +/- 0.8 ml.kg-1.min-1, respectively, in controls and in men receiving rifampin or troleandomycin.",The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232132/),[ml] / [kg·min],1.5,65602,DB01045,Rifampicin
,849678,elimination half-life,The average elimination half-life of hexobarbital had decreased from 407 to 171 min and its metabolic clearance had increased almost threefold.,Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),min,407 to 171,65632,DB01045,Rifampicin
,849678,elimination half-life,"In contrast, the average elimination half-life of antipyrine was virtually the same on both occasions (6.9 and 7.2 hr) and there was no change in metabolic clearance.",Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),h,6.9,65633,DB01045,Rifampicin
,849678,elimination half-life,"In contrast, the average elimination half-life of antipyrine was virtually the same on both occasions (6.9 and 7.2 hr) and there was no change in metabolic clearance.",Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/849678/),h,7.2,65634,DB01045,Rifampicin
,3957493,peak heights,Our results in group 1 show peak heights of serum levels of rifampicin ranging from 13.6 to 21.0 micrograms X ml-1 (mean value was 17.6 micrograms X ml-1).,Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957493/),[μg] / [ml],13.6 to 21.0,66143,DB01045,Rifampicin
,3957493,peak heights,Our results in group 1 show peak heights of serum levels of rifampicin ranging from 13.6 to 21.0 micrograms X ml-1 (mean value was 17.6 micrograms X ml-1).,Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957493/),[μg] / [ml],17.6,66144,DB01045,Rifampicin
,3957493,AUC,AUC values ranged from 81.1 to 177.9 micrograms X ml-1h (mean value was 145.2 micrograms X ml-1 h.),Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957493/),[μg] / [ml],81.1 to 177.9,66145,DB01045,Rifampicin
,3957493,AUC,AUC values ranged from 81.1 to 177.9 micrograms X ml-1h (mean value was 145.2 micrograms X ml-1 h.),Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957493/),[h·μg] / [ml],145.2,66146,DB01045,Rifampicin
,3957493,peak heights,Respective figures with 600 mg rifampicin were 11.0 to 27 micrograms X ml-1 (mean = 20.0 micrograms X ml-1) for peak heights and 132.0 to 260.6 micrograms X ml-1h (mean value = 181.1 micrograms X ml-1h) for AUC.,Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957493/),[μg] / [ml],20.0,66147,DB01045,Rifampicin
,3957493,AUC,Respective figures with 600 mg rifampicin were 11.0 to 27 micrograms X ml-1 (mean = 20.0 micrograms X ml-1) for peak heights and 132.0 to 260.6 micrograms X ml-1h (mean value = 181.1 micrograms X ml-1h) for AUC.,Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957493/),[μg] / [ml],181.1,66148,DB01045,Rifampicin
,24614383,clearance,"The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters · h(-1), respectively, after a single dose to 2.2 and 5.0 liters · h(-1), respectively, after 14 once-daily doses, with no plateau being reached by day 14.",Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24614383/),[l] / [h],1.2,66172,DB01045,Rifampicin
,24614383,clearance,"The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters · h(-1), respectively, after a single dose to 2.2 and 5.0 liters · h(-1), respectively, after 14 once-daily doses, with no plateau being reached by day 14.",Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24614383/),[l] / [h],3.1,66173,DB01045,Rifampicin
,24614383,clearance,"The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters · h(-1), respectively, after a single dose to 2.2 and 5.0 liters · h(-1), respectively, after 14 once-daily doses, with no plateau being reached by day 14.",Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24614383/),[l] / [h],2.2,66174,DB01045,Rifampicin
,24614383,clearance,"The autoinduction model suggested a dose-independent linear increase in clearance of the parent drug and metabolite over time from 1.2 and 3.1 liters · h(-1), respectively, after a single dose to 2.2 and 5.0 liters · h(-1), respectively, after 14 once-daily doses, with no plateau being reached by day 14.",Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24614383/),[l] / [h],5.0,66175,DB01045,Rifampicin
,18584334,mass,"PLA microsphere formulations revealed lack of cytotoxicity and a mass median aerodynamic diameter (MMDA) of 2.22-2.86 mum, while PLGA particles were larger (MMDA of 4.67-5.11 mum).",Slow release formulations of inhaled rifampin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18584334/),mum,2.22-2.86,66349,DB01045,Rifampicin
,18584334,aerodynamic diameter (MMDA),"PLA microsphere formulations revealed lack of cytotoxicity and a mass median aerodynamic diameter (MMDA) of 2.22-2.86 mum, while PLGA particles were larger (MMDA of 4.67-5.11 mum).",Slow release formulations of inhaled rifampin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18584334/),mum,2.22-2.86,66350,DB01045,Rifampicin
,18584334,M,"PLA microsphere formulations revealed lack of cytotoxicity and a mass median aerodynamic diameter (MMDA) of 2.22-2.86 mum, while PLGA particles were larger (MMDA of 4.67-5.11 mum).",Slow release formulations of inhaled rifampin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18584334/),mum,4.67-5.11,66351,DB01045,Rifampicin
,18584334,t (max),Pharmacokinetics differed among the formulations with the 10% PLA formulation showing a distinct sustained release (t (max) of 2 h vs 0.5 h of free drug) and a systemic bioavailability similar to that of free drug.,Slow release formulations of inhaled rifampin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18584334/),h,2,66352,DB01045,Rifampicin
,18584334,t (max),Pharmacokinetics differed among the formulations with the 10% PLA formulation showing a distinct sustained release (t (max) of 2 h vs 0.5 h of free drug) and a systemic bioavailability similar to that of free drug.,Slow release formulations of inhaled rifampin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18584334/),h,0.5,66353,DB01045,Rifampicin
,18584334,relative bioavailability,Formulations with high polymer content showed a lower relative bioavailability (30%).,Slow release formulations of inhaled rifampin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18584334/),%,30,66354,DB01045,Rifampicin
,32857315,terminal elimination half-life (t1/2),The mean terminal elimination half-life (t1/2) for ozanimod was approximately 20-22 h while the mean t1/2 for CC112273 and CC1084037 were approximately 10 days.,"Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32857315/),h,20-22,66946,DB01045,Rifampicin
,32857315,t1/2,The mean terminal elimination half-life (t1/2) for ozanimod was approximately 20-22 h while the mean t1/2 for CC112273 and CC1084037 were approximately 10 days.,"Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32857315/),d,10,66947,DB01045,Rifampicin
,31581274,concentrations,"Following a 600 mg oral administration of linezolid 24 h before surgery, median concentrations of linezolid in plasma and diseased bone tissue for the 9 patients were 1.98 mg/L (range 0.30-3.44 mg/L) and 0.60 mg/L (range 0.18-2.13 mg/L), respectively, at resection time.",Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31581274/),[mg] / [l],1.98,67343,DB01045,Rifampicin
,31581274,concentrations,"Following a 600 mg oral administration of linezolid 24 h before surgery, median concentrations of linezolid in plasma and diseased bone tissue for the 9 patients were 1.98 mg/L (range 0.30-3.44 mg/L) and 0.60 mg/L (range 0.18-2.13 mg/L), respectively, at resection time.",Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31581274/),[mg] / [l],0.60,67344,DB01045,Rifampicin
,31581274,concentration ratio,The median diseased bone/plasma linezolid concentration ratio was 0.48 (range 0.30-0.67).,Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31581274/),,0.48,67345,DB01045,Rifampicin
,30597025,(,The highest (peak) concentration in vivo was 39.1 mg/L (high-dose group).,Protein binding of rifampicin is not saturated when using high-dose rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30597025/),[mg] / [l],39.1,67467,DB01045,Rifampicin
,30597025,peak) concentration,The highest (peak) concentration in vivo was 39.1 mg/L (high-dose group).,Protein binding of rifampicin is not saturated when using high-dose rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30597025/),[mg] / [l],39.1,67468,DB01045,Rifampicin
,30597025,percentage unbound to,"The arithmetic mean percentage unbound to total AUC0-24in vivo was 13.3% (range = 8.1%-24.9%) and 11.1% (range = 8.6%-13.6%) for the standard group and the high-dose group, respectively (P = 0.214).",Protein binding of rifampicin is not saturated when using high-dose rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30597025/),,13,67469,DB01045,Rifampicin
,30597025,percentage unbound to,"The arithmetic mean percentage unbound to total AUC0-24in vivo was 13.3% (range = 8.1%-24.9%) and 11.1% (range = 8.6%-13.6%) for the standard group and the high-dose group, respectively (P = 0.214).",Protein binding of rifampicin is not saturated when using high-dose rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30597025/),,11,67470,DB01045,Rifampicin
,3282749,bioavaila,"With the exception of norfloxacin, which is only 30 to 40% bioavailable from the oral route, the 4-quinolones are 80 to 100% bioavailable, absorption occurring within 1 to 3 hours.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,80 to 100,67687,DB01045,Rifampicin
greater,3282749,volumes of distribution,"The 4-quinolones are widely distributed throughout the body, with volumes of distribution greater than 1.5 L/kg.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),[l] / [kg],1.5,67688,DB01045,Rifampicin
less,3282749,Protein binding,Protein binding is less than 30% in most cases.,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,30,67689,DB01045,Rifampicin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,3 and 5,67690,DB01045,Rifampicin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,8 to 14,67691,DB01045,Rifampicin
,18765687,half-life (t(1/2)),"For moxifloxacin, the mean area under the concentration-time curve from 0 to 24 h (AUC(0-24)) decreased by 17.2% (P = 0.0006) when the drug was coadministered with rifapentine, and the mean half-life (t(1/2)) decreased from 11.1 to 8.9 h (P = 0.0033).",Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765687/),h,11.1,67812,DB01045,Rifampicin
,18765687,half-life (t(1/2)),"For moxifloxacin, the mean area under the concentration-time curve from 0 to 24 h (AUC(0-24)) decreased by 17.2% (P = 0.0006) when the drug was coadministered with rifapentine, and the mean half-life (t(1/2)) decreased from 11.1 to 8.9 h (P = 0.0033).",Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765687/),h,8.9,67813,DB01045,Rifampicin
,18765687,t(1/2),"For rifapentine, the mean AUC(0-48) after seven thrice-weekly doses decreased by 20.3% (P = 0.0035) compared to the AUC(0-48) after the first dose, and the mean t(1/2) decreased from 18.5 to 14.8 h (P = 0.0004).",Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765687/),h,18.5,67814,DB01045,Rifampicin
,18765687,t(1/2),"For rifapentine, the mean AUC(0-48) after seven thrice-weekly doses decreased by 20.3% (P = 0.0035) compared to the AUC(0-48) after the first dose, and the mean t(1/2) decreased from 18.5 to 14.8 h (P = 0.0004).",Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18765687/),h,14.8,67815,DB01045,Rifampicin
,15656696,volume of distribution,"Enfuvirtide exhibits a small volume of distribution (5.48 L), low systemic clearance (1.4 L/h) and high plasma protein binding (92%).","Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15656696/),l,5.48,68070,DB01045,Rifampicin
,15656696,systemic clearance,"Enfuvirtide exhibits a small volume of distribution (5.48 L), low systemic clearance (1.4 L/h) and high plasma protein binding (92%).","Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15656696/),[l] / [h],1.4,68071,DB01045,Rifampicin
,15656696,Bioavailability,Bioavailability is high (84.3%) and the elimination half-life (3.8 hours) supports twice-daily administration.,"Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15656696/),%,84.3,68072,DB01045,Rifampicin
,15656696,elimination half-life,Bioavailability is high (84.3%) and the elimination half-life (3.8 hours) supports twice-daily administration.,"Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15656696/),h,3.8,68073,DB01045,Rifampicin
,18514353,Stability constants,Stability constants calculated for a 1:1 molar ratio of CD/rifampicin were 73.4 +/- 8.2 M(-1) for RAMEB and 68.5 +/- 5.2 M(-1) for HPbetaCD.,Formulation of rifampicin-cyclodextrin complexes for lung nebulization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514353/),1/[M],73.4,68144,DB01045,Rifampicin
,18514353,Stability constants,Stability constants calculated for a 1:1 molar ratio of CD/rifampicin were 73.4 +/- 8.2 M(-1) for RAMEB and 68.5 +/- 5.2 M(-1) for HPbetaCD.,Formulation of rifampicin-cyclodextrin complexes for lung nebulization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18514353/),1/[M],68.5,68145,DB01045,Rifampicin
,30175245,oral bioavailability,"Rifampicin, the cornerstone of TB therapy, has 70% oral bioavailability and ~10-20% cerebrospinal fluid (CSF) penetration.",High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30175245/),%,70,68240,DB01045,Rifampicin
,1752112,minimum (12-hour) plasma concentration,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[mg] / [l],4.26,68292,DB01045,Rifampicin
,1752112,area under the concentration-time curve,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[mg] / [l],2.70,68293,DB01045,Rifampicin
,1752112,area under the concentration-time curve,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[h·mg] / [l],78.91,68294,DB01045,Rifampicin
,1752112,area under the concentration-time curve,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[h·mg] / [l],57.81,68295,DB01045,Rifampicin
,1752112,elimination half-life,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[h·mg] / [l],57.81,68296,DB01045,Rifampicin
,1752112,elimination half-life,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),h,14.46,68297,DB01045,Rifampicin
,1752112,elimination half-life,"The kinetics of pefloxacin are significantly influenced by rifampin: The minimum (12-hour) plasma concentration, area under the concentration-time curve, and elimination half-life decreased respectively from 4.26 +/- 1.57 to 2.70 +/- 1.00 mg/L, 78.91 +/- 22.82 to 57.81 +/- 16.69 mg.hr/L, 14.46 +/- 3.46 to 10.08 +/- 2.44 hours (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),h,10.08,68298,DB01045,Rifampicin
,1752112,plasma clearance,"The renal clearance of pefloxacin was unchanged, but the plasma clearance increased from 94.04 +/- 39.04 to 126.82 +/- 47.36 ml/min (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[ml] / [min],94.04,68299,DB01045,Rifampicin
,1752112,plasma clearance,"The renal clearance of pefloxacin was unchanged, but the plasma clearance increased from 94.04 +/- 39.04 to 126.82 +/- 47.36 ml/min (p less than 0.05).",Influence of rifampin on the pharmacokinetics of pefloxacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752112/),[ml] / [min],126.82,68300,DB01045,Rifampicin
,31051278,AUC0-24/MIC ratio,"Across all simulated patients on the first treatment day, 85% attained the target AUC0-24/MIC ratio of 30 under a weight-based dosing scheme approximating 10 mg/kg.",Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051278/),,30,68760,DB01045,Rifampicin
,31051278,MIC,"At the rifampicin MIC of 0.5 mg/l, the probability of AUC0-24/MIC target attainment was 26%.",Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051278/),[mg] / [l],0.5,68761,DB01045,Rifampicin
,31051278,MIC,"With an intensified dosing strategy corresponding to 20 mg/kg, target attainment increased to 99%, including 93% with a MIC of 0.5 mg/l.",Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051278/),[mg] / [l],0.5,68762,DB01045,Rifampicin
≥,31051278,MIC,"Under standard dosing guidelines, few TB meningitis patients would be expected to attain therapeutic rifampicin exposures in CSF when the MIC is ≥0.5 mg/l.",Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051278/),[mg] / [l],0.5,68763,DB01045,Rifampicin
,11406737,elimination half-life,The elimination half-life of glyburide was shortened from 2.0 to 1.7 hours (P <.05) by rifampin.,Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,2.0,69073,DB01045,Rifampicin
,11406737,elimination half-life,The elimination half-life of glyburide was shortened from 2.0 to 1.7 hours (P <.05) by rifampin.,Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,1.7,69074,DB01045,Rifampicin
,11406737,half-life,"In study II, rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01).",Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,3.0,69075,DB01045,Rifampicin
,11406737,half-life,"In study II, rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01).",Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,1.9,69076,DB01045,Rifampicin
,33915288,steady-state concentration,"Comparing monotherapy with combination-therapy groups, the former's median steady-state concentration was two-fold higher after IV administration (8.49 versus 3.82 mg/L, p < 0.001) and its median AUC0-8h was 12 times higher after oral intake (37.7 versus 3.1 mg.h/L, p < 0.001).",Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915288/),[mg] / [l],8.49,69555,DB01045,Rifampicin
,33915288,steady-state concentration,"Comparing monotherapy with combination-therapy groups, the former's median steady-state concentration was two-fold higher after IV administration (8.49 versus 3.82 mg/L, p < 0.001) and its median AUC0-8h was 12 times higher after oral intake (37.7 versus 3.1 mg.h/L, p < 0.001).",Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915288/),[mg] / [l],3.82,69556,DB01045,Rifampicin
,33915288,AUC0-8h,"Comparing monotherapy with combination-therapy groups, the former's median steady-state concentration was two-fold higher after IV administration (8.49 versus 3.82 mg/L, p < 0.001) and its median AUC0-8h was 12 times higher after oral intake (37.7 versus 3.1 mg.h/L, p < 0.001).",Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915288/),[h·mg] / [l],37.7,69557,DB01045,Rifampicin
,33915288,AUC0-8h,"Comparing monotherapy with combination-therapy groups, the former's median steady-state concentration was two-fold higher after IV administration (8.49 versus 3.82 mg/L, p < 0.001) and its median AUC0-8h was 12 times higher after oral intake (37.7 versus 3.1 mg.h/L, p < 0.001).",Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915288/),[h·mg] / [l],3.1,69558,DB01045,Rifampicin
,33915288,Riv,"Riv, Rpo and Rf were 2.68, 18.8 and 7.0 respectively.",Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915288/),,2.68,69559,DB01045,Rifampicin
,33915288,Rpo,"Riv, Rpo and Rf were 2.68, 18.8 and 7.0 respectively.",Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915288/),,18.8,69560,DB01045,Rifampicin
,33915288,Rf,"Riv, Rpo and Rf were 2.68, 18.8 and 7.0 respectively.",Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33915288/),,7.0,69561,DB01045,Rifampicin
,16699292,C(max),C(max) was reduced from 15.4 +/- 5.6 to 5.4 +/- 3.3 microg/ml.,Effect of oral administration of crude aqueous extract of garlic on pharmacokinetic parameters of isoniazid and rifampicin in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699292/),[μg] / [ml],15.4,70480,DB01045,Rifampicin
,16699292,C(max),C(max) was reduced from 15.4 +/- 5.6 to 5.4 +/- 3.3 microg/ml.,Effect of oral administration of crude aqueous extract of garlic on pharmacokinetic parameters of isoniazid and rifampicin in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699292/),[μg] / [ml],5.4,70481,DB01045,Rifampicin
,16699292,AUC((0-24)),AUC((0-24)) was reduced from 76.7 +/- 25.0 to 34.3 +/- 19.2 microg/ml.h.,Effect of oral administration of crude aqueous extract of garlic on pharmacokinetic parameters of isoniazid and rifampicin in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699292/),[μg] / [h·ml],76.7,70482,DB01045,Rifampicin
,16699292,AUC((0-24)),AUC((0-24)) was reduced from 76.7 +/- 25.0 to 34.3 +/- 19.2 microg/ml.h.,Effect of oral administration of crude aqueous extract of garlic on pharmacokinetic parameters of isoniazid and rifampicin in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16699292/),[μg] / [h·ml],34.3,70483,DB01045,Rifampicin
,29555827,hepatic uptake clearance (CLuptake,"The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],544,73280,DB01045,Rifampicin
,29555827,hepatic uptake clearance (CLuptake,"The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],10.2,73281,DB01045,Rifampicin
,29555827,hepatic uptake clearance (CLuptake,"The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],1800,73282,DB01045,Rifampicin
,29555827,hepatic uptake clearance (CLuptake,"The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],298,73283,DB01045,Rifampicin
,29555827,"canalicular efflux clearance (CLint, bile)","The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],10.2,73284,DB01045,Rifampicin
,29555827,"canalicular efflux clearance (CLint, bile)","The hepatic uptake clearance (CLuptake, liver) and canalicular efflux clearance (CLint, bile) of [11C]DPV (544 ± 204 and 10.2 ± 3.5 µl/min per gram liver, respectively) in humans were lower than the previously reported corresponding parameters in rats (1800 and 298 µl/min per gram liver, respectively) (Shingaki et al., 2013).",A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29555827/),[μl] / [gram·liver·min],298,73285,DB01045,Rifampicin
,7751591,plasma half-life,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),h,6.2,73374,DB01045,Rifampicin
,7751591,plasma half-life,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),h,3.5,73375,DB01045,Rifampicin
,7751591,plasma clearance,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),[ml] / [kg·min],1.3,73376,DB01045,Rifampicin
,7751591,plasma clearance,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),[ml] / [kg·min],2.2,73377,DB01045,Rifampicin
,27317801,plasma concentrations,"Average plasma concentrations of CP-I and CP-III prior to drug administration were 0.91 ± 0.21 and 0.15 ± 0.04 nM, respectively, with minimum fluctuation over the three periods.",Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317801/),nM,0.91,73998,DB01045,Rifampicin
,27317801,plasma concentrations,"Average plasma concentrations of CP-I and CP-III prior to drug administration were 0.91 ± 0.21 and 0.15 ± 0.04 nM, respectively, with minimum fluctuation over the three periods.",Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27317801/),nM,0.15,73999,DB01045,Rifampicin
,7163641,half life,The mean theophylline half life before rifampin treatment of 5.11 +/- 0.71 hrs was not different (p greater than 0.10) from the half life of 4.54 +/- 0.71 hrs after treatment with rifampin.,Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,5.11,74274,DB01045,Rifampicin
,7163641,half life,The mean theophylline half life before rifampin treatment of 5.11 +/- 0.71 hrs was not different (p greater than 0.10) from the half life of 4.54 +/- 0.71 hrs after treatment with rifampin.,Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,4.54,74275,DB01045,Rifampicin
,7163641,half life,"In the non-rifampin treated rabbits, the initial mean theophylline half life of 4.78 +/- 1.05 was not different p greater than 0.80) from the half life of 4.94 +/- 1.92 hrs after fourteen days.",Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),,4.78,74276,DB01045,Rifampicin
,7163641,half life,"In the non-rifampin treated rabbits, the initial mean theophylline half life of 4.78 +/- 1.05 was not different p greater than 0.80) from the half life of 4.94 +/- 1.92 hrs after fourteen days.",Noneffect of rifampin on theophylline disposition in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7163641/),h,4.94,74277,DB01045,Rifampicin
,19380594,MIC,"At the lowest MIC (0.01 mg/liter), after the administration of one 600-mg oral dose, the rates of target attainment for C(max)/MIC (> or =175) were 95% in ACs, 48.8% in plasma, and 35.9% in ELF.",Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19380594/),[mg] / [l],0.01,74590,DB01045,Rifampicin
>,19380594,rates of target attainment for C(max)/MIC,"At the lowest MIC (0.01 mg/liter), after the administration of one 600-mg oral dose, the rates of target attainment for C(max)/MIC (> or =175) were 95% in ACs, 48.8% in plasma, and 35.9% in ELF.",Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19380594/),%,or,74591,DB01045,Rifampicin
>,19380594,rates of target attainment for C(max)/MIC,"At the lowest MIC (0.01 mg/liter), after the administration of one 600-mg oral dose, the rates of target attainment for C(max)/MIC (> or =175) were 95% in ACs, 48.8% in plasma, and 35.9% in ELF.",Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19380594/),%,175,74592,DB01045,Rifampicin
>,19380594,rates of target attainment for C(max)/MIC,"At the lowest MIC (0.01 mg/liter), after the administration of one 600-mg oral dose, the rates of target attainment for C(max)/MIC (> or =175) were 95% in ACs, 48.8% in plasma, and 35.9% in ELF.",Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19380594/),%,95,74593,DB01045,Rifampicin
,19380594,rates of target attainment for C(max)/MIC,"At the lowest MIC (0.01 mg/liter), after the administration of one 600-mg oral dose, the rates of target attainment for C(max)/MIC (> or =175) were 95% in ACs, 48.8% in plasma, and 35.9% in ELF.",Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19380594/),%,48.8,74594,DB01045,Rifampicin
,19380594,rates of target attainment for C(max)/MIC,"At the lowest MIC (0.01 mg/liter), after the administration of one 600-mg oral dose, the rates of target attainment for C(max)/MIC (> or =175) were 95% in ACs, 48.8% in plasma, and 35.9% in ELF.",Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19380594/),%,35.9,74595,DB01045,Rifampicin
>,19380594,AUC(0-24)/MIC,"Under the same conditions, the target attainment results for the killing effect were 100% in plasma (AUC(0-24)/MIC > or = 271) but only 54.5% in ELF (AUC(0-24)/MIC > or = 665).",Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19380594/),,271,74596,DB01045,Rifampicin
>,19380594,AUC(0-24)/MIC,"Under the same conditions, the target attainment results for the killing effect were 100% in plasma (AUC(0-24)/MIC > or = 271) but only 54.5% in ELF (AUC(0-24)/MIC > or = 665).",Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19380594/),,665,74597,DB01045,Rifampicin
,12586573,maximal concentrations,"After insertion of a polyurethane catheter loaded with these antibiotics, the maximal concentrations after catheter placement were determined as 6 microg/L at 10.7h for rifampicin, and 13 microg/L at 28.6 h for miconazole.",Pharmacokinetics of the antimicrobial agents rifampicin and miconazole released from a loaded central venous catheter. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586573/),[μg] / [l],6,74715,DB01045,Rifampicin
,12586573,maximal concentrations,"After insertion of a polyurethane catheter loaded with these antibiotics, the maximal concentrations after catheter placement were determined as 6 microg/L at 10.7h for rifampicin, and 13 microg/L at 28.6 h for miconazole.",Pharmacokinetics of the antimicrobial agents rifampicin and miconazole released from a loaded central venous catheter. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586573/),[μg] / [l],13,74716,DB01045,Rifampicin
,12586573,maximal concentrations,"Assuming that the total amount of antibiotics incorporated in the catheter matrix were bioavailable ('worst case'), the resulting maximal concentrations calculated by simulation are 10 microg/L for rifampicin and 65 microg/L for miconazole.",Pharmacokinetics of the antimicrobial agents rifampicin and miconazole released from a loaded central venous catheter. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586573/),[μg] / [l],10,74717,DB01045,Rifampicin
,12586573,maximal concentrations,"Assuming that the total amount of antibiotics incorporated in the catheter matrix were bioavailable ('worst case'), the resulting maximal concentrations calculated by simulation are 10 microg/L for rifampicin and 65 microg/L for miconazole.",Pharmacokinetics of the antimicrobial agents rifampicin and miconazole released from a loaded central venous catheter. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586573/),[μg] / [l],65,74718,DB01045,Rifampicin
,34398956,AUC12,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[h·ng] / [ml],157 203,74788,DB01045,Rifampicin
,34398956,Ctrough,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[ng] / [ml],9876,74789,DB01045,Rifampicin
,34398956,AUC24,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[h·ng] / [ml],7374,74790,DB01045,Rifampicin
,34398956,Ctrough,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[ng] / [ml],208,74791,DB01045,Rifampicin
<,34398956,Cmax,"Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL.",Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34398956/),[ng] / [ml],250,74792,DB01045,Rifampicin
,29643253,uptake Km,"In vitro studies using plated cynomolgus monkey hepatocytes showed active uptake Km values of 2.0 and 3.9 µM for OATP1B probe substrates, pitavastatin and rosuvastatin, respectively.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,2.0,74942,DB01045,Rifampicin
,29643253,uptake Km,"In vitro studies using plated cynomolgus monkey hepatocytes showed active uptake Km values of 2.0 and 3.9 µM for OATP1B probe substrates, pitavastatin and rosuvastatin, respectively.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,3.9,74943,DB01045,Rifampicin
,29643253,IC50,"Rifampicin inhibited pitavastatin and rosuvastatin active uptake in monkey hepatocytes with IC50 values of 3.0 and 0.54 µM, respectively, following preincubation with the inhibitor.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,3.0,74944,DB01045,Rifampicin
,29643253,IC50,"Rifampicin inhibited pitavastatin and rosuvastatin active uptake in monkey hepatocytes with IC50 values of 3.0 and 0.54 µM, respectively, following preincubation with the inhibitor.",In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,0.54,74945,DB01045,Rifampicin
,29643253,IC50,Use of in vitro IC50 obtained following 1 hour preincubation with rifampicin (0.54 µM) predicted correctly the change in mean i.v. clearance and oral exposure of statins as a function of mean unbound maximum plasma concentration of rifampicin.,In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29643253/),μM,0.54,74946,DB01045,Rifampicin
,22087865,AUC from 0 to 72 hours (AUC(72h)),"Rifampicin reduced the mean AUC from 0 to 72 hours (AUC(72h)) of bortezomib by approximately 45% (223 ng · h/mL in cycle 2 vs 123 ng · h/mL in cycle 3), while dexamethasone had no effect (mean AUC(72h): 179 ng · h/mL in cycle 2 vs 170 ng · h/mL in cycle 3).","Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22087865/),[h·ng] / [ml],223,75193,DB01045,Rifampicin
,22087865,AUC from 0 to 72 hours (AUC(72h)),"Rifampicin reduced the mean AUC from 0 to 72 hours (AUC(72h)) of bortezomib by approximately 45% (223 ng · h/mL in cycle 2 vs 123 ng · h/mL in cycle 3), while dexamethasone had no effect (mean AUC(72h): 179 ng · h/mL in cycle 2 vs 170 ng · h/mL in cycle 3).","Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22087865/),[h·ng] / [ml],123,75194,DB01045,Rifampicin
,22087865,AUC(72h),"Rifampicin reduced the mean AUC from 0 to 72 hours (AUC(72h)) of bortezomib by approximately 45% (223 ng · h/mL in cycle 2 vs 123 ng · h/mL in cycle 3), while dexamethasone had no effect (mean AUC(72h): 179 ng · h/mL in cycle 2 vs 170 ng · h/mL in cycle 3).","Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22087865/),[h·ng] / [ml],179,75195,DB01045,Rifampicin
,22087865,AUC(72h),"Rifampicin reduced the mean AUC from 0 to 72 hours (AUC(72h)) of bortezomib by approximately 45% (223 ng · h/mL in cycle 2 vs 123 ng · h/mL in cycle 3), while dexamethasone had no effect (mean AUC(72h): 179 ng · h/mL in cycle 2 vs 170 ng · h/mL in cycle 3).","Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22087865/),[h·ng] / [ml],170,75196,DB01045,Rifampicin
,28546104,concentration (Cd7),"The validated model was utilised to assess the concomitant treatment of rifampicin and lumefantrine under standard body-weight based treatment regimens for 2-5year olds, and demonstrated that no subjects attained the target day 7 concentration (Cd7) of 280ng/mL, highlighting the importance of this DDI and the potential risk of malaria-TB based DDIs.",Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28546104/),[ng] / [ml],280,75219,DB01045,Rifampicin
,2379538,peak serum concentrations,The peak serum concentrations ranged from 13.5-26.7 micrograms.,"Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379538/),μg,13.5-26.7,75675,DB01045,Rifampicin
,2379538,cerebrospinal fluid concentrations,ml-1; cerebrospinal fluid concentrations ranged from 0.12-3.0 (mean: 1.4) micrograms.,"Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379538/),μg,1.4,75676,DB01045,Rifampicin
,2379538,total clearance,"The mean total clearance, apparent distribution volume, and elimination half-life were 0.29 l.kg-1.h-1, 1.11.kg-1, and 2.8 h.","Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379538/),[l] / [h·kg],0.29,75677,DB01045,Rifampicin
,2379538,apparent distribution volume,"The mean total clearance, apparent distribution volume, and elimination half-life were 0.29 l.kg-1.h-1, 1.11.kg-1, and 2.8 h.","Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379538/),1/[kg],1.11,75678,DB01045,Rifampicin
,2379538,elimination half-life,"The mean total clearance, apparent distribution volume, and elimination half-life were 0.29 l.kg-1.h-1, 1.11.kg-1, and 2.8 h.","Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379538/),h,2.8,75679,DB01045,Rifampicin
,8257135,urinary output,The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h.,Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[μg] / [4·h],160.8,76179,DB01045,Rifampicin
,8257135,urinary output,The extent of hepatic enzyme induction by rifampin was confirmed by a significant increase of 6-beta-hydroxycortisol urinary output from 160.8 +/- 41.4 to 544.8 +/- 120.7 micrograms/4 h.,Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[μg] / [4·h],544.8,76180,DB01045,Rifampicin
,8257135,peak fleroxacin concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[mg] / [l],6.3,76181,DB01045,Rifampicin
,8257135,peak fleroxacin concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[mg] / [l],6.2,76182,DB01045,Rifampicin
,8257135,time to maximum concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,1.1,76183,DB01045,Rifampicin
,8257135,time to maximum concentration,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,1.3,76184,DB01045,Rifampicin
,8257135,renal clearance,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],58.3,76185,DB01045,Rifampicin
,8257135,renal clearance,"There were no significant changes in the peak fleroxacin concentration in plasma (6.3 +/- 1.2 versus 6.2 +/- 1.9 mg/liter), time to maximum concentration of fleroxacin in plasma (1.1 +/- 0.9 versus 1.3 +/- 1.1 h), or renal clearance (58.3 +/- 16.4 versus 61.9 +/- 19.2 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],61.9,76186,DB01045,Rifampicin
,8257135,area under the curve AUC,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[h·mg] / [l],71.4,76187,DB01045,Rifampicin
,8257135,area under the curve AUC,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[h·mg] / [l],62.2,76188,DB01045,Rifampicin
,8257135,terminal half-life,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,11.4,76189,DB01045,Rifampicin
,8257135,terminal half-life,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),h,9.2,76190,DB01045,Rifampicin
,8257135,total plasma clearance,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],97.7,76191,DB01045,Rifampicin
,8257135,total plasma clearance,"The area under the curve AUC (71.4 +/- 15.8 versus 62.2 +/- 13.7 mg.h/liter) and the terminal half-life of fleroxacin (11.4 +/- 2.2 versus 9.2 +/- 1.1 h) decreased (P < 0.05), while the total plasma clearance increased from 97.7 +/- 21.6 to 112.3 +/- 25.8 ml/min (P < 0.01).",Influence of rifampin on fleroxacin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],112.3,76192,DB01045,Rifampicin
,8257135,Metabolic clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],6.9,76193,DB01045,Rifampicin
,8257135,Metabolic clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],12.5,76194,DB01045,Rifampicin
,8257135,clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],5.8,76195,DB01045,Rifampicin
,8257135,clearance,"Metabolic clearance by N demethylation was increased ( 6.9 +/- 2.4 versus 12.5 +/- 3.2 ml/min; P < 0.01), whereas clearance by N oxidation did not change (5.8 +/- 1.1 versus 5.8 +/- 1.5 ml/min).",Influence of rifampin on fleroxacin pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8257135/),[ml] / [min],5.8,76196,DB01045,Rifampicin
,3086830,peak concentrations,"Of the three oral preparations, the syrup produced the highest peak concentrations (8.3 and 6.9 micrograms/mL).",Effect of dose formulation on isoniazid absorption in two young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3086830/),[μg] / [ml],8.3,76816,DB01045,Rifampicin
,3086830,peak concentrations,"Of the three oral preparations, the syrup produced the highest peak concentrations (8.3 and 6.9 micrograms/mL).",Effect of dose formulation on isoniazid absorption in two young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3086830/),[μg] / [ml],6.9,76817,DB01045,Rifampicin
,3086830,peak concentrations,The crushed tablets in apple sauce produced the lowest peak concentrations (1.4 and 2.4 micrograms/mL).,Effect of dose formulation on isoniazid absorption in two young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3086830/),[μg] / [ml],1.4,76818,DB01045,Rifampicin
,3086830,peak concentrations,The crushed tablets in apple sauce produced the lowest peak concentrations (1.4 and 2.4 micrograms/mL).,Effect of dose formulation on isoniazid absorption in two young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3086830/),[μg] / [ml],2.4,76819,DB01045,Rifampicin
,33730100,lag phase,The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h (CI90%: 17.0-19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1-5.9 pg/h).,The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33730100/),h,18.5,77232,DB01045,Rifampicin
,33730100,zero-order elimination rate,The kinetics of ivermectin were characterised by an initial lag phase of 18.5 h (CI90%: 17.0-19.8 h) followed by a slow zero-order elimination rate of 5.5 pg/h (CI90%: 5.1-5.9 pg/h).,The pharmacokinetics and drug-drug interactions of ivermectin in Aedes aegypti mosquitoes. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33730100/),[pg] / [h],5.5,77233,DB01045,Rifampicin
,7445531,half-life,"5. Rifampicin treatment (7.5 mg/kg/day, orally) for 8 days decreased the half-life of total 14C in plasma following a single oral dose of 4-[14C]ethynodiol diacetate (0.15 mg/kg) from 44 +/- to 24 +/- 2 h.",Metabolism of ethynodiol diacetate in the rhesus monkey before and after administration of rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7445531/),h,44,77342,DB01045,Rifampicin
,7445531,half-life,"5. Rifampicin treatment (7.5 mg/kg/day, orally) for 8 days decreased the half-life of total 14C in plasma following a single oral dose of 4-[14C]ethynodiol diacetate (0.15 mg/kg) from 44 +/- to 24 +/- 2 h.",Metabolism of ethynodiol diacetate in the rhesus monkey before and after administration of rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7445531/),h,24,77343,DB01045,Rifampicin
,25936632,trough,"Mean trough and peak serum concentrations of clindamycin in the clindamycin-rifampicin arm were lower than in the clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p < 0.001, and 3.48 ± 1.1 μg/ml vs 10.2 ± 1.8 μg/ml, p < 0.001, respectively).",Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25936632/),[μg] / [ml],0.79,79784,DB01045,Rifampicin
,25936632,trough,"Mean trough and peak serum concentrations of clindamycin in the clindamycin-rifampicin arm were lower than in the clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p < 0.001, and 3.48 ± 1.1 μg/ml vs 10.2 ± 1.8 μg/ml, p < 0.001, respectively).",Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25936632/),[μg] / [ml],4.7,79785,DB01045,Rifampicin
,25936632,peak serum concentrations,"Mean trough and peak serum concentrations of clindamycin in the clindamycin-rifampicin arm were lower than in the clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p < 0.001, and 3.48 ± 1.1 μg/ml vs 10.2 ± 1.8 μg/ml, p < 0.001, respectively).",Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25936632/),[μg] / [ml],3.48,79786,DB01045,Rifampicin
,25936632,peak serum concentrations,"Mean trough and peak serum concentrations of clindamycin in the clindamycin-rifampicin arm were lower than in the clindamycin-levofloxacin arm during the time of oral antibiotic regimen (0.79 ± 0.3 μg/ml vs 4.7 ± 1.2 μg/ml, p < 0.001, and 3.48 ± 1.1 μg/ml vs 10.2 ± 1.8 μg/ml, p < 0.001, respectively).",Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25936632/),[μg] / [ml],10.2,79787,DB01045,Rifampicin
,9849746,oral bioavailability,Concomitant intake of rifampicin (600 mg/die) induced especially the presystemic (prehepatic) metabolism of verapamil so that oral bioavailability approached zero and PD effects almost diminished.,Effect of age on pharmacokinetics and pharmacodynamics in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9849746/),,zero,80042,DB01045,Rifampicin
,21255533,AUC0-72,"Baseline mean AUC0-72 was 46.80 ± 9.27 µg/ml.h, AUC0-inf was 96.38 ± 38.10 µg/ml.h, Cmax 2.19 ± 0.68 µg/ml.h, tmax 4.50 ± 0.93 h, and t1/2 96.60 ± 42.38 h.",Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255533/),[μg] / [h·ml],46.80,80265,DB01045,Rifampicin
,21255533,AUC0-inf,"Baseline mean AUC0-72 was 46.80 ± 9.27 µg/ml.h, AUC0-inf was 96.38 ± 38.10 µg/ml.h, Cmax 2.19 ± 0.68 µg/ml.h, tmax 4.50 ± 0.93 h, and t1/2 96.60 ± 42.38 h.",Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255533/),[μg] / [h·ml],96.38,80266,DB01045,Rifampicin
,21255533,Cmax,"Baseline mean AUC0-72 was 46.80 ± 9.27 µg/ml.h, AUC0-inf was 96.38 ± 38.10 µg/ml.h, Cmax 2.19 ± 0.68 µg/ml.h, tmax 4.50 ± 0.93 h, and t1/2 96.60 ± 42.38 h.",Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255533/),[μg] / [h·ml],2.19,80267,DB01045,Rifampicin
,21255533,tmax,"Baseline mean AUC0-72 was 46.80 ± 9.27 µg/ml.h, AUC0-inf was 96.38 ± 38.10 µg/ml.h, Cmax 2.19 ± 0.68 µg/ml.h, tmax 4.50 ± 0.93 h, and t1/2 96.60 ± 42.38 h.",Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255533/),h,4.50,80268,DB01045,Rifampicin
,21255533,t1/2,"Baseline mean AUC0-72 was 46.80 ± 9.27 µg/ml.h, AUC0-inf was 96.38 ± 38.10 µg/ml.h, Cmax 2.19 ± 0.68 µg/ml.h, tmax 4.50 ± 0.93 h, and t1/2 96.60 ± 42.38 h.",Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255533/),h,96.60,80269,DB01045,Rifampicin
,21255533,AUC0-72,"Post-induction values were significantly increased: AUC0-72 9.53 ± 11.26 µg/ml.h (p < 0.05; CI95% = 0.112 - 18.940), AUC0-inf 37.24 ± 42.43 (p < 0.05; CI95% = 0.021 - 0.406) µg/ml.h, and tmax 1.13 ± 0.99 h (p < 0.05; CI95% = 0.296 - 1.953).",Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255533/),[μg] / [h·ml],9.53,80270,DB01045,Rifampicin
,21255533,AUC0-inf,"Post-induction values were significantly increased: AUC0-72 9.53 ± 11.26 µg/ml.h (p < 0.05; CI95% = 0.112 - 18.940), AUC0-inf 37.24 ± 42.43 (p < 0.05; CI95% = 0.021 - 0.406) µg/ml.h, and tmax 1.13 ± 0.99 h (p < 0.05; CI95% = 0.296 - 1.953).",Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255533/),[μg] / [h·ml],37.24,80271,DB01045,Rifampicin
,21255533,tmax,"Post-induction values were significantly increased: AUC0-72 9.53 ± 11.26 µg/ml.h (p < 0.05; CI95% = 0.112 - 18.940), AUC0-inf 37.24 ± 42.43 (p < 0.05; CI95% = 0.021 - 0.406) µg/ml.h, and tmax 1.13 ± 0.99 h (p < 0.05; CI95% = 0.296 - 1.953).",Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21255533/),h,1.13,80272,DB01045,Rifampicin
,31132448,systemic absorption,The in vitro-in vivo correlation (IVIVC) plus module of GastroPlusTM simulation showed a good IVIVC between in vitro release and in vivo absorption with a predicted systemic absorption of ∼96.5%.,"Solidified SNEDDS for the oral delivery of rifampicin: Evaluation, proof of concept, in vivo kinetics, and in silico GastroPlusTM simulation. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31132448/),%,∼96.5,80814,DB01045,Rifampicin
,26248378,maximum concentration of drug in plasma (Cmax),"The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 μg/ml (2.474 to 5.596 μg/ml), area under the curve from 0 to 24 h (AUC0-∞) of 21.32 μg/ml · h (13.57 to 28.60 μg/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 μg/ml (2.979 to 4.544 μg/ml), AUC0-24 of 22.5 (14.75 to 34.59 μg/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 μg/ml (30.00 to 41.60 μg/ml), AUC0-24 of 386.6 μg/ml · h (320.0 to 463.7 μg/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 μg/ml (1.694 to 3.098 μg/ml), AUC0-24 of 20.41 μg/ml · h (16.18 to 26.27 μg/ml · h), and half-life of 7.507 (6.517 to 8.696 h).",Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248378/),[μg] / [ml],4.129,80869,DB01045,Rifampicin
,26248378,area under the curve from 0 to 24 h (AUC0-∞),"The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 μg/ml (2.474 to 5.596 μg/ml), area under the curve from 0 to 24 h (AUC0-∞) of 21.32 μg/ml · h (13.57 to 28.60 μg/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 μg/ml (2.979 to 4.544 μg/ml), AUC0-24 of 22.5 (14.75 to 34.59 μg/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 μg/ml (30.00 to 41.60 μg/ml), AUC0-24 of 386.6 μg/ml · h (320.0 to 463.7 μg/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 μg/ml (1.694 to 3.098 μg/ml), AUC0-24 of 20.41 μg/ml · h (16.18 to 26.27 μg/ml · h), and half-life of 7.507 (6.517 to 8.696 h).",Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248378/),[μg] / [h·ml],21.32,80870,DB01045,Rifampicin
,26248378,half-life,"The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 μg/ml (2.474 to 5.596 μg/ml), area under the curve from 0 to 24 h (AUC0-∞) of 21.32 μg/ml · h (13.57 to 28.60 μg/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 μg/ml (2.979 to 4.544 μg/ml), AUC0-24 of 22.5 (14.75 to 34.59 μg/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 μg/ml (30.00 to 41.60 μg/ml), AUC0-24 of 386.6 μg/ml · h (320.0 to 463.7 μg/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 μg/ml (1.694 to 3.098 μg/ml), AUC0-24 of 20.41 μg/ml · h (16.18 to 26.27 μg/ml · h), and half-life of 7.507 (6.517 to 8.696 h).",Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248378/),h,2.45,80871,DB01045,Rifampicin
,26248378,Cmax,"The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 μg/ml (2.474 to 5.596 μg/ml), area under the curve from 0 to 24 h (AUC0-∞) of 21.32 μg/ml · h (13.57 to 28.60 μg/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 μg/ml (2.979 to 4.544 μg/ml), AUC0-24 of 22.5 (14.75 to 34.59 μg/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 μg/ml (30.00 to 41.60 μg/ml), AUC0-24 of 386.6 μg/ml · h (320.0 to 463.7 μg/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 μg/ml (1.694 to 3.098 μg/ml), AUC0-24 of 20.41 μg/ml · h (16.18 to 26.27 μg/ml · h), and half-life of 7.507 (6.517 to 8.696 h).",Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248378/),[μg] / [ml],3.97,80872,DB01045,Rifampicin
,26248378,AUC0-24,"The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 μg/ml (2.474 to 5.596 μg/ml), area under the curve from 0 to 24 h (AUC0-∞) of 21.32 μg/ml · h (13.57 to 28.60 μg/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 μg/ml (2.979 to 4.544 μg/ml), AUC0-24 of 22.5 (14.75 to 34.59 μg/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 μg/ml (30.00 to 41.60 μg/ml), AUC0-24 of 386.6 μg/ml · h (320.0 to 463.7 μg/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 μg/ml (1.694 to 3.098 μg/ml), AUC0-24 of 20.41 μg/ml · h (16.18 to 26.27 μg/ml · h), and half-life of 7.507 (6.517 to 8.696 h).",Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248378/),,22.5,80873,DB01045,Rifampicin
,26248378,half-life,"The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 μg/ml (2.474 to 5.596 μg/ml), area under the curve from 0 to 24 h (AUC0-∞) of 21.32 μg/ml · h (13.57 to 28.60 μg/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 μg/ml (2.979 to 4.544 μg/ml), AUC0-24 of 22.5 (14.75 to 34.59 μg/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 μg/ml (30.00 to 41.60 μg/ml), AUC0-24 of 386.6 μg/ml · h (320.0 to 463.7 μg/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 μg/ml (1.694 to 3.098 μg/ml), AUC0-24 of 20.41 μg/ml · h (16.18 to 26.27 μg/ml · h), and half-life of 7.507 (6.517 to 8.696 h).",Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248378/),h,3.93,80874,DB01045,Rifampicin
,26248378,Cmax,"The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 μg/ml (2.474 to 5.596 μg/ml), area under the curve from 0 to 24 h (AUC0-∞) of 21.32 μg/ml · h (13.57 to 28.60 μg/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 μg/ml (2.979 to 4.544 μg/ml), AUC0-24 of 22.5 (14.75 to 34.59 μg/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 μg/ml (30.00 to 41.60 μg/ml), AUC0-24 of 386.6 μg/ml · h (320.0 to 463.7 μg/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 μg/ml (1.694 to 3.098 μg/ml), AUC0-24 of 20.41 μg/ml · h (16.18 to 26.27 μg/ml · h), and half-life of 7.507 (6.517 to 8.696 h).",Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248378/),[μg] / [ml],34.21,80875,DB01045,Rifampicin
,26248378,AUC0-24,"The pharmacokinetic parameters were as follows (median [interquartile range]): for rifampin, maximum concentration of drug in plasma (Cmax) of 4.129 μg/ml (2.474 to 5.596 μg/ml), area under the curve from 0 to 24 h (AUC0-∞) of 21.32 μg/ml · h (13.57 to 28.60 μg/ml · h), and half-life of 2.45 h (1.86 to 3.08 h); for isoniazid, Cmax of 3.97 μg/ml (2.979 to 4.544 μg/ml), AUC0-24 of 22.5 (14.75 to 34.59 μg/ml · h), and half-life of 3.93 h (3.18 to 4.73 h); for pyrazinamide, Cmax of 34.21 μg/ml (30.00 to 41.60 μg/ml), AUC0-24 of 386.6 μg/ml · h (320.0 to 463.7 μg/ml · h), and half-life of 6.821 h (5.71 to 8.042 h); and for ethambutol, Cmax of 2.278 μg/ml (1.694 to 3.098 μg/ml), AUC0-24 of 20.41 μg/ml · h (16.18 to 26.27 μg/ml · h), and half-life of 7.507 (6.517 to 8.696 h).",Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26248378/),-1·μg,386.6,80876,DB01045,Rifampicin
,19374892,IC50,Rifampicin is a potent inhibitor of SLCO1B1 (IC50 1.5 umol/l) and SLCO1B1 521T>C functional genetic polymorphism alters the kinetics of atorvastatin in vivo.,Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19374892/),[umol] / [l],1.5,81142,DB01045,Rifampicin
,14586385,concentration,"The median alprazolam concentration measured 10 hours after dosage was 8.1 mug/L (range, 4.5-14.6 mug/L) before and 1.7 mug/L (range, 0.3-4.1 mug/L) after rifampin treatment.",Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586385/),[μg] / [l],8.1,81143,DB01045,Rifampicin
,14586385,concentration,"The median alprazolam concentration measured 10 hours after dosage was 8.1 mug/L (range, 4.5-14.6 mug/L) before and 1.7 mug/L (range, 0.3-4.1 mug/L) after rifampin treatment.",Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586385/),[μg] / [l],1.7,81144,DB01045,Rifampicin
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,11.3 to 8.4,81404,DB01045,Rifampicin
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.7 to 7.6,81405,DB01045,Rifampicin
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,12.2 to 8.6,81406,DB01045,Rifampicin
,2016843,half-life,"The half-life of antipyrine decreased (patient 1 from 11.3 to 8.4 h and patient 2 from 10.7 to 7.6 h after rifampin, patient 3 from 12.2 to 8.6 h after fucidic acid, and patient 4 from 10.6 to 8.6 h after zidovudine).",Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2016843/),h,10.6 to 8.6,81407,DB01045,Rifampicin
,12709315,parasite clearance times,"Although parasite clearance times were shorter in the quinine-rifampin-treated patients (mean +/- standard deviation, 70 +/- 21 versus 82 +/- 18 h; P = 0.023), recrudescence rates were five times higher (n = 15 of 23; 65%) than those obtained with quinine alone (n = 3 of 25; 12%), P < 0.001.",Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709315/),h,70,81503,DB01045,Rifampicin
,12709315,parasite clearance times,"Although parasite clearance times were shorter in the quinine-rifampin-treated patients (mean +/- standard deviation, 70 +/- 21 versus 82 +/- 18 h; P = 0.023), recrudescence rates were five times higher (n = 15 of 23; 65%) than those obtained with quinine alone (n = 3 of 25; 12%), P < 0.001.",Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709315/),h,82,81504,DB01045,Rifampicin
,12709315,area under the plasma drug concentration-time curve,"Patients receiving rifampin had significantly greater conversion of quinine to 3-hydroxyquinine and consequently considerably lower concentrations of quinine in their plasma after the second day of treatment (median area under the plasma drug concentration-time curve from day zero to day 7 = 11.7 versus 47.5 micro g/ml. day, P < 0.001).",Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709315/),[μg] / [d·ml],11.7,81505,DB01045,Rifampicin
,12709315,area under the plasma drug concentration-time curve,"Patients receiving rifampin had significantly greater conversion of quinine to 3-hydroxyquinine and consequently considerably lower concentrations of quinine in their plasma after the second day of treatment (median area under the plasma drug concentration-time curve from day zero to day 7 = 11.7 versus 47.5 micro g/ml. day, P < 0.001).",Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12709315/),[μg] / [d·ml],47.5,81506,DB01045,Rifampicin
,11103752,elimination half-life,The elimination half-life of repaglinide was shortened from 1.5 to 1.1 hours (P < .01).,Rifampin decreases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),h,1.5,82164,DB01045,Rifampicin
,11103752,elimination half-life,The elimination half-life of repaglinide was shortened from 1.5 to 1.1 hours (P < .01).,Rifampin decreases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),h,1.1,82165,DB01045,Rifampicin
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],0.94,82166,DB01045,Rifampicin
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],-,82167,DB01045,Rifampicin
,11103752,area under the concentration-time curve from 0 to 3 hours,"The blood glucose decremental area under the concentration-time curve from 0 to 3 hours was reduced from 0.94 to -0.23 mmol/L x h (P < .05), and the maximum decrease in blood glucose concentration from 1.6 to 1.0 mmol/L (P < .05) by rifampin.",Rifampin decreases the plasma concentrations and effects of repaglinide. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103752/),[mM] / [h·l],0.23,82168,DB01045,Rifampicin
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],3.1,82553,DB01045,Rifampicin
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],7.0,82554,DB01045,Rifampicin
,2260347,Protein binding,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),%,11,82555,DB01045,Rifampicin
,2260347,cerebrospinal fluid to serum ratio,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),,0.58 to 0.89,82556,DB01045,Rifampicin
,2260347,Serum half-life,Serum half-life is long (22-32 hours) and elimination is via renal clearance of unchanged drug.,Fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),h,22-32,82557,DB01045,Rifampicin
,19448042,CL/F,"The mean+/-SD of CL/F and V/F of the 106 patients were 23.5+/-7.2 L/h and 232.3+/-71.5 L, respectively.",Population pharmacokinetic study of cyclosporine in patients with nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448042/),[l] / [h],23.5,82610,DB01045,Rifampicin
,19448042,V/F,"The mean+/-SD of CL/F and V/F of the 106 patients were 23.5+/-7.2 L/h and 232.3+/-71.5 L, respectively.",Population pharmacokinetic study of cyclosporine in patients with nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448042/),l,232.3,82611,DB01045,Rifampicin
,30145051,MIC,"In screening of our library of pleuromutilin derivatives, UT-800 (1) was identified to kill replicating- and non-replicating Mtb with the MIC values of 0.83 and 1.20 μg/mL, respectively.",An antimycobacterial pleuromutilin analogue effective against dormant bacilli. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30145051/),[μg] / [ml],0.83,82869,DB01045,Rifampicin
,30145051,MIC,"In screening of our library of pleuromutilin derivatives, UT-800 (1) was identified to kill replicating- and non-replicating Mtb with the MIC values of 0.83 and 1.20 μg/mL, respectively.",An antimycobacterial pleuromutilin analogue effective against dormant bacilli. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30145051/),[μg] / [ml],1.20,82870,DB01045,Rifampicin
,30145051,F-,Pharmacokinetic studies indicate that 1 has an oral bioavailability with an average F-value of 27.6%.,An antimycobacterial pleuromutilin analogue effective against dormant bacilli. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30145051/),%,27.6,82871,DB01045,Rifampicin
,27321774,apparent terminal half-life (t½ ),"The harmonic mean ± jackknife standard deviation apparent terminal half-life (t½ ) was 71.6 ± 10.2 hours for odanacatib alone and 16.0 ± 3.4 hours for odanacatib + rifampin, indicating greater odanacatib clearance following coadministration with rifampin.",Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27321774/),h,71.6,83277,DB01045,Rifampicin
,27321774,apparent terminal half-life (t½ ),"The harmonic mean ± jackknife standard deviation apparent terminal half-life (t½ ) was 71.6 ± 10.2 hours for odanacatib alone and 16.0 ± 3.4 hours for odanacatib + rifampin, indicating greater odanacatib clearance following coadministration with rifampin.",Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27321774/),h,16.0,83278,DB01045,Rifampicin
,6643696,time to reach peak concentration,Administration of rifampicin with food reduced mean peak plasma concentration and prolonged the time to reach peak concentration (2 versus 4 hours).,Effect of food on bioavailability of rifampicin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6643696/),h,2,84512,DB01045,Rifampicin
,6643696,time to reach peak concentration,Administration of rifampicin with food reduced mean peak plasma concentration and prolonged the time to reach peak concentration (2 versus 4 hours).,Effect of food on bioavailability of rifampicin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6643696/),h,4,84513,DB01045,Rifampicin
,24841364,Peak plasma concentration,"Peak plasma concentration ranged from 6.4 to 19.9 mg/l, which was subtherapeutic for 15% of the study participants in both groups, mostly in men (71.4%).",Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24841364/),[mg] / [l],6.4 to 19.9,84579,DB01045,Rifampicin
,19695392,C(max),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[ng] / [ml],315.7,85082,DB01045,Rifampicin
,19695392,C(max),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[ng] / [ml],115.8,85083,DB01045,Rifampicin
,19695392,AUC(0-12),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[h·ng] / [ml],604.8,85084,DB01045,Rifampicin
,19695392,AUC(0-12),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[h·ng] / [ml],259.0,85085,DB01045,Rifampicin
,19695392,AUC(0-infinity)),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[h·ng] / [ml],623.3,85086,DB01045,Rifampicin
,19695392,AUC(0-infinity)),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[h·ng] / [ml],275.1,85087,DB01045,Rifampicin
,19695392,apparent oral clearance (CL/F),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[l] / [h·kg],0.52,85088,DB01045,Rifampicin
,19695392,apparent oral clearance (CL/F),"The mean pharmacokinetic parameters for pravastatin that changed significantly were as follows (rifampicin and placebo groups, respectively): C(max) (315.7 [227.2] and 115.8 [77.5] ng . mL(-1) [P = 0.009]); AUC(0-12) (604.8 [73.3] and 259.0 [133.4] ng . h . mL(-1) [P < 0.001]); AUC(0-infinity)) (623.3 [248.8] and 275.1 [58.5] ng . h . mL(-1) [P < 0.001]); and apparent oral clearance (CL/F) (0.52 [0.18] and 1.30 [0.58] L . h(-1) . kg(-1) [P < 0.001]).","Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695392/),[l] / [h·kg],1.30,85089,DB01045,Rifampicin
,12920173,IC50,Subsequent studies showed that DPC 681 was a potent inhibitor of human CYP3A4 (IC50 = 0.039 microM) and rat CYP3A (IC50 = 1.62 microM).,Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920173/),μM,0.039,85324,DB01045,Rifampicin
,12920173,IC50,Subsequent studies showed that DPC 681 was a potent inhibitor of human CYP3A4 (IC50 = 0.039 microM) and rat CYP3A (IC50 = 1.62 microM).,Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920173/),μM,1.62,85325,DB01045,Rifampicin
,12920173,KI,"Moreover, DPC 681 was a mechanism-based inactivator of CYP3A4 with KI and kinact of 0.24 microM and 0.22 min-1, respectively.",Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920173/),μM,0.24,85326,DB01045,Rifampicin
,12920173,kinact,"Moreover, DPC 681 was a mechanism-based inactivator of CYP3A4 with KI and kinact of 0.24 microM and 0.22 min-1, respectively.",Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920173/),1/[min],0.22,85327,DB01045,Rifampicin
,8125594,time to achieve maximum concentrations (Tmax),"For RIF, the time to achieve maximum concentrations (Tmax) was 2 hours, range of mean of maximum concentration (Cmax) 3.38 to 3.88 micrograms/ml, terminal half life elimination (T1/2) 3.03 to 3.81 hours and area under serum concentration curve (AUC) 0-8 hours 24.7 to 28.3 micrograms/ml hours in different forms of tuberculosis.",Serum concentrations of rifampicin and isoniazid in tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125594/),h,2,86027,DB01045,Rifampicin
,8125594,maximum concentration (Cmax),"For RIF, the time to achieve maximum concentrations (Tmax) was 2 hours, range of mean of maximum concentration (Cmax) 3.38 to 3.88 micrograms/ml, terminal half life elimination (T1/2) 3.03 to 3.81 hours and area under serum concentration curve (AUC) 0-8 hours 24.7 to 28.3 micrograms/ml hours in different forms of tuberculosis.",Serum concentrations of rifampicin and isoniazid in tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125594/),[μg] / [ml],3.38 to 3.88,86028,DB01045,Rifampicin
,8125594,terminal half life elimination (T1/2),"For RIF, the time to achieve maximum concentrations (Tmax) was 2 hours, range of mean of maximum concentration (Cmax) 3.38 to 3.88 micrograms/ml, terminal half life elimination (T1/2) 3.03 to 3.81 hours and area under serum concentration curve (AUC) 0-8 hours 24.7 to 28.3 micrograms/ml hours in different forms of tuberculosis.",Serum concentrations of rifampicin and isoniazid in tuberculosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125594/),h,3.03 to 3.81,86029,DB01045,Rifampicin
,8125594,area under serum concentration curve (AUC) 0-8 hours,"For RIF, the time to achieve maximum concentrations (Tmax) was 2 hours, range of mean of maximum concentration (Cmax) 3.38 to 3.88 micrograms/ml, terminal half life elimination (T1/2) 3.03 to 3.81 hours and area under serum concentration curve (AUC) 0-8 hours 24.7 to 28.3 micrograms/ml hours in different forms of tuberculosis.",Serum concentrations of rifampicin and isoniazid in tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125594/),[μg] / [h·ml],24.7 to 28.3,86030,DB01045,Rifampicin
,8125594,Tmax,"INH had a Tmax of 1 h, Cmax 4.38 to 8.17 micrograms/ml, T1/2 4.0 to 4.98 hours and AUC 0-7 hours 34.1 to 57.5 micrograms/ml hours.",Serum concentrations of rifampicin and isoniazid in tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125594/),h,1,86031,DB01045,Rifampicin
,8125594,Cmax,"INH had a Tmax of 1 h, Cmax 4.38 to 8.17 micrograms/ml, T1/2 4.0 to 4.98 hours and AUC 0-7 hours 34.1 to 57.5 micrograms/ml hours.",Serum concentrations of rifampicin and isoniazid in tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125594/),[μg] / [ml],4.38 to 8.17,86032,DB01045,Rifampicin
,8125594,T1/2,"INH had a Tmax of 1 h, Cmax 4.38 to 8.17 micrograms/ml, T1/2 4.0 to 4.98 hours and AUC 0-7 hours 34.1 to 57.5 micrograms/ml hours.",Serum concentrations of rifampicin and isoniazid in tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125594/),h,4.0 to 4.98,86033,DB01045,Rifampicin
,8125594,AUC 0-7 hours,"INH had a Tmax of 1 h, Cmax 4.38 to 8.17 micrograms/ml, T1/2 4.0 to 4.98 hours and AUC 0-7 hours 34.1 to 57.5 micrograms/ml hours.",Serum concentrations of rifampicin and isoniazid in tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8125594/),[μg] / [h·ml],34.1 to 57.5,86034,DB01045,Rifampicin
more,30529029,minimum concentrations (Cmin),The primary outcome was the comparison of the proportion of children with predicted lopinavir morning minimum concentrations (Cmin) of more than 1·0 mg/L during super-boosting with the proportion of more than 1·0 mg/L during standard lopinavir-ritonavir treatment without rifampicin.,Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30529029/),[mg] / [l],1·0,86575,DB01045,Rifampicin
less,30529029,Cmin,A non-linear mixed-effects model was implemented to interpret the data and Monte Carlo simulations were used to compare the percentage of lopinavir with morning Cmin values of less than 1·0 mg/L for the two dosing schemes.,Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30529029/),[mg] / [l],1·0,86576,DB01045,Rifampicin
,15105105,C(max),The geometric mean C(max) of rifampin was 13.5 mg/liter (day 24) and was similar between the two arms.,Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15105105/),[mg] / [l],13.5,87470,DB01045,Rifampicin
,32935287,time to steady state,"Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.",Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935287/),d,5,87831,DB01045,Rifampicin
,32935287,time to steady state,"Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.",Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935287/),d,13-14,87832,DB01045,Rifampicin
,26501782,oral clearance,Patients with a slow NAT2 genotype had higher isoniazid exposure and a lower estimate of oral clearance (15.5 L/h) than rapid/intermediate NAT2 genotype (26.1 L/h).,"Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501782/),[l] / [h],15.5,88505,DB01045,Rifampicin
,26501782,oral clearance,Patients with a slow NAT2 genotype had higher isoniazid exposure and a lower estimate of oral clearance (15.5 L/h) than rapid/intermediate NAT2 genotype (26.1 L/h).,"Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501782/),[l] / [h],26.1,88506,DB01045,Rifampicin
,26501782,clearance,"Pyrazinamide clearance had an estimated typical value of 3.32 L/h, and it was found to increase with time on treatment, with a 16.3% increase after the first 2 months of anti-TB treatment.","Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501782/),[l] / [h],3.32,88507,DB01045,Rifampicin
,26501782,clearance,"The typical clearance of ethambutol was estimated to be 40.7 L/h, and was found to decrease with age, at a rate of 1.41% per year.","Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501782/),[l] / [h],40.7,88508,DB01045,Rifampicin
,26658225,t1/2,The t1/2 for CYP3A4 mRNA was 26 hours and that for the functional protein was 49 hours.,Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,26,88520,DB01045,Rifampicin
,26658225,t1/2,The t1/2 for CYP3A4 mRNA was 26 hours and that for the functional protein was 49 hours.,Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,49,88521,DB01045,Rifampicin
,26658225,t1/2,"The t1/2 of CYP2B6 was 38 hours (mRNA) and 68 hours (activity), which is longer than CYP3A4 and shows the differential turnover of these two proteins.",Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,38,88522,DB01045,Rifampicin
,26658225,t1/2,"The t1/2 of CYP2B6 was 38 hours (mRNA) and 68 hours (activity), which is longer than CYP3A4 and shows the differential turnover of these two proteins.",Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26658225/),h,68,88523,DB01045,Rifampicin
,24784025,time to reach it (Tmax),"Even when the maximal concentration (Cmax) of RMP also predicts its sterilizing effect, the time to reach it (Tmax) takes 40 minutes to 6 hours.",Limited sampling strategies to predict the area under the concentration-time curve for rifampicin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24784025/),min,40,88530,DB01045,Rifampicin
,24784025,time to reach it (Tmax),"Even when the maximal concentration (Cmax) of RMP also predicts its sterilizing effect, the time to reach it (Tmax) takes 40 minutes to 6 hours.",Limited sampling strategies to predict the area under the concentration-time curve for rifampicin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24784025/),h,6,88531,DB01045,Rifampicin
,24784025,AUC0-24,"The mean AUC0-24 in the current study was 91.46 ± 36.7 mg·h·L, and the most convenient sampling time points to predict it were 2, 4 and 12 hours postdose (slope [m] = 0.955 ± 0.06; r = 0.92).",Limited sampling strategies to predict the area under the concentration-time curve for rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24784025/),h·l·mg,91.46,88532,DB01045,Rifampicin
,16928785,EC(50),"In monkey hepatocytes, rifampin markedly induced DF 4'-hydroxylase activity, with values for EC(50) of 0.2 to 0.4 microM and E(max) of 2- to 5-fold over control.","Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928785/),μM,0.2 to 0.4,88587,DB01045,Rifampicin
,16928785,EC(50),"Under similar treatment conditions, rifampin was previously shown to induce midazolam (MDZ) 1'-hydroxylation in rhesus monkey hepatocytes (EC(50) and E(max) values approximately 0.2 microM and approximately 2- to 3-fold, respectively), and markedly affected the in vivo pharmacokinetics of MDZ (>10-fold decreases in the i.pv.","Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16928785/),μM,0.2,88588,DB01045,Rifampicin
,10824630,bioavailability,"However, bioavailability of propafenone dropped from 30% +/- 24% to 4% +/- 3% (P < .05).",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),%,30,90523,DB01045,Rifampicin
,10824630,bioavailability,"However, bioavailability of propafenone dropped from 30% +/- 24% to 4% +/- 3% (P < .05).",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),%,4,90524,DB01045,Rifampicin
,10824630,clearances,"After oral propafenone was administered, clearances through N-dealkylation (6 +/- 3 mL/min versus 26 +/- 16 mL/min; P < .05) and glucuronidation (178 +/- 75 mL/min versus 739 +/- 533 mL/min; P < .05), but not 5-hydroxylation, were increased by rifampin, indicating substantial enzyme induction.",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),[ml] / [min],6,90525,DB01045,Rifampicin
,10824630,clearances,"After oral propafenone was administered, clearances through N-dealkylation (6 +/- 3 mL/min versus 26 +/- 16 mL/min; P < .05) and glucuronidation (178 +/- 75 mL/min versus 739 +/- 533 mL/min; P < .05), but not 5-hydroxylation, were increased by rifampin, indicating substantial enzyme induction.",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),[ml] / [min],26,90526,DB01045,Rifampicin
,10824630,clearances,"After oral propafenone was administered, clearances through N-dealkylation (6 +/- 3 mL/min versus 26 +/- 16 mL/min; P < .05) and glucuronidation (178 +/- 75 mL/min versus 739 +/- 533 mL/min; P < .05), but not 5-hydroxylation, were increased by rifampin, indicating substantial enzyme induction.",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),[ml] / [min],178,90527,DB01045,Rifampicin
,10824630,clearances,"After oral propafenone was administered, clearances through N-dealkylation (6 +/- 3 mL/min versus 26 +/- 16 mL/min; P < .05) and glucuronidation (178 +/- 75 mL/min versus 739 +/- 533 mL/min; P < .05), but not 5-hydroxylation, were increased by rifampin, indicating substantial enzyme induction.",Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824630/),[ml] / [min],739,90528,DB01045,Rifampicin
,31956998,exposure,Rifampin 15 mg/kg increased plasma and cerebrospinal fluid (CSF) exposures compared with 10 mg/kg: day 14 exposure increased from 48.2 hour·mg/L (range 18.2-93.8) to 82.5 hour·mg/L (range 8.7-161.0) in plasma and from 3.5 hour·mg/L (range 1.2-9.6) to 6.0 hour·mg/L (range 0.7-15.1) in CSF.,Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956998/),[h·mg] / [l],48.2,90694,DB01045,Rifampicin
,31956998,exposure,Rifampin 15 mg/kg increased plasma and cerebrospinal fluid (CSF) exposures compared with 10 mg/kg: day 14 exposure increased from 48.2 hour·mg/L (range 18.2-93.8) to 82.5 hour·mg/L (range 8.7-161.0) in plasma and from 3.5 hour·mg/L (range 1.2-9.6) to 6.0 hour·mg/L (range 0.7-15.1) in CSF.,Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956998/),[h·mg] / [l],82.5,90695,DB01045,Rifampicin
,31956998,exposure,Rifampin 15 mg/kg increased plasma and cerebrospinal fluid (CSF) exposures compared with 10 mg/kg: day 14 exposure increased from 48.2 hour·mg/L (range 18.2-93.8) to 82.5 hour·mg/L (range 8.7-161.0) in plasma and from 3.5 hour·mg/L (range 1.2-9.6) to 6.0 hour·mg/L (range 0.7-15.1) in CSF.,Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956998/),[h·mg] / [l],3.5,90696,DB01045,Rifampicin
,31956998,exposure,Rifampin 15 mg/kg increased plasma and cerebrospinal fluid (CSF) exposures compared with 10 mg/kg: day 14 exposure increased from 48.2 hour·mg/L (range 18.2-93.8) to 82.5 hour·mg/L (range 8.7-161.0) in plasma and from 3.5 hour·mg/L (range 1.2-9.6) to 6.0 hour·mg/L (range 0.7-15.1) in CSF.,Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31956998/),[h·mg] / [l],6.0,90697,DB01045,Rifampicin
,34323955,area under the concentration-time curve (AUCSS),"1.53 L/h, p<0.001), with area under the concentration-time curve (AUCSS) of 786 and 673 mg*hr/L, respectively.",Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34323955/),[h·mg] / [l],786,91241,DB01045,Rifampicin
,34323955,area under the concentration-time curve (AUCSS),"1.53 L/h, p<0.001), with area under the concentration-time curve (AUCSS) of 786 and 673 mg*hr/L, respectively.",Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34323955/),[h·mg] / [l],673,91242,DB01045,Rifampicin
,34323955,AUCss,"In pregnant women with HIV, clearance was 30% higher than women without HIV (p<0.001), resulting in a lower AUCss (522 mg*h/L); clearance did not change significantly between pregnancy and postpartum.",Pharmacokinetics and Safety of Three Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34323955/),[h·mg] / [l],522,91243,DB01045,Rifampicin
,22108776,Apparent,Apparent EFV clearance after oral administration in fast metabolizers was 12.9 L/h/70 kg whilst off tuberculosis treatment and 9.1 L/h/70 kg when on tuberculosis treatment.,The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108776/),[l] / [70·h·kg],12.9,91467,DB01045,Rifampicin
,22108776,Apparent,Apparent EFV clearance after oral administration in fast metabolizers was 12.9 L/h/70 kg whilst off tuberculosis treatment and 9.1 L/h/70 kg when on tuberculosis treatment.,The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108776/),[l] / [70·h·kg],9.1,91468,DB01045,Rifampicin
,22108776,clearance,"In slow metabolizers, the clearance estimates were 3.3 and 4.7 L/h/70 kg in the presence and absence of TB treatment, respectively.",The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108776/),[l] / [70·h·kg],3.3,91469,DB01045,Rifampicin
,22108776,clearance,"In slow metabolizers, the clearance estimates were 3.3 and 4.7 L/h/70 kg in the presence and absence of TB treatment, respectively.",The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22108776/),[l] / [70·h·kg],4.7,91470,DB01045,Rifampicin
,29844047,maximal kill (maximum effect [Emax]),Coincubation of M. kansasii with different clofazimine concentrations over 7 days in test tubes resulted in a maximal kill (maximum effect [Emax]) of 2.03 log10 CFU/ml below the day 0 bacterial burden.,Clofazimine for the Treatment of Mycobacterium kansasii. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29844047/),[cfu·log10] / [ml],2.03,91619,DB01045,Rifampicin
,29844047,Emax,"On day 14, when the clofazimine microbial effect was maximal, the Emax was 2.57 log10 CFU/ml, while the dose associated with Emax was 100 mg/day.",Clofazimine for the Treatment of Mycobacterium kansasii. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29844047/),[cfu·log10] / [ml],2.57,91620,DB01045,Rifampicin
,29844047,kill rate constants,"The effect of standard therapy was consistent with a biexponential decline, with kill rate constants of 1.85 per day (half-life = 0.37 days) and 0.06 per day (half-life = 12.76 days) (r2 > 0.99).",Clofazimine for the Treatment of Mycobacterium kansasii. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29844047/),1/[d],1.85,91621,DB01045,Rifampicin
,29844047,half-life,"The effect of standard therapy was consistent with a biexponential decline, with kill rate constants of 1.85 per day (half-life = 0.37 days) and 0.06 per day (half-life = 12.76 days) (r2 > 0.99).",Clofazimine for the Treatment of Mycobacterium kansasii. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29844047/),d,0.37,91622,DB01045,Rifampicin
,29844047,half-life,"The effect of standard therapy was consistent with a biexponential decline, with kill rate constants of 1.85 per day (half-life = 0.37 days) and 0.06 per day (half-life = 12.76 days) (r2 > 0.99).",Clofazimine for the Treatment of Mycobacterium kansasii. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29844047/),1/[d],0.06,91623,DB01045,Rifampicin
,29844047,half-life,"The effect of standard therapy was consistent with a biexponential decline, with kill rate constants of 1.85 per day (half-life = 0.37 days) and 0.06 per day (half-life = 12.76 days) (r2 > 0.99).",Clofazimine for the Treatment of Mycobacterium kansasii. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29844047/),d,12.76,91624,DB01045,Rifampicin
,14700343,bioavailability indices,"The bioavailability indices based on AUC were 0.96 with RE, 0.76 with RH, 1.08 with RZ and 0.65 with REHZ.",Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14700343/),,0.96,92129,DB01045,Rifampicin
,14700343,bioavailability indices,"The bioavailability indices based on AUC were 0.96 with RE, 0.76 with RH, 1.08 with RZ and 0.65 with REHZ.",Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14700343/),,0.76,92130,DB01045,Rifampicin
,14700343,bioavailability indices,"The bioavailability indices based on AUC were 0.96 with RE, 0.76 with RH, 1.08 with RZ and 0.65 with REHZ.",Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14700343/),,1.08,92131,DB01045,Rifampicin
,14700343,bioavailability indices,"The bioavailability indices based on AUC were 0.96 with RE, 0.76 with RH, 1.08 with RZ and 0.65 with REHZ.",Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14700343/),,0.65,92132,DB01045,Rifampicin
,30792988,time to attain undetectable HIV-VL,"Median time to attain undetectable HIV-VL was 70 days in both arms, with HIV-VL overlapping trajectories during follow-up.",Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30792988/),d,70,92210,DB01045,Rifampicin
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼1.1,92275,DB01045,Rifampicin
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.014,92276,DB01045,Rifampicin
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼0.3,92277,DB01045,Rifampicin
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.007,92278,DB01045,Rifampicin
,26825153,peak concentration (Cmax),Children with HIV and TB had significantly lower RMP peak concentration (Cmax) (2.6 vs. 5.1 μg/mL; P < 0.001) and exposure [area under the time-concentration curve (AUC0-8); 10.4 vs. 23.4 μg/mL h; P < 0.001] than those with TB.,Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825153/),[μg] / [ml],2.6,93106,DB01045,Rifampicin
,26825153,peak concentration (Cmax),Children with HIV and TB had significantly lower RMP peak concentration (Cmax) (2.6 vs. 5.1 μg/mL; P < 0.001) and exposure [area under the time-concentration curve (AUC0-8); 10.4 vs. 23.4 μg/mL h; P < 0.001] than those with TB.,Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825153/),[μg] / [ml],5.1,93107,DB01045,Rifampicin
,26825153,area under the time-concentration curve (AUC0-8),Children with HIV and TB had significantly lower RMP peak concentration (Cmax) (2.6 vs. 5.1 μg/mL; P < 0.001) and exposure [area under the time-concentration curve (AUC0-8); 10.4 vs. 23.4 μg/mL h; P < 0.001] than those with TB.,Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825153/),[μg] / [h·ml],10.4,93108,DB01045,Rifampicin
,26825153,area under the time-concentration curve (AUC0-8),Children with HIV and TB had significantly lower RMP peak concentration (Cmax) (2.6 vs. 5.1 μg/mL; P < 0.001) and exposure [area under the time-concentration curve (AUC0-8); 10.4 vs. 23.4 μg/mL h; P < 0.001] than those with TB.,Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825153/),[μg] / [h·ml],23.4,93109,DB01045,Rifampicin
,22692377,half-life,The blood-effect site equilibration half-life ranged from 0 (cognitive flexibility) to 11.8 (pain intensity) min and was 6.1 min averaged across all endpoints.,Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22692377/),min,0,94814,DB01045,Rifampicin
,22692377,half-life,The blood-effect site equilibration half-life ranged from 0 (cognitive flexibility) to 11.8 (pain intensity) min and was 6.1 min averaged across all endpoints.,Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22692377/),min,11.8,94815,DB01045,Rifampicin
,22692377,half-life,The blood-effect site equilibration half-life ranged from 0 (cognitive flexibility) to 11.8 (pain intensity) min and was 6.1 min averaged across all endpoints.,Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22692377/),min,6.1,94816,DB01045,Rifampicin
,29239016,plasma exposure,Rifampicin significantly (P<0.05) increased the plasma exposure of gamithromycin (16.2 ± 4.77 vs. 8.57 ± 3.10 μg × h/mL) by decreasing the total body clearance.,Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29239016/),μ,16.2,96122,DB01045,Rifampicin
,29239016,plasma exposure,Rifampicin significantly (P<0.05) increased the plasma exposure of gamithromycin (16.2 ± 4.77 vs. 8.57 ± 3.10 μg × h/mL) by decreasing the total body clearance.,Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29239016/),μ,8.57,96123,DB01045,Rifampicin
,7858395,Cmax,"Pharmacokinetic parameters (mean +/- SEM) were: Cmax 13.514 +/- 1.775 micrograms/ml, tmax 1.88 +/- 0.30 h, AUC 73.61 +/- 9.48 micrograms.h/ml and half-life 2.98 +/- 0.29 h.",Determination of oral rifampin pharmacokinetic parameters in Mexicans and comparison with other populations: absence of evidence for interethnic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7858395/),[μg] / [ml],13.514,97217,DB01045,Rifampicin
,7858395,tmax,"Pharmacokinetic parameters (mean +/- SEM) were: Cmax 13.514 +/- 1.775 micrograms/ml, tmax 1.88 +/- 0.30 h, AUC 73.61 +/- 9.48 micrograms.h/ml and half-life 2.98 +/- 0.29 h.",Determination of oral rifampin pharmacokinetic parameters in Mexicans and comparison with other populations: absence of evidence for interethnic variability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7858395/),h,1.88,97218,DB01045,Rifampicin
,7858395,AUC,"Pharmacokinetic parameters (mean +/- SEM) were: Cmax 13.514 +/- 1.775 micrograms/ml, tmax 1.88 +/- 0.30 h, AUC 73.61 +/- 9.48 micrograms.h/ml and half-life 2.98 +/- 0.29 h.",Determination of oral rifampin pharmacokinetic parameters in Mexicans and comparison with other populations: absence of evidence for interethnic variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7858395/),[h·μg] / [ml],73.61,97219,DB01045,Rifampicin
,7858395,half-life,"Pharmacokinetic parameters (mean +/- SEM) were: Cmax 13.514 +/- 1.775 micrograms/ml, tmax 1.88 +/- 0.30 h, AUC 73.61 +/- 9.48 micrograms.h/ml and half-life 2.98 +/- 0.29 h.",Determination of oral rifampin pharmacokinetic parameters in Mexicans and comparison with other populations: absence of evidence for interethnic variability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7858395/),h,2.98,97220,DB01045,Rifampicin
,26387492,apparent clearance (CL/F),"Typical population values of apparent clearance (CL/F) and apparent volume of distribution (VD /F) were 4.02 L/h and 57.8 L, respectively.",Population Pharmacokinetics of Rifampicin in Chinese Patients With Pulmonary Tuberculosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387492/),[l] / [h],4.02,97465,DB01045,Rifampicin
,26387492,apparent volume of distribution (VD /F),"Typical population values of apparent clearance (CL/F) and apparent volume of distribution (VD /F) were 4.02 L/h and 57.8 L, respectively.",Population Pharmacokinetics of Rifampicin in Chinese Patients With Pulmonary Tuberculosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26387492/),l,57.8,97466,DB01045,Rifampicin
,25535219,terminal half-life,"Its terminal half-life is extremely long (5-6 months), complicating evaluations of drug-drug interactions.","Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25535219/),month,5-6,97765,DB01045,Rifampicin
<,18096560,Cmin,Nevirapine Cmin was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed virological failure) and in none afterwards.,Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18096560/),[mg] / [l],3,97835,DB01045,Rifampicin
,9626920,limit of detection,The limit of detection for itraconazole concentration was 16 ng x ml(-1).,Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[ng] / [ml],16,97908,DB01045,Rifampicin
,9626920,AUC0-24,"The mean AUC0-24 was 3.28 vs 0.39 microg x h x ml(-1) in phase 1 and 2, respectively, in healthy normal volunteers.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],3.28,97909,DB01045,Rifampicin
,9626920,AUC0-24,"The mean AUC0-24 was 3.28 vs 0.39 microg x h x ml(-1) in phase 1 and 2, respectively, in healthy normal volunteers.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],0.39,97910,DB01045,Rifampicin
,9626920,AUC0-24,"The mean AUC0-24 was 1.07 vs 0.38 microg x h x ml(-1) in phase 1 and 2, respectively, in AIDS patients.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],1.07,97911,DB01045,Rifampicin
,9626920,AUC0-24,"The mean AUC0-24 was 1.07 vs 0.38 microg x h x ml(-1) in phase 1 and 2, respectively, in AIDS patients.",Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626920/),[h·μg] / [ml],0.38,97912,DB01045,Rifampicin
,17576825,concentration of drug in serum at 12 h (C(12 h)),"During period 1, the mean concentration of drug in serum at 12 h (C(12 h)) was 811 ng/ml (range, 363 to 2,484 ng/ml) for atazanavir, similar to historic seronegative data for once-daily treatment with 300 mg atazanavir boosted with 100 mg ritonavir.",Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576825/),[ng] / [ml],811,98153,DB01045,Rifampicin
,17576825,C(12 h),"During periods 2 and 3, the mean C(12 h) values for atazanavir were 44 ng/ml (range, <25 to 187 ng/ml) and 113 ng/ml (range, 39 to 260 ng/ml), respectively, well below historic seronegative data for once-daily treatment with 400 mg atazanavir without ritonavir.",Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576825/),[ng] / [ml],44,98154,DB01045,Rifampicin
,17576825,C(12 h),"During periods 2 and 3, the mean C(12 h) values for atazanavir were 44 ng/ml (range, <25 to 187 ng/ml) and 113 ng/ml (range, 39 to 260 ng/ml), respectively, well below historic seronegative data for once-daily treatment with 400 mg atazanavir without ritonavir.",Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17576825/),[ng] / [ml],113,98155,DB01045,Rifampicin
,28063154,distribution volume,The distribution volume of rifampicin administered i.v. was ~0.85 L/kg.,Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),[l] / [kg],0.85,98481,DB01045,Rifampicin
,28063154,Terminal elimination half-life,Terminal elimination half-life was ~11 h.,Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),h,11,98482,DB01045,Rifampicin
,28063154,Tmax,"Orally given rifampicin was slowly absorbed (Tmax , range: 2.5-8.0 h) and eliminated with apparent half-lives of ~6-8 h.",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),h,2.5-8.0,98483,DB01045,Rifampicin
,28063154,apparent half-lives,"Orally given rifampicin was slowly absorbed (Tmax , range: 2.5-8.0 h) and eliminated with apparent half-lives of ~6-8 h.",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),h,6-8,98484,DB01045,Rifampicin
,28063154,Trough concentrations,"Trough concentrations in ELF and BALC were 1.01 ± 0.20 μg/mL and 1.25 ± 0.29 μg/mL, respectively, after 10 mg/kg bwt rifampicin and 2.71 ± 1.25 μg/mL and 3.09 ± 1.63 μg/mL, respectively, after 20 mg/kg bwt rifampicin.",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),[μg] / [ml],1.01,98485,DB01045,Rifampicin
,28063154,Trough concentrations,"Trough concentrations in ELF and BALC were 1.01 ± 0.20 μg/mL and 1.25 ± 0.29 μg/mL, respectively, after 10 mg/kg bwt rifampicin and 2.71 ± 1.25 μg/mL and 3.09 ± 1.63 μg/mL, respectively, after 20 mg/kg bwt rifampicin.",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),[μg] / [ml],1.25,98486,DB01045,Rifampicin
,28063154,Trough concentrations,"Trough concentrations in ELF and BALC were 1.01 ± 0.20 μg/mL and 1.25 ± 0.29 μg/mL, respectively, after 10 mg/kg bwt rifampicin and 2.71 ± 1.25 μg/mL and 3.09 ± 1.63 μg/mL, respectively, after 20 mg/kg bwt rifampicin.",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),[μg] / [ml],2.71,98487,DB01045,Rifampicin
,28063154,Trough concentrations,"Trough concentrations in ELF and BALC were 1.01 ± 0.20 μg/mL and 1.25 ± 0.29 μg/mL, respectively, after 10 mg/kg bwt rifampicin and 2.71 ± 1.25 μg/mL and 3.09 ± 1.63 μg/mL, respectively, after 20 mg/kg bwt rifampicin.",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),[μg] / [ml],3.09,98488,DB01045,Rifampicin
,28063154,ratios of area under the plasma concentration time curve during an administration interval of 24 h (AUC0-24 h ) to,"The average ratios of area under the plasma concentration time curve during an administration interval of 24 h (AUC0-24 h ) to minimum inhibitory concentration (MIC) were 145 and 322 h, respectively, for less susceptible strains of R. equi (MIC90 : 0.5 μg/mL).",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),h,145,98489,DB01045,Rifampicin
,28063154,ratios of area under the plasma concentration time curve during an administration interval of 24 h (AUC0-24 h ) to,"The average ratios of area under the plasma concentration time curve during an administration interval of 24 h (AUC0-24 h ) to minimum inhibitory concentration (MIC) were 145 and 322 h, respectively, for less susceptible strains of R. equi (MIC90 : 0.5 μg/mL).",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),h,322,98490,DB01045,Rifampicin
,28063154,minimum inhibitory concentration (MIC),"The average ratios of area under the plasma concentration time curve during an administration interval of 24 h (AUC0-24 h ) to minimum inhibitory concentration (MIC) were 145 and 322 h, respectively, for less susceptible strains of R. equi (MIC90 : 0.5 μg/mL).",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),h,145,98491,DB01045,Rifampicin
,28063154,minimum inhibitory concentration (MIC),"The average ratios of area under the plasma concentration time curve during an administration interval of 24 h (AUC0-24 h ) to minimum inhibitory concentration (MIC) were 145 and 322 h, respectively, for less susceptible strains of R. equi (MIC90 : 0.5 μg/mL).",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),h,322,98492,DB01045,Rifampicin
,28063154,MIC90,"The average ratios of area under the plasma concentration time curve during an administration interval of 24 h (AUC0-24 h ) to minimum inhibitory concentration (MIC) were 145 and 322 h, respectively, for less susceptible strains of R. equi (MIC90 : 0.5 μg/mL).",Pharmacological indices and pulmonary distribution of rifampicin after repeated oral administration in healthy foals. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28063154/),[μg] / [ml],0.5,98493,DB01045,Rifampicin
,25081933,Cmin,"Median efavirenz Cmin during pregnancy was 1.35 µg/mL (interquartile range [IQR], 0.90-2.07 µg/mL; 27% had an efavirenz Cmin of < 1 µg/mL), compared with a median postpartum value of 2.00 µg/mL (IQR, 1.40-3.59 µg/mL; 13% had an efavirenz Cmin of < 1 µg/mL).",Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25081933/),[μg] / [ml],1.35,98921,DB01045,Rifampicin
<,25081933,Cmin,"Median efavirenz Cmin during pregnancy was 1.35 µg/mL (interquartile range [IQR], 0.90-2.07 µg/mL; 27% had an efavirenz Cmin of < 1 µg/mL), compared with a median postpartum value of 2.00 µg/mL (IQR, 1.40-3.59 µg/mL; 13% had an efavirenz Cmin of < 1 µg/mL).",Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25081933/),[μg] / [ml],1,98922,DB01045,Rifampicin
,25081933,Cmin,"Median efavirenz Cmin during pregnancy was 1.35 µg/mL (interquartile range [IQR], 0.90-2.07 µg/mL; 27% had an efavirenz Cmin of < 1 µg/mL), compared with a median postpartum value of 2.00 µg/mL (IQR, 1.40-3.59 µg/mL; 13% had an efavirenz Cmin of < 1 µg/mL).",Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25081933/),[μg] / [ml],2.00,98923,DB01045,Rifampicin
<,25081933,Cmin,A total of 72% of pregnant women with extensive CYP2B6 genotypes had an efavirenz Cmin of <1 µg/mL.,Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25081933/),[μg] / [ml],1,98924,DB01045,Rifampicin
,23480028,clearance,"In the clinical trial, fentanyl clearance was 18.8 ± 8.2 mL/min.",Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23480028/),[ml] / [min],18.8,99004,DB01045,Rifampicin
,23480028,clearance,"During rifampicin, fentanyl clearance was 15.0 ± 4.4 mL/min/kg in SLCO1B1*1a and 16.7 ± 5.9 mL/min/kg in SLCO1B1*15 carriers (p > 0.5).",Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23480028/),[ml] / [kg·min],15.0,99005,DB01045,Rifampicin
,23480028,clearance,"During rifampicin, fentanyl clearance was 15.0 ± 4.4 mL/min/kg in SLCO1B1*1a and 16.7 ± 5.9 mL/min/kg in SLCO1B1*15 carriers (p > 0.5).",Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23480028/),[ml] / [kg·min],16.7,99006,DB01045,Rifampicin
,16941365,AUC(0-6 h),"Geometric means of rifampicin exposure (AUC(0-6 h)) were 12.3 mg x h/L (95% confidence interval [CI], 8.0-24.2) in patients with TB and DM, and 25.9 mg x h/L (95% CI, 21.4-40.2) in patients with TB only (P=.003).",Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941365/),[h·mg] / [l],12.3,99949,DB01045,Rifampicin
,16941365,AUC(0-6 h),"Geometric means of rifampicin exposure (AUC(0-6 h)) were 12.3 mg x h/L (95% confidence interval [CI], 8.0-24.2) in patients with TB and DM, and 25.9 mg x h/L (95% CI, 21.4-40.2) in patients with TB only (P=.003).",Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941365/),[h·mg] / [l],25.9,99950,DB01045,Rifampicin
,16941365,AUC(0-6 h),"The AUC(0-6 h) of desacetylrifampicin was also much lower in patients with TB and DM versus patients with TB only (geometric mean, 0.60 vs. 3.2 mg x h/L; P=.001).",Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941365/),[h·mg] / [l],0.60,99951,DB01045,Rifampicin
,16941365,AUC(0-6 h),"The AUC(0-6 h) of desacetylrifampicin was also much lower in patients with TB and DM versus patients with TB only (geometric mean, 0.60 vs. 3.2 mg x h/L; P=.001).",Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16941365/),[h·mg] / [l],3.2,99952,DB01045,Rifampicin
,22486719,clearance,"The typical population estimates (interindividual variability) for clearance, volume of distribution and absorption rate constant were 16.2 l h(-1) (0.39), 70.2 l and 0.92 h(-1) , respectively.",Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22486719/),[l] / [h],16.2,100215,DB01045,Rifampicin
,22486719,volume of distribution,"The typical population estimates (interindividual variability) for clearance, volume of distribution and absorption rate constant were 16.2 l h(-1) (0.39), 70.2 l and 0.92 h(-1) , respectively.",Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22486719/),l,70.2,100216,DB01045,Rifampicin
,22486719,absorption rate constant,"The typical population estimates (interindividual variability) for clearance, volume of distribution and absorption rate constant were 16.2 l h(-1) (0.39), 70.2 l and 0.92 h(-1) , respectively.",Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22486719/),1/[h],0.92,100217,DB01045,Rifampicin
,22486719,bioavailability,The bioavailability of the oral form was estimated to be 87.6%.,Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22486719/),%,87.6,100218,DB01045,Rifampicin
,22486719,C(min),"According to BW, theoretical doses needed to reach a C(min) of 2 mg l(-1) were then calculated.",Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22486719/),[mg] / [l],2,100219,DB01045,Rifampicin
,18728241,area under the curve,"Mean plasma efavirenz area under the curve was significantly higher in patients with CYP2B6 c.516TT than in those with GT (107 vs 27.6 microg x h/mL, P< .0001) or GG genotype (107 vs 23.0 microg x h/mL, P< .0001).",Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728241/),[h·μg] / [ml],107,101099,DB01045,Rifampicin
,18728241,area under the curve,"Mean plasma efavirenz area under the curve was significantly higher in patients with CYP2B6 c.516TT than in those with GT (107 vs 27.6 microg x h/mL, P< .0001) or GG genotype (107 vs 23.0 microg x h/mL, P< .0001).",Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728241/),[h·μg] / [ml],27.6,101100,DB01045,Rifampicin
,18728241,area under the curve,"Mean plasma efavirenz area under the curve was significantly higher in patients with CYP2B6 c.516TT than in those with GT (107 vs 27.6 microg x h/mL, P< .0001) or GG genotype (107 vs 23.0 microg x h/mL, P< .0001).",Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728241/),[h·μg] / [ml],23.0,101101,DB01045,Rifampicin
,18728241,Apparent oral clearance (CL/F),"Apparent oral clearance (CL/F) was significantly lower in patients with CYP2B6 c.516TT than in those with GT genotype (2.1 vs 8.4 mL/min/kg, P<0.0001) and GG genotype (2.1 vs 9.9 mL/min/kg, P< .0001).",Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728241/),[ml] / [kg·min],2.1,101102,DB01045,Rifampicin
,18728241,Apparent oral clearance (CL/F),"Apparent oral clearance (CL/F) was significantly lower in patients with CYP2B6 c.516TT than in those with GT genotype (2.1 vs 8.4 mL/min/kg, P<0.0001) and GG genotype (2.1 vs 9.9 mL/min/kg, P< .0001).",Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728241/),[ml] / [kg·min],8.4,101103,DB01045,Rifampicin
,18728241,Apparent oral clearance (CL/F),"Apparent oral clearance (CL/F) was significantly lower in patients with CYP2B6 c.516TT than in those with GT genotype (2.1 vs 8.4 mL/min/kg, P<0.0001) and GG genotype (2.1 vs 9.9 mL/min/kg, P< .0001).",Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18728241/),[ml] / [kg·min],9.9,101104,DB01045,Rifampicin
,25132417,flow rate,"The rat plasma samples (100 μL) were injected directly onto pre-column, where RIP was retained and pre-concentrated, while proteins were washed to waste using a methanol-water (5:95) as the mobile phase at a flow rate of 1 mL/min.",Determination of rifampicin in rat plasma by modified large-volume direct injection RAM-HPLC and its application to a pharmcokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132417/),[ml] / [min],1,101163,DB01045,Rifampicin
,25132417,flow rate,"Then, by rotation of the switching valve at 5 min, the RIP were eluted from the pre-column and transferred to an Luna C18 analytical column by the chromatographic mobile phase consisting of methanol-acetonitrile-10 mm ammonium format (60:5:35) at a flow rate of 1 mL/min.",Determination of rifampicin in rat plasma by modified large-volume direct injection RAM-HPLC and its application to a pharmcokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132417/),[ml] / [min],1,101164,DB01045,Rifampicin
,25132417,total analytical run time,The total analytical run time was 15 min with UV detection wavelength at 254 nm.,Determination of rifampicin in rat plasma by modified large-volume direct injection RAM-HPLC and its application to a pharmcokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132417/),min,15,101165,DB01045,Rifampicin
,25132417,recoveries,The recoveries were in the range of from 99.98-113.66% for plasma.,Determination of rifampicin in rat plasma by modified large-volume direct injection RAM-HPLC and its application to a pharmcokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25132417/),%,99.98-113.66,101166,DB01045,Rifampicin
,33155304,Peak plasma concentration (Cmax ),"Peak plasma concentration (Cmax ) values of tulathromycin were 1,390 ± 173, 958 ± 106, and 807 ± 116 ng/ml in groups A, B, and C, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),[ng] / [ml],"1,390",101706,DB01045,Rifampicin
,33155304,Peak plasma concentration (Cmax ),"Peak plasma concentration (Cmax ) values of tulathromycin were 1,390 ± 173, 958 ± 106, and 807 ± 116 ng/ml in groups A, B, and C, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),[ng] / [ml],958,101707,DB01045,Rifampicin
,33155304,Peak plasma concentration (Cmax ),"Peak plasma concentration (Cmax ) values of tulathromycin were 1,390 ± 173, 958 ± 106, and 807 ± 116 ng/ml in groups A, B, and C, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),[ng] / [ml],807,101708,DB01045,Rifampicin
,33155304,Mean residence time based on time zero to last sample time (MRTlast ),"Mean residence time based on time zero to last sample time (MRTlast ) values were 52 ± 1, 56 ± 4 and 66 ± 4 hr in A, B, and C groups, respectively whereas mean residence time based on time zero extrapolated to infinity (MRTINF_obs ) values were 69 ± 4, 85 ± 5, and 86 ± 4 hr, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),h,52,101709,DB01045,Rifampicin
,33155304,Mean residence time based on time zero to last sample time (MRTlast ),"Mean residence time based on time zero to last sample time (MRTlast ) values were 52 ± 1, 56 ± 4 and 66 ± 4 hr in A, B, and C groups, respectively whereas mean residence time based on time zero extrapolated to infinity (MRTINF_obs ) values were 69 ± 4, 85 ± 5, and 86 ± 4 hr, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),h,56,101710,DB01045,Rifampicin
,33155304,Mean residence time based on time zero to last sample time (MRTlast ),"Mean residence time based on time zero to last sample time (MRTlast ) values were 52 ± 1, 56 ± 4 and 66 ± 4 hr in A, B, and C groups, respectively whereas mean residence time based on time zero extrapolated to infinity (MRTINF_obs ) values were 69 ± 4, 85 ± 5, and 86 ± 4 hr, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),h,66,101711,DB01045,Rifampicin
,33155304,mean residence time based on time zero extrapolated to infinity (MRTINF_obs ),"Mean residence time based on time zero to last sample time (MRTlast ) values were 52 ± 1, 56 ± 4 and 66 ± 4 hr in A, B, and C groups, respectively whereas mean residence time based on time zero extrapolated to infinity (MRTINF_obs ) values were 69 ± 4, 85 ± 5, and 86 ± 4 hr, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),h,69,101712,DB01045,Rifampicin
,33155304,mean residence time based on time zero extrapolated to infinity (MRTINF_obs ),"Mean residence time based on time zero to last sample time (MRTlast ) values were 52 ± 1, 56 ± 4 and 66 ± 4 hr in A, B, and C groups, respectively whereas mean residence time based on time zero extrapolated to infinity (MRTINF_obs ) values were 69 ± 4, 85 ± 5, and 86 ± 4 hr, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),h,85,101713,DB01045,Rifampicin
,33155304,mean residence time based on time zero extrapolated to infinity (MRTINF_obs ),"Mean residence time based on time zero to last sample time (MRTlast ) values were 52 ± 1, 56 ± 4 and 66 ± 4 hr in A, B, and C groups, respectively whereas mean residence time based on time zero extrapolated to infinity (MRTINF_obs ) values were 69 ± 4, 85 ± 5, and 86 ± 4 hr, respectively.",Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33155304/),h,86,101714,DB01045,Rifampicin
,30117017,time to reach maximum plasma concentration,"Ixazomib absorption is rapid, with a median time to reach maximum plasma concentration of approximately 1 h post-dose.",Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),h,1,102068,DB01045,Rifampicin
,30117017,terminal half-life,Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9.5 days) with first-order linear absorption (oral bioavailability of 58%).,Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),d,9.5,102069,DB01045,Rifampicin
,30117017,oral bioavailability,Ixazomib pharmacokinetics (PK) are adequately described by a three-compartment model (terminal half-life of 9.5 days) with first-order linear absorption (oral bioavailability of 58%).,Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117017/),%,58,102070,DB01045,Rifampicin
,21988334,Twenty-four hour,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,5.9,102209,DB01045,Rifampicin
,21988334,Twenty-four hour,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,7.7,102210,DB01045,Rifampicin
,21988334,urine volume,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,5.9,102211,DB01045,Rifampicin
,21988334,urine volume,Twenty-four hour urine volume increased from 5.9 to 7.7 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,7.7,102212,DB01045,Rifampicin
,21988334,Twenty-four hour urine volume,Twenty-four hour urine volume decreased from 12.3 to 8.8 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,12.3,102213,DB01045,Rifampicin
,21988334,Twenty-four hour urine volume,Twenty-four hour urine volume decreased from 12.3 to 8.8 l.,"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988334/),l,8.8,102214,DB01045,Rifampicin
,15329598,area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),[h·ng] / [ml],5.9,103159,DB01045,Rifampicin
,15329598,area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),[h·ng] / [ml],2.2,103160,DB01045,Rifampicin
,15329598,area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),[h·ng] / [ml],10.4,103161,DB01045,Rifampicin
,15329598,area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),[h·ng] / [ml],5.8,103162,DB01045,Rifampicin
,15329598,plasma area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),,0.92,103163,DB01045,Rifampicin
,15329598,plasma area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),,3.2,103164,DB01045,Rifampicin
,15329598,plasma area under the curve,"After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h x ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control).",Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329598/),,0,103165,DB01045,Rifampicin
,20660695,area under the concentration-time curve from 0 to 24 h [AUC(0-24)],Rifampin pharmacokinetic values were similar between tuberculosis patients and controls (geometric mean [GM] area under the concentration-time curve from 0 to 24 h [AUC(0-24)] of 40.2 versus 40.9 μg.h/ml; P = 0.9).,"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660695/),[h·μg] / [ml],40.2,104764,DB01045,Rifampicin
,20660695,area under the concentration-time curve from 0 to 24 h [AUC(0-24)],Rifampin pharmacokinetic values were similar between tuberculosis patients and controls (geometric mean [GM] area under the concentration-time curve from 0 to 24 h [AUC(0-24)] of 40.2 versus 40.9 μg.h/ml; P = 0.9).,"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660695/),[h·μg] / [ml],40.9,104765,DB01045,Rifampicin
,20660695,AUC(0-24),"The adjusted rifampin AUC(0-24) was also 36% lower among participants with SLCO1B1 genotype c.463CA than that among participants with SLCO1B1 genotype c.463CC (adjusted GM, 29.8 versus 46.7 μg.h/ml; P = 0.001).","Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660695/),[h·μg] / [ml],29.8,104766,DB01045,Rifampicin
,20660695,AUC(0-24),"The adjusted rifampin AUC(0-24) was also 36% lower among participants with SLCO1B1 genotype c.463CA than that among participants with SLCO1B1 genotype c.463CC (adjusted GM, 29.8 versus 46.7 μg.h/ml; P = 0.001).","Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660695/),[h·μg] / [ml],46.7,104767,DB01045,Rifampicin
,20660695,GM,"The adjusted rifampin AUC(0-24) was also 36% lower among participants with SLCO1B1 genotype c.463CA than that among participants with SLCO1B1 genotype c.463CC (adjusted GM, 29.8 versus 46.7 μg.h/ml; P = 0.001).","Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660695/),[h·μg] / [ml],29.8,104768,DB01045,Rifampicin
,20660695,GM,"The adjusted rifampin AUC(0-24) was also 36% lower among participants with SLCO1B1 genotype c.463CA than that among participants with SLCO1B1 genotype c.463CC (adjusted GM, 29.8 versus 46.7 μg.h/ml; P = 0.001).","Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20660695/),[h·μg] / [ml],46.7,104769,DB01045,Rifampicin
<,23676165,Cmax,"Children aged <3 years had significantly lower RMP, INH and PZA concentrations than older children, and 90% of all children had sub-therapeutic RMP Cmax (<8 μg/ml).","Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676165/),[μg] / [ml],8,105572,DB01045,Rifampicin
,10223941,maximum concentrations,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),[μg] / [ml],14.09,106924,DB01045,Rifampicin
,10223941,maximum concentrations,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),[μg] / [ml],373.63,106925,DB01045,Rifampicin
,10223941,maximum concentrations,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),μg,9.42,106926,DB01045,Rifampicin
,10223941,maximum concentrations,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),μg,256.10,106927,DB01045,Rifampicin
,10223941,areas under the curve from time zero to infinity,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),[μg] / [ml],373.63,106928,DB01045,Rifampicin
,10223941,areas under the curve from time zero to infinity,"Mean (+/- the standard deviation) maximum concentrations of rifapentine in serum and areas under the curve from time zero to infinity following a high-fat breakfast were 14.09 +/- 2.81 and 373.63 +/- 78.19 micrograms/ml, respectively, and following a fasting period they were 9.42 +/- 2.67 and 256.10 +/- 86.39 micrograms.",Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223941/),μg,256.10,106929,DB01045,Rifampicin
,4087830,systemic clearance,"It was found that, due to autoinduction of its metabolizing hepatic enzymes, the systemic clearance of rifampicin increased from 5.69 to 9.03 l/h after 3 weeks of multiple dosing.",Pharmacokinetics of oral and intravenous rifampicin during chronic administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087830/),[l] / [h],5.69,107699,DB01045,Rifampicin
,4087830,systemic clearance,"It was found that, due to autoinduction of its metabolizing hepatic enzymes, the systemic clearance of rifampicin increased from 5.69 to 9.03 l/h after 3 weeks of multiple dosing.",Pharmacokinetics of oral and intravenous rifampicin during chronic administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087830/),[l] / [h],9.03,107700,DB01045,Rifampicin
,4087830,bioavailability,"The bioavailability of the active, orally administered rifampicin decreased from 93% after the first single oral dose to 68% after 3 weeks of oral and intravenous rifampicin therapy.",Pharmacokinetics of oral and intravenous rifampicin during chronic administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087830/),%,93,107701,DB01045,Rifampicin
,4087830,bioavailability,"The bioavailability of the active, orally administered rifampicin decreased from 93% after the first single oral dose to 68% after 3 weeks of oral and intravenous rifampicin therapy.",Pharmacokinetics of oral and intravenous rifampicin during chronic administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087830/),%,68,107702,DB01045,Rifampicin
lower,4087830,bioavailability,"Relating to the increase in systemic (hepatic) clearance, a bioavailability no lower than 90% can be predicted.",Pharmacokinetics of oral and intravenous rifampicin during chronic administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4087830/),%,90,107703,DB01045,Rifampicin
,10228130,blood flow rate,"Six were given single oral doses (INH 300 mg, RIF 600 mg, PZA 1000 mg, and EMB 25 mg/kg) 2 h before hemodialysis (Cobe Centrysystem 3 hemodialysis machine; Fresenius F80B dialyzer; median blood flow rate 400 ml/min; dialysate flow rate 600 ml/min; median hemodialysis time 3.5 h).","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),[ml] / [min],400,107997,DB01045,Rifampicin
,10228130,flow rate,"Six were given single oral doses (INH 300 mg, RIF 600 mg, PZA 1000 mg, and EMB 25 mg/kg) 2 h before hemodialysis (Cobe Centrysystem 3 hemodialysis machine; Fresenius F80B dialyzer; median blood flow rate 400 ml/min; dialysate flow rate 600 ml/min; median hemodialysis time 3.5 h).","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),[ml] / [min],600,107998,DB01045,Rifampicin
,10228130,recoveries,"Median recoveries of drug in dialysate were 9% (INH), 4% (RIF), 45% (PZA), and 2% (EMB) of the doses administered.","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),%,9,107999,DB01045,Rifampicin
,10228130,recoveries,"Median recoveries of drug in dialysate were 9% (INH), 4% (RIF), 45% (PZA), and 2% (EMB) of the doses administered.","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),%,4,108000,DB01045,Rifampicin
,10228130,recoveries,"Median recoveries of drug in dialysate were 9% (INH), 4% (RIF), 45% (PZA), and 2% (EMB) of the doses administered.","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),%,45,108001,DB01045,Rifampicin
,10228130,recoveries,"Median recoveries of drug in dialysate were 9% (INH), 4% (RIF), 45% (PZA), and 2% (EMB) of the doses administered.","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),%,2,108002,DB01045,Rifampicin
,10228130,clearances,"Median hemodialysis clearances calculated by dividing the amount recovered in dialysate by the serum area under the curve during hemodialysis were 124 (INH), 40 (RIF), 270 (PZA), and 46 (EMB) ml/min.","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),[ml] / [min],124,108003,DB01045,Rifampicin
,10228130,clearances,"Median hemodialysis clearances calculated by dividing the amount recovered in dialysate by the serum area under the curve during hemodialysis were 124 (INH), 40 (RIF), 270 (PZA), and 46 (EMB) ml/min.","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),[ml] / [min],40,108004,DB01045,Rifampicin
,10228130,clearances,"Median hemodialysis clearances calculated by dividing the amount recovered in dialysate by the serum area under the curve during hemodialysis were 124 (INH), 40 (RIF), 270 (PZA), and 46 (EMB) ml/min.","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),[ml] / [min],270,108005,DB01045,Rifampicin
,10228130,clearances,"Median hemodialysis clearances calculated by dividing the amount recovered in dialysate by the serum area under the curve during hemodialysis were 124 (INH), 40 (RIF), 270 (PZA), and 46 (EMB) ml/min.","The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228130/),[ml] / [min],46,108006,DB01045,Rifampicin
,26903278,time,Adjunctive treatment with 60 mg/kg simvastatin shortened the time required to achieve culture-negative lungs from 4.5 to 3.5 months.,Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),month,4.5,108363,DB01045,Rifampicin
,26903278,time,Adjunctive treatment with 60 mg/kg simvastatin shortened the time required to achieve culture-negative lungs from 4.5 to 3.5 months.,Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),month,3.5,108364,DB01045,Rifampicin
,26903278,relapse rates,"Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group.",Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),%,100,108365,DB01045,Rifampicin
,26903278,relapse rates,"Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group.",Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),%,50,108366,DB01045,Rifampicin
,26903278,relapse rates,"Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group.",Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),%,0,108367,DB01045,Rifampicin
,26903278,relapse rates,"Following 2.5, 3.5 and 4.5 months of treatment, relapse rates were 100%, 50% and 0%, respectively, in the control group and 50% (P = 0.03), 20% and 0%, respectively, in the statin group.",Statin adjunctive therapy shortens the duration of TB treatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26903278/),%,20,108368,DB01045,Rifampicin
,2877885,peak plasma levels (Cssmax),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [ml],55.5,108453,DB01045,Rifampicin
,2877885,area under the plasma level-time curve (AUC tau),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [h·ml],597,108454,DB01045,Rifampicin
,2877885,total body clearance (CL),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[l] / [h],15.8,108455,DB01045,Rifampicin
,2877885,elimination half-lives (t1/2 beta),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),h,10.1,108456,DB01045,Rifampicin
,2877885,Cssmax,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [ml],43.0,108457,DB01045,Rifampicin
,2877885,AUC tau,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [h·ml],397,108458,DB01045,Rifampicin
,2877885,t1/2 beta,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),h,6.2,108459,DB01045,Rifampicin
,2877885,total body clearance,"Accordingly, total body clearance increased to 23.8 +/- 2.5 l/h (p less than 0.05).",Interaction of bisoprolol with cimetidine and rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[l] / [h],23.8,108460,DB01045,Rifampicin
,8061850,terminal half-life,"After intravenous infusion, the disposition of spirapril is monophasic with a terminal half-life of 20-50 minutes.",Spirapril: pharmacokinetic properties and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),min,20-50,108588,DB01045,Rifampicin
,8061850,Plasma clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],56,108589,DB01045,Rifampicin
,8061850,renal clearance,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],11,108590,DB01045,Rifampicin
,8061850,volume of distribution,Plasma clearance was 56 l/h and renal clearance was 11 l/h; the volume of distribution was 28 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,28,108591,DB01045,Rifampicin
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,2,108592,DB01045,Rifampicin
,8061850,half-lives,"After intravenous infusion of spiraprilat, the disposition was biphasic with half-lives of 2 hours and 35 hours, respectively.",Spirapril: pharmacokinetic properties and drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),h,35,108593,DB01045,Rifampicin
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],10,108594,DB01045,Rifampicin
,8061850,Plasma clearance,"Plasma clearance of spiraprilat was 10 l/h, of which 7.6 l/h was cleared by the kidneys.",Spirapril: pharmacokinetic properties and drug interactions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),[l] / [h],7.6,108595,DB01045,Rifampicin
,8061850,volume of distribution,The volume of distribution was 43 litres.,Spirapril: pharmacokinetic properties and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),l,43,108596,DB01045,Rifampicin
,8061850,bioavailability,The bioavailability of orally administered spirapril was 50% whereas the bioavailability of orally administered spiraprilat was virtually zero.,Spirapril: pharmacokinetic properties and drug interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061850/),%,50,108597,DB01045,Rifampicin
,31665299,half-life for distribution plasma to CSF,"Rifampicin CSF concentrations were described by a partition coefficient (5.5%; 95% confidence interval [CI], 4.5%-6.4%) and half-life for distribution plasma to CSF (2.1 hours; 95% CI, 1.3-2.9 hours).",Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31665299/),h,2.1,108881,DB01045,Rifampicin
,23698061,C(12),"For artemether, mean (±SD) C(12) was 0.5(±1.0) and 5.9(±2.5) ng/ml in phases 1 and 2, respectively.","Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698061/),[ng] / [ml],0.5,109045,DB01045,Rifampicin
,23698061,C(12),"For artemether, mean (±SD) C(12) was 0.5(±1.0) and 5.9(±2.5) ng/ml in phases 1 and 2, respectively.","Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698061/),[ng] / [ml],5.9,109046,DB01045,Rifampicin
,32901368,dissolution efficiencies,"The dissolution efficiencies (15 min) confirmed release segregation in acid media with 7.8 and 65.6% for AA-INH and CMC-RIF, respectively.",Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901368/),%,15,109159,DB01045,Rifampicin
,32901368,dissolution efficiencies,"The dissolution efficiencies (15 min) confirmed release segregation in acid media with 7.8 and 65.6% for AA-INH and CMC-RIF, respectively.",Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901368/),%,7.8,109160,DB01045,Rifampicin
,32901368,dissolution efficiencies,"The dissolution efficiencies (15 min) confirmed release segregation in acid media with 7.8 and 65.6% for AA-INH and CMC-RIF, respectively.",Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901368/),%,65.6,109161,DB01045,Rifampicin
,32901368,acid degradation,The acid degradation of RIF was significantly reduced (36.7%) when both systems were combined and oral administration to dogs revealed a 42% increase in RIF bioavailability.,Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901368/),,36,109162,DB01045,Rifampicin
,28175315,Oral clearance (CL/F),"Oral clearance (CL/F) of moxifloxacin during rifampicin-based TB treatment was 24.3 L/h for a typical patient (fat-free mass of 47 kg), resulting in an AUC of 16.5 mg·h/L.",Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28175315/),[l] / [h],24.3,109965,DB01045,Rifampicin
,28175315,AUC,"Oral clearance (CL/F) of moxifloxacin during rifampicin-based TB treatment was 24.3 L/h for a typical patient (fat-free mass of 47 kg), resulting in an AUC of 16.5 mg·h/L.",Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28175315/),[h·mg] / [l],16.5,109966,DB01045,Rifampicin
,12659608,AUC(0-24),"Nelfinavir concentrations had improved, but remained low when compared with adult population values of 1250 mg every 12 hours: AUC(0-24) 21.9 versus 47.6 mg/L*h (46%) and 12-hour trough level (C(12)) 0.25 versus 0.85 mg/L (29%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [h·l],21.9,110211,DB01045,Rifampicin
,12659608,AUC(0-24),"Nelfinavir concentrations had improved, but remained low when compared with adult population values of 1250 mg every 12 hours: AUC(0-24) 21.9 versus 47.6 mg/L*h (46%) and 12-hour trough level (C(12)) 0.25 versus 0.85 mg/L (29%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [h·l],47.6,110212,DB01045,Rifampicin
,12659608,12-hour,"Nelfinavir concentrations had improved, but remained low when compared with adult population values of 1250 mg every 12 hours: AUC(0-24) 21.9 versus 47.6 mg/L*h (46%) and 12-hour trough level (C(12)) 0.25 versus 0.85 mg/L (29%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [l],0.25,110213,DB01045,Rifampicin
,12659608,trough level (C(12)),"Nelfinavir concentrations had improved, but remained low when compared with adult population values of 1250 mg every 12 hours: AUC(0-24) 21.9 versus 47.6 mg/L*h (46%) and 12-hour trough level (C(12)) 0.25 versus 0.85 mg/L (29%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [l],0.25,110214,DB01045,Rifampicin
,12659608,trough level (C(12)),"Nelfinavir concentrations had improved, but remained low when compared with adult population values of 1250 mg every 12 hours: AUC(0-24) 21.9 versus 47.6 mg/L*h (46%) and 12-hour trough level (C(12)) 0.25 versus 0.85 mg/L (29%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [l],0.85,110215,DB01045,Rifampicin
,12659608,AUC(0-24),"However, concentrations of M8 considerably exceeded population values: AUC(0-24) 57.5 versus 13.6 mg/L*h (443%) and C(12) 1.35 versus 0.28 mg/L (482%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [h·l],57.5,110216,DB01045,Rifampicin
,12659608,AUC(0-24),"However, concentrations of M8 considerably exceeded population values: AUC(0-24) 57.5 versus 13.6 mg/L*h (443%) and C(12) 1.35 versus 0.28 mg/L (482%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [h·l],13.6,110217,DB01045,Rifampicin
,12659608,C(12),"However, concentrations of M8 considerably exceeded population values: AUC(0-24) 57.5 versus 13.6 mg/L*h (443%) and C(12) 1.35 versus 0.28 mg/L (482%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [l],1.35,110218,DB01045,Rifampicin
,12659608,C(12),"However, concentrations of M8 considerably exceeded population values: AUC(0-24) 57.5 versus 13.6 mg/L*h (443%) and C(12) 1.35 versus 0.28 mg/L (482%).",Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659608/),[mg] / [l],0.28,110219,DB01045,Rifampicin
,28607022,area under the concentration-time curve from 0 to 24 h,More than 50% of patients with weight less than 55 kg achieved lower pyrazinamide exposures at steady state than the targeted area under the concentration-time curve from 0 to 24 h of 363 mg · h/liter.,Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28607022/),[h·mg] / [l],363,110588,DB01045,Rifampicin
,24200276,peak plasma concentrations (C(max)),"The median peak plasma concentrations (C(max)) of INH, RMP and PZA were respectively 2.5, 4.0 and 43.6 μg/ml; 81% of the patients had drug plasma concentrations lower than the target ranges for at least one administered drug.","Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24200276/),[μg] / [ml],2.5,110707,DB01045,Rifampicin
,24200276,peak plasma concentrations (C(max)),"The median peak plasma concentrations (C(max)) of INH, RMP and PZA were respectively 2.5, 4.0 and 43.6 μg/ml; 81% of the patients had drug plasma concentrations lower than the target ranges for at least one administered drug.","Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24200276/),[μg] / [ml],4.0,110708,DB01045,Rifampicin
,24200276,peak plasma concentrations (C(max)),"The median peak plasma concentrations (C(max)) of INH, RMP and PZA were respectively 2.5, 4.0 and 43.6 μg/ml; 81% of the patients had drug plasma concentrations lower than the target ranges for at least one administered drug.","Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24200276/),[μg] / [ml],43.6,110709,DB01045,Rifampicin
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,107.7,111419,DB01045,Rifampicin
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,212,111420,DB01045,Rifampicin
,23400746,K(i),"In vitro studies indicated that ketoconazole inhibited the uptake of fimasartan into cells expressing OATP1B1 with a K(i) of 107.7 µM, and rifampicin inhibited OAT1- and OATP1B1-mediated fimasartan transport with a K(i) of 212 µM and 12.2 µM, respectively.","Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400746/),μM,12.2,111421,DB01045,Rifampicin
,28333342,C max,"Faropenem C max and AUC were 5.4 mg/L and 16.2 mg·h/L, respectively, and MIC for Mtb H37Rv was 5-10 mg/L.",Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28333342/),[mg] / [l],5.4,111750,DB01045,Rifampicin
,28333342,AUC,"Faropenem C max and AUC were 5.4 mg/L and 16.2 mg·h/L, respectively, and MIC for Mtb H37Rv was 5-10 mg/L.",Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28333342/),[h·mg] / [l],16.2,111751,DB01045,Rifampicin
,28333342,MIC,"Faropenem C max and AUC were 5.4 mg/L and 16.2 mg·h/L, respectively, and MIC for Mtb H37Rv was 5-10 mg/L.",Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28333342/),[mg] / [l],5-10,111752,DB01045,Rifampicin
,30105453,"Cmax,ss","In Period 1, siponimod geometric mean Cmax,ss (28.6 ng/mL) was achieved in 4 h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546 h × ng/mL.","Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30105453/),[ng] / [ml],28.6,111898,DB01045,Rifampicin
,30105453,"Tmax,ss","In Period 1, siponimod geometric mean Cmax,ss (28.6 ng/mL) was achieved in 4 h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546 h × ng/mL.","Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30105453/),,1.58-8.00,111899,DB01045,Rifampicin
,30105453,"AUCtau,ss","In Period 1, siponimod geometric mean Cmax,ss (28.6 ng/mL) was achieved in 4 h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546 h × ng/mL.","Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30105453/),[h·ng] / [ml],546,111900,DB01045,Rifampicin
,30105453,"Cmax,ss","In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7 ng/mL and 235 h × ng/mL, respectively; median Tmax remained unchanged (4 h).","Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30105453/),[ng] / [ml],15.7,111901,DB01045,Rifampicin
,30105453,"AUCtau,ss","In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7 ng/mL and 235 h × ng/mL, respectively; median Tmax remained unchanged (4 h).","Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30105453/),[h·ng] / [ml],235,111902,DB01045,Rifampicin
,30105453,Tmax,"In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7 ng/mL and 235 h × ng/mL, respectively; median Tmax remained unchanged (4 h).","Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30105453/),h,4,111903,DB01045,Rifampicin
,23180085,clearance,The calculated mean clearance of rifampicin due to chemical degradation was 0.098 ml/min accounting for 12.2 % of its clinical total clearance (CL = 0.8 ml/min) based on population PK data.,Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated drug clearance of rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180085/),[ml] / [min],0.098,112173,DB01045,Rifampicin
,23180085,total clearance (CL,The calculated mean clearance of rifampicin due to chemical degradation was 0.098 ml/min accounting for 12.2 % of its clinical total clearance (CL = 0.8 ml/min) based on population PK data.,Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated drug clearance of rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23180085/),[ml] / [min],0.8,112174,DB01045,Rifampicin
,23167603,apparent clearance CL/F,"The final population pharmacokinetic model obtained was as follows: apparent clearance CL/F = 8·17 L/h (1·40 as high for males), apparent distribution volume V(d)/F = 50·1 L (1·29 as high for males), absorption rate constant K(aA) = 0·391/h, K(aB,C,D) = 2·70/h, relative bioavailability F(A) = 0·468, F(B,C,D) = 1, lag time in the absorption phase T(lag) = 0·264 h.",Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167603/),[l] / [h],8·17,113007,DB01045,Rifampicin
,23167603,apparent distribution volume V(d)/F,"The final population pharmacokinetic model obtained was as follows: apparent clearance CL/F = 8·17 L/h (1·40 as high for males), apparent distribution volume V(d)/F = 50·1 L (1·29 as high for males), absorption rate constant K(aA) = 0·391/h, K(aB,C,D) = 2·70/h, relative bioavailability F(A) = 0·468, F(B,C,D) = 1, lag time in the absorption phase T(lag) = 0·264 h.",Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167603/),l,50·1,113008,DB01045,Rifampicin
,23167603,absorption rate constant K(aA),"The final population pharmacokinetic model obtained was as follows: apparent clearance CL/F = 8·17 L/h (1·40 as high for males), apparent distribution volume V(d)/F = 50·1 L (1·29 as high for males), absorption rate constant K(aA) = 0·391/h, K(aB,C,D) = 2·70/h, relative bioavailability F(A) = 0·468, F(B,C,D) = 1, lag time in the absorption phase T(lag) = 0·264 h.",Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167603/),1/[h],0·391,113009,DB01045,Rifampicin
,23167603,"K(aB,","The final population pharmacokinetic model obtained was as follows: apparent clearance CL/F = 8·17 L/h (1·40 as high for males), apparent distribution volume V(d)/F = 50·1 L (1·29 as high for males), absorption rate constant K(aA) = 0·391/h, K(aB,C,D) = 2·70/h, relative bioavailability F(A) = 0·468, F(B,C,D) = 1, lag time in the absorption phase T(lag) = 0·264 h.",Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167603/),1/[h],2·70,113010,DB01045,Rifampicin
,23167603,relative bioavailability F(A),"The final population pharmacokinetic model obtained was as follows: apparent clearance CL/F = 8·17 L/h (1·40 as high for males), apparent distribution volume V(d)/F = 50·1 L (1·29 as high for males), absorption rate constant K(aA) = 0·391/h, K(aB,C,D) = 2·70/h, relative bioavailability F(A) = 0·468, F(B,C,D) = 1, lag time in the absorption phase T(lag) = 0·264 h.",Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167603/),,0·468,113011,DB01045,Rifampicin
,23167603,F,"The final population pharmacokinetic model obtained was as follows: apparent clearance CL/F = 8·17 L/h (1·40 as high for males), apparent distribution volume V(d)/F = 50·1 L (1·29 as high for males), absorption rate constant K(aA) = 0·391/h, K(aB,C,D) = 2·70/h, relative bioavailability F(A) = 0·468, F(B,C,D) = 1, lag time in the absorption phase T(lag) = 0·264 h.",Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167603/),,1,113012,DB01045,Rifampicin
,23167603,lag time in the absorption phase T(lag),"The final population pharmacokinetic model obtained was as follows: apparent clearance CL/F = 8·17 L/h (1·40 as high for males), apparent distribution volume V(d)/F = 50·1 L (1·29 as high for males), absorption rate constant K(aA) = 0·391/h, K(aB,C,D) = 2·70/h, relative bioavailability F(A) = 0·468, F(B,C,D) = 1, lag time in the absorption phase T(lag) = 0·264 h.",Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167603/),h,0·264,113013,DB01045,Rifampicin
,29917079,area under the curve,"The expected proportion of patients with stable culture conversion on liquid medium at week 8 was predicted to increase from 39% (95% confidence interval, 37%-41%) to 55% (49%-61%), with the rifampicin area under the curve increasing from 20 to 175 mg/L·h (representative for 10 and 35 mg/kg, respectively).",The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29917079/),[mg] / [h·l],20,113125,DB01045,Rifampicin
,29917079,area under the curve,"The expected proportion of patients with stable culture conversion on liquid medium at week 8 was predicted to increase from 39% (95% confidence interval, 37%-41%) to 55% (49%-61%), with the rifampicin area under the curve increasing from 20 to 175 mg/L·h (representative for 10 and 35 mg/kg, respectively).",The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29917079/),[mg] / [h·l],175,113126,DB01045,Rifampicin
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB01045,Rifampicin
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB01045,Rifampicin
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB01045,Rifampicin
,27550361,early bactericidal activity,"No bactericidal activity was detected at doses of AZD5847 of 500 mg once daily (mean early bactericidal activity [EBA], 0.02 [95% CI, -0.01, 0.05]), 1,200 mg once daily (mean EBA, 0.02 [95% CI, -0.01, 0.05]), and 800 mg twice daily (mean EBA, 0.02 [95% CI, -0.01, 0.05]).",Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550361/),,0,113881,DB01045,Rifampicin
,27550361,E,"No bactericidal activity was detected at doses of AZD5847 of 500 mg once daily (mean early bactericidal activity [EBA], 0.02 [95% CI, -0.01, 0.05]), 1,200 mg once daily (mean EBA, 0.02 [95% CI, -0.01, 0.05]), and 800 mg twice daily (mean EBA, 0.02 [95% CI, -0.01, 0.05]).",Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550361/),,0,113882,DB01045,Rifampicin
,34417912,IC50,"In vitro, entrectinib is a CYP3A4/5 inhibitor (IC50 2 μM) and a weak CYP3A4 inducer.","In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417912/),μM,2,114198,DB01045,Rifampicin
,34417912,IC50,Entrectinib inhibited P-glycoprotein (IC50 1.33 μM) but is a poor substrate.,"In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417912/),μM,1.33,114199,DB01045,Rifampicin
,24188983,peak plasma concentration,"RMP-PC exhibited higher peak plasma concentration (54.3 vs. 48.5 μg/mL), increased AUC0-∞ (472.4 vs. 147.71 5.812 ± 0.49 μg h/mL), increased T1/2 (8.3 vs. 1.5h) when compared to free RMP implying improved bioavailability of the drug.","Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188983/),[μg] / [ml],54.3,115858,DB01045,Rifampicin
,24188983,peak plasma concentration,"RMP-PC exhibited higher peak plasma concentration (54.3 vs. 48.5 μg/mL), increased AUC0-∞ (472.4 vs. 147.71 5.812 ± 0.49 μg h/mL), increased T1/2 (8.3 vs. 1.5h) when compared to free RMP implying improved bioavailability of the drug.","Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188983/),[μg] / [ml],48.5,115859,DB01045,Rifampicin
,24188983,AUC0-∞,"RMP-PC exhibited higher peak plasma concentration (54.3 vs. 48.5 μg/mL), increased AUC0-∞ (472.4 vs. 147.71 5.812 ± 0.49 μg h/mL), increased T1/2 (8.3 vs. 1.5h) when compared to free RMP implying improved bioavailability of the drug.","Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188983/),[h·μg] / [ml],472.4,115860,DB01045,Rifampicin
,24188983,AUC0-∞,"RMP-PC exhibited higher peak plasma concentration (54.3 vs. 48.5 μg/mL), increased AUC0-∞ (472.4 vs. 147.71 5.812 ± 0.49 μg h/mL), increased T1/2 (8.3 vs. 1.5h) when compared to free RMP implying improved bioavailability of the drug.","Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188983/),[h·μg] / [ml],147.71,115861,DB01045,Rifampicin
,24188983,AUC0-∞,"RMP-PC exhibited higher peak plasma concentration (54.3 vs. 48.5 μg/mL), increased AUC0-∞ (472.4 vs. 147.71 5.812 ± 0.49 μg h/mL), increased T1/2 (8.3 vs. 1.5h) when compared to free RMP implying improved bioavailability of the drug.","Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188983/),[h·μg] / [ml],5.812,115862,DB01045,Rifampicin
,24188983,T1/2,"RMP-PC exhibited higher peak plasma concentration (54.3 vs. 48.5 μg/mL), increased AUC0-∞ (472.4 vs. 147.71 5.812 ± 0.49 μg h/mL), increased T1/2 (8.3 vs. 1.5h) when compared to free RMP implying improved bioavailability of the drug.","Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188983/),h,8.3,115863,DB01045,Rifampicin
,24188983,T1/2,"RMP-PC exhibited higher peak plasma concentration (54.3 vs. 48.5 μg/mL), increased AUC0-∞ (472.4 vs. 147.71 5.812 ± 0.49 μg h/mL), increased T1/2 (8.3 vs. 1.5h) when compared to free RMP implying improved bioavailability of the drug.","Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24188983/),h,1.5,115864,DB01045,Rifampicin
,25837442,C min,"Target C min was 1.7 mg/L, to reach the desired bone concentration/MIC >2, assuming a 30% diffusion into bone and MIC = 2.5 mg/L.",Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25837442/),[mg] / [l],1.7,116299,DB01045,Rifampicin
>,25837442,bone concentration/MIC,"Target C min was 1.7 mg/L, to reach the desired bone concentration/MIC >2, assuming a 30% diffusion into bone and MIC = 2.5 mg/L.",Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25837442/),,2,116300,DB01045,Rifampicin
,25837442,MIC,"Target C min was 1.7 mg/L, to reach the desired bone concentration/MIC >2, assuming a 30% diffusion into bone and MIC = 2.5 mg/L.",Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25837442/),[mg] / [l],2.5,116301,DB01045,Rifampicin
,25837442,C min,"Median C min value was 1.39 mg/L, with 58% of the values below the threshold value of 1.7 mg/L.",Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25837442/),[mg] / [l],1.39,116302,DB01045,Rifampicin
,25837442,C min,"Median C min value was 1.39 mg/L, with 58% of the values below the threshold value of 1.7 mg/L.",Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25837442/),[mg] / [l],1.7,116303,DB01045,Rifampicin
,25837442,C min,"Median C min was significantly lower for patients taking rifampicin (0.46 vs 1.52 mg/L, p = 0.034).",Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25837442/),[mg] / [l],0.46,116304,DB01045,Rifampicin
,25837442,C min,"Median C min was significantly lower for patients taking rifampicin (0.46 vs 1.52 mg/L, p = 0.034).",Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25837442/),[mg] / [l],1.52,116305,DB01045,Rifampicin
,25837442,maximal C min,No patient with rifampicin co-administration reached the target concentration (maximal C min: 0.85 mg/L).,Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25837442/),[mg] / [l],0.85,116306,DB01045,Rifampicin
,3961887,Cl,A mean increase of 52.0% in Cl (3.10-4.72 L/h/m2) and a mean decrease of 27.0% in t1/2 (2.38-1.73 h) were observed when data collected during the first 2 days of therapy were compared with data collected following 8 or more days of therapy.,Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961887/),[l] / [h·m2],3.10-4.72,116800,DB01045,Rifampicin
,3961887,t1/2,A mean increase of 52.0% in Cl (3.10-4.72 L/h/m2) and a mean decrease of 27.0% in t1/2 (2.38-1.73 h) were observed when data collected during the first 2 days of therapy were compared with data collected following 8 or more days of therapy.,Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961887/),h,2.38-1.73,116801,DB01045,Rifampicin
,3961887,Peak concentrations,"Peak concentrations extrapolated to the end of infusion were 27.0 +/- 8.2 micrograms/ml, and concentrations at 8 h after the dose were only 1.9 +/- 1.5 micrograms/ml.",Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961887/),[μg] / [ml],27.0,116802,DB01045,Rifampicin
,3961887,Peak concentrations,"Peak concentrations extrapolated to the end of infusion were 27.0 +/- 8.2 micrograms/ml, and concentrations at 8 h after the dose were only 1.9 +/- 1.5 micrograms/ml.",Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961887/),[μg] / [ml],1.9,116803,DB01045,Rifampicin
,20937187,peak plasma concentration (C(max)),"Mean pharmacokinetic parameter values obtained for the test and reference product were respectively 3.13 ± 2.01 μg/ml and 9.95 ± 2.66 μg/ml for peak plasma concentration (C(max)), 15.51 ± 9.77 μg.h/ml and 58.03 ± 16.1 μg.h/ml for area under the concentration (AUC) time curve to the last measurable concentration (AUC(0-12h)) and 17.92 ± 10.66 and 68.43 ± 22.39 μg.h/ml for AUC up to time infinity (AUC(0-∞)).",Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937187/),[μg] / [ml],3.13,117875,DB01045,Rifampicin
,20937187,peak plasma concentration (C(max)),"Mean pharmacokinetic parameter values obtained for the test and reference product were respectively 3.13 ± 2.01 μg/ml and 9.95 ± 2.66 μg/ml for peak plasma concentration (C(max)), 15.51 ± 9.77 μg.h/ml and 58.03 ± 16.1 μg.h/ml for area under the concentration (AUC) time curve to the last measurable concentration (AUC(0-12h)) and 17.92 ± 10.66 and 68.43 ± 22.39 μg.h/ml for AUC up to time infinity (AUC(0-∞)).",Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937187/),[μg] / [ml],9.95,117876,DB01045,Rifampicin
,20937187,area under the concentration (AUC) time curve to the last measurable concentration (AUC(0-12h)),"Mean pharmacokinetic parameter values obtained for the test and reference product were respectively 3.13 ± 2.01 μg/ml and 9.95 ± 2.66 μg/ml for peak plasma concentration (C(max)), 15.51 ± 9.77 μg.h/ml and 58.03 ± 16.1 μg.h/ml for area under the concentration (AUC) time curve to the last measurable concentration (AUC(0-12h)) and 17.92 ± 10.66 and 68.43 ± 22.39 μg.h/ml for AUC up to time infinity (AUC(0-∞)).",Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937187/),[h·μg] / [ml],15.51,117877,DB01045,Rifampicin
,20937187,area under the concentration (AUC) time curve to the last measurable concentration (AUC(0-12h)),"Mean pharmacokinetic parameter values obtained for the test and reference product were respectively 3.13 ± 2.01 μg/ml and 9.95 ± 2.66 μg/ml for peak plasma concentration (C(max)), 15.51 ± 9.77 μg.h/ml and 58.03 ± 16.1 μg.h/ml for area under the concentration (AUC) time curve to the last measurable concentration (AUC(0-12h)) and 17.92 ± 10.66 and 68.43 ± 22.39 μg.h/ml for AUC up to time infinity (AUC(0-∞)).",Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937187/),[h·μg] / [ml],58.03,117878,DB01045,Rifampicin
,20937187,AUC up to time infinity (AUC(0-∞)),"Mean pharmacokinetic parameter values obtained for the test and reference product were respectively 3.13 ± 2.01 μg/ml and 9.95 ± 2.66 μg/ml for peak plasma concentration (C(max)), 15.51 ± 9.77 μg.h/ml and 58.03 ± 16.1 μg.h/ml for area under the concentration (AUC) time curve to the last measurable concentration (AUC(0-12h)) and 17.92 ± 10.66 and 68.43 ± 22.39 μg.h/ml for AUC up to time infinity (AUC(0-∞)).",Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937187/),[h·μg] / [ml],17.92,117879,DB01045,Rifampicin
,20937187,AUC up to time infinity (AUC(0-∞)),"Mean pharmacokinetic parameter values obtained for the test and reference product were respectively 3.13 ± 2.01 μg/ml and 9.95 ± 2.66 μg/ml for peak plasma concentration (C(max)), 15.51 ± 9.77 μg.h/ml and 58.03 ± 16.1 μg.h/ml for area under the concentration (AUC) time curve to the last measurable concentration (AUC(0-12h)) and 17.92 ± 10.66 and 68.43 ± 22.39 μg.h/ml for AUC up to time infinity (AUC(0-∞)).",Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937187/),[h·μg] / [ml],68.43,117880,DB01045,Rifampicin
,11092591,flow-rate,"Separation of the diastereoisomeric propafenone glucuronides was achieved on a Spherisorb ODS 2 column (150 x 2.0 mm I.D., particle size 5 microm) at a flow-rate of 0.3 ml/min using a linear gradient from 20% B to 50% B in 15 min.",Determination of propafenone and its phase I and phase II metabolites in plasma and urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11092591/),[ml] / [min],0.3,118698,DB01045,Rifampicin
,21191377,half-life,The midazolam AUC(0-∞) returned to baseline with a half-life of ~8 days.,Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21191377/),d,8,118747,DB01045,Rifampicin
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],2955,119005,DB01045,Rifampicin
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],5524,119006,DB01045,Rifampicin
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],2632,119007,DB01045,Rifampicin
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],7091,119008,DB01045,Rifampicin
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],1760,119009,DB01045,Rifampicin
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],4608,119010,DB01045,Rifampicin
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],2210,119011,DB01045,Rifampicin
,11240975,oral clearance,"All of the groups had a significant increase (P <.05) in the oral clearance of fexofenadine after rifampin treatment: young men, 2955 +/- 1516 versus 5524 +/- 3410 mL/min; young women, 2632 +/- 996 versus 7091 +/- 5,379 mL/min; elderly men, 1760 +/- 850 versus 4608 +/- 1159 mL/min; and elderly women, 2210 +/- 554 versus 4845 +/- 1600 mL/min.",The effect of rifampin administration on the disposition of fexofenadine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],4845,119012,DB01045,Rifampicin
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],77,119013,DB01045,Rifampicin
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],52,119014,DB01045,Rifampicin
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],72,119015,DB01045,Rifampicin
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],36,119016,DB01045,Rifampicin
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],106,119017,DB01045,Rifampicin
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],52,119018,DB01045,Rifampicin
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],76,119019,DB01045,Rifampicin
,11240975,peak serum concentration,"The peak serum concentration of fexofenadine was also significantly reduced (P <.05) by rifampin treatment: young men, 77 +/- 31 versus 52 +/- 17 ng/mL; young women, 72 +/- 19 versus 36 +/- 14 ng/mL; elderly men, 106 +/- 42 versus 52 +/- 14 ng/mL; elderly women, 76 +/- 23 versus 46 +/- 19 ng/mL.",The effect of rifampin administration on the disposition of fexofenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ng] / [ml],46,119020,DB01045,Rifampicin
,11240975,Half-life,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),min,150 to 230,119021,DB01045,Rifampicin
,11240975,time to maximum concentration,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),min,130 to 205,119022,DB01045,Rifampicin
,11240975,renal clearance,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[ml] / [min],95 to 153,119023,DB01045,Rifampicin
,11240975,fraction unbound,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),%,2.9,119024,DB01045,Rifampicin
,11240975,fraction unbound,"Half-life (150 to 230 minutes), time to maximum concentration (130 to 205 minutes), renal clearance (95 to 153 mL/min), and fraction unbound (2.9% to 3.7%) of fexofenadine showed no significant difference between control and treatment.",The effect of rifampin administration on the disposition of fexofenadine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),%,3.7,119025,DB01045,Rifampicin
,11240975,serum trough rifampin concentration,No effect of age or sex on fexofenadine disposition or serum trough rifampin concentration (0.2 microg/mL to 1.8 microg/mL) was observed before or after rifampin treatment.,The effect of rifampin administration on the disposition of fexofenadine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[μg] / [ml],0.2,119026,DB01045,Rifampicin
,11240975,serum trough rifampin concentration,No effect of age or sex on fexofenadine disposition or serum trough rifampin concentration (0.2 microg/mL to 1.8 microg/mL) was observed before or after rifampin treatment.,The effect of rifampin administration on the disposition of fexofenadine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240975/),[μg] / [ml],1.8,119027,DB01045,Rifampicin
,27526979,plasma AUC0-24,"In the first days of treatment, the geometric mean (range) plasma AUC0-24 values following rifampicin 750 mg orally, 900 mg orally and 600 mg i.v. were 131.4 (38.1-275.1), 164.8 (66.9-291.2) and 145.7 (77.7-430.2) mg⋅h/L, respectively; Cmax values were 14.3 (6.1-22.2), 16.2 (5.7-28.3) and 24.7 (13.9-37.8) mg/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[h·mg] / [l],131.4,119343,DB01045,Rifampicin
,27526979,plasma AUC0-24,"In the first days of treatment, the geometric mean (range) plasma AUC0-24 values following rifampicin 750 mg orally, 900 mg orally and 600 mg i.v. were 131.4 (38.1-275.1), 164.8 (66.9-291.2) and 145.7 (77.7-430.2) mg⋅h/L, respectively; Cmax values were 14.3 (6.1-22.2), 16.2 (5.7-28.3) and 24.7 (13.9-37.8) mg/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[h·mg] / [l],164.8,119344,DB01045,Rifampicin
,27526979,plasma AUC0-24,"In the first days of treatment, the geometric mean (range) plasma AUC0-24 values following rifampicin 750 mg orally, 900 mg orally and 600 mg i.v. were 131.4 (38.1-275.1), 164.8 (66.9-291.2) and 145.7 (77.7-430.2) mg⋅h/L, respectively; Cmax values were 14.3 (6.1-22.2), 16.2 (5.7-28.3) and 24.7 (13.9-37.8) mg/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[h·mg] / [l],145.7,119345,DB01045,Rifampicin
,27526979,Cmax,"In the first days of treatment, the geometric mean (range) plasma AUC0-24 values following rifampicin 750 mg orally, 900 mg orally and 600 mg i.v. were 131.4 (38.1-275.1), 164.8 (66.9-291.2) and 145.7 (77.7-430.2) mg⋅h/L, respectively; Cmax values were 14.3 (6.1-22.2), 16.2 (5.7-28.3) and 24.7 (13.9-37.8) mg/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[mg] / [l],14.3,119346,DB01045,Rifampicin
,27526979,Cmax,"In the first days of treatment, the geometric mean (range) plasma AUC0-24 values following rifampicin 750 mg orally, 900 mg orally and 600 mg i.v. were 131.4 (38.1-275.1), 164.8 (66.9-291.2) and 145.7 (77.7-430.2) mg⋅h/L, respectively; Cmax values were 14.3 (6.1-22.2), 16.2 (5.7-28.3) and 24.7 (13.9-37.8) mg/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[mg] / [l],16.2,119347,DB01045,Rifampicin
,27526979,Cmax,"In the first days of treatment, the geometric mean (range) plasma AUC0-24 values following rifampicin 750 mg orally, 900 mg orally and 600 mg i.v. were 131.4 (38.1-275.1), 164.8 (66.9-291.2) and 145.7 (77.7-430.2) mg⋅h/L, respectively; Cmax values were 14.3 (6.1-22.2), 16.2 (5.7-28.3) and 24.7 (13.9-37.8) mg/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[mg] / [l],24.7,119348,DB01045,Rifampicin
,27526979,AUC0-24,"After ≥9 days, AUC0-24 values had decreased to 100.1, 101.2 and 94.9 mg⋅h/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[h·mg] / [l],100.1,119349,DB01045,Rifampicin
,27526979,AUC0-24,"After ≥9 days, AUC0-24 values had decreased to 100.1, 101.2 and 94.9 mg⋅h/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[h·mg] / [l],101.2,119350,DB01045,Rifampicin
,27526979,AUC0-24,"After ≥9 days, AUC0-24 values had decreased to 100.1, 101.2 and 94.9 mg⋅h/L.",Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27526979/),[h·mg] / [l],94.9,119351,DB01045,Rifampicin
,12948278,Cmax,Mean +/- SD of Cmax was 9.61 +/- 2.17 microg/ml occurred at 1.68 +/- 1.21 hours.,Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948278/),[μg] / [ml],9.61,119717,DB01045,Rifampicin
,12948278,AUC(0-24),"Means +/- SD of AUC(0-24) and AUC(0-infinity) were 70.57 +/- 26.40 and 82.45 +/- 43.64 microg x h/ml, respectively.",Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948278/),[h·μg] / [ml],70.57,119718,DB01045,Rifampicin
,12948278,AUC(0-infinity),"Means +/- SD of AUC(0-24) and AUC(0-infinity) were 70.57 +/- 26.40 and 82.45 +/- 43.64 microg x h/ml, respectively.",Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948278/),[h·μg] / [ml],82.45,119719,DB01045,Rifampicin
,12948278,Vss/F,Ofloxacin distributed widely with a mean +/- SD of Vss/F of 1.37 +/- 0.24 L/kg.,Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948278/),[l] / [kg],1.37,119720,DB01045,Rifampicin
,12948278,CL/F,"Mean +/- SD of CL/F was 8.19 +/- 2.53 L/h, whereas mean +/- SD of T(1/2beta) and mean residence time were 8.03 +/- 3.37 and 10.77 +/- 4.55 hours, respectively.",Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948278/),[l] / [h],8.19,119721,DB01045,Rifampicin
,12948278,T(1/2beta),"Mean +/- SD of CL/F was 8.19 +/- 2.53 L/h, whereas mean +/- SD of T(1/2beta) and mean residence time were 8.03 +/- 3.37 and 10.77 +/- 4.55 hours, respectively.",Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948278/),h,8.03,119722,DB01045,Rifampicin
,12948278,mean residence time,"Mean +/- SD of CL/F was 8.19 +/- 2.53 L/h, whereas mean +/- SD of T(1/2beta) and mean residence time were 8.03 +/- 3.37 and 10.77 +/- 4.55 hours, respectively.",Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948278/),h,10.77,119723,DB01045,Rifampicin
,12948278,Cmax/MIC,The free Cmax/MIC of Mycobacterium tuberculosis of 7.7-15.4:1 was estimated.,Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948278/),:1,7.7-15.4,119724,DB01045,Rifampicin
,30412245,Cmax,The median rifampicin Cmax and AUC0-6 were higher during fasting than non-fasting: 7.02 versus 6.59 mg/L (P = 0.054) and 28.64 versus 24.31 mg·h/L (P = 0.002).,Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412245/),[mg] / [l],7.02,120205,DB01045,Rifampicin
,30412245,Cmax,The median rifampicin Cmax and AUC0-6 were higher during fasting than non-fasting: 7.02 versus 6.59 mg/L (P = 0.054) and 28.64 versus 24.31 mg·h/L (P = 0.002).,Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412245/),[mg] / [l],6.59,120206,DB01045,Rifampicin
,30412245,AUC0-6,The median rifampicin Cmax and AUC0-6 were higher during fasting than non-fasting: 7.02 versus 6.59 mg/L (P = 0.054) and 28.64 versus 24.31 mg·h/L (P = 0.002).,Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412245/),[h·mg] / [l],28.64,120207,DB01045,Rifampicin
,30412245,AUC0-6,The median rifampicin Cmax and AUC0-6 were higher during fasting than non-fasting: 7.02 versus 6.59 mg/L (P = 0.054) and 28.64 versus 24.31 mg·h/L (P = 0.002).,Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412245/),[h·mg] / [l],24.31,120208,DB01045,Rifampicin
,30412245,Cmax,"Concerning isoniazid, there were significant differences in the Cmax during non-fasting (median = 3.51 mg/L) compared with fasting (4.54 mg/L).",Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412245/),[mg] / [l],3.51,120209,DB01045,Rifampicin
,30412245,Cmax,"Concerning isoniazid, there were significant differences in the Cmax during non-fasting (median = 3.51 mg/L) compared with fasting (4.54 mg/L).",Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412245/),[mg] / [l],4.54,120210,DB01045,Rifampicin
,15058595,flow-rate,The flow-rate was 1 ml/min and the effluent was monitored at 333 nm.,High-performance liquid-chromatographic determination of rifampicin in plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058595/),[ml] / [min],1,120532,DB01045,Rifampicin
,15058595,Recoveries,"Recoveries averaged 83 and 95% for plasma and liver, respectively.",High-performance liquid-chromatographic determination of rifampicin in plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058595/),%,83,120533,DB01045,Rifampicin
,15058595,Recoveries,"Recoveries averaged 83 and 95% for plasma and liver, respectively.",High-performance liquid-chromatographic determination of rifampicin in plasma and tissues. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058595/),%,95,120534,DB01045,Rifampicin
,27159505,area under the concentration-time curve (AUC0-24),"Median rifapentine area under the concentration-time curve (AUC0-24) was 313 mcg*h/mL, similar to recent studies of rifapentine dosed at 450-600 mg daily.",A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27159505/),[h·mcg] / [ml],313,120720,DB01045,Rifampicin
,27159505,AUC0-24,"Median moxifloxacin AUC0-24 was 28.0 mcg*h/mL, much lower than in trials where rifapentine was given only intermittently with moxifloxacin.",A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27159505/),[h·mcg] / [ml],28.0,120721,DB01045,Rifampicin
,24709267,maximum concentration of drug in serum (Cmax),"HIV coinfection in patients not receiving the supplementation was found to decrease bioavailability by 21.8%, with a median maximum concentration of drug in serum (Cmax) and area under the concentration-time curve from 0 to 24 h (AUC0-24) of 5.6 μg/ml and 28.6 μg · h/ml, respectively.",Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709267/),[μg] / [ml],5.6,120891,DB01045,Rifampicin
,24709267,area under the concentration-time curve from 0 to 24 h (AUC0-24),"HIV coinfection in patients not receiving the supplementation was found to decrease bioavailability by 21.8%, with a median maximum concentration of drug in serum (Cmax) and area under the concentration-time curve from 0 to 24 h (AUC0-24) of 5.6 μg/ml and 28.6 μg · h/ml, respectively.",Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709267/),[h·μg] / [ml],28.6,120892,DB01045,Rifampicin
,24709267,Cmax,"HIV-coinfected patients on nutritional supplementation achieved higher Cmax and AUC0-24 values of 6.4 μg/ml and 31.6 μg · h/ml, respectively, and only 13.3% bioavailability reduction.",Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709267/),[μg] / [ml],6.4,120893,DB01045,Rifampicin
,24709267,AUC0-24,"HIV-coinfected patients on nutritional supplementation achieved higher Cmax and AUC0-24 values of 6.4 μg/ml and 31.6 μg · h/ml, respectively, and only 13.3% bioavailability reduction.",Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709267/),[h·μg] / [ml],31.6,120894,DB01045,Rifampicin
,24709267,AUC0-24,"HIV-coinfected patients on nutritional supplementation achieved higher Cmax and AUC0-24 values of 6.4 μg/ml and 31.6 μg · h/ml, respectively, and only 13.3% bioavailability reduction.",Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709267/),%,13.3,120895,DB01045,Rifampicin
,24709267,bioavailability,"HIV-coinfected patients on nutritional supplementation achieved higher Cmax and AUC0-24 values of 6.4 μg/ml and 31.6 μg · h/ml, respectively, and only 13.3% bioavailability reduction.",Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709267/),%,13.3,120896,DB01045,Rifampicin
,33387374,bioavailability,"Nadolol is a hydrophilic and nonselective β-adrenoceptor blocker with a bioavailability of 30%, relatively longer half-life, negligible metabolism, and predominant renal excretion.",Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P-Glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33387374/),%,30,121647,DB01045,Rifampicin
,12492608,"AUC(0,4 h)","In particular, there was no significant difference between homozygous carriers of the C and T allele in exon 26 3435 (AUC(0,4 h) 9.24 and 9.38 micro g l-1 h, Cmax 4.73 and 3.81 micro g l-1, tmax 0,83 and 01.14 h).",MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492608/),[h·μg] / [l],9.24,121828,DB01045,Rifampicin
,12492608,"AUC(0,4 h)","In particular, there was no significant difference between homozygous carriers of the C and T allele in exon 26 3435 (AUC(0,4 h) 9.24 and 9.38 micro g l-1 h, Cmax 4.73 and 3.81 micro g l-1, tmax 0,83 and 01.14 h).",MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492608/),[h·μg] / [l],9.38,121829,DB01045,Rifampicin
,12492608,Cmax,"In particular, there was no significant difference between homozygous carriers of the C and T allele in exon 26 3435 (AUC(0,4 h) 9.24 and 9.38 micro g l-1 h, Cmax 4.73 and 3.81 micro g l-1, tmax 0,83 and 01.14 h).",MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492608/),[μg] / [l],4.73,121830,DB01045,Rifampicin
,12492608,Cmax,"In particular, there was no significant difference between homozygous carriers of the C and T allele in exon 26 3435 (AUC(0,4 h) 9.24 and 9.38 micro g l-1 h, Cmax 4.73 and 3.81 micro g l-1, tmax 0,83 and 01.14 h).",MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492608/),[μg] / [l],3.81,121831,DB01045,Rifampicin
,12492608,tmax,"In particular, there was no significant difference between homozygous carriers of the C and T allele in exon 26 3435 (AUC(0,4 h) 9.24 and 9.38 micro g l-1 h, Cmax 4.73 and 3.81 micro g l-1, tmax 0,83 and 01.14 h).",MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492608/),h,"0,",121832,DB01045,Rifampicin
,12492608,tmax,"In particular, there was no significant difference between homozygous carriers of the C and T allele in exon 26 3435 (AUC(0,4 h) 9.24 and 9.38 micro g l-1 h, Cmax 4.73 and 3.81 micro g l-1, tmax 0,83 and 01.14 h).",MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492608/),h,83,121833,DB01045,Rifampicin
,12492608,tmax,"In particular, there was no significant difference between homozygous carriers of the C and T allele in exon 26 3435 (AUC(0,4 h) 9.24 and 9.38 micro g l-1 h, Cmax 4.73 and 3.81 micro g l-1, tmax 0,83 and 01.14 h).",MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12492608/),h,01.14,121834,DB01045,Rifampicin
,21194606,C(max),"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [ml],7.20,122423,DB01045,Rifampicin
,21194606,T(max),"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),h,1.32,122424,DB01045,Rifampicin
,21194606,T(max),"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],37.12,122425,DB01045,Rifampicin
,21194606,T(max),"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],38.92,122426,DB01045,Rifampicin
,21194606,AUC₀₋₂₄,"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),h,1.32,122427,DB01045,Rifampicin
,21194606,AUC₀₋₂₄,"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],37.12,122428,DB01045,Rifampicin
,21194606,AUC₀₋(∞)),"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],39.69,122429,DB01045,Rifampicin
,21194606,AUC₀₋(∞)),"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],38.92,122430,DB01045,Rifampicin
,21194606,AUC₀₋(∞)),"The mean values for C(max), T(max) , AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation of rifampicin were 7.20 μg/mL, 1.32 hours, 37.12 μg/mL · h, and 39.69 μg/mL · h, respectively; for the reference formulation, the values were 7.65 μg/mL, 1.71 hours, 38.92 μg/mL · h, and 42.24 μg/ mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],42.24,122431,DB01045,Rifampicin
,21194606,C(max),"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [ml],0.63,122432,DB01045,Rifampicin
,21194606,T(max),"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),h,3.45,122433,DB01045,Rifampicin
,21194606,T(max),"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],4.92,122434,DB01045,Rifampicin
,21194606,AUC₀₋₂₄,"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),h,3.45,122435,DB01045,Rifampicin
,21194606,AUC₀₋₂₄,"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],4.92,122436,DB01045,Rifampicin
,21194606,AUC₀₋(∞)),"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],6.27,122437,DB01045,Rifampicin
,21194606,AUC₀₋(∞)),"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [ml],0.7,122438,DB01045,Rifampicin
,21194606,AUC₀₋(∞)),"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),h,3.27,122439,DB01045,Rifampicin
,21194606,AUC₀₋(∞)),"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],5.23,122440,DB01045,Rifampicin
,21194606,AUC₀₋(∞)),"For 25-desacetyl rifampicin, the mean values for C(max), T(max), AUC₀₋₂₄, and AUC₀₋(∞)) with the test formulation were 0.63 μg/mL, 3.45 hours, 4.92 μg/mL · h, and 6.27 μg/mL · h; for the reference formulation, the values were 0.7 μg/mL, 3.27 hours, 5.23 μg/mL · h, and 6.84 μg/mL · h.","A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21194606/),[μg] / [h·ml],6.84,122441,DB01045,Rifampicin
,26749408,absolute oral bioavailability,Apixaban absolute oral bioavailability was 49 % when administered alone and 39 % following induction by rifampin.,"Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26749408/),%,49,122501,DB01045,Rifampicin
,26749408,absolute oral bioavailability,Apixaban absolute oral bioavailability was 49 % when administered alone and 39 % following induction by rifampin.,"Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26749408/),%,39,122502,DB01045,Rifampicin
,17686907,Km,"CP-671,305 was a substrate of human OATP2B1 with a high affinity (Km = 4 microM) but not a substrate for human OATP1B1 or OATP1B3.","Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17686907/),μM,4,122906,DB01045,Rifampicin
,17686907,Km,"Upon examination as a substrate for major rat hepatic Oatps, CP-671,305 displayed high affinity (Km = 12 microM) for Oatp1a4.","Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17686907/),μM,12,122907,DB01045,Rifampicin
,24504545,apparent clearance (CL/F),The apparent clearance (CL/F) of nevirapine estimated from this population was 2.51 l/h which is lower than the values previously reported in other populations.,Population pharmacokinetics of nevirapine in Thai HIV-infected patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504545/),[l] / [h],2.51,123262,DB01045,Rifampicin
,31712201,oral clearance,"Estimates of oral clearance and volume of distribution were 77.4 liters/h and 76.2 liters, respectively.",Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIV. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31712201/),[l] / [h],77.4,123414,DB01045,Rifampicin
,31712201,volume of distribution,"Estimates of oral clearance and volume of distribution were 77.4 liters/h and 76.2 liters, respectively.",Population Pharmacokinetics and Pharmacogenetics of Ethambutol in Adult Patients Coinfected with Tuberculosis and HIV. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31712201/),l,76.2,123415,DB01045,Rifampicin
≥,29618565,penetration coefficients,"Both drugs penetrated rabbit lung cellular lesions, as well as the fibrotic cavity wall of cavitary lesions (penetration coefficients ≥1 compared to plasma).",Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29618565/),,1,125242,DB01045,Rifampicin
,29618565,penetration coefficient,"For the necrotic liquefied material inside cavitary lesions known as caseum (which contains high numbers of bacteria), the penetration coefficient was 1.0 for rifampin but only 0.25 for rifapentine.",Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29618565/),,1.0,125243,DB01045,Rifampicin
,29618565,penetration coefficient,"For the necrotic liquefied material inside cavitary lesions known as caseum (which contains high numbers of bacteria), the penetration coefficient was 1.0 for rifampin but only 0.25 for rifapentine.",Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29618565/),,0.25,125244,DB01045,Rifampicin
,28559269,area under the concentration-time curve from 0 to 6 h,"The median area under the concentration-time curve from 0 to 6 h (interquartile range) was 24.9 (17.6 to 32.1), 43.1 (30.3 to 57.5), or 55.5 (35.7 to 73.2) h · μg/ml.",Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559269/),[h·μg] / [ml],24.9,125665,DB01045,Rifampicin
,28559269,area under the concentration-time curve from 0 to 6 h,"The median area under the concentration-time curve from 0 to 6 h (interquartile range) was 24.9 (17.6 to 32.1), 43.1 (30.3 to 57.5), or 55.5 (35.7 to 73.2) h · μg/ml.",Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559269/),[h·μg] / [ml],43.1,125666,DB01045,Rifampicin
,28559269,area under the concentration-time curve from 0 to 6 h,"The median area under the concentration-time curve from 0 to 6 h (interquartile range) was 24.9 (17.6 to 32.1), 43.1 (30.3 to 57.5), or 55.5 (35.7 to 73.2) h · μg/ml.",Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559269/),[h·μg] / [ml],55.5,125667,DB01045,Rifampicin
,28559269,maximum drug concentration,The median maximum drug concentration in serum in the experimental arms reached the target of 8 μg/ml.,Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559269/),[μg] / [ml],8,125668,DB01045,Rifampicin
,29637542,AUCss,"Based on published clinical data, an AUCss value of 1,000 pg/ml.h was selected as the threshold for breakthrough bleeding.",Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29637542/),[pg] / [h·ml],"1,000",125794,DB01045,Rifampicin
,15260278,peak plasma concentrations,"Median peak plasma concentrations for RPT in the patient cohort were 15.19 and 15.48 microg/ml on study days 1 and 5, respectively.",Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260278/),[μg] / [ml],15.19,126702,DB01045,Rifampicin
,15260278,peak plasma concentrations,"Median peak plasma concentrations for RPT in the patient cohort were 15.19 and 15.48 microg/ml on study days 1 and 5, respectively.",Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260278/),[μg] / [ml],15.48,126703,DB01045,Rifampicin
,15260278,Time to reach these concentrations,"Time to reach these concentrations was 5.00 and 5.08 h and plasma elimination half-lives were 11.63 and 12.03 h, respectively.",Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260278/),h,5.00,126704,DB01045,Rifampicin
,15260278,Time to reach these concentrations,"Time to reach these concentrations was 5.00 and 5.08 h and plasma elimination half-lives were 11.63 and 12.03 h, respectively.",Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260278/),h,5.08,126705,DB01045,Rifampicin
,15260278,plasma elimination half-lives,"Time to reach these concentrations was 5.00 and 5.08 h and plasma elimination half-lives were 11.63 and 12.03 h, respectively.",Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260278/),h,11.63,126706,DB01045,Rifampicin
,15260278,plasma elimination half-lives,"Time to reach these concentrations was 5.00 and 5.08 h and plasma elimination half-lives were 11.63 and 12.03 h, respectively.",Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260278/),h,12.03,126707,DB01045,Rifampicin
,15260278,Areas under the plasma concentration-time curve (0-72 h),"Areas under the plasma concentration-time curve (0-72 h) were 355.81 and 371.89 microg x h/ml on the two occasions, respectively.",Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260278/),[h·μg] / [ml],355.81,126708,DB01045,Rifampicin
,15260278,Areas under the plasma concentration-time curve (0-72 h),"Areas under the plasma concentration-time curve (0-72 h) were 355.81 and 371.89 microg x h/ml on the two occasions, respectively.",Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260278/),[h·μg] / [ml],371.89,126709,DB01045,Rifampicin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB01045,Rifampicin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB01045,Rifampicin
,19223781,Cmin,Efavirenz Cmin was not significantly different during vs. after antitubercular treatment (median 0.83 mg/L interquartile range 0.59-6.57 vs. median 0.86 mg/L interquartile range 0.61-3.56; P = 0.125).,Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223781/),[mg] / [l],0.83,127487,DB01045,Rifampicin
,19223781,Cmin,Efavirenz Cmin was not significantly different during vs. after antitubercular treatment (median 0.83 mg/L interquartile range 0.59-6.57 vs. median 0.86 mg/L interquartile range 0.61-3.56; P = 0.125).,Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223781/),[mg] / [l],0.86,127488,DB01045,Rifampicin
<,19223781,Cmin,"Nine (60%) and 8 (53%) children had subtherapeutic Cmin (<1 mg/L) during and after antitubercular treatment, respectively.",Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223781/),[mg] / [l],1,127489,DB01045,Rifampicin
<,19223781,Cmin,The substantial proportion of participants with estimated Cmin <1 mg/L could result in the rapid emergence of efavirenz-resistant mutations and treatment failure.,Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19223781/),,1,127490,DB01045,Rifampicin
,16782766,EC50,"In monkey hepatocytes, rifampin markedly induced CYP3A64 mRNA (EC50 = 0.5 microM; Emax = 6-fold) and midazolam (MDZ) 1'-hydroxylase activity (EC50 = 0.2 microM; Emax = 2-fold).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.5,128314,DB01045,Rifampicin
,16782766,EC50,"In monkey hepatocytes, rifampin markedly induced CYP3A64 mRNA (EC50 = 0.5 microM; Emax = 6-fold) and midazolam (MDZ) 1'-hydroxylase activity (EC50 = 0.2 microM; Emax = 2-fold).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.2,128315,DB01045,Rifampicin
,16782766,KI,"Compound A (N-[2(R)-hydroxy-1(S)-indanyl-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)-methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide), a known potent and mechanism-based inhibitor of CYP3A4, strongly inhibited the formation of 1'-hydroxy MDZ by recombinant CYP3A64 in a concentration- and time-dependent manner (KI = 0.25 microM; k(inact) = 0.4 min(-1)).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),μM,0.25,128316,DB01045,Rifampicin
,16782766,k(inact),"Compound A (N-[2(R)-hydroxy-1(S)-indanyl-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)-methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide), a known potent and mechanism-based inhibitor of CYP3A4, strongly inhibited the formation of 1'-hydroxy MDZ by recombinant CYP3A64 in a concentration- and time-dependent manner (KI = 0.25 microM; k(inact) = 0.4 min(-1)).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),1/[min],0.4,128317,DB01045,Rifampicin
,16782766,hepatic availability (Fh,"In rhesus monkeys, MDZ exhibited a relatively high metabolic clearance (primarily via 1'-hydroxylation followed by glucuronidation) and a low hepatic availability (Fh = 16%).",In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16782766/),%,16,128318,DB01045,Rifampicin
,27745744,CL/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],8.16,128571,DB01045,Rifampicin
,27745744,CL/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],3.05,128572,DB01045,Rifampicin
,27745744,Vz/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,192,128573,DB01045,Rifampicin
,27745744,Vz/F,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,75.1,128574,DB01045,Rifampicin
,27745744,t½,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.0,128575,DB01045,Rifampicin
,27745744,t½,"Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t½ was unchanged (15.0 vs 15.6 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.6,128576,DB01045,Rifampicin
,27745744,C,"Co-administration of olaparib with rifampin resulted in a statistically significant decrease in the relative bioavailability of olaparib: Cmax treatment ratio, 0.29 (90% CI, 0.24-0.33); mean AUC treatment ratio, 0.13 (90% CI, 0.11-0.16).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),,0.29,128577,DB01045,Rifampicin
,27745744,AU,"Co-administration of olaparib with rifampin resulted in a statistically significant decrease in the relative bioavailability of olaparib: Cmax treatment ratio, 0.29 (90% CI, 0.24-0.33); mean AUC treatment ratio, 0.13 (90% CI, 0.11-0.16).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),,0.13,128578,DB01045,Rifampicin
,27745744,CL/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],6.36,128579,DB01045,Rifampicin
,27745744,CL/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),[l] / [h],48.3,128580,DB01045,Rifampicin
,27745744,Vz/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,112,128581,DB01045,Rifampicin
,27745744,Vz/F,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),l,1076,128582,DB01045,Rifampicin
,27745744,t½,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,13.0,128583,DB01045,Rifampicin
,27745744,t½,"CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t½ was unchanged (13.0 vs 15.8 hours).",Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27745744/),h,15.8,128584,DB01045,Rifampicin
,9470318,Cmax,The mean Cmax was 9.81 +/- 4.41 ug/ml.,The pharmacokinetics of oral rifampicin in AIDS patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470318/),[ug] / [ml],9.81,129167,DB01045,Rifampicin
,9470318,Tmax,The mean Tmax was 2.25 +/- 0.71 h.,The pharmacokinetics of oral rifampicin in AIDS patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470318/),h,2.25,129168,DB01045,Rifampicin
,9470318,AUC0-24,The mean AUC0-24 was 60.25 +/- 36.88 ug.h/ml.,The pharmacokinetics of oral rifampicin in AIDS patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9470318/),[h·ug] / [ml],60.25,129169,DB01045,Rifampicin
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,3.23,129349,DB01045,Rifampicin
,32978634,steady-state AUC0-∞,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129350,DB01045,Rifampicin
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,2.26,129351,DB01045,Rifampicin
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.90,129352,DB01045,Rifampicin
,32978634,Cmax ratios,"Predicted ivosidenib geometric mean steady-state AUC0-∞ and Cmax ratios were 3.23 and 2.26 with ketoconazole, and 1.90 and 1.52 with fluconazole, respectively.",Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32978634/),,1.52,129353,DB01045,Rifampicin
,28181840,peak concentrations,"After EP transdermal delivery, the mean peak concentrations of isoniazid and rifampin in skin were 771.0 ± 163.4 μg/mL and 81.2 ± 17.3 μg/mL respectively.",Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28181840/),[μg] / [ml],771.0,130913,DB01045,Rifampicin
,28181840,peak concentrations,"After EP transdermal delivery, the mean peak concentrations of isoniazid and rifampin in skin were 771.0 ± 163.4 μg/mL and 81.2 ± 17.3 μg/mL respectively.",Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28181840/),[μg] / [ml],81.2,130914,DB01045,Rifampicin
,23629715,AUC0-24s,"The geometric mean AUC0-24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter.",Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23629715/),[h·mg] / [l],11.0,131881,DB01045,Rifampicin
,23629715,AUC0-24s,"The geometric mean AUC0-24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter.",Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23629715/),[h·mg] / [l],39.9,131882,DB01045,Rifampicin
,23629715,AUC0-24s,"The geometric mean AUC0-24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter.",Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23629715/),[h·mg] / [l],344,131883,DB01045,Rifampicin
,23629715,AUC0-24s,"The geometric mean AUC0-24s were as follows: isoniazid, 11.0 h · mg/liter; rifampin, 39.9 h · mg/liter; pyrazinamide, 344 h · mg/liter; and ethambutol, 20.2 h · mg/liter.",Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23629715/),[h·mg] / [l],20.2,131884,DB01045,Rifampicin
,22252827,oral clearance,"In a typical 55-kg male without HIV infection, the oral clearance, which was 7.76 liters · h⁻¹ at the first dose, increased 1.82- and 1.85-fold at steady state after daily dosing with 450 and 600 mg, respectively.",A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252827/),h⁻¹·l,7.76,132632,DB01045,Rifampicin
,22252827,half-life,The turnover of the inducible process was estimated to have a half-life of approximately 8 days in a typical patient.,A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252827/),d,8,132633,DB01045,Rifampicin
more,2191442,oral bioavailability,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,90,132916,DB01045,Rifampicin
,2191442,plasma protein binding,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,12,132917,DB01045,Rifampicin
,2191442,elimination half-life,The mean elimination half-life is approximately 30 hours.,The clinical pharmacology of fluconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),h,30,132918,DB01045,Rifampicin
,6740733,oral clearance,The mean oral clearance of theophylline was significantly increased from 54.9 +/- 21.2 to 68.9 +/- 26.5 ml/h/kg.,Effect of rifampin on theophylline disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740733/),[ml] / [h·kg],54.9,135319,DB01045,Rifampicin
,6740733,oral clearance,The mean oral clearance of theophylline was significantly increased from 54.9 +/- 21.2 to 68.9 +/- 26.5 ml/h/kg.,Effect of rifampin on theophylline disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6740733/),[ml] / [h·kg],68.9,135320,DB01045,Rifampicin
,25224007,maximum plasma concentration (Cmax),"The median maximum plasma concentration (Cmax) and area under the concentration-time curve from 0 to 6 h (AUC0-6) were 2.77 mg/liter and 9.71 mg · h/liter, respectively, for daily administration and 8.74 mg/liter and 37.8 mg · h/liter, respectively, for biweekly administration.","Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224007/),[mg] / [l],2.77,135464,DB01045,Rifampicin
,25224007,maximum plasma concentration (Cmax),"The median maximum plasma concentration (Cmax) and area under the concentration-time curve from 0 to 6 h (AUC0-6) were 2.77 mg/liter and 9.71 mg · h/liter, respectively, for daily administration and 8.74 mg/liter and 37.8 mg · h/liter, respectively, for biweekly administration.","Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224007/),[mg] / [l],8.74,135465,DB01045,Rifampicin
,25224007,area under the concentration-time curve from 0 to 6 h (AUC0-6),"The median maximum plasma concentration (Cmax) and area under the concentration-time curve from 0 to 6 h (AUC0-6) were 2.77 mg/liter and 9.71 mg · h/liter, respectively, for daily administration and 8.74 mg/liter and 37.8 mg · h/liter, respectively, for biweekly administration.","Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224007/),[h·mg] / [l],9.71,135466,DB01045,Rifampicin
,25224007,area under the concentration-time curve from 0 to 6 h (AUC0-6),"The median maximum plasma concentration (Cmax) and area under the concentration-time curve from 0 to 6 h (AUC0-6) were 2.77 mg/liter and 9.71 mg · h/liter, respectively, for daily administration and 8.74 mg/liter and 37.8 mg · h/liter, respectively, for biweekly administration.","Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25224007/),[h·mg] / [l],37.8,135467,DB01045,Rifampicin
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB01045,Rifampicin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB01045,Rifampicin
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB01045,Rifampicin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136808,DB01045,Rifampicin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136809,DB01045,Rifampicin
,16580903,Oral midazolam,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136810,DB01045,Rifampicin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136811,DB01045,Rifampicin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],2.7,136812,DB01045,Rifampicin
,16580903,clearance,"Oral midazolam clearance decreased after pretreatment with ketoconazole (from a geometric mean of 25 mL x min(-1) x kg(-1) [range, 12-57 mL x min(-1) x kg(-1)] to 2.7 mL x min(-1) x kg(-1) [range, 1.2-8.5 mL x min(-1) x kg(-1)], P < .001) and increased after pretreatment with rifampin (to a geometric mean of 203 mL x min(-1) x kg(-1) [range, 125-371 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],203,136813,DB01045,Rifampicin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],312,136814,DB01045,Rifampicin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],25,136815,DB01045,Rifampicin
,16580903,clearance,"Oral simvastatin clearance decreased after ketoconazole (from a geometric mean of 312 mL x min(-1) x kg(-1) [range, 151-1478 mL x min(-1) x kg(-1)] to 25 mL x min(-1) x kg(-1) [range, 8.0-147 mL x min(-1) x kg(-1)], P < .001) and increased after rifampin (to a geometric mean of 3536 mL x min(-1) x kg(-1) [range, 413-10,329 mL x min(-1) x kg(-1)], P < .001).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),[ml] / [kg·min],3536,136816,DB01045,Rifampicin
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,9.4,136817,DB01045,Rifampicin
,16580903,area under the concentration-time curve inhibitory ratio,"The area under the concentration-time curve inhibitory ratio for midazolam was 9.4 versus 12.4 for simvastatin (r = 0.3, P = .03).",Comparison of midazolam and simvastatin as cytochrome P450 3A probes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580903/),,12.4,136818,DB01045,Rifampicin
,546432,biological half-life,"It was found that the biological half-life of RMP was 3.79 h, the distribution at the initial stage 38%, and after a few weeks of treatment 52.1%.",Studies on pharmacokinetics of rifampicin in the body of patients with pulmonary tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/546432/),h,3.79,137069,DB01045,Rifampicin
,546432,biological half-life,"It was found that the biological half-life of RMP was 3.79 h, the distribution at the initial stage 38%, and after a few weeks of treatment 52.1%.",Studies on pharmacokinetics of rifampicin in the body of patients with pulmonary tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/546432/),%,52,137070,DB01045,Rifampicin
,29117990,area under the curve ratio,The simulated midazolam area under the curve ratio of 0.54 and an accompanying observed 1.9-fold increase in the CYP3A4 activity of biomarker 4β-hydroxycholesterol indicated a weak-to-moderate CYP3A4 induction by midostaurin and its metabolites at steady state in patients with advSM.,Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29117990/),,0.54,137187,DB01045,Rifampicin
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,6.23,137989,DB01045,Rifampicin
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,0.79,137990,DB01045,Rifampicin
,15114429,total,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,56.1,137991,DB01045,Rifampicin
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,6.23,137992,DB01045,Rifampicin
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,0.79,137993,DB01045,Rifampicin
,15114429,ratios,"After oral administration of 75 micro g midazolam, the 30-min total (unconjugated + conjugated) 1'OH-midazolam/midazolam ratios measured in the groups without co-medication, with ketoconazole and with rifampicin were (mean+/-SD): 6.23+/-2.61, 0.79+/-0.39 and 56.1+/-12.4, respectively.",Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114429/),,56.1,137994,DB01045,Rifampicin
,1506352,Peak CSF concentrations,Peak CSF concentrations obtained 0-8 h (median = 1 h) after the end of the infusion ranged from 0.57 to 1.24 mg/L (median = 0.73 mg/L).,Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506352/),[mg] / [l],0.57 to 1.24,138076,DB01045,Rifampicin
,1506352,Peak CSF concentrations,Peak CSF concentrations obtained 0-8 h (median = 1 h) after the end of the infusion ranged from 0.57 to 1.24 mg/L (median = 0.73 mg/L).,Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506352/),[mg] / [l],0.73,138077,DB01045,Rifampicin
,1506352,T1/2 beta,"Elimination from CSF was slower than from serum (T1/2 beta CSF: 9.1-21.0 h (median = 14.5 h, n = 5); T1/2 beta serum: 2.2-5.8 h (median = 3.6 h, n = 7)).",Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506352/),h,9.1-21.0,138078,DB01045,Rifampicin
,1506352,T1/2 beta,"Elimination from CSF was slower than from serum (T1/2 beta CSF: 9.1-21.0 h (median = 14.5 h, n = 5); T1/2 beta serum: 2.2-5.8 h (median = 3.6 h, n = 7)).",Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506352/),h,14.5,138079,DB01045,Rifampicin
,1506352,T1/2 beta serum,"Elimination from CSF was slower than from serum (T1/2 beta CSF: 9.1-21.0 h (median = 14.5 h, n = 5); T1/2 beta serum: 2.2-5.8 h (median = 3.6 h, n = 7)).",Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506352/),h,2.2-5.8,138080,DB01045,Rifampicin
,1506352,T1/2 beta serum,"Elimination from CSF was slower than from serum (T1/2 beta CSF: 9.1-21.0 h (median = 14.5 h, n = 5); T1/2 beta serum: 2.2-5.8 h (median = 3.6 h, n = 7)).",Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1506352/),h,3.6,138081,DB01045,Rifampicin
≤,33278623,MICs,All the 12 recovered isolates had MICs ≤0.5 μg/mL for linezolid.,Bone penetration of linezolid in osteoarticular tuberculosis patients of China. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33278623/),[μg] / [ml],0.5,138417,DB01045,Rifampicin
,33278623,bone/plasma penetration ratio,The median bone/plasma penetration ratio was 0.42 (range 0.14-0.95 μg/mL).,Bone penetration of linezolid in osteoarticular tuberculosis patients of China. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33278623/),[μg] / [ml],0.42,138418,DB01045,Rifampicin
,24962564,"overall exposure (AUC(0,∞))","Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2827,139737,DB01045,Rifampicin
,24962564,"overall exposure (AUC(0,∞))","Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2072,139738,DB01045,Rifampicin
,24962564,peak exposure (Cmax ),"Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[ng] / [ml],247,139739,DB01045,Rifampicin
,24962564,peak exposure (Cmax ),"Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[ng] / [ml],236,139740,DB01045,Rifampicin
,24962564,"AUC(0,∞)","Multiple doses of rifampicin increase apremilast clearance ≈3.6-fold and decrease apremilast mean AUC(0,∞) by ≈72% (3120 vs. 869 ng ml(-1) h, 90% CI = 25.7, 30.4) and Cmax (from 290 vs.",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],869,139741,DB01045,Rifampicin
,24962564,Cmax,"Multiple doses of rifampicin increase apremilast clearance ≈3.6-fold and decrease apremilast mean AUC(0,∞) by ≈72% (3120 vs. 869 ng ml(-1) h, 90% CI = 25.7, 30.4) and Cmax (from 290 vs.",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),,290,139742,DB01045,Rifampicin
,24962564,"AUC(0,∞))","A 30 min intravenous infusion of rifampicin 600 mg had negligible effects on the overall exposure (AUC(0,∞)) of apremilast (2980 vs. 3120 ng ml(-1) h, 90% CI = 88.0, 104.1).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2980,139743,DB01045,Rifampicin
,24962564,"AUC(0,∞))","A 30 min intravenous infusion of rifampicin 600 mg had negligible effects on the overall exposure (AUC(0,∞)) of apremilast (2980 vs. 3120 ng ml(-1) h, 90% CI = 88.0, 104.1).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],3120,139744,DB01045,Rifampicin
below,23094704,Cmax,25 patients (83%) had an isoniazid Cmax below 3 mg/l and 23 patients (77%) had a rifampicin Cmax below 8 mg/l.,Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094704/),[mg] / [l],3,140080,DB01045,Rifampicin
below,23094704,Cmax,25 patients (83%) had an isoniazid Cmax below 3 mg/l and 23 patients (77%) had a rifampicin Cmax below 8 mg/l.,Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094704/),[mg] / [l],8,140081,DB01045,Rifampicin
below,23094704,Cmax,One patient (3%) had a pyrazinamide Cmax below 20 mg/l.,Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094704/),[mg] / [l],20,140082,DB01045,Rifampicin
,23094704,AUC0-24,"The geometric mean AUC0-24 for isoniazid was much lower in fast acetylators than in slow acetylators (5.2 vs. 12.0, P < 0.01).",Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094704/),,5.2,140083,DB01045,Rifampicin
,23094704,AUC0-24,"The geometric mean AUC0-24 for isoniazid was much lower in fast acetylators than in slow acetylators (5.2 vs. 12.0, P < 0.01).",Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23094704/),,12.0,140084,DB01045,Rifampicin
,30198595,minimum plasma concentration,"However, all scenarios suggest that a dose of 62.5 mg weekly achieves or exceeds the exposure in adults following a 250 mg weekly dose and results in a minimum plasma concentration of 620 ng ml-1 , which is considered necessary to achieve 95% prophylactic efficacy.",Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30198595/),[ng] / [ml],620,140651,DB01045,Rifampicin
,18509604,systemic clearance,A two-compartment model described MEB (2.5 mCi) systemic disposition in humans (systemic clearance = 16.2 +/- 2.7 ml min(-1) kg(-1)); biliary excretion was the predominant route of hepatic elimination (efflux rate constants ratio canalicular/sinusoidal = 3.4 +/- 0.8).,"Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18509604/),[ml] / [kg·min],16.2,141859,DB01045,Rifampicin
,18509604,efflux rate constants ratio,A two-compartment model described MEB (2.5 mCi) systemic disposition in humans (systemic clearance = 16.2 +/- 2.7 ml min(-1) kg(-1)); biliary excretion was the predominant route of hepatic elimination (efflux rate constants ratio canalicular/sinusoidal = 3.4 +/- 0.8).,"Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18509604/),,3.4,141860,DB01045,Rifampicin
,23677771,effective plasma half-life,"Axitinib has a short effective plasma half-life (range 2.5-6.1 h), and the plasma accumulation of axitinib is in agreement with what is expected based on the plasma half-life of the drug.",Clinical pharmacology of axitinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677771/),h,2.5-6.1,143799,DB01045,Rifampicin
,23677771,absolute bioavailability,The mean absolute bioavailability of axitinib is 58 %.,Clinical pharmacology of axitinib. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677771/),%,58,143800,DB01045,Rifampicin
,23677771,C max,"In patients with advanced renal cell carcinoma, at the 5-mg twice-daily dose in the fed state, the geometric mean (% coefficient of variation) C max and area under the plasma concentration-time curve (AUC) from time 0-24 h (AUC24) were 27.8 ng/mL (79 %) and 265 ng·h/mL (77 %), respectively.",Clinical pharmacology of axitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677771/),[ng] / [ml],27.8,143801,DB01045,Rifampicin
,23677771,area under the plasma concentration-time curve (AUC) from time 0-24 h (AUC24),"In patients with advanced renal cell carcinoma, at the 5-mg twice-daily dose in the fed state, the geometric mean (% coefficient of variation) C max and area under the plasma concentration-time curve (AUC) from time 0-24 h (AUC24) were 27.8 ng/mL (79 %) and 265 ng·h/mL (77 %), respectively.",Clinical pharmacology of axitinib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677771/),[h·ng] / [ml],265,143802,DB01045,Rifampicin
,26082504,apparent oral clearance,"Median efavirenz apparent oral clearance was 9.3 L/hour (IQR, 6.42-13.22 L/hour) at baseline and 9.8 L/hour (IQR, 7.04-15.59 L/hour) during rifapentine/isoniazid treatment (GMR, 1.04 [90% confidence interval, .97-1.13]).",Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082504/),[l] / [h],9.3,143962,DB01045,Rifampicin
,26082504,apparent oral clearance,"Median efavirenz apparent oral clearance was 9.3 L/hour (IQR, 6.42-13.22 L/hour) at baseline and 9.8 L/hour (IQR, 7.04-15.59 L/hour) during rifapentine/isoniazid treatment (GMR, 1.04 [90% confidence interval, .97-1.13]).",Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082504/),[l] / [h],9.8,143963,DB01045,Rifampicin
,1767982,total body clearance,"Analysis by the noncompartmental model of rifampin serum concentrations after IV administration yielded a mean +/- SD total body clearance of 1.16 +/- 0.21 ml/min/kg, apparent volume of distribution at steady state of 0.45 +/- 0.06 L/kg, and terminal elimination rate constant of 0.15 +/- 0.04 hour-1.",Pharmacokinetics of rifampin in adult sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767982/),[ml] / [kg·min],1.16,144236,DB01045,Rifampicin
,1767982,apparent volume of distribution at steady state,"Analysis by the noncompartmental model of rifampin serum concentrations after IV administration yielded a mean +/- SD total body clearance of 1.16 +/- 0.21 ml/min/kg, apparent volume of distribution at steady state of 0.45 +/- 0.06 L/kg, and terminal elimination rate constant of 0.15 +/- 0.04 hour-1.",Pharmacokinetics of rifampin in adult sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767982/),[l] / [kg],0.45,144237,DB01045,Rifampicin
,1767982,terminal elimination rate constant,"Analysis by the noncompartmental model of rifampin serum concentrations after IV administration yielded a mean +/- SD total body clearance of 1.16 +/- 0.21 ml/min/kg, apparent volume of distribution at steady state of 0.45 +/- 0.06 L/kg, and terminal elimination rate constant of 0.15 +/- 0.04 hour-1.",Pharmacokinetics of rifampin in adult sheep. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767982/),1/[h],0.15,144238,DB01045,Rifampicin
,1767982,elimination half-life,The harmonic mean of the elimination half-life was 4.56 hours.,Pharmacokinetics of rifampin in adult sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1767982/),h,4.56,144239,DB01045,Rifampicin
,1233266,elimination half-life,The average elimination half-life of hexobarbital had decreased from 325 to 122 min and of tolbutamide from 418 to 183 min following rifampicin treatment.,Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233266/),min,325 to 122,144728,DB01045,Rifampicin
,1233266,elimination half-life,The average elimination half-life of hexobarbital had decreased from 325 to 122 min and of tolbutamide from 418 to 183 min following rifampicin treatment.,Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233266/),min,418 to 183,144729,DB01045,Rifampicin
,34183327,AUC0-24,"Among 20 eligible patients, geometric mean AUC0-24 of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively.","Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34183327/),[hour∙mg] / [l],18.5,145322,DB01045,Rifampicin
,34183327,AUC0-24,"Among 20 eligible patients, geometric mean AUC0-24 of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively.","Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34183327/),[hour∙mg] / [l],66.9,145323,DB01045,Rifampicin
,34183327,AUC0-24,"Among 20 eligible patients, geometric mean AUC0-24 of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively.","Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34183327/),[hour∙mg] / [l],315.5,145324,DB01045,Rifampicin
,34183327,AUC0-24,"Among 20 eligible patients, geometric mean AUC0-24 of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively.","Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34183327/),[hour∙mg] / [l],14.5,145325,DB01045,Rifampicin
,34183327,AUC0-24,"Among 20 eligible patients, geometric mean AUC0-24 of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively.","Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34183327/),[hour∙mg] / [l],71.8,145326,DB01045,Rifampicin
,34183327,AUC0-24,"Among 20 eligible patients, geometric mean AUC0-24 of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively.","Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34183327/),[hour∙mg] / [l],328.4,145327,DB01045,Rifampicin
,23774436,AUC0-∞,"The median AUC0-∞ of 41.2 μg · h/ml decreased on average by 14.3% (90% confidence interval [CI], -90.5% to +61.5%) following multiple 400-mg daily doses.",Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774436/),[h·μg] / [ml],41.2,146018,DB01045,Rifampicin
≥,23774436,fAUC/MIC,"At steady state, 90% of patients achieved an fAUC/MIC of ≥125 only when the MIC was <0.125 μg/ml.",Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774436/),,125,146019,DB01045,Rifampicin
<,23774436,MIC,"At steady state, 90% of patients achieved an fAUC/MIC of ≥125 only when the MIC was <0.125 μg/ml.",Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774436/),[μg] / [ml],0.125,146020,DB01045,Rifampicin
,10954343,clearance over bioavailability (CL/F),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],2.60,146191,DB01045,Rifampicin
,10954343,renal clearance (CLR),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],0.10,146192,DB01045,Rifampicin
,10954343,terminal half-life (t1/2),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,23.8,146193,DB01045,Rifampicin
,10954343,peak serum concentration (Cmax),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [l],0.29,146194,DB01045,Rifampicin
,10954343,time to reach Cmax (tmax),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,1.6,146195,DB01045,Rifampicin
,10954343,total area under the serum concentration-time curve (AUC0-infinity),"The values of the pharmacokinetic parameters of lamotrigine were: clearance over bioavailability (CL/F) 2.60+/-0.40 l/h, renal clearance (CLR) 0.10+/-0.03 l/h, terminal half-life (t1/2) 23.8+/-2.1 h, mean peak serum concentration (Cmax) 0.29+/-0.02 microg/l, time to reach Cmax (tmax) 1.6+/-0.28 h, and total area under the serum concentration-time curve (AUC0-infinity) 703.99+/-82.31 microg/ ml/min (mean +/- SEM).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [min·ml],703.99,146196,DB01045,Rifampicin
,10954343,amount,The amount of lamotrigine excreted as glucuronide was 8.90+/-0.77 mg.,Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),mg,8.90,146197,DB01045,Rifampicin
,10954343,excreted,The amount of lamotrigine excreted as glucuronide was 8.90+/-0.77 mg.,Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),mg,8.90,146198,DB01045,Rifampicin
,10954343,CL/F,"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[l] / [h],5.13,146199,DB01045,Rifampicin
,10954343,t1/2,"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),h,14.1,146200,DB01045,Rifampicin
,10954343,AUC(0-infinity),"Rifampicin significantly increased CL/F (5.13+/-1.05 l/h) and the amount of lamotrigine excreted as glucuronide (12.12+/-0.94 mg), whereas both t1/2 (14.1+/-1.7 h) and AUC(0-infinity) (396.24+/-60.18 microg/ml/min) were decreased (P<0.05).",Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954343/),[μg] / [min·ml],396.24,146201,DB01045,Rifampicin
,18197120,maximum concentration (Cmax),"Lopinavir pharmacokinetic measures (median [interquartile range]) for children with and without rifampicin, respectively, were maximum concentration (Cmax) of 10.5 [7.1 to 14.3] versus 14.2 [11.9 to 23.5] mg/L (P = 0.018), area under the curve from 0 to 12 hours (AUC0-12) of 80.9 [50.9 to 121.7] versus 117.8 [80.4 to 176.1] mg/h/L (P = 0.036), and trough concentration (Cmin) of 3.94 [2.26 to 7.66] versus 4.64 [2.32 to 10.40] mg/L (P = 0.468).",Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197120/),[mg] / [l],10.5,146269,DB01045,Rifampicin
,18197120,maximum concentration (Cmax),"Lopinavir pharmacokinetic measures (median [interquartile range]) for children with and without rifampicin, respectively, were maximum concentration (Cmax) of 10.5 [7.1 to 14.3] versus 14.2 [11.9 to 23.5] mg/L (P = 0.018), area under the curve from 0 to 12 hours (AUC0-12) of 80.9 [50.9 to 121.7] versus 117.8 [80.4 to 176.1] mg/h/L (P = 0.036), and trough concentration (Cmin) of 3.94 [2.26 to 7.66] versus 4.64 [2.32 to 10.40] mg/L (P = 0.468).",Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197120/),[mg] / [l],14.2,146270,DB01045,Rifampicin
,18197120,area under the curve from 0 to 12 hours (AUC0-12),"Lopinavir pharmacokinetic measures (median [interquartile range]) for children with and without rifampicin, respectively, were maximum concentration (Cmax) of 10.5 [7.1 to 14.3] versus 14.2 [11.9 to 23.5] mg/L (P = 0.018), area under the curve from 0 to 12 hours (AUC0-12) of 80.9 [50.9 to 121.7] versus 117.8 [80.4 to 176.1] mg/h/L (P = 0.036), and trough concentration (Cmin) of 3.94 [2.26 to 7.66] versus 4.64 [2.32 to 10.40] mg/L (P = 0.468).",Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197120/),[mg] / [h·l],80.9,146271,DB01045,Rifampicin
,18197120,area under the curve from 0 to 12 hours (AUC0-12),"Lopinavir pharmacokinetic measures (median [interquartile range]) for children with and without rifampicin, respectively, were maximum concentration (Cmax) of 10.5 [7.1 to 14.3] versus 14.2 [11.9 to 23.5] mg/L (P = 0.018), area under the curve from 0 to 12 hours (AUC0-12) of 80.9 [50.9 to 121.7] versus 117.8 [80.4 to 176.1] mg/h/L (P = 0.036), and trough concentration (Cmin) of 3.94 [2.26 to 7.66] versus 4.64 [2.32 to 10.40] mg/L (P = 0.468).",Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197120/),[mg] / [h·l],117.8,146272,DB01045,Rifampicin
,18197120,trough concentration (Cmin),"Lopinavir pharmacokinetic measures (median [interquartile range]) for children with and without rifampicin, respectively, were maximum concentration (Cmax) of 10.5 [7.1 to 14.3] versus 14.2 [11.9 to 23.5] mg/L (P = 0.018), area under the curve from 0 to 12 hours (AUC0-12) of 80.9 [50.9 to 121.7] versus 117.8 [80.4 to 176.1] mg/h/L (P = 0.036), and trough concentration (Cmin) of 3.94 [2.26 to 7.66] versus 4.64 [2.32 to 10.40] mg/L (P = 0.468).",Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197120/),[mg] / [l],3.94,146273,DB01045,Rifampicin
,18197120,trough concentration (Cmin),"Lopinavir pharmacokinetic measures (median [interquartile range]) for children with and without rifampicin, respectively, were maximum concentration (Cmax) of 10.5 [7.1 to 14.3] versus 14.2 [11.9 to 23.5] mg/L (P = 0.018), area under the curve from 0 to 12 hours (AUC0-12) of 80.9 [50.9 to 121.7] versus 117.8 [80.4 to 176.1] mg/h/L (P = 0.036), and trough concentration (Cmin) of 3.94 [2.26 to 7.66] versus 4.64 [2.32 to 10.40] mg/L (P = 0.468).",Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197120/),[mg] / [l],4.64,146274,DB01045,Rifampicin
greater,18197120,minimum therapeutic concentration,Thirteen of 15 children receiving antitubercular treatment (87%) had a lopinavir Cmin greater than the recommended minimum therapeutic concentration (1 mg/L).,Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197120/),[mg] / [l],1,146275,DB01045,Rifampicin
,3793963,total clearance,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[ml] / [kg·min],0.88,147237,DB01045,Rifampicin
,3793963,total clearance,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[ml] / [kg·min],1.21,147238,DB01045,Rifampicin
,3793963,terminal elimination rate constant,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),1/[h],0.104,147239,DB01045,Rifampicin
,3793963,terminal elimination rate constant,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),1/[h],0.148,147240,DB01045,Rifampicin
,3793963,area under the theophylline concentration-time curve,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[hr-mg] / [l],104,147241,DB01045,Rifampicin
,3793963,area under the theophylline concentration-time curve,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),[hr-mg] / [l],76,147242,DB01045,Rifampicin
,3793963,half-life,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),h,7.0,147243,DB01045,Rifampicin
,3793963,half-life,"In every subject, rifampin caused an increase in total clearance (from 0.88 +/- 0.21 to 1.21 +/- 0.29 mL/min/kg) and terminal elimination rate constant (from 0.104 +/- 0.023 to 0.148 +/- 0.030 hr-1) and a decrease in the area under the theophylline concentration-time curve (from 104 +/- 29 to 76 +/- 19 hr-mg/L) and half-life of theophylline (from 7.0 +/- 1.7 to 4.8 +/- 0.9 hr).",The effect of rifampin on theophylline kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793963/),h,4.8,147244,DB01045,Rifampicin
,6129140,elimination half-life,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,8.5,148024,DB01045,Rifampicin
,6129140,elimination half-life,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,5.0,148025,DB01045,Rifampicin
,6129140,nonrenal clearance,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],435,148026,DB01045,Rifampicin
,6129140,nonrenal clearance,"The absorption and distribution of mexiletine were not changed after rifampicin, but its elimination half-life fell from 8.5 +/- 0.8 h (mean +/- SE) to 5.0 +/- 0.4 h (p less than 0.01), and its nonrenal clearance increased from 435 +/- 68 ml/min to 711 +/- 101 ml/min (p less than 0.01).",Effect of rifampicin treatment on the kinetics of mexiletine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],711,148027,DB01045,Rifampicin
,6129140,amount,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,32,148028,DB01045,Rifampicin
,6129140,amount,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,18,148029,DB01045,Rifampicin
,6129140,excreted,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,32,148030,DB01045,Rifampicin
,6129140,excreted,The amount of unchanged mexiletine excreted in urine over two days decreased from 32 +/- 7 to 18 +/- 3 mg (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),mg,18,148031,DB01045,Rifampicin
,6129140,half-life,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,11.8,148032,DB01045,Rifampicin
,6129140,half-life,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),h,5.5,148033,DB01045,Rifampicin
,6129140,clearance,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),ml,40,148034,DB01045,Rifampicin
,6129140,clearance,The half-life of antipyrine fell from 11.8 +/- 0.4 to 5.5 +/- 0.3 h and its clearance increased from 40 +/- 3 ml to 74 +/- 3 ml/min (p less than 0.01).,Effect of rifampicin treatment on the kinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129140/),[ml] / [min],74,148035,DB01045,Rifampicin
,24629633,maximal effect,"Rifampicin, Isoniazid, and Ethambutol dosed per orally exhibited bactericidality and good dose response with maximal effect of 5.66, 4.66, and 4.80 log10 CFU reductions in the lungs, respectively.",Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24629633/),cfu·log10·reductions,5.66,148813,DB01045,Rifampicin
,24629633,maximal effect,"Rifampicin, Isoniazid, and Ethambutol dosed per orally exhibited bactericidality and good dose response with maximal effect of 5.66, 4.66, and 4.80 log10 CFU reductions in the lungs, respectively.",Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24629633/),cfu·log10·reductions,4.66,148814,DB01045,Rifampicin
,24629633,maximal effect,"Rifampicin, Isoniazid, and Ethambutol dosed per orally exhibited bactericidality and good dose response with maximal effect of 5.66, 4.66, and 4.80 log10 CFU reductions in the lungs, respectively.",Pharmacokinetics and dose response of anti-TB drugs in rat infection model of tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24629633/),cfu·log10·reductions,4.80,148815,DB01045,Rifampicin
,16252264,flow-rate,"Plasma samples were deproteinized with acetonitrile and separated by HPLC on a RP-18 (125 x 4 mm, 5 microm) column and gradient elution with potassium dihydrogen phosphate solution (pH 4.5; 50 mm) and acetonitrile at a flow-rate of 1.0 mL/min.",Simultaneous determination of rifampicin and sulbactam in mouse plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16252264/),[ml] / [min],1.0,149158,DB01045,Rifampicin
,16252264,recoveries,"Average recoveries of rifampicin and sulbactam from mice plasma were 98.2 and 89.3%, respectively.",Simultaneous determination of rifampicin and sulbactam in mouse plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16252264/),%,98.2,149159,DB01045,Rifampicin
,16252264,recoveries,"Average recoveries of rifampicin and sulbactam from mice plasma were 98.2 and 89.3%, respectively.",Simultaneous determination of rifampicin and sulbactam in mouse plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16252264/),%,89.3,149160,DB01045,Rifampicin
,23796067,AUC0-24,We describe a patient treated with caspofungin and rifampin; after increasing the dosage of the former (70 mg/day) we observed an unexpectedly lower plasma exposure (AUC0-24 79.5 μg/ml*h vs. 108.8 μg/ml*h).,Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23796067/),[μg] / [h·ml],79.5,151784,DB01045,Rifampicin
,23796067,AUC0-24,We describe a patient treated with caspofungin and rifampin; after increasing the dosage of the former (70 mg/day) we observed an unexpectedly lower plasma exposure (AUC0-24 79.5 μg/ml*h vs. 108.8 μg/ml*h).,Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23796067/),[μg] / [h·ml],108.8,151785,DB01045,Rifampicin
,32451120,oral clearance,"The efavirenz oral clearance were 11.9, 8.0, and 2.8 L/h in patients weighing 57 kg and having the CYP2B6 516 GG, 516 GT, and 516 TT genotypes, respectively.",Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32451120/),[l] / [h],11.9,152434,DB01045,Rifampicin
,32451120,oral clearance,"The efavirenz oral clearance were 11.9, 8.0, and 2.8 L/h in patients weighing 57 kg and having the CYP2B6 516 GG, 516 GT, and 516 TT genotypes, respectively.",Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32451120/),[l] / [h],8.0,152435,DB01045,Rifampicin
,32451120,oral clearance,"The efavirenz oral clearance were 11.9, 8.0, and 2.8 L/h in patients weighing 57 kg and having the CYP2B6 516 GG, 516 GT, and 516 TT genotypes, respectively.",Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32451120/),[l] / [h],2.8,152436,DB01045,Rifampicin
,31051051,CL,"Typical midazolam CL and F estimates were 32.9 L/h and 0.31 for the constituent state, while the ratio of inducer/inhibitor for midazolam CL and CL/F for the induced/inhibited (rifampin/ketoconazole) states were 14.2 and 85.3.","Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051051/),[l] / [h],32.9,152473,DB01045,Rifampicin
,31051051,F,"Typical midazolam CL and F estimates were 32.9 L/h and 0.31 for the constituent state, while the ratio of inducer/inhibitor for midazolam CL and CL/F for the induced/inhibited (rifampin/ketoconazole) states were 14.2 and 85.3.","Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31051051/),,0.31,152474,DB01045,Rifampicin
<,16267738,maximum concentration,"With daily dosing of rifampin (600 mg), 26 (77%) of 34 patients (95% confidence interval [CI], 59%-89%]) had a low maximum concentration of rifampin (<8 microg/mL), and 12 (35%; 95% CI, 20%-54%) had a very low maximum concentration (<4 microg/mL).",The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16267738/),[μg] / [ml],8,153092,DB01045,Rifampicin
<,16267738,maximum concentration,"With daily dosing of rifampin (600 mg), 26 (77%) of 34 patients (95% confidence interval [CI], 59%-89%]) had a low maximum concentration of rifampin (<8 microg/mL), and 12 (35%; 95% CI, 20%-54%) had a very low maximum concentration (<4 microg/mL).",The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16267738/),[μg] / [ml],4,153093,DB01045,Rifampicin
<,16267738,maximum concentration,"With daily ethambutol dosing (20 mg/kg), 33 (69%) of 48 patients (95% CI, 55%-81%) had a low maximum concentration of ethambutol (<2 microg/mL), and 18 (38%; 95% CI, 24%-53%) had a very low maximum concentration (<1 microg/mL).",The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16267738/),[μg] / [ml],2,153094,DB01045,Rifampicin
<,16267738,maximum concentration,"With daily ethambutol dosing (20 mg/kg), 33 (69%) of 48 patients (95% CI, 55%-81%) had a low maximum concentration of ethambutol (<2 microg/mL), and 18 (38%; 95% CI, 24%-53%) had a very low maximum concentration (<1 microg/mL).",The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16267738/),[μg] / [ml],1,153095,DB01045,Rifampicin
<,16267738,maximum concentration,"With intermittent ethambutol dosing (50 mg/kg twice weekly or 30 mg/kg thrice weekly), 13 (72%) of 18 patients (95% CI, 47%-88%) had a low maximum concentration of ethambutol (<4 microg/mL), and 5 (28%; 95% CI, 12%-54%]) had a very low maximum concentration (<2 microg/mL).",The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16267738/),[μg] / [ml],4,153096,DB01045,Rifampicin
<,16267738,maximum concentration,"With intermittent ethambutol dosing (50 mg/kg twice weekly or 30 mg/kg thrice weekly), 13 (72%) of 18 patients (95% CI, 47%-88%) had a low maximum concentration of ethambutol (<4 microg/mL), and 5 (28%; 95% CI, 12%-54%]) had a very low maximum concentration (<2 microg/mL).",The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16267738/),[μg] / [ml],2,153097,DB01045,Rifampicin
,9862241,plasma clearance,The lignocaine plasma clearance increased from 7.5+/-1.2 ml min(-1) kg(-1) before to 8.6+/-2ml min(-1) kg(-1) (P=0.026) after induction.,The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862241/),[ml] / [kg·min],7.5,153171,DB01045,Rifampicin
,9862241,plasma clearance,The lignocaine plasma clearance increased from 7.5+/-1.2 ml min(-1) kg(-1) before to 8.6+/-2ml min(-1) kg(-1) (P=0.026) after induction.,The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862241/),[ml] / [kg·min],8.6,153172,DB01045,Rifampicin
,9862241,concentrations,The normalised MEGX30min concentrations increased from 61+/-14 (day 7) to 82+/-34 microg l(-1) (day 14) by a mean of 21 microg l(-1) (95% confidence interval: -3 to 44 microg l(-1)) (P=0.055).,The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862241/),[μg] / [l],61,153173,DB01045,Rifampicin
,9862241,concentrations,The normalised MEGX30min concentrations increased from 61+/-14 (day 7) to 82+/-34 microg l(-1) (day 14) by a mean of 21 microg l(-1) (95% confidence interval: -3 to 44 microg l(-1)) (P=0.055).,The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862241/),[μg] / [l],82,153174,DB01045,Rifampicin
,17099560,bioavailability,Its mean bioavailability is around 75%.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,75,153478,DB01045,Rifampicin
,17099560,volume of distribution,Its volume of distribution is of around 4 L/kg.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[l] / [kg],4,153479,DB01045,Rifampicin
,17099560,half-life elimination,The value of half-life elimination is of around 22 hours.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),h,22,153480,DB01045,Rifampicin
,17099560,bioavibility,"Thus, bioavibility ranges from 36 to 100%.",[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),%,36 to 100,153481,DB01045,Rifampicin
,17099560,plasmatic target,The methadone plasmatic target value of 400 microg/ml can be recommended for therapeutic drug monitoring.,[Methadone: from pharmacokinetic profile to clinical pharmacology]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17099560/),[μg] / [ml],400,153482,DB01045,Rifampicin
,21750119,half-lives,"With rifampin and moxifloxacin, there is a discordance between the half-lives of these agents (1.9 versus 6.5 h when employed in combination).",Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750119/),h,1.9,153488,DB01045,Rifampicin
,21750119,half-lives,"With rifampin and moxifloxacin, there is a discordance between the half-lives of these agents (1.9 versus 6.5 h when employed in combination).",Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21750119/),h,6.5,153489,DB01045,Rifampicin
,34260082,clearance at steady state,"The estimated typical clearance at steady state was 10.7 L/h in a child weighing 9.8 kg co-treated with lopinavir/ritonavir, and was 12% higher in children receiving efavirenz.","Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34260082/),[l] / [h],10.7,153567,DB01045,Rifampicin
,19386087,area under the curve 0 to 6 hours,"The mean rifampin area under the curve 0 to 6 hours after dosing was 14.9 and 18.1 microg/hour/ml (P = 0.25) 1 month after starting treatment in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children, respectively, and 16.52 and 17.94 microg/hour/ml (P = 0.59) after 4 months of treatment.","Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19386087/),[μg] / [h·ml],14.9,153813,DB01045,Rifampicin
,19386087,area under the curve 0 to 6 hours,"The mean rifampin area under the curve 0 to 6 hours after dosing was 14.9 and 18.1 microg/hour/ml (P = 0.25) 1 month after starting treatment in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children, respectively, and 16.52 and 17.94 microg/hour/ml (P = 0.59) after 4 months of treatment.","Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19386087/),[μg] / [h·ml],18.1,153814,DB01045,Rifampicin
,19386087,area under the curve 0 to 6 hours,"The mean rifampin area under the curve 0 to 6 hours after dosing was 14.9 and 18.1 microg/hour/ml (P = 0.25) 1 month after starting treatment in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children, respectively, and 16.52 and 17.94 microg/hour/ml (P = 0.59) after 4 months of treatment.","Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19386087/),[μg] / [h·ml],16.52,153815,DB01045,Rifampicin
,19386087,area under the curve 0 to 6 hours,"The mean rifampin area under the curve 0 to 6 hours after dosing was 14.9 and 18.1 microg/hour/ml (P = 0.25) 1 month after starting treatment in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children, respectively, and 16.52 and 17.94 microg/hour/ml (P = 0.59) after 4 months of treatment.","Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19386087/),[μg] / [h·ml],17.94,153816,DB01045,Rifampicin
,19386087,concentrations,The mean calculated 2-hour rifampin concentrations in these human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children were 3.9 and 4.8 microg/ml (P = 0.20) at 1 month after the start of treatment and 4.0 and 4.6 microg/ml (P = 0.33) after 4 months of treatment.,"Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19386087/),,3,153817,DB01045,Rifampicin
,19386087,concentrations,The mean calculated 2-hour rifampin concentrations in these human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children were 3.9 and 4.8 microg/ml (P = 0.20) at 1 month after the start of treatment and 4.0 and 4.6 microg/ml (P = 0.33) after 4 months of treatment.,"Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19386087/),,4.8,153818,DB01045,Rifampicin
,19386087,concentrations,The mean calculated 2-hour rifampin concentrations in these human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children were 3.9 and 4.8 microg/ml (P = 0.20) at 1 month after the start of treatment and 4.0 and 4.6 microg/ml (P = 0.33) after 4 months of treatment.,"Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19386087/),,4.,153819,DB01045,Rifampicin
,19386087,concentrations,The mean calculated 2-hour rifampin concentrations in these human immunodeficiency virus-infected and human immunodeficiency virus-uninfected children were 3.9 and 4.8 microg/ml (P = 0.20) at 1 month after the start of treatment and 4.0 and 4.6 microg/ml (P = 0.33) after 4 months of treatment.,"Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19386087/),,4.6,153820,DB01045,Rifampicin
,10530584,MIC,The 2-h postdose plasma concentrations of rifapentine (6.59 to 9.05 microg/ml) and 25-desacetyl rifapentine (0.57 to 2.64 microg/ml) far exceeded the MIC of Mycobacterium tuberculosis to rifapentine (approximately 0.12 microg/ml).,Rifapentine pharmacokinetics in adolescents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530584/),[μg] / [ml],0.12,154326,DB01045,Rifampicin
,10530584,Cmax,"The combination of a high Cmax (rifapentine, 9.95 to 18.63 microg/ml; 25-desacetyl rifapentine, 3.73 to 7.46 microg/ml) and lengthy terminal elimination phase t1/2 (rifapentine, 10 to 23 h; 25-desacetyl rifapentine, 14 to 35 h) resulted in potentially effective plasma concentrations of both compounds that persisted for at least 48 h in most subjects.",Rifapentine pharmacokinetics in adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530584/),[μg] / [ml],9.95 to 18.63,154327,DB01045,Rifampicin
,10530584,Cmax,"The combination of a high Cmax (rifapentine, 9.95 to 18.63 microg/ml; 25-desacetyl rifapentine, 3.73 to 7.46 microg/ml) and lengthy terminal elimination phase t1/2 (rifapentine, 10 to 23 h; 25-desacetyl rifapentine, 14 to 35 h) resulted in potentially effective plasma concentrations of both compounds that persisted for at least 48 h in most subjects.",Rifapentine pharmacokinetics in adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530584/),[μg] / [ml],3.73 to 7.46,154328,DB01045,Rifampicin
,10530584,terminal elimination phase t1/2,"The combination of a high Cmax (rifapentine, 9.95 to 18.63 microg/ml; 25-desacetyl rifapentine, 3.73 to 7.46 microg/ml) and lengthy terminal elimination phase t1/2 (rifapentine, 10 to 23 h; 25-desacetyl rifapentine, 14 to 35 h) resulted in potentially effective plasma concentrations of both compounds that persisted for at least 48 h in most subjects.",Rifapentine pharmacokinetics in adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530584/),h,10 to 23,154329,DB01045,Rifampicin
,10530584,terminal elimination phase t1/2,"The combination of a high Cmax (rifapentine, 9.95 to 18.63 microg/ml; 25-desacetyl rifapentine, 3.73 to 7.46 microg/ml) and lengthy terminal elimination phase t1/2 (rifapentine, 10 to 23 h; 25-desacetyl rifapentine, 14 to 35 h) resulted in potentially effective plasma concentrations of both compounds that persisted for at least 48 h in most subjects.",Rifapentine pharmacokinetics in adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10530584/),h,14 to 35,154330,DB01045,Rifampicin
,9784933,absolute bioavailability,"Although nisoldipine is almost completely absorbed, its absolute bioavailability from the CC tablet is only 5.5%, as a result of significant first-pass metabolism in the gut and liver.",Clinical pharmacokinetics of nisoldipine coat-core. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9784933/),%,5.5,154456,DB01045,Rifampicin
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,5.19,155201,DB01045,Rifampicin
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,3.68,155202,DB01045,Rifampicin
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,1.04,155203,DB01045,Rifampicin
,27174018,IC50,"3. Inhibition study using rosuvastatin as the substrate in OATP1B1- and OATP1B3-transfected cells indicated that curcumin was an OATP1B1 and 1B3 inhibitor, with IC50 at 5.19 ± 0.05 and 3.68 ± 0.05 μM, respectively; the data for COG were 1.04 ± 0.01 and 1.08 ± 0.02 μM, respectively.",Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27174018/),μM,1.08,155204,DB01045,Rifampicin
,3800115,peak serum rifampin concentration,The mean peak serum rifampin concentration was 6.7 micrograms/ml at 4 hours after treatment.,Pharmacokinetics of rifampin given as a single oral dose in foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800115/),[μg] / [ml],6.7,155223,DB01045,Rifampicin
,3800115,elimination half-life,"The elimination half-life was 17.5 hours, and the elimination rate constant was 0.04/hr.",Pharmacokinetics of rifampin given as a single oral dose in foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800115/),h,17.5,155224,DB01045,Rifampicin
,3800115,elimination rate constant,"The elimination half-life was 17.5 hours, and the elimination rate constant was 0.04/hr.",Pharmacokinetics of rifampin given as a single oral dose in foals. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800115/),1/[h],0.04,155225,DB01045,Rifampicin
>,29241821,Cmax,Ninety-two percent of patients had an INH Cmax > 3 µg/mL.,Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29241821/),[μg] / [ml],3,155241,DB01045,Rifampicin
<,29241821,Cmax,Seventy-seven percent of patients had a RIF Cmax < 8 µg/mL and 28% of patients had a RIF AUC0-24h < 13 mg ⋅ h/L.,Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29241821/),[μg] / [ml],8,155242,DB01045,Rifampicin
<,29241821,AUC0-24h,Seventy-seven percent of patients had a RIF Cmax < 8 µg/mL and 28% of patients had a RIF AUC0-24h < 13 mg ⋅ h/L.,Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29241821/),[h·mg] / [l],13,155243,DB01045,Rifampicin
<,25406657,AUC0-24,"86% of patients on the tiw rifabutin arm had an AUC0-24 < 4.5 μg.h/mL, which has previously been associated with acquired rifamycin resistance (ARR).",Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25406657/),[h·μg] / [ml],4.5,155340,DB01045,Rifampicin
,32170944,Cmax,"Using a Cmax target of 8 mg/L, the area under the receiver operating characteristic curve was 80.1% (range, 47.2%-100%).",Determination of Rifampin Concentrations by Urine Colorimetry and Mobile Phone Readout for Personalized Dosing in Tuberculosis Treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32170944/),[mg] / [l],8,155786,DB01045,Rifampicin
,9822352,clearance,"The results revealed a significant decrease in rifampicin levels for rats after multiple exposure, compared to single dosing; the mean clearance determined by intravenous dosing increased by 43% from 3.7 ml/min/kg and the half-life decreased by 24% from 238 min.",Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9822352/),[ml] / [kg·min],3.7,156188,DB01045,Rifampicin
,9822352,half-life,"The results revealed a significant decrease in rifampicin levels for rats after multiple exposure, compared to single dosing; the mean clearance determined by intravenous dosing increased by 43% from 3.7 ml/min/kg and the half-life decreased by 24% from 238 min.",Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9822352/),min,238,156189,DB01045,Rifampicin
,9822352,absolute oral bioavailability,"However, the extent of decrease in rifampicin exposure following multiple dosing was substantially greater for rats dosed orally than intravenously; estimated absolute oral bioavailability decreased by 15% from 0.89 on day 1 to 0.76 on day 8.",Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9822352/),,0.89,156190,DB01045,Rifampicin
,9822352,absolute oral bioavailability,"However, the extent of decrease in rifampicin exposure following multiple dosing was substantially greater for rats dosed orally than intravenously; estimated absolute oral bioavailability decreased by 15% from 0.89 on day 1 to 0.76 on day 8.",Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9822352/),,0.76,156191,DB01045,Rifampicin
,19731452,area under the curve,"In 16 enrolled subjects, the median value of the area under the curve of NVP was reduced by 25.6% at T1 compared with NVP alone (43.7 vs. 58.7 microg x mL(-1) x h(-1); P = 0.02).",Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19731452/),[μg] / [h·ml],43.7,156836,DB01045,Rifampicin
,19731452,area under the curve,"In 16 enrolled subjects, the median value of the area under the curve of NVP was reduced by 25.6% at T1 compared with NVP alone (43.7 vs. 58.7 microg x mL(-1) x h(-1); P = 0.02).",Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19731452/),[μg] / [h·ml],58.7,156837,DB01045,Rifampicin
,19731452,C trough,The median C trough was reduced of 19.5% at T1 compared with T3 (3.3 vs. 4.2 microg/mL; P = 0.02) and of 7.1% at T2 compared with T3 (3.9 vs. 4.2 microg/mL; P = 0.17).,Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19731452/),[μg] / [ml],3.3,156838,DB01045,Rifampicin
,19731452,C trough,The median C trough was reduced of 19.5% at T1 compared with T3 (3.3 vs. 4.2 microg/mL; P = 0.02) and of 7.1% at T2 compared with T3 (3.9 vs. 4.2 microg/mL; P = 0.17).,Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19731452/),[μg] / [ml],4.2,156839,DB01045,Rifampicin
,19731452,C trough,The median C trough was reduced of 19.5% at T1 compared with T3 (3.3 vs. 4.2 microg/mL; P = 0.02) and of 7.1% at T2 compared with T3 (3.9 vs. 4.2 microg/mL; P = 0.17).,Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19731452/),[μg] / [ml],3.9,156840,DB01045,Rifampicin
<or=,19731452,C trough,"The proportion of subjects with C trough values <or=3 microg/mL was 31.2% (5 of 16), 40.0% (6 of 15), and 7.7% (1 of 13) at T1, T2, and T3, respectively.",Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19731452/),[μg] / [ml],3,156841,DB01045,Rifampicin
,8345562,half-life,The harmonic mean of the half-life of rifampin decreased significantly from 13.3 h after a single oral dose of 7.99 h after the seventh oral dose.,Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345562/),h,13.3,157279,DB01045,Rifampicin
,8345562,half-life,The harmonic mean of the half-life of rifampin decreased significantly from 13.3 h after a single oral dose of 7.99 h after the seventh oral dose.,Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345562/),h,7.99,157280,DB01045,Rifampicin
,8345562,serum protein binding,The mean serum protein binding of rifampin over the concentration range of 2-20 micrograms/ml was 78%.,Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345562/),%,78,157281,DB01045,Rifampicin
,8345562,trough serum concentrations,Mean trough serum concentrations of unbound rifampin after multiple oral doses ranged from 0.67 micrograms/ml at 24 h to 0.40 micrograms/ml at 72 h.,Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345562/),[μg] / [ml],0.67,157282,DB01045,Rifampicin
,8345562,trough serum concentrations,Mean trough serum concentrations of unbound rifampin after multiple oral doses ranged from 0.67 micrograms/ml at 24 h to 0.40 micrograms/ml at 72 h.,Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345562/),[μg] / [ml],0.40,157283,DB01045,Rifampicin
,8345562,unbound serum rifampin concentration,"The mean unbound serum rifampin concentration at 84 h (i.e., 12 h after the final dose) was 0.30 micrograms/ml.",Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345562/),[μg] / [ml],0.30,157284,DB01045,Rifampicin
less,8345562,minimum inhibitory concentrations,All organisms with minimum inhibitory concentrations less than 0.125 micrograms/ml were considered susceptible.,Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345562/),[μg] / [ml],0.125,157285,DB01045,Rifampicin
,29332645,Cmax,"Mean±1SD of Cmax of Rifampicin was 7.75±2.82μg/ml, mean±1SD of AUC0-10 was 42.17±17.25μgh/ml, adjusted Tmax was 4.25h.",Plasma levels of Rifampicin and Pyrazinamide with pre and post meal administration in tuberculosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332645/),[μg] / [ml],7.75,157367,DB01045,Rifampicin
,29332645,AUC0-10,"Mean±1SD of Cmax of Rifampicin was 7.75±2.82μg/ml, mean±1SD of AUC0-10 was 42.17±17.25μgh/ml, adjusted Tmax was 4.25h.",Plasma levels of Rifampicin and Pyrazinamide with pre and post meal administration in tuberculosis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332645/),[μgh] / [ml],42.17,157368,DB01045,Rifampicin
,29332645,Tmax,"Mean±1SD of Cmax of Rifampicin was 7.75±2.82μg/ml, mean±1SD of AUC0-10 was 42.17±17.25μgh/ml, adjusted Tmax was 4.25h.",Plasma levels of Rifampicin and Pyrazinamide with pre and post meal administration in tuberculosis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332645/),h,4.25,157369,DB01045,Rifampicin
,29332645,Cmax,"Mean±1SD of Cmax levels of Pyrazinamide was 54.49±21.86μg/ml, mean±1SD of AUC0-10 was 337.94±124.28μgh/ml and adjusted Tmax was 3.49h.",Plasma levels of Rifampicin and Pyrazinamide with pre and post meal administration in tuberculosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332645/),[μg] / [ml],54.49,157370,DB01045,Rifampicin
,29332645,AUC0-10,"Mean±1SD of Cmax levels of Pyrazinamide was 54.49±21.86μg/ml, mean±1SD of AUC0-10 was 337.94±124.28μgh/ml and adjusted Tmax was 3.49h.",Plasma levels of Rifampicin and Pyrazinamide with pre and post meal administration in tuberculosis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332645/),[μgh] / [ml],337.94,157371,DB01045,Rifampicin
,29332645,Tmax,"Mean±1SD of Cmax levels of Pyrazinamide was 54.49±21.86μg/ml, mean±1SD of AUC0-10 was 337.94±124.28μgh/ml and adjusted Tmax was 3.49h.",Plasma levels of Rifampicin and Pyrazinamide with pre and post meal administration in tuberculosis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29332645/),h,3.49,157372,DB01045,Rifampicin
,31002950,C24h,"Median C24h of DTG 50 mg + RIF and DTG 100 mg + RIF were 251 (range 129-706) ng/mL and 140 (range 73-426) ng/mL, respectively.",Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002950/),[ng] / [ml],251,158702,DB01045,Rifampicin
,31002950,C24h,"Median C24h of DTG 50 mg + RIF and DTG 100 mg + RIF were 251 (range 129-706) ng/mL and 140 (range 73-426) ng/mL, respectively.",Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002950/),[ng] / [ml],140,158703,DB01045,Rifampicin
,31002950,IC90,"Although there were substantial reductions in DTG C24h when co-administered with RIF, concentrations of both DTG 50 mg and 100 mg once daily with RIF were still above the protein-binding-adjusted IC90 (drug concentration required to inhibit 90% of in-vitro viral replication) of 64 ng/mL.",Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002950/),[ng] / [ml],64,158704,DB01045,Rifampicin
,33972248,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The rifampicin geometric mean area under the concentration-time curve from 0 to 24 h (AUC0-24) values were 42.9 μg · h/ml (95% confidence interval [CI], 24.5 to 75.0 μg · h/ml) for the standard dose, 295.2 μg · h/ml (95% CI, 189.9 to 458.8 μg · h/ml) for the high oral dose, and 206.5 μg · h/ml (95% CI, 154.6 to 275.8 μg · h/ml) for intravenous administration.",Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33972248/),[h·μg] / [ml],42.9,160043,DB01045,Rifampicin
,33972248,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The rifampicin geometric mean area under the concentration-time curve from 0 to 24 h (AUC0-24) values were 42.9 μg · h/ml (95% confidence interval [CI], 24.5 to 75.0 μg · h/ml) for the standard dose, 295.2 μg · h/ml (95% CI, 189.9 to 458.8 μg · h/ml) for the high oral dose, and 206.5 μg · h/ml (95% CI, 154.6 to 275.8 μg · h/ml) for intravenous administration.",Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33972248/),[h·μg] / [ml],295.2,160044,DB01045,Rifampicin
,33972248,area under the concentration-time curve from 0 to 24 h (AUC0-24),"The rifampicin geometric mean area under the concentration-time curve from 0 to 24 h (AUC0-24) values were 42.9 μg · h/ml (95% confidence interval [CI], 24.5 to 75.0 μg · h/ml) for the standard dose, 295.2 μg · h/ml (95% CI, 189.9 to 458.8 μg · h/ml) for the high oral dose, and 206.5 μg · h/ml (95% CI, 154.6 to 275.8 μg · h/ml) for intravenous administration.",Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33972248/),[h·μg] / [ml],206.5,160045,DB01045,Rifampicin
,22430968,EBA,"The mean 14-day EBA of HRZE was consistent with previous studies (0.177 ± 0.042), and that of PA-824 at 50 mg, 100 mg, 150 mg, and 200 mg was 0.063 ± 0.058, 0.091 ± 0.073, 0.078 ± 0.074, and 0.112 ± 0.070, respectively.",Phase II dose-ranging trial of the early bactericidal activity of PA-824. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22430968/),,0.177,160159,DB01045,Rifampicin
,22430968,EBA,"The mean 14-day EBA of HRZE was consistent with previous studies (0.177 ± 0.042), and that of PA-824 at 50 mg, 100 mg, 150 mg, and 200 mg was 0.063 ± 0.058, 0.091 ± 0.073, 0.078 ± 0.074, and 0.112 ± 0.070, respectively.",Phase II dose-ranging trial of the early bactericidal activity of PA-824. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22430968/),,0.063,160160,DB01045,Rifampicin
,22430968,EBA,"The mean 14-day EBA of HRZE was consistent with previous studies (0.177 ± 0.042), and that of PA-824 at 50 mg, 100 mg, 150 mg, and 200 mg was 0.063 ± 0.058, 0.091 ± 0.073, 0.078 ± 0.074, and 0.112 ± 0.070, respectively.",Phase II dose-ranging trial of the early bactericidal activity of PA-824. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22430968/),,0.091,160161,DB01045,Rifampicin
,22430968,EBA,"The mean 14-day EBA of HRZE was consistent with previous studies (0.177 ± 0.042), and that of PA-824 at 50 mg, 100 mg, 150 mg, and 200 mg was 0.063 ± 0.058, 0.091 ± 0.073, 0.078 ± 0.074, and 0.112 ± 0.070, respectively.",Phase II dose-ranging trial of the early bactericidal activity of PA-824. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22430968/),,0.078,160162,DB01045,Rifampicin
,22430968,EBA,"The mean 14-day EBA of HRZE was consistent with previous studies (0.177 ± 0.042), and that of PA-824 at 50 mg, 100 mg, 150 mg, and 200 mg was 0.063 ± 0.058, 0.091 ± 0.073, 0.078 ± 0.074, and 0.112 ± 0.070, respectively.",Phase II dose-ranging trial of the early bactericidal activity of PA-824. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22430968/),,0.112,160163,DB01045,Rifampicin
,16251279,oral clearance,"The RFP oral clearance and volume of distribution were found to increase by 0.049 liter/h and 0.691 liter, respectively, with a 1-kg increase from the median weight of 50 kg.",Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16251279/),[l] / [h],0.049,160529,DB01045,Rifampicin
,16251279,volume of distribution,"The RFP oral clearance and volume of distribution were found to increase by 0.049 liter/h and 0.691 liter, respectively, with a 1-kg increase from the median weight of 50 kg.",Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16251279/),l,0.691,160530,DB01045,Rifampicin
,26055359,AUC0-24,"The geometric mean AUC0-24 value was 41.5 (range, 13.5 to 117) mg · h/liter.",Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26055359/),[h·mg] / [l],41.5,161050,DB01045,Rifampicin
,26055359,time to maximum concentration of drug in serum (Tmax),"The median time to maximum concentration of drug in serum (Tmax) was 2.2 h, ranging from 0.4 to 5.7 h.",Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26055359/),h,2.2,161051,DB01045,Rifampicin
,17452486,area under the concentration-time curve from 0 to 24 h [AUC(0-24)],The geometric means of exposure to rifampin (area under the concentration-time curve from 0 to 24 h [AUC(0-24)]) were increased by 65% (P < 0.001) in the higher-dose group (79.7 mg.h/liter) compared to the standard-dose group (48.5 mg.h/liter).,Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452486/),[h·mg] / [l],79.7,161065,DB01045,Rifampicin
,17452486,area under the concentration-time curve from 0 to 24 h [AUC(0-24)],The geometric means of exposure to rifampin (area under the concentration-time curve from 0 to 24 h [AUC(0-24)]) were increased by 65% (P < 0.001) in the higher-dose group (79.7 mg.h/liter) compared to the standard-dose group (48.5 mg.h/liter).,Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452486/),[h·mg] / [l],48.5,161066,DB01045,Rifampicin
,17452486,Maximum rifampin concentrations (C(max)),Maximum rifampin concentrations (C(max)) were 15.6 mg/liter versus 10.5 mg/liter (49% increase; P < 0.001).,Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452486/),[mg] / [l],15.6,161067,DB01045,Rifampicin
,17452486,Maximum rifampin concentrations (C(max)),Maximum rifampin concentrations (C(max)) were 15.6 mg/liter versus 10.5 mg/liter (49% increase; P < 0.001).,Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452486/),[mg] / [l],10.5,161068,DB01045,Rifampicin
> or =,17452486,C(max),The percentage of patients for whom the rifampin C(max) was > or =8 mg/liter was 96% versus 79% (P = 0.094).,Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452486/),[mg] / [l],8,161069,DB01045,Rifampicin
,23103177,area under the time-concentration curve up to 6 h after dose (AUC(0-6),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[h·mg] / [l],78·7,161379,DB01045,Rifampicin
,23103177,area under the time-concentration curve up to 6 h after dose (AUC(0-6),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[h·mg] / [l],26·0,161380,DB01045,Rifampicin
,23103177,maximum plasma concentrations (C(max),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],22·1,161381,DB01045,Rifampicin
,23103177,maximum plasma concentrations (C(max),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],6·3,161382,DB01045,Rifampicin
,23103177,maximum plasma concentrations (C(max),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],0·60,161383,DB01045,Rifampicin
,23103177,maximum plasma concentrations (C(max),"A 33% higher dose of rifampicin, intravenously, led to a three times higher geometric mean area under the time-concentration curve up to 6 h after dose (AUC(0-6); 78·7 mg.h/L [95% CI 71·0-87·3] vs 26·0 mg.h/L [19·0-35·6]), maximum plasma concentrations (C(max); 22·1 mg/L [19·9-24·6] vs 6·3 mg/L [4·9-8·3]), and concentrations in cerebrospinal fluid (0·60 mg/L [0·46-0·78] vs 0·21 mg/L [0·16-0·27]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],0·21,161384,DB01045,Rifampicin
,23103177,plasma AUC(0-6),"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[h·mg] / [l],31·5,161385,DB01045,Rifampicin
,23103177,plasma AUC(0-6),"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[h·mg] / [l],15·1,161386,DB01045,Rifampicin
,23103177,C(max),"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],7·4,161387,DB01045,Rifampicin
,23103177,C(max),"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],3·9,161388,DB01045,Rifampicin
,23103177,concentrations,"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],2·43,161389,DB01045,Rifampicin
,23103177,concentrations,"Doubling the dose of moxifloxacin resulted in a proportional increase in plasma AUC(0-6) (31·5 mg.h/L [24·1-41·1] vs 15·1 mg.h/L [12·8-17·7]), C(max) (7·4 mg/L [5·6-9·6] vs 3·9 mg/L [3·2-4·8]), and drug concentrations in the cerebrospinal fluid (2·43 mg/L [1·81-3·27] vs 1·52 mg/L [1·28-1·82]).","Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23103177/),[mg] / [l],1·52,161390,DB01045,Rifampicin
,34267655,CL,"Typical values of CL, Q, V1, and V2 were 11.8 L/h, 3.26 L/h, 14.2 L, and 3.12 L, respectively.",The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34267655/),[l] / [h],11.8,161418,DB01045,Rifampicin
,34267655,Q,"Typical values of CL, Q, V1, and V2 were 11.8 L/h, 3.26 L/h, 14.2 L, and 3.12 L, respectively.",The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34267655/),[l] / [h],3.26,161419,DB01045,Rifampicin
,34267655,Q,"Typical values of CL, Q, V1, and V2 were 11.8 L/h, 3.26 L/h, 14.2 L, and 3.12 L, respectively.",The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34267655/),l,14.2,161420,DB01045,Rifampicin
,34267655,V1,"Typical values of CL, Q, V1, and V2 were 11.8 L/h, 3.26 L/h, 14.2 L, and 3.12 L, respectively.",The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34267655/),[l] / [h],3.26,161421,DB01045,Rifampicin
,34267655,V1,"Typical values of CL, Q, V1, and V2 were 11.8 L/h, 3.26 L/h, 14.2 L, and 3.12 L, respectively.",The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34267655/),l,14.2,161422,DB01045,Rifampicin
,34267655,V2,"Typical values of CL, Q, V1, and V2 were 11.8 L/h, 3.26 L/h, 14.2 L, and 3.12 L, respectively.",The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34267655/),l,3.12,161423,DB01045,Rifampicin
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.8,161897,DB01045,Rifampicin
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.4,161898,DB01045,Rifampicin
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.3,161899,DB01045,Rifampicin
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,2.1,161900,DB01045,Rifampicin
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,2.5,161901,DB01045,Rifampicin
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,3.5,161902,DB01045,Rifampicin
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],139,161903,DB01045,Rifampicin
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],141,161904,DB01045,Rifampicin
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],722,161905,DB01045,Rifampicin
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],114,161906,DB01045,Rifampicin
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],75,161907,DB01045,Rifampicin
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],153,161908,DB01045,Rifampicin
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.3,161909,DB01045,Rifampicin
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.4,161910,DB01045,Rifampicin
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.2,161911,DB01045,Rifampicin
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB01045,Rifampicin
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB01045,Rifampicin
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB01045,Rifampicin
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB01045,Rifampicin
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB01045,Rifampicin
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB01045,Rifampicin
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162611,DB01045,Rifampicin
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162612,DB01045,Rifampicin
,8068867,CLH,An increase to 72 +/- 25 mL min-1 in the CLH of cortisol to 6 beta-hydroxycortisol was calculated following rifampicin treatment.,Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],72,162613,DB01045,Rifampicin
,9579709,MICs,The range of MICs was 0.12-0.5 mg/L for both roxithromycin and erythromycin.,The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],0.12-0.5,162953,DB01045,Rifampicin
,9579709,MBC,"Roxithromycin was bactericidal, with an MBC of 1 mg/L (as compared with 0.5 mg/L for erythromycin).",The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],1,162954,DB01045,Rifampicin
,9579709,MBC,"Roxithromycin was bactericidal, with an MBC of 1 mg/L (as compared with 0.5 mg/L for erythromycin).",The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],0.5,162955,DB01045,Rifampicin
,11576768,bioavailability,Significant decrease in the bioavailability ( approximately 32% as RIF and approximately 28% as 25-DAR) of RIF from FDC capsules was observed.,Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11576768/),%,32,165088,DB01045,Rifampicin
,11576768,bioavailability,Significant decrease in the bioavailability ( approximately 32% as RIF and approximately 28% as 25-DAR) of RIF from FDC capsules was observed.,Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11576768/),%,28,165089,DB01045,Rifampicin
,9706063,terminal half-life,Disposition of rifapentine was monophasic with a mean terminal half-life of 19.6 hours.,Single-dose pharmacokinetics of rifapentine in elderly men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706063/),h,19.6,165208,DB01045,Rifampicin
,9706063,t1/2,"The peak plasma concentration of 25 desacetyl-rifapentine was found 21.7 hours, on average, after the rifapentine dose; the mean 25-desacetyl-rifapentine t1/2 was 22.9 hours.",Single-dose pharmacokinetics of rifapentine in elderly men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706063/),h,22.9,165209,DB01045,Rifampicin
,29991405,release kinetics,"The PBPK model identified 1500 mg of delamanid and 250 mg of rifapentine as sufficient doses for monthly intramuscular administration, if a formulation or device can deliver the required release kinetics of 0.001-0.0025 h-1 and 0.0015-0.0025 h-1, respectively.",Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29991405/),1/[h],0.001-0.0025,165856,DB01045,Rifampicin
,29991405,release kinetics,"The PBPK model identified 1500 mg of delamanid and 250 mg of rifapentine as sufficient doses for monthly intramuscular administration, if a formulation or device can deliver the required release kinetics of 0.001-0.0025 h-1 and 0.0015-0.0025 h-1, respectively.",Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29991405/),1/[h],0.0015-0.0025,165857,DB01045,Rifampicin
,25620089,un,"The extent of distribution to ELF and AC was described by unbound ELF/plasma concentration ratio (R ELF/unbound-plasma) and unbound AC/plasma concentration ratio (R AC/unbound-plasma) which typical values were predicted to be 1.28 and 5.5, respectively.",A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--using rifampicin as an example. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25620089/),,1.28,166929,DB01045,Rifampicin
,25620089,un,"The extent of distribution to ELF and AC was described by unbound ELF/plasma concentration ratio (R ELF/unbound-plasma) and unbound AC/plasma concentration ratio (R AC/unbound-plasma) which typical values were predicted to be 1.28 and 5.5, respectively.",A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells--using rifampicin as an example. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25620089/),,5.5,166930,DB01045,Rifampicin
,25236765,Cmax,The median Cmax of 6.07 μg/mL was below the target range of 8-24 μg/mL.,Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25236765/),[μg] / [ml],6.07,167013,DB01045,Rifampicin
,25236765,MIC,"Monte Carlo simulations predicted the highest treatable MIC of 0.25 μg/mL with the current initial dosing recommendation of 10 mg/kg, based upon a previously published target AUC0-24/MIC > 271 (fAUC > 41).",Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25236765/),[μg] / [ml],0.25,167014,DB01045,Rifampicin
>,25236765,AUC0-24/MIC,"Monte Carlo simulations predicted the highest treatable MIC of 0.25 μg/mL with the current initial dosing recommendation of 10 mg/kg, based upon a previously published target AUC0-24/MIC > 271 (fAUC > 41).",Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25236765/),,271,167015,DB01045,Rifampicin
>,25236765,fAUC,"Monte Carlo simulations predicted the highest treatable MIC of 0.25 μg/mL with the current initial dosing recommendation of 10 mg/kg, based upon a previously published target AUC0-24/MIC > 271 (fAUC > 41).",Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25236765/),,41,167016,DB01045,Rifampicin
up to,25236765,MICs,Simulations from the population model indicate that the current dose of 10 mg/kg may be adequate for MICs up to 0.25 μg/mL.,Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25236765/),[μg] / [ml],0.25,167017,DB01045,Rifampicin
,8878578,maximum concentration,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[ng] / [ml],113.0,167478,DB01045,Rifampicin
,8878578,maximum concentration,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[ng] / [ml],6.2,167479,DB01045,Rifampicin
,8878578,area under the concentration-time curve,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[h·ng] / [ml],"1,652.7",167480,DB01045,Rifampicin
,8878578,area under the concentration-time curve,"Coadministration of rifampin resulted in an 18-fold decrease in the maximum concentration of itraconazole in serum, from 113.0 (standard deviation [SD] 17.2) to 6.2 (SD, 3.9) ng/ml and a 22-fold decrease in the area under the concentration-time curve, from 1,652.7 (SD, 297.7) to 75.6 (SD, 30.0) ng.h/ml.",Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878578/),[h·ng] / [ml],75.6,167481,DB01045,Rifampicin
,26552972,half-life,"Autoinduction was characterized by using an exponential-maturation model: hepatic clearance almost doubled from the baseline to steady state, with a half-life of around 4.5 days.",Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26552972/),d,4.5,167820,DB01045,Rifampicin
,21968358,C(max),"The mean C(max) (μg/ml) following the administration of previous/revised dosages were as follows: INH, 3.19/8.11; RMP, 6.36/11.69; PZA, 29.94/47.11.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[μg] / [ml],3.19,167868,DB01045,Rifampicin
,21968358,C(max),"The mean C(max) (μg/ml) following the administration of previous/revised dosages were as follows: INH, 3.19/8.11; RMP, 6.36/11.69; PZA, 29.94/47.11.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[μg] / [ml],6.36,167869,DB01045,Rifampicin
,21968358,C(max),"The mean C(max) (μg/ml) following the administration of previous/revised dosages were as follows: INH, 3.19/8.11; RMP, 6.36/11.69; PZA, 29.94/47.11.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[μg] / [ml],29.94,167870,DB01045,Rifampicin
,21968358,AUC,"The mean AUC (μg·h/ml) were as follows: INH, 8.09/20.36; RMP, 17.78/36.95; PZA, 118.0/175.2.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[h·μg] / [ml],8.09,167871,DB01045,Rifampicin
,21968358,AUC,"The mean AUC (μg·h/ml) were as follows: INH, 8.09/20.36; RMP, 17.78/36.95; PZA, 118.0/175.2.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[h·μg] / [ml],20.36,167872,DB01045,Rifampicin
,21968358,AUC,"The mean AUC (μg·h/ml) were as follows: INH, 8.09/20.36; RMP, 17.78/36.95; PZA, 118.0/175.2.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[h·μg] / [ml],17.78,167873,DB01045,Rifampicin
,21968358,AUC,"The mean AUC (μg·h/ml) were as follows: INH, 8.09/20.36; RMP, 17.78/36.95; PZA, 118.0/175.2.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[h·μg] / [ml],36.95,167874,DB01045,Rifampicin
,21968358,AUC,"The mean AUC (μg·h/ml) were as follows: INH, 8.09/20.36; RMP, 17.78/36.95; PZA, 118.0/175.2.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[h·μg] / [ml],118.0,167875,DB01045,Rifampicin
,21968358,AUC,"The mean AUC (μg·h/ml) were as follows: INH, 8.09/20.36; RMP, 17.78/36.95; PZA, 118.0/175.2.","Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968358/),[h·μg] / [ml],175.2,167876,DB01045,Rifampicin
,28396527,Cmax,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,0.06,168541,DB01045,Rifampicin
,28396527,Cmax,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,0.66,168542,DB01045,Rifampicin
,28396527,Cmax,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,2.57,168543,DB01045,Rifampicin
,28396527,Cmax,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,7.79,168544,DB01045,Rifampicin
≤,28396527,IC50,"In the search for novel bile acid (BA) biomarkers of liver organic anion-transporting polypeptides (OATPs), cynomolgus monkeys received oral rifampicin (RIF) at four dose levels (1, 3, 10, and 30 mg/kg) that generated plasma-free Cmax values (0.06, 0.66, 2.57, and 7.79 µM, respectively) spanning the reported in vitro IC50 values for OATP1B1 and OATP1B3 (≤1.7 μM).",Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28396527/),μM,1.7,168545,DB01045,Rifampicin
,29189941,terminal half-life,"The pharmacokinetics of vortioxetine are linear and dose proportional, with a mean terminal half-life of approximately 66 h and steady-state plasma concentrations generally achieved within 2 weeks of dosing.",Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189941/),h,66,169321,DB01045,Rifampicin
,29189941,absolute oral bioavailability,The mean absolute oral bioavailability of vortioxetine is 75%.,Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189941/),%,75,169322,DB01045,Rifampicin
,20876786,AUC ratio,"Among the CYP2B6*6 carriers (n = 13), the NR1I2 TGT (-25385T + g.7635G + g.8055T) carriers exhibited a significantly lower AUC ratio, representing the CYP2B6 hydroxylation activity, compared with the TGT noncarriers, in the induced state (11.9 versus 20.3, p = 0.045).",Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876786/),,11.9,169327,DB01045,Rifampicin
,20876786,AUC ratio,"Among the CYP2B6*6 carriers (n = 13), the NR1I2 TGT (-25385T + g.7635G + g.8055T) carriers exhibited a significantly lower AUC ratio, representing the CYP2B6 hydroxylation activity, compared with the TGT noncarriers, in the induced state (11.9 versus 20.3, p = 0.045).",Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876786/),,20.3,169328,DB01045,Rifampicin
,26643345,area under the concentration-time curve over 24 h (AUC0-24),The median (interquartile range) model-estimated rifampin area under the concentration-time curve over 24 h (AUC0-24) during pregnancy or intrapartum was 40.8 h · mg/liter (27.1 to 54.2 h · mg/liter) compared to 37.4 h · mg/liter (26.8 to 50.3 h · mg/liter) postpartum.,"Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643345/),[h·mg] / [l],40.8,169662,DB01045,Rifampicin
,26643345,area under the concentration-time curve over 24 h (AUC0-24),The median (interquartile range) model-estimated rifampin area under the concentration-time curve over 24 h (AUC0-24) during pregnancy or intrapartum was 40.8 h · mg/liter (27.1 to 54.2 h · mg/liter) compared to 37.4 h · mg/liter (26.8 to 50.3 h · mg/liter) postpartum.,"Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643345/),[h·mg] / [l],37.4,169663,DB01045,Rifampicin
,3579252,maximum drug levels,At the moment of the infusion discontinuation the maximum drug levels in serum averaged to 14.05 micrograms/ml.,[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),[μg] / [ml],14.05,170131,DB01045,Rifampicin
,3579252,total clearance,"The mean values of the total clearance, distribution of the kinetic volume and half-lives were 93.2 ml/(h X kg), 1016.1 ml/kg and 8.1 h respectively.",[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),[ml] / [h·kg],93.2,170132,DB01045,Rifampicin
,3579252,distribution of the kinetic volume,"The mean values of the total clearance, distribution of the kinetic volume and half-lives were 93.2 ml/(h X kg), 1016.1 ml/kg and 8.1 h respectively.",[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),[ml] / [kg],1016.1,170133,DB01045,Rifampicin
,3579252,half-lives,"The mean values of the total clearance, distribution of the kinetic volume and half-lives were 93.2 ml/(h X kg), 1016.1 ml/kg and 8.1 h respectively.",[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),h,8.1,170134,DB01045,Rifampicin
,3579252,Cumulative excretion,"Cumulative excretion of the total rifampicin within 24 hours amounted to 19.4 per cent of the administered dose, the proportions of the main metabolite (25-O-desacetyl rifampicin) and intact rifampicin being equal to 29 and 71 per cent respectively.",[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),%,19.4,170135,DB01045,Rifampicin
,3579252,Cumulative excretion,"Cumulative excretion of the total rifampicin within 24 hours amounted to 19.4 per cent of the administered dose, the proportions of the main metabolite (25-O-desacetyl rifampicin) and intact rifampicin being equal to 29 and 71 per cent respectively.",[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),%,29,170136,DB01045,Rifampicin
,3579252,Cumulative excretion,"Cumulative excretion of the total rifampicin within 24 hours amounted to 19.4 per cent of the administered dose, the proportions of the main metabolite (25-O-desacetyl rifampicin) and intact rifampicin being equal to 29 and 71 per cent respectively.",[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),%,71,170137,DB01045,Rifampicin
,3579252,renal,The renal and nonrenal clearance of rifampicin amounted to 14.2 and 79 ml/(h X kg) respectively.,[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),[ml] / [h·kg],14.2,170138,DB01045,Rifampicin
,3579252,nonrenal clearance,The renal and nonrenal clearance of rifampicin amounted to 14.2 and 79 ml/(h X kg) respectively.,[Pharmacokinetics of rifampicin administered intravenously to pulmonary tuberculosis patients]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3579252/),[ml] / [h·kg],79,170139,DB01045,Rifampicin
,3961891,elimination half-life,The rifampin elimination half-life following i.v. administration (2.25 +/- 0.64 h) was not different from that observed following p.o. dose administration (2.61 +/- 1.35 h).,Pharmacokinetics of rifampin in children. Oral bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961891/),h,2.25,170194,DB01045,Rifampicin
,3961891,elimination half-life,The rifampin elimination half-life following i.v. administration (2.25 +/- 0.64 h) was not different from that observed following p.o. dose administration (2.61 +/- 1.35 h).,Pharmacokinetics of rifampin in children. Oral bioavailability. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961891/),h,2.61,170195,DB01045,Rifampicin
,3961891,Peak rifampin concentrations,Peak rifampin concentrations were significantly higher following i.v. administration when corrected to a 300 mg/m2 dose (27.4 vs.,Pharmacokinetics of rifampin in children. Oral bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3961891/),,27.4,170196,DB01045,Rifampicin
,6878255,total body clearance,The total body clearance of prednisolone increased from 73.5 +/- 14.6ml/min to 142.7 +/- 35.8ml/min (p less than 0.01).,Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6878255/),[ml] / [min],73.5,171021,DB01045,Rifampicin
,6878255,total body clearance,The total body clearance of prednisolone increased from 73.5 +/- 14.6ml/min to 142.7 +/- 35.8ml/min (p less than 0.01).,Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6878255/),[ml] / [min],142.7,171022,DB01045,Rifampicin
,21555825,concentrations,"Pre-dose lopinavir concentrations were reduced by >80% in children with tuberculosis (median 0.7 mg/l, IQR 0.1-2.0) compared with controls (4.2 mg/l, IQR 3.4-8.1; P<0.001) and were below the minimum recommended concentration of 1 mg/l in 12 of 20 (60%) children with tuberculosis versus 2 of 24 (8%) controls (P<0.001).",Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21555825/),mg,0,172591,DB01045,Rifampicin
,21555825,concentrations,"Pre-dose lopinavir concentrations were reduced by >80% in children with tuberculosis (median 0.7 mg/l, IQR 0.1-2.0) compared with controls (4.2 mg/l, IQR 3.4-8.1; P<0.001) and were below the minimum recommended concentration of 1 mg/l in 12 of 20 (60%) children with tuberculosis versus 2 of 24 (8%) controls (P<0.001).",Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21555825/),,4,172592,DB01045,Rifampicin
,21555825,minimum recommended concentration,"Pre-dose lopinavir concentrations were reduced by >80% in children with tuberculosis (median 0.7 mg/l, IQR 0.1-2.0) compared with controls (4.2 mg/l, IQR 3.4-8.1; P<0.001) and were below the minimum recommended concentration of 1 mg/l in 12 of 20 (60%) children with tuberculosis versus 2 of 24 (8%) controls (P<0.001).",Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21555825/),[mg] / [l],1,172593,DB01045,Rifampicin
,31789383,Cmax,"Median (IQR) Cmax and Tmax were 10.2 (8.1-12.5) mg/L and 1.7 (1.125-2.218) h, respectively.",Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31789383/),[mg] / [l],10.2,172747,DB01045,Rifampicin
,31789383,Tmax,"Median (IQR) Cmax and Tmax were 10.2 (8.1-12.5) mg/L and 1.7 (1.125-2.218) h, respectively.",Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31789383/),h,1.7,172748,DB01045,Rifampicin
below,31789383,Cmax,Twenty-four percent of patients exhibited Cmax below the recommended 8-24 mg/L range.,Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31789383/),[mg] / [l],8-24,172749,DB01045,Rifampicin
,4857860,milk/serum ultrafiltrate concentrations ratios,"Under constant serum drug concentrations, the observed milk/serum ultrafiltrate concentrations ratios (0.19 to 0.29 for rifamycin SV, and 0.90 to 1.28 for rifampin) were close to the calculated ratios derived from the pH-pK passive diffusion concept.",Evaluation of rifamycin SV and rifampin kinetics in lactating ewes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4857860/),,0.19 to 0.29,173747,DB01045,Rifampicin
,14962821,area under the plasma concentration-time curve (AUC(0-infinity)),"Mean area under the plasma concentration-time curve (AUC(0-infinity)) increased significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.hour/ml at 600, 900, and 1,200 mg, respectively; p = 0.02 by linear regression).","Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962821/),[h·μg] / [ml],296,174846,DB01045,Rifampicin
,14962821,AUC(0- infinity),"Mean area under the plasma concentration-time curve (AUC(0-infinity)) increased significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.hour/ml at 600, 900, and 1,200 mg, respectively; p = 0.02 by linear regression).","Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962821/),[h·μg] / [ml],296,174847,DB01045,Rifampicin
,14962821,AUC(0- infinity),"Mean area under the plasma concentration-time curve (AUC(0-infinity)) increased significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.hour/ml at 600, 900, and 1,200 mg, respectively; p = 0.02 by linear regression).","Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962821/),[h·μg] / [ml],410,174848,DB01045,Rifampicin
,14962821,AUC(0- infinity),"Mean area under the plasma concentration-time curve (AUC(0-infinity)) increased significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.hour/ml at 600, 900, and 1,200 mg, respectively; p = 0.02 by linear regression).","Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14962821/),[h·μg] / [ml],477,174849,DB01045,Rifampicin
,24663014,maximum concentration of drug in serum (Cmax),"When rifampin was administered alone, the median maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve (AUC) at steady state were 6.59 mg/liter (range, 2.70 to 14.07 mg/liter) and 27.69 mg · h/liter (range, 11.41 to 109.75 mg · h/liter), respectively.",Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24663014/),[mg] / [l],6.59,175276,DB01045,Rifampicin
,24663014,area under the concentration-time curve (AUC) at steady state,"When rifampin was administered alone, the median maximum concentration of drug in serum (Cmax) and the area under the concentration-time curve (AUC) at steady state were 6.59 mg/liter (range, 2.70 to 14.07 mg/liter) and 27.69 mg · h/liter (range, 11.41 to 109.75 mg · h/liter), respectively.",Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24663014/),[h·mg] / [l],27.69,175277,DB01045,Rifampicin
,24663014,Cmax,"When isoniazid was administered alone, the median isoniazid Cmax and AUC at steady state were 5.08 mg/liter (range, 1.26 to 11.51 mg/liter) and 20.92 mg · h/liter (range, 7.73 to 56.95 mg · h/liter), respectively.",Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24663014/),[mg] / [l],5.08,175278,DB01045,Rifampicin
,24663014,AUC at steady state,"When isoniazid was administered alone, the median isoniazid Cmax and AUC at steady state were 5.08 mg/liter (range, 1.26 to 11.51 mg/liter) and 20.92 mg · h/liter (range, 7.73 to 56.95 mg · h/liter), respectively.",Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24663014/),[h·mg] / [l],20.92,175279,DB01045,Rifampicin
,29061739,AUC0-336,"Steady-state rifampin reduced bedaquiline AUC0-336 approximately 45%, from 47.69 h·μg/ml in period 1 to 26.33 h·μg/ml in period 2.","Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29061739/),[h·μg] / [ml],47.69,175789,DB01045,Rifampicin
,29061739,AUC0-336,"Steady-state rifampin reduced bedaquiline AUC0-336 approximately 45%, from 47.69 h·μg/ml in period 1 to 26.33 h·μg/ml in period 2.","Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29061739/),[h·μg] / [ml],26.33,175790,DB01045,Rifampicin
,29061739,apparent clearance,Bedaquiline apparent clearance accelerated 24% in rifampin-treated subjects from 6.59 liters/h in period 1 to 8.19 liters/h in period 2.,"Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29061739/),[l] / [h],6.59,175791,DB01045,Rifampicin
,29061739,apparent clearance,Bedaquiline apparent clearance accelerated 24% in rifampin-treated subjects from 6.59 liters/h in period 1 to 8.19 liters/h in period 2.,"Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29061739/),[l] / [h],8.19,175792,DB01045,Rifampicin
,19939597,total analysis time,"The total analysis time was 4.5min with DPT and RFM eluting at 1.9 and 2.1min, respectively.",Simultaneous quantification of daptomycin and rifampicin in plasma by ultra performance liquid chromatography: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19939597/),min,4.5,175831,DB01045,Rifampicin
,19939597,total analysis time,"The total analysis time was 4.5min with DPT and RFM eluting at 1.9 and 2.1min, respectively.",Simultaneous quantification of daptomycin and rifampicin in plasma by ultra performance liquid chromatography: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19939597/),min,1.9,175832,DB01045,Rifampicin
,19939597,total analysis time,"The total analysis time was 4.5min with DPT and RFM eluting at 1.9 and 2.1min, respectively.",Simultaneous quantification of daptomycin and rifampicin in plasma by ultra performance liquid chromatography: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19939597/),min,2.1,175833,DB01045,Rifampicin
,25199779,relative bioavailability,Posaconazole relative bioavailability was 55% lower in patients who received posaconazole than in healthy volunteers.,Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25199779/),%,55,177817,DB01045,Rifampicin
,34207312,exposure over 24 h (AUC0-24),"Isoniazid had the lowest serum attainment, with only 4.1% achieving a target exposure over 24 h (AUC0-24) of 52 mg·h/L despite appropriate weight-based dosing.",Population Pharmacokinetics and Significant Under-Dosing of Anti-Tuberculosis Medications in People with HIV and Critical Illness. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34207312/),[h·mg] / [l],52,177952,DB01045,Rifampicin
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,3.9,178571,DB01045,Rifampicin
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,1.1,178572,DB01045,Rifampicin
,2698437,half-life,Mean half-life of Isoniazid was 3.9 +/- 1.4 hs in 7 slow acetylators and 1.1 hs in one fast acetylator when given one at a time and 4.4 +/- 1.5 hs when given simultaneously.,"[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,4.4,178573,DB01045,Rifampicin
,2698437,half-life,"Mean half-life of Rifampicin was 3.5 +/- 0.8 and 4.2 +/- 1.1 hs, respectively, when it was given alone and concurrently.","[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,3.5,178574,DB01045,Rifampicin
,2698437,half-life,"Mean half-life of Rifampicin was 3.5 +/- 0.8 and 4.2 +/- 1.1 hs, respectively, when it was given alone and concurrently.","[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2698437/),hs,4.2,178575,DB01045,Rifampicin
≥,31081020,Cmin,To evaluate the proportion of children with lopinavir Cmin ≥1 mg/L when receiving a novel 8-hourly lopinavir/ritonavir dosing strategy during rifampicin co-treatment.,Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081020/),[mg] / [l],1,179033,DB01045,Rifampicin
,31081020,Cmin,The median (IQR) lopinavir Cmin was 3.0 (0.1-5.5) mg/L. Seven (63.6%) of the 11 children had Cmin values ≥1 mg/L.,Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081020/),[mg] / [l],3.0,179034,DB01045,Rifampicin
≥,31081020,Cmin,The median (IQR) lopinavir Cmin was 3.0 (0.1-5.5) mg/L. Seven (63.6%) of the 11 children had Cmin values ≥1 mg/L.,Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081020/),[mg] / [l],1,179035,DB01045,Rifampicin
<,31081020,Cmin,Children with a lopinavir mg/kg dose below the median 21.5 were more likely to have Cmin <1 mg/L (P = 0.02).,Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081020/),[mg] / [l],1,179036,DB01045,Rifampicin
,24839071,Active hepatic uptake,"Active hepatic uptake was found to be significantly higher than the passive uptake clearance (15.8 versus 5.3 μL/min/10(6)-hepatocytes), using the sandwich-cultured hepatocyte model.",Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839071/),[min·μl] / [10(6],15.8,179669,DB01045,Rifampicin
,24839071,passive uptake clearance,"Active hepatic uptake was found to be significantly higher than the passive uptake clearance (15.8 versus 5.3 μL/min/10(6)-hepatocytes), using the sandwich-cultured hepatocyte model.",Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839071/),[min·μl] / [10(6],5.3,179670,DB01045,Rifampicin
,24839071,intrinsic clearance,"In vitro, glyburide is metabolized (intrinsic clearance, 52.9 μL/min/mg-microsomal protein) by CYP3A4, CYP2C9, and CYP2C8 with fraction metabolism of 0.53, 0.36, and 0.11, respectively.",Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839071/),[μl] / [mg-·min],52.9,179671,DB01045,Rifampicin
,24839071,fraction metabolism,"In vitro, glyburide is metabolized (intrinsic clearance, 52.9 μL/min/mg-microsomal protein) by CYP3A4, CYP2C9, and CYP2C8 with fraction metabolism of 0.53, 0.36, and 0.11, respectively.",Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839071/),,0,179672,DB01045,Rifampicin
,26392246,aerodynamic diameter,"Mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were found to be 2.72±0.13 μm and 3.28±0.12, respectively.",Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26392246/),μm,2.72,180046,DB01045,Rifampicin
,26392246,aerodynamic diameter,"Mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were found to be 2.72±0.13 μm and 3.28±0.12, respectively.",Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26392246/),,3.28,180047,DB01045,Rifampicin
,26392246,targeting factor,"The pulmonary pharmacokinetic study demonstrated improved bioavailability, longer residence of drug in the lung and targeting factor of 8.03 for lipospheres as compared to rifampicin-aqueous solution.",Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26392246/),,8.03,180048,DB01045,Rifampicin
,15536460,Bioavailability (Foral),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.26,180275,DB01045,Rifampicin
,15536460,Bioavailability (Foral),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.42,180276,DB01045,Rifampicin
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.52,180277,DB01045,Rifampicin
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180278,DB01045,Rifampicin
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.42,180279,DB01045,Rifampicin
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.28,180280,DB01045,Rifampicin
,15536460,hepatic extraction (EH),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180281,DB01045,Rifampicin
,15536460,intestinal availability (FG),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180282,DB01045,Rifampicin
,15536460,intestinal availability (FG),"Bioavailability (Foral), hepatic extraction (EH), and intestinal availability (FG) were 0.26 +/- 0.08, 0.52 +/- 0.09, and 0.56 +/- 0.20, respectively, for MDZ and 0.42 +/- 0.15, 0.28 +/- 0.09, and 0.56 +/- 0.18, respectively, for ALF.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.56,180283,DB01045,Rifampicin
,15536460,Oral clearance (CL/F),Oral clearance (CL/F) was 34.7 +/- 12.8 and 10.9 +/- 3.5 mL.,Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),ml,34.7,180284,DB01045,Rifampicin
,15536460,Oral clearance (CL/F),Oral clearance (CL/F) was 34.7 +/- 12.8 and 10.9 +/- 3.5 mL.,Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),ml,10.9,180285,DB01045,Rifampicin
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.04,180286,DB01045,Rifampicin
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.99,180287,DB01045,Rifampicin
,15536460,F oral,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.62,180288,DB01045,Rifampicin
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.69,180289,DB01045,Rifampicin
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.04,180290,DB01045,Rifampicin
,15536460,E H,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.26,180291,DB01045,Rifampicin
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.16,180292,DB01045,Rifampicin
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,1.0,180293,DB01045,Rifampicin
,15536460,F G,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.85,180294,DB01045,Rifampicin
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,339,180295,DB01045,Rifampicin
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,0.62,180296,DB01045,Rifampicin
,15536460,CL/F,"After rifampin, TAO, and grapefruit juice, ALF F oral was 0.04 +/- 0.02 (P <.05, versus control), 0.99 +/- 0.18 (P <.05, versus control), and 0.62 +/- 0.18 (P <.05, versus control), respectively; E H was 0.69 +/- 0.14 (P < .05, versus control), 0.04 +/- 0.01 (P <.05, versus control), and 0.26 +/- 0.08, respectively; F G was 0.16 +/- 0.10 (P <.05, versus control), 1.0 +/- 0.2 (P <.05, versus control), and 0.85 +/- 0.30 (P <.05, versus control), respectively; CL/F was 339 +/- 233 (P <.05, versus control), 0.62 +/- 0.26 (P <.05, versus control), and 6.7 +/- 2.5 (P <.05, versus control), respectively, and effect clearance was 2.1 +/- 1.1 (P <.05, versus control), 0.087 +/- 0.056 (P <.05, versus control), and 0.54 +/- 0.30 (0.73 +/- 0.43 mg.mm -1.h -1 in controls), respectively.",Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15536460/),,6.7,180297,DB01045,Rifampicin
,22250979,time,The median time between initiating rifampicin and IDV/r was 4.5 months.,Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22250979/),,4.5,180867,DB01045,Rifampicin
,22250979,AUC(0-12),"The geometric means (GM) of indinavir AUC(0-12) and C(12) were 8.11 mg*h/liter and 0.03 mg/liter, respectively.",Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22250979/),[h·mg] / [l],8.11,180868,DB01045,Rifampicin
,22250979,C(12),"The geometric means (GM) of indinavir AUC(0-12) and C(12) were 8.11 mg*h/liter and 0.03 mg/liter, respectively.",Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22250979/),[mg] / [l],0.03,180869,DB01045,Rifampicin
,22250979,C(12),"After stopping rifampicin and reducing IDV/r to 400/100 bid, the GM indinavir C(12) increased to 0.68 mg/liter (p=0.004).",Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22250979/),[mg] / [l],0.68,180870,DB01045,Rifampicin
,23093043,maximum plasma concentration (Cmax),"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),[ng] / [ml],109,181360,DB01045,Rifampicin
,23093043,area under the plasma concentration-time curve from time zero to infinity (AUC),"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),[h·ng] / [ml],62,181361,DB01045,Rifampicin
,23093043,plasma half-life,"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),h,8,181362,DB01045,Rifampicin
,23093043,plasma half-life,"Compared with administration of ticagrelor alone, co-administration of ticagrelor and rifampicin significantly decreased the maximum plasma concentration (Cmax) of ticagrelor from 1091 to 297.8 ng/ml, area under the plasma concentration-time curve from time zero to infinity (AUC) of ticagrelor from 6225 to 864.0 ng.h/ml, and also decreased plasma half-life of ticagrelor from 8.4 to 2.8 h; reductions of 73 %, 86 % and 67 % respectively.",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093043/),h,2,181363,DB01045,Rifampicin
,31689263,AUC12 h,Pharmacological targets [geometric mean (GM) AUC12 h of 14-45 μmol/l h and GM C12 h ≥75 nmol/l) were reached in both cohort 1 (28.8 μmol/l h and 229 nmol/l) and cohort 2 (38.8 μmol/l h and 228 nmol/l).,Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31689263/),[μM] / [h·l],14-45,181578,DB01045,Rifampicin
≥,31689263,C12 h,Pharmacological targets [geometric mean (GM) AUC12 h of 14-45 μmol/l h and GM C12 h ≥75 nmol/l) were reached in both cohort 1 (28.8 μmol/l h and 229 nmol/l) and cohort 2 (38.8 μmol/l h and 228 nmol/l).,Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31689263/),[nM] / [l],75,181579,DB01045,Rifampicin
,31689263,C12 h,Pharmacological targets [geometric mean (GM) AUC12 h of 14-45 μmol/l h and GM C12 h ≥75 nmol/l) were reached in both cohort 1 (28.8 μmol/l h and 229 nmol/l) and cohort 2 (38.8 μmol/l h and 228 nmol/l).,Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31689263/),[μM] / [h·l],28.8,181580,DB01045,Rifampicin
,31689263,C12 h,Pharmacological targets [geometric mean (GM) AUC12 h of 14-45 μmol/l h and GM C12 h ≥75 nmol/l) were reached in both cohort 1 (28.8 μmol/l h and 229 nmol/l) and cohort 2 (38.8 μmol/l h and 228 nmol/l).,Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31689263/),[nM] / [l],229,181581,DB01045,Rifampicin
,31689263,C12 h,Pharmacological targets [geometric mean (GM) AUC12 h of 14-45 μmol/l h and GM C12 h ≥75 nmol/l) were reached in both cohort 1 (28.8 μmol/l h and 229 nmol/l) and cohort 2 (38.8 μmol/l h and 228 nmol/l).,Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31689263/),[μM] / [h·l],38.8,181582,DB01045,Rifampicin
,31689263,C12 h,Pharmacological targets [geometric mean (GM) AUC12 h of 14-45 μmol/l h and GM C12 h ≥75 nmol/l) were reached in both cohort 1 (28.8 μmol/l h and 229 nmol/l) and cohort 2 (38.8 μmol/l h and 228 nmol/l).,Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31689263/),[nM] / [l],228,181583,DB01045,Rifampicin
,31863284,time to recovery,Transaminase levels subsequently returned to normal (median time to recovery: 15 days).,"The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31863284/),d,15,182055,DB01045,Rifampicin
,17879915,time to reach peak plasma concentration,The median time to reach peak plasma concentration for moxifloxacin was prolonged from 1 h to 2.5 h when combined with rifampicin and isoniazid (P=.003).,Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879915/),h,1,182552,DB01045,Rifampicin
,17879915,time to reach peak plasma concentration,The median time to reach peak plasma concentration for moxifloxacin was prolonged from 1 h to 2.5 h when combined with rifampicin and isoniazid (P=.003).,Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879915/),h,2.5,182553,DB01045,Rifampicin
,10320950,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[μg] / [l],2.5,183615,DB01045,Rifampicin
under,10320950,time to reach the peak,"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,1,183616,DB01045,Rifampicin
,10320950,absolute bioavailability,The absolute bioavailability of buspirone is approximately 4%.,"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),%,4,183617,DB01045,Rifampicin
,10320950,volume of distribution,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [kg],5.3,183618,DB01045,Rifampicin
,10320950,systemic clearance,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [h·kg],1.7,183619,DB01045,Rifampicin
,10320950,elimination half-life,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,2.5,183620,DB01045,Rifampicin
,32505794,Bioavailability,Bioavailability of RIF (F5 gel) was improved by transdermal absorption as evidenced with AUC0→24 of transdermal F5 gel (56.23±2.7 µg.hr/mL) and oral drug suspension (41.71±5.2 µg.hr/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[h·μg] / [ml],56.23,183716,DB01045,Rifampicin
,32505794,AUC0→24,Bioavailability of RIF (F5 gel) was improved by transdermal absorption as evidenced with AUC0→24 of transdermal F5 gel (56.23±2.7 µg.hr/mL) and oral drug suspension (41.71±5.2 µg.hr/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[h·μg] / [ml],56.23,183717,DB01045,Rifampicin
,32505794,AUC0→24,Bioavailability of RIF (F5 gel) was improved by transdermal absorption as evidenced with AUC0→24 of transdermal F5 gel (56.23±2.7 µg.hr/mL) and oral drug suspension (41.71±5.2 µg.hr/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[h·μg] / [ml],41.71,183718,DB01045,Rifampicin
,32505794,transdermal Cmax,A lower value of transdermal Cmax (6.9 ± 0.8 µg/mL) validated sustained delivery for improved tuberculosis management than oral delivery (10.5 ± 1.46.9 ± 0.8 µg/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[μg] / [ml],6.9,183719,DB01045,Rifampicin
,32505794,transdermal Cmax,A lower value of transdermal Cmax (6.9 ± 0.8 µg/mL) validated sustained delivery for improved tuberculosis management than oral delivery (10.5 ± 1.46.9 ± 0.8 µg/mL).,"Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32505794/),[μg] / [ml],10.5,183720,DB01045,Rifampicin
,25798741,effective permeability (Peff),2. In-situ intestinal absorption studies were conducted on rats pretreated with rifampicin and LPS or both to estimate effective permeability (Peff) of 97/78.,Combined effect of rifampicin-induced P-glycoprotein expression and lipopolysaccharide-induced intestinal sepsis on the effective permeability and pharmacokinetics of an anti-malarial candidate CDRI 97/78 in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25798741/),,97/78,183945,DB01045,Rifampicin
,25798741,Peff,In-situ studies revealed that Peff value decreased to 64% (2.7 ± 0.6) × 10(-4 )cm/s in rats pretreated with rifampicin.,Combined effect of rifampicin-induced P-glycoprotein expression and lipopolysaccharide-induced intestinal sepsis on the effective permeability and pharmacokinetics of an anti-malarial candidate CDRI 97/78 in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25798741/),[cm] / [s],2.7,183946,DB01045,Rifampicin
,25798741,relative bioavailability (RB),"For PK studies, it was found that relative bioavailability (RB) was decreased to 22.56% in rifampicin-pretreated rats and to 8.02% in rats pretreated both with rifampicin and LPS.",Combined effect of rifampicin-induced P-glycoprotein expression and lipopolysaccharide-induced intestinal sepsis on the effective permeability and pharmacokinetics of an anti-malarial candidate CDRI 97/78 in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25798741/),%,22.56,183947,DB01045,Rifampicin
,25798741,relative bioavailability (RB),"For PK studies, it was found that relative bioavailability (RB) was decreased to 22.56% in rifampicin-pretreated rats and to 8.02% in rats pretreated both with rifampicin and LPS.",Combined effect of rifampicin-induced P-glycoprotein expression and lipopolysaccharide-induced intestinal sepsis on the effective permeability and pharmacokinetics of an anti-malarial candidate CDRI 97/78 in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25798741/),%,8.02,183948,DB01045,Rifampicin
,3266736,elimination half-life,The elimination half-life of the untreated control group (n = 27) was 4.62 h.,Effects of drugs on aminophylline elimination in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,4.62,184893,DB01045,Rifampicin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.09,184894,DB01045,Rifampicin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.47,184895,DB01045,Rifampicin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.19,184896,DB01045,Rifampicin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2,184897,DB01045,Rifampicin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.85,184898,DB01045,Rifampicin
,3266736,half-life,"The half-life of aminophylline after phenobarbital (10 mg/kg, 7 days, n = 29) was 2.09 h; after phenytoin (10 mg/kg, 7 days, n = 29), 2.47 h; after carbamazepine (400 mg/d, 7 days, n = 25), 2.19 h; after cimetidine (in cimetidine-treated group the blood samples were collected 0.5, 4 and 7 h after the aminophylline injection) (40 mg/kg, 7 days, n = 13), 1.77 h; after erythromycin (800 mg/d, 7 days, n = 28), 2.51 h; after the combination of sulfamethoxazole + trimethoprim in ratio of 5:1 (50 mg/kg, 7 days, n = 23), 2.85 h; and after rifampicin (300 mg/kg, 21 days, n = 23), 2.74 h.",Effects of drugs on aminophylline elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266736/),h,2.74,184899,DB01045,Rifampicin
,27734291,terminal plasma half-life,Cabozantinib displays a long terminal plasma half-life (~120 h) and accumulates ~fivefold by day 15 following daily dosing based on area under the plasma concentration-time curve (AUC).,Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734291/),h,120,185601,DB01045,Rifampicin
,2185691,oral clearance,"The mean ciprofloxacin oral clearance values were 0.35 +/- 0.06, 0.41 +/- 0.15, and 0.38 +/- 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.35,185862,DB01045,Rifampicin
,2185691,oral clearance,"The mean ciprofloxacin oral clearance values were 0.35 +/- 0.06, 0.41 +/- 0.15, and 0.38 +/- 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.41,185863,DB01045,Rifampicin
,2185691,oral clearance,"The mean ciprofloxacin oral clearance values were 0.35 +/- 0.06, 0.41 +/- 0.15, and 0.38 +/- 0.11 liter/h per kg for doses 1, 13, and 28, respectively, in group A patients.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.38,185864,DB01045,Rifampicin
,2185691,oral clearance,"The mean oral clearance values in group B patients for the respective doses were 0.53 +/- 0.36, 0.32 +/- 0.13, and 0.36 +/- 0.17 liter/h per kg.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.53,185865,DB01045,Rifampicin
,2185691,oral clearance,"The mean oral clearance values in group B patients for the respective doses were 0.53 +/- 0.36, 0.32 +/- 0.13, and 0.36 +/- 0.17 liter/h per kg.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.32,185866,DB01045,Rifampicin
,2185691,oral clearance,"The mean oral clearance values in group B patients for the respective doses were 0.53 +/- 0.36, 0.32 +/- 0.13, and 0.36 +/- 0.17 liter/h per kg.",Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185691/),[l] / [h·kg],0.36,185867,DB01045,Rifampicin
,19480557,oral,The compound appeared to have low to intermediate total body clearance and was orally bioavailable (24-100%).,"Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480557/),%,24-100,186131,DB01045,Rifampicin
>or=,19480557,V(ss),"BMS-299897 was distributed into extravascular space (V(ss) >or= 1.3 l kg(-1)), including brain (brain-to-plasma ratio = 0.13-0.50).","Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480557/),[l] / [kg],1.3,186132,DB01045,Rifampicin
,19480557,brain-to-plasma ratio,"BMS-299897 was distributed into extravascular space (V(ss) >or= 1.3 l kg(-1)), including brain (brain-to-plasma ratio = 0.13-0.50).","Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19480557/),,0.13-0.50,186133,DB01045,Rifampicin
,14613962,mass median aerodynamic diameter,"The aerosolized particles exhibited a mass median aerodynamic diameter of 1.88 +/- 0.11 microm, favourable for bronchoalveolar lung delivery.",Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14613962/),μm,1.88,186575,DB01045,Rifampicin
less,19124658,trough concentration,The trough concentration of efavirenz was subtherapeutic (less than 1.0 microg/ml) in 6 (8%) of 72 patients.,CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19124658/),[μg] / [ml],1.0,187134,DB01045,Rifampicin
,22944286,AUC(0-6h),"The average AUC(0-6h) for levofloxacin was 46.59 mg.h/l, the average Cmax 10.7 mg/l, the average AUIC 932, and the average Cmax/MIC 107.5.",Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22944286/),[h·mg] / [l],46.59,187163,DB01045,Rifampicin
,22944286,Cmax,"The average AUC(0-6h) for levofloxacin was 46.59 mg.h/l, the average Cmax 10.7 mg/l, the average AUIC 932, and the average Cmax/MIC 107.5.",Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22944286/),[mg] / [l],10.7,187164,DB01045,Rifampicin
,22944286,AUIC,"The average AUC(0-6h) for levofloxacin was 46.59 mg.h/l, the average Cmax 10.7 mg/l, the average AUIC 932, and the average Cmax/MIC 107.5.",Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22944286/),,932,187165,DB01045,Rifampicin
,22944286,Cmax/MIC,"The average AUC(0-6h) for levofloxacin was 46.59 mg.h/l, the average Cmax 10.7 mg/l, the average AUIC 932, and the average Cmax/MIC 107.5.",Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22944286/),,107.5,187166,DB01045,Rifampicin
,15289787,systemic clearance,"However, during the inhibited metabolic state, the CYP3A5*3/*3 group showed a greater decrease in systemic clearance than was seen in the CYP3A5*1/*1 group (8.5 +/- 3.8 L. h(-1). 70 kg(-1) versus 13.5 +/- 2.7 L. h(-1). 70 kg(-1), P =.027).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),[l] / [70·h·kg],8.5,187223,DB01045,Rifampicin
,15289787,systemic clearance,"However, during the inhibited metabolic state, the CYP3A5*3/*3 group showed a greater decrease in systemic clearance than was seen in the CYP3A5*1/*1 group (8.5 +/- 3.8 L. h(-1). 70 kg(-1) versus 13.5 +/- 2.7 L. h(-1). 70 kg(-1), P =.027).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),[l] / [70·h·kg],13.5,187224,DB01045,Rifampicin
,15289787,area under the plasma concentration-time curve ratio,"The 1'-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),,0.58,187225,DB01045,Rifampicin
,15289787,area under the plasma concentration-time curve ratio,"The 1'-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026).",Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289787/),,1.09,187226,DB01045,Rifampicin
,22330931,time to the peak concentration,"Unexpectedly, the overall median 2- and 6-h levels of rifampin were 1.6 and 3.2 mg/liter, respectively, and the time to the peak concentration was 6 h (slow absorber) instead of 2 h (fast absorber) for 61 patients (62.2%).",Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330931/),h,6,187889,DB01045,Rifampicin
,22330931,time to the peak concentration,"Unexpectedly, the overall median 2- and 6-h levels of rifampin were 1.6 and 3.2 mg/liter, respectively, and the time to the peak concentration was 6 h (slow absorber) instead of 2 h (fast absorber) for 61 patients (62.2%).",Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330931/),h,2,187890,DB01045,Rifampicin
,22330931,peak concentration of drug in serum (C(max)),The geometric mean peak concentration of drug in serum (C(max)) was significantly higher in fast absorbers than in slow absorbers (5.0 versus 3.8 mg/liter; P = 0.05).,Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330931/),[mg] / [l],5.0,187891,DB01045,Rifampicin
,22330931,peak concentration of drug in serum (C(max)),The geometric mean peak concentration of drug in serum (C(max)) was significantly higher in fast absorbers than in slow absorbers (5.0 versus 3.8 mg/liter; P = 0.05).,Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330931/),[mg] / [l],3.8,187892,DB01045,Rifampicin
,22330931,C(max),The rifampin C(max) was significantly lower in male patients than in female patients (3.3 versus 6.3 mg/liter; P < 0.001).,Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330931/),[mg] / [l],3.3,187893,DB01045,Rifampicin
,22330931,C(max),The rifampin C(max) was significantly lower in male patients than in female patients (3.3 versus 6.3 mg/liter; P < 0.001).,Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330931/),[mg] / [l],6.3,187894,DB01045,Rifampicin
,22330931,time to maximum concentration of drug in serum (T(max)),An analysis of variance regression analysis showed that female gender (P < 0.001) and the time to maximum concentration of drug in serum (T(max)) at 2 h (P = 0.012) were independently correlated with increased exposure to rifampin.,Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22330931/),h,2,187895,DB01045,Rifampicin
,10423226,Cmax,"The mean values of RMP in brand N (Cmax 6.49+/-0.52 microg/mL, Tmax 2.33+/-0.18 h, AUC(0-24h) 39.83+/-3.44 microg/mL.h) were comparable with those obtained with brand R (Cmax 5.22+/-0.59 microg/mL, Tmax 2.50+/-0.12 h, AUC(0-24h) 33.33+/-3.47 microg/mL.h).",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),[μg] / [ml],6.49,188240,DB01045,Rifampicin
,10423226,Tmax,"The mean values of RMP in brand N (Cmax 6.49+/-0.52 microg/mL, Tmax 2.33+/-0.18 h, AUC(0-24h) 39.83+/-3.44 microg/mL.h) were comparable with those obtained with brand R (Cmax 5.22+/-0.59 microg/mL, Tmax 2.50+/-0.12 h, AUC(0-24h) 33.33+/-3.47 microg/mL.h).",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),h,2.33,188241,DB01045,Rifampicin
,10423226,AUC(0-24h),"The mean values of RMP in brand N (Cmax 6.49+/-0.52 microg/mL, Tmax 2.33+/-0.18 h, AUC(0-24h) 39.83+/-3.44 microg/mL.h) were comparable with those obtained with brand R (Cmax 5.22+/-0.59 microg/mL, Tmax 2.50+/-0.12 h, AUC(0-24h) 33.33+/-3.47 microg/mL.h).",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),[μg] / [h·ml],39.83,188242,DB01045,Rifampicin
,10423226,Cmax,"The mean values of RMP in brand N (Cmax 6.49+/-0.52 microg/mL, Tmax 2.33+/-0.18 h, AUC(0-24h) 39.83+/-3.44 microg/mL.h) were comparable with those obtained with brand R (Cmax 5.22+/-0.59 microg/mL, Tmax 2.50+/-0.12 h, AUC(0-24h) 33.33+/-3.47 microg/mL.h).",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),[μg] / [ml],5.22,188243,DB01045,Rifampicin
,10423226,Tmax,"The mean values of RMP in brand N (Cmax 6.49+/-0.52 microg/mL, Tmax 2.33+/-0.18 h, AUC(0-24h) 39.83+/-3.44 microg/mL.h) were comparable with those obtained with brand R (Cmax 5.22+/-0.59 microg/mL, Tmax 2.50+/-0.12 h, AUC(0-24h) 33.33+/-3.47 microg/mL.h).",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),h,2.50,188244,DB01045,Rifampicin
,10423226,AUC(0-24h),"The mean values of RMP in brand N (Cmax 6.49+/-0.52 microg/mL, Tmax 2.33+/-0.18 h, AUC(0-24h) 39.83+/-3.44 microg/mL.h) were comparable with those obtained with brand R (Cmax 5.22+/-0.59 microg/mL, Tmax 2.50+/-0.12 h, AUC(0-24h) 33.33+/-3.47 microg/mL.h).",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),[μg] / [h·ml],33.33,188245,DB01045,Rifampicin
,10423226,Cmax,"The mean values of RMP in brand L (Cmax 3.05+/-0.52 microg/ mL, Tmax 3.79+/-0.57 h and AUC(0-24h) 21.78+/-3.67 microg/ mL.h) were significantly different from those in brand R.",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),[μg] / [ml],3.05,188246,DB01045,Rifampicin
,10423226,Tmax,"The mean values of RMP in brand L (Cmax 3.05+/-0.52 microg/ mL, Tmax 3.79+/-0.57 h and AUC(0-24h) 21.78+/-3.67 microg/ mL.h) were significantly different from those in brand R.",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),h,3.79,188247,DB01045,Rifampicin
,10423226,AUC(0-24h),"The mean values of RMP in brand L (Cmax 3.05+/-0.52 microg/ mL, Tmax 3.79+/-0.57 h and AUC(0-24h) 21.78+/-3.67 microg/ mL.h) were significantly different from those in brand R.",Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423226/),[μg] / [h·ml],21.78,188248,DB01045,Rifampicin
,33241266,trough concentrations,"Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL.",Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33241266/),[ng] / [ml],",",189709,DB01045,Rifampicin
,33241266,trough concentrations,"Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL.",Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33241266/),[ng] / [ml],7322,189710,DB01045,Rifampicin
,33241266,trough concentrations,"Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL.",Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33241266/),[ng] / [ml],",",189711,DB01045,Rifampicin
,33241266,trough concentrations,"Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL.",Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33241266/),[ng] / [ml],5537,189712,DB01045,Rifampicin
,33241266,trough concentrations,"Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL.",Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33241266/),[ng] / [ml],",",189713,DB01045,Rifampicin
,33241266,trough concentrations,"Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266-9302) ng/mL; week 2, 5537 (3552-8462) ng/mL; and week 4, 5388 (3516-8243) ng/mL.",Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33241266/),[ng] / [ml],5388,189714,DB01045,Rifampicin
,33241266,CL/F,"Median (IQR) nevirapine CL/F values were: week 0 pre-rifapentine/isoniazid, 2.03 (1.58-2.58) L/h; and during rifapentine/isoniazid, 2.62 (1.81-3.42) L/h.",Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33241266/),[l] / [h],2.03,189715,DB01045,Rifampicin
,33241266,CL/F,"Median (IQR) nevirapine CL/F values were: week 0 pre-rifapentine/isoniazid, 2.03 (1.58-2.58) L/h; and during rifapentine/isoniazid, 2.62 (1.81-3.42) L/h.",Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33241266/),[l] / [h],2.62,189716,DB01045,Rifampicin
,2495879,elimination rate constant,"Significant differences in elimination rate constant (average increase, 0.0545 to 0.0748 hr-1), elimination half-life (average reduction, 13.2 to 9.4 hours), oral clearance, and area under the concentration-time curve (average reduction, 76.8 to 55.0 mg.hr/L) between the control and rifampin treatment phases were observed.",Influence of rifampin on tocainide pharmacokinetics in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495879/),1/[h],0.0545 to 0.0748,189987,DB01045,Rifampicin
,7853151,rectal absorption,The rectal absorption of RFP from the suppositories containing no PAS-Na (control suppositories) was significantly lower compared to oral administration of it (26%) in human subjects.,[Enhancement of rectal absorption of rifampicin by sodium para-aminosalicylate dihydrate in human subjects]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853151/),%,26,190489,DB01045,Rifampicin
up to,30910890,bioavailability,"Additionally, the concomitant use of efavirenz increased isoniazid clearance by 24.1%, while bioavailability and absorption of rifampin and isoniazid varied up to 30% in patients on different formulations.",Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30910890/),%,30,190776,DB01045,Rifampicin
up to,30910890,absorption,"Additionally, the concomitant use of efavirenz increased isoniazid clearance by 24.1%, while bioavailability and absorption of rifampin and isoniazid varied up to 30% in patients on different formulations.",Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30910890/),%,30,190777,DB01045,Rifampicin
,8690816,bioavailability,"The results of fecal analysis indicated that transit of the two compounds in the gastrointestinal tract were similar, and bioavailability of CGP 43371 was calculated to be 9% based on the difference between the cumulative amounts of the nonabsorbable radioactive marker and CGP 43371 found in the feces.",Explaining variable absorption of a hypolipidemic agent (CGP 43371) in healthy subjects by gamma scintigraphy and pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690816/),%,9,191103,DB01045,Rifampicin
,6282204,half life,The half life ranged from 2.0 to 3.3 h.,"Disposition of ketoconazole, an oral antifungal, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282204/),h,2.0 to 3.3,192001,DB01045,Rifampicin
up to,6282204,Peak serum concentrations,"Peak serum concentrations up to 50 micrograms/ml were detected in this study, and potentially therapeutic concentrations were detectable up to 26 h after high doses.","Disposition of ketoconazole, an oral antifungal, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282204/),[μg] / [ml],50,192002,DB01045,Rifampicin
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,70,192332,DB01045,Rifampicin
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,22,192333,DB01045,Rifampicin
,15371986,oral bioavailability,"Methadone had high oral bioavailability (70%) and low intestinal (22%) and hepatic (9%) extraction, and there was a significant correlation ( r = 0.94, P <.001) between oral bioavailability and intestinal (but not hepatic) availability.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),%,9,192334,DB01045,Rifampicin
,15371986,IV clearance,Rifampin decreased bioavailability and oral and IV methadone plasma concentrations and increased IV clearance (4.42 +/- 1.00 mL.,"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,4.42,192335,DB01045,Rifampicin
,15371986,oral clearance,"kg -1. min -1, P <.05) and oral clearance (8.50 +/- 3.68 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,8.50,192336,DB01045,Rifampicin
,15371986,area under the curve (AUC) ratios,"kg -1. min -1, P <.05), EDDP/methadone area under the curve (AUC) ratios, EDDP formation clearances, and hepatic extraction (0.27 +/- 0.06 versus 0.09 +/- 0.04, P <.05).","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.27,192337,DB01045,Rifampicin
,15371986,formation clearances,"kg -1. min -1, P <.05), EDDP/methadone area under the curve (AUC) ratios, EDDP formation clearances, and hepatic extraction (0.27 +/- 0.06 versus 0.09 +/- 0.04, P <.05).","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.09,192338,DB01045,Rifampicin
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.17,192339,DB01045,Rifampicin
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.14,192340,DB01045,Rifampicin
,15371986,AUC ratio,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),,0.27,192341,DB01045,Rifampicin
,15371986,IV,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,1.29,192342,DB01045,Rifampicin
,15371986,clearance,"Troleandomycin and grapefruit juice decreased the EDDP/methadone AUC ratio after oral methadone (0.17 +/- 0.10 and 0.14 +/- 0.06 versus 0.27 +/- 0.20, P <.05) but not IV methadone and had no effect on methadone plasma concentrations, IV clearance (1.29 +/- 0.41 mL.","Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,1.29,192343,DB01045,Rifampicin
,15371986,oral clearance,kg -1. min -1 ) or oral clearance (2.05 +/- 1.52 mL.,"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371986/),ml,2.05,192344,DB01045,Rifampicin
≤,33509903,logP,"In vitro transport studies using primary monkey and human hepatocytes showed uptake inhibition by rifampicin (100 µM) for compounds with logP ≤6.5 but not for the very lipophilic acids (logP > 6.5), which generally showed high nonspecific binding in hepatocyte incubations.",Organic Anion-Transporting Polypeptide 1B1/1B3-Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro-In Vivo Evaluation in Cynomolgus Monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33509903/),,6.5,192377,DB01045,Rifampicin
>,33509903,logP,"In vitro transport studies using primary monkey and human hepatocytes showed uptake inhibition by rifampicin (100 µM) for compounds with logP ≤6.5 but not for the very lipophilic acids (logP > 6.5), which generally showed high nonspecific binding in hepatocyte incubations.",Organic Anion-Transporting Polypeptide 1B1/1B3-Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro-In Vivo Evaluation in Cynomolgus Monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33509903/),,6.5,192378,DB01045,Rifampicin
,10331734,t(1/2),Mean rifapentine t(1/2) ranged from 13.2-14.1 hours and was similar across the 150-600 mg dose range.,Single and multiple dose pharmacokinetics of rifapentine in man: part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10331734/),h,13.2-14.1,192738,DB01045,Rifampicin
,10331734,Tmax,"The active 25-desacetyl metabolite appeared slowly in plasma, with mean Tmax of 14.4-17.8 hours.",Single and multiple dose pharmacokinetics of rifapentine in man: part II. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10331734/),h,14.4-17.8,192739,DB01045,Rifampicin
,10331734,t(1/2),Mean t(1/2) for 25-desacetyl-rifapentine ranged from 13.3-24.3 hours.,Single and multiple dose pharmacokinetics of rifapentine in man: part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10331734/),h,13.3-24.3,192740,DB01045,Rifampicin
,26260983,plasma area under the curve (AUC)0-24,A population PK/pharmacodynamic (PD) model using adult data defined rifampin target exposures (plasma area under the curve (AUC)0-24 = 92 mg*h/L).,Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26260983/),[h·mg] / [l],92,193505,DB01045,Rifampicin
,3360051,elimination half-life,Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23).,Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360051/),h,40.,193525,DB01045,Rifampicin
,3360051,elimination half-life,Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23).,Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360051/),h,25,193526,DB01045,Rifampicin
<,21518840,concentration (C(24)),"Five subjects had a 24-hour efavirenz concentration (C(24)) of <1,000 ng/ml on rifampin.",Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518840/),[ng] / [ml],"1,000",193706,DB01045,Rifampicin
,6430705,total radioactivity exhaled,"The total radioactivity exhaled remained constant at 56 +/- 4.5% (SD) of the applied dose throughout a tenfold dose range of methacetin (0.6, 4.0 and 6.0 mg/kg i.p.), administered to groups of three rats each and measured over a period of 4 hours.","A kinetic evaluation of 14CO2 in expired air after 14C-methacetin administration in rats, used for the in vivo study of the metabolism of drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430705/),%,56,194116,DB01045,Rifampicin
greater,21695772,area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ),The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ) for mycophenolic acid (MPA) greater than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194863,DB01045,Rifampicin
less,21695772,AUC(0-12),Thirteen of the 15 patients had an MPA AUC(0-12) value less than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194864,DB01045,Rifampicin
greater,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194865,DB01045,Rifampicin
,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[mg] / [·d·m(2)],371 to 1014,194866,DB01045,Rifampicin
greater,21695772,AUC(0-12),"In conclusion, an initial MMF dose of 600 mg/m(2) twice a day led to MPA AUC(0-12) values greater than the 30 mg hour/L threshold except when rifampin was coadministered.",Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194867,DB01045,Rifampicin
,20585115,area under the plasma concentration-time curve (AUC),"Comedication with CLA resulted in a 60% statistically nonsignificant increase in the area under the plasma concentration-time curve (AUC) for RIF of 25.8 mg x h/liter (interquartile ratio [IQR], 21.7 to 31.5 mg x h/liter), whereas the AUC of RIF was 15.2 mg x h/liter (IQR, 15.0 to 17.5 mg x h/liter) in patients comedicated with SM (P = 0.09).",Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585115/),[h·mg] / [l],25.8,194904,DB01045,Rifampicin
,20585115,AUC,"Comedication with CLA resulted in a 60% statistically nonsignificant increase in the area under the plasma concentration-time curve (AUC) for RIF of 25.8 mg x h/liter (interquartile ratio [IQR], 21.7 to 31.5 mg x h/liter), whereas the AUC of RIF was 15.2 mg x h/liter (IQR, 15.0 to 17.5 mg x h/liter) in patients comedicated with SM (P = 0.09).",Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585115/),[h·mg] / [l],15.2,194905,DB01045,Rifampicin
,20585115,AUCs,"The median AUCs of CLA and 14-hydroxyclarithromycin (14OH-CLA) were 2.9 mg x h/liter (IQR, 1.5 to 3.8 mg x h/liter) and 8.0 mg x h/liter (IQR, 6.7 to 8.6 mg x h/liter), respectively.",Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585115/),[h·mg] / [l],2.9,194906,DB01045,Rifampicin
,20585115,AUCs,"The median AUCs of CLA and 14-hydroxyclarithromycin (14OH-CLA) were 2.9 mg x h/liter (IQR, 1.5 to 3.8 mg x h/liter) and 8.0 mg x h/liter (IQR, 6.7 to 8.6 mg x h/liter), respectively.",Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585115/),[h·mg] / [l],8.0,194907,DB01045,Rifampicin
,27550347,peak plasma concentration,"The mean peak plasma concentration and mean area under the concentration-time curve from time zero to 24 h for tedizolid were 12 μg/ml and 60 μg · h/ml, respectively.",Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550347/),[μg] / [ml],12,195535,DB01045,Rifampicin
,27550347,area under the concentration-time curve from time zero to 24 h,"The mean peak plasma concentration and mean area under the concentration-time curve from time zero to 24 h for tedizolid were 12 μg/ml and 60 μg · h/ml, respectively.",Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550347/),[h·μg] / [ml],60,195536,DB01045,Rifampicin
,27550347,plasma trough concentrations,The range of mean plasma trough concentrations in the tedizolid group was 0.44 to 0.73 μg/ml.,Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27550347/),[μg] / [ml],0.44 to 0.73,195537,DB01045,Rifampicin
,6648039,dissolution ratios,"The dissolution ratios of the DI product in the second fluid and de-aerated water at 60 min are 72.0% and 95.0%, and the CB product ratios are 10.0% and 5.5% respectively.",The dissolution and bioavailability of rifampicin products in healthy subjects and tubercular patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6648039/),%,72.0,195821,DB01045,Rifampicin
,6648039,dissolution ratios,"The dissolution ratios of the DI product in the second fluid and de-aerated water at 60 min are 72.0% and 95.0%, and the CB product ratios are 10.0% and 5.5% respectively.",The dissolution and bioavailability of rifampicin products in healthy subjects and tubercular patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6648039/),%,95.0,195822,DB01045,Rifampicin
,6648039,product ratios,"The dissolution ratios of the DI product in the second fluid and de-aerated water at 60 min are 72.0% and 95.0%, and the CB product ratios are 10.0% and 5.5% respectively.",The dissolution and bioavailability of rifampicin products in healthy subjects and tubercular patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6648039/),%,10.0,195823,DB01045,Rifampicin
,6648039,product ratios,"The dissolution ratios of the DI product in the second fluid and de-aerated water at 60 min are 72.0% and 95.0%, and the CB product ratios are 10.0% and 5.5% respectively.",The dissolution and bioavailability of rifampicin products in healthy subjects and tubercular patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6648039/),%,5.5,195824,DB01045,Rifampicin
,6845400,maximal plasma concentrations (Cmax),"The maximal plasma concentrations (Cmax) and the elimination half-lives (t 1/2 beta) of RMP are 8.83 +/- 1.72 mg L-1 and 4.09 +/- 2.59 h, respectively.",Pharmacokinetic studies of rifampicin in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845400/),[mg] / [l],8.83,196554,DB01045,Rifampicin
,6845400,elimination half-lives (t 1/2 beta),"The maximal plasma concentrations (Cmax) and the elimination half-lives (t 1/2 beta) of RMP are 8.83 +/- 1.72 mg L-1 and 4.09 +/- 2.59 h, respectively.",Pharmacokinetic studies of rifampicin in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845400/),h,4.09,196555,DB01045,Rifampicin
,6845400,Cmax,The same applies to the Cmax value (1.93 +/- 0.53 mg L-1) and t 1/2 beta value (4.65 +/- 2.61 h) of DA-RMP.,Pharmacokinetic studies of rifampicin in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845400/),[mg] / [l],1.93,196556,DB01045,Rifampicin
,6845400,t 1/2 beta,The same applies to the Cmax value (1.93 +/- 0.53 mg L-1) and t 1/2 beta value (4.65 +/- 2.61 h) of DA-RMP.,Pharmacokinetic studies of rifampicin in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845400/),h,4.65,196557,DB01045,Rifampicin
,6845400,renal clearance,"However, the renal clearance of RMP (0.0075 +/- 0.0036 L h-1) and the amounts of RMP (20.7 +/- 9.9 mg) and DA-RMP (13.3 +/- 5.6 mg) excreted in the urine during a 24-h period are lower than those reported in young adults.",Pharmacokinetic studies of rifampicin in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845400/),[l] / [h],0.0075,196558,DB01045,Rifampicin
,6845400,renal clearance,"However, the renal clearance of RMP (0.0075 +/- 0.0036 L h-1) and the amounts of RMP (20.7 +/- 9.9 mg) and DA-RMP (13.3 +/- 5.6 mg) excreted in the urine during a 24-h period are lower than those reported in young adults.",Pharmacokinetic studies of rifampicin in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6845400/),mg,13.3,196559,DB01045,Rifampicin
,22170330,IC(50),"CLR was an inhibitor of OATP1B3 (IC(50) = 9.50 ± 3.50 μM), OATP1B1 (IC(50) = 46.0 ± 2.27 μM), OATP1A2 (IC(50) = 92.6 ± 1.49 μM), and OATP2B1 (IC(50) = 384 ± 5.30 μM) but was not a substrate for these transporters in transfected human embryonic kidney cells.",Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22170330/),μM,9.50,197484,DB01045,Rifampicin
,22170330,IC(50),"CLR was an inhibitor of OATP1B3 (IC(50) = 9.50 ± 3.50 μM), OATP1B1 (IC(50) = 46.0 ± 2.27 μM), OATP1A2 (IC(50) = 92.6 ± 1.49 μM), and OATP2B1 (IC(50) = 384 ± 5.30 μM) but was not a substrate for these transporters in transfected human embryonic kidney cells.",Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22170330/),μM,46.0,197485,DB01045,Rifampicin
,22170330,IC(50),"CLR was an inhibitor of OATP1B3 (IC(50) = 9.50 ± 3.50 μM), OATP1B1 (IC(50) = 46.0 ± 2.27 μM), OATP1A2 (IC(50) = 92.6 ± 1.49 μM), and OATP2B1 (IC(50) = 384 ± 5.30 μM) but was not a substrate for these transporters in transfected human embryonic kidney cells.",Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22170330/),μM,92.6,197486,DB01045,Rifampicin
,22170330,IC(50),"CLR was an inhibitor of OATP1B3 (IC(50) = 9.50 ± 3.50 μM), OATP1B1 (IC(50) = 46.0 ± 2.27 μM), OATP1A2 (IC(50) = 92.6 ± 1.49 μM), and OATP2B1 (IC(50) = 384 ± 5.30 μM) but was not a substrate for these transporters in transfected human embryonic kidney cells.",Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22170330/),μM,384,197487,DB01045,Rifampicin
,32536870,AUC0-24h,"The AUC0-24h in the typical individual varied substantially between simulated sampling occasions [95% prediction interval (PI): 122.2 to 331.2 h mg/L], equivalent to an IOV in AUC0-24h of 25.8%, compared to an inter-individual variability of 25.4%.",Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing-Using Rifampicin as an Example. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32536870/),[h·mg] / [l],122.2 to 331.2,197945,DB01045,Rifampicin
,27934638,liver tissue-to-plasma concentration ratio (Kpliver),"The liver tissue-to-plasma concentration ratio (Kpliver) decreased from 41.8 to 5.07 by rifampicin, and this decrement was consistent with the decrease in distribution volume from 247 to 59 ml/rat.",Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27934638/),,41.8,198137,DB01045,Rifampicin
,27934638,liver tissue-to-plasma concentration ratio (Kpliver),"The liver tissue-to-plasma concentration ratio (Kpliver) decreased from 41.8 to 5.07 by rifampicin, and this decrement was consistent with the decrease in distribution volume from 247 to 59 ml/rat.",Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27934638/),,5.07,198138,DB01045,Rifampicin
,27934638,distribution volume,"The liver tissue-to-plasma concentration ratio (Kpliver) decreased from 41.8 to 5.07 by rifampicin, and this decrement was consistent with the decrease in distribution volume from 247 to 59 ml/rat.",Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27934638/),[ml] / [rat],247,198139,DB01045,Rifampicin
,27934638,distribution volume,"The liver tissue-to-plasma concentration ratio (Kpliver) decreased from 41.8 to 5.07 by rifampicin, and this decrement was consistent with the decrease in distribution volume from 247 to 59 ml/rat.",Comparative Evaluation of Dehydroepiandrosterone Sulfate Potential to Predict Hepatic Organic Anion Transporting Polypeptide Transporter-Based Drug-Drug Interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27934638/),[ml] / [rat],59,198140,DB01045,Rifampicin
,19417618,Oral bioavailability,Oral bioavailability of oxycodone was decreased from 69% to 21% (P < 0.001).,Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417618/),%,69,198466,DB01045,Rifampicin
,19417618,Oral bioavailability,Oral bioavailability of oxycodone was decreased from 69% to 21% (P < 0.001).,Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417618/),%,21,198467,DB01045,Rifampicin
,2920698,half-life of elimination,The half-life of elimination of phenylbutazone alone was about 4 h.,"Interactions between chloramphenicol, acepromazine, phenylbutazone, rifampin and thiamylal in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920698/),h,4,198483,DB01045,Rifampicin
,23242004,Bioavailability,Bioavailability of oral tramadol was reduced by rifampicin from 66 to 49 % (P = 0.002).,Rifampicin markedly decreases the exposure to oral and intravenous tramadol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242004/),%,66 to 49,198780,DB01045,Rifampicin
,9773393,area under the rifapentine plasma concentration-time curve [AUC(0-->infinity)],The mean area under the rifapentine plasma concentration-time curve [AUC(0-->infinity)] was 325 micrograms.,Single-dose pharmacokinetics of rifapentine in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773393/),μg,325,199537,DB01045,Rifampicin
,9773393,elimination half-life (t1/2),hr ml and the mean elimination half-life (t1/2) was 16.3 hr.,Single-dose pharmacokinetics of rifapentine in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773393/),h,16.3,199538,DB01045,Rifampicin
,9773393,terminal half-life,Plasma concentrations for the 25-desacetyl metabolite peaked at 15.4 hr after the rifapentine dose and declined with a terminal half-life of 17.3 hr.,Single-dose pharmacokinetics of rifapentine in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773393/),h,17.3,199539,DB01045,Rifampicin
,577076,half-life of the second phase,The half-life of the second phase was 7.5+/-1.7 (SD) hours.,Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577076/),h,7.5,200712,DB01045,Rifampicin
,577076,half-life,Administration of rifampicin (600 mg for 6 days) shifted the half-life of ethinyloestradiol to 3.3+/-0.9 h while the apparent volume of distribution for the second phase of elimination was not changed.,Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577076/),h,3.3,200713,DB01045,Rifampicin
<,30084943,VL,All maintained VL <50 copies/mL throughout the study.,Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30084943/),[copies] / [ml],50,200776,DB01045,Rifampicin
,30224525,clearance,"There were no significant changes from baseline in the clearance (0.53 versus 0.55 liters/h, P = 1.00), volume of distribution (7.0 versus 7.2 liter, P = 0.62), or half-life (9.7 versus 9.6 h, P = 0.89) of daptomycin after exposure to rifampin.",Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224525/),[l] / [h],0.53,201754,DB01045,Rifampicin
,30224525,clearance,"There were no significant changes from baseline in the clearance (0.53 versus 0.55 liters/h, P = 1.00), volume of distribution (7.0 versus 7.2 liter, P = 0.62), or half-life (9.7 versus 9.6 h, P = 0.89) of daptomycin after exposure to rifampin.",Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224525/),[l] / [h],0.55,201755,DB01045,Rifampicin
,30224525,volume of distribution,"There were no significant changes from baseline in the clearance (0.53 versus 0.55 liters/h, P = 1.00), volume of distribution (7.0 versus 7.2 liter, P = 0.62), or half-life (9.7 versus 9.6 h, P = 0.89) of daptomycin after exposure to rifampin.",Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224525/),l,7.0,201756,DB01045,Rifampicin
,30224525,volume of distribution,"There were no significant changes from baseline in the clearance (0.53 versus 0.55 liters/h, P = 1.00), volume of distribution (7.0 versus 7.2 liter, P = 0.62), or half-life (9.7 versus 9.6 h, P = 0.89) of daptomycin after exposure to rifampin.",Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224525/),l,7.2,201757,DB01045,Rifampicin
,30224525,half-life,"There were no significant changes from baseline in the clearance (0.53 versus 0.55 liters/h, P = 1.00), volume of distribution (7.0 versus 7.2 liter, P = 0.62), or half-life (9.7 versus 9.6 h, P = 0.89) of daptomycin after exposure to rifampin.",Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224525/),h,9.7,201758,DB01045,Rifampicin
,30224525,half-life,"There were no significant changes from baseline in the clearance (0.53 versus 0.55 liters/h, P = 1.00), volume of distribution (7.0 versus 7.2 liter, P = 0.62), or half-life (9.7 versus 9.6 h, P = 0.89) of daptomycin after exposure to rifampin.",Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224525/),h,9.6,201759,DB01045,Rifampicin
,24365552,relative bioavailability,"The average relative bioavailability calculated for maximum serum concentration area under the concentration-time curve (AUC), AUC(0-24h) and AUC(0-∞) of the test 3FDC formulation vs. the 3FDC reference were respectively 64.84% (90%CI 56.01-75.06), 59.05% (90%CI 50.27-69.36) and 57.26% (90%CI 46.93-69.84).",Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365552/),%,64.84,201875,DB01045,Rifampicin
,24365552,relative bioavailability,"The average relative bioavailability calculated for maximum serum concentration area under the concentration-time curve (AUC), AUC(0-24h) and AUC(0-∞) of the test 3FDC formulation vs. the 3FDC reference were respectively 64.84% (90%CI 56.01-75.06), 59.05% (90%CI 50.27-69.36) and 57.26% (90%CI 46.93-69.84).",Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365552/),%,59.05,201876,DB01045,Rifampicin
,24365552,relative bioavailability,"The average relative bioavailability calculated for maximum serum concentration area under the concentration-time curve (AUC), AUC(0-24h) and AUC(0-∞) of the test 3FDC formulation vs. the 3FDC reference were respectively 64.84% (90%CI 56.01-75.06), 59.05% (90%CI 50.27-69.36) and 57.26% (90%CI 46.93-69.84).",Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365552/),%,57.26,201877,DB01045,Rifampicin
,16256437,encapsulation efficiency,"The SLNs were prepared by the ""emulsion solvent diffusion"" technique with an encapsulation efficiency of 51+/-5% for rifampicin, 45+/-4% for isoniazid and 41+/-4% for pyrazinamide.",Oral solid lipid nanoparticle-based antitubercular chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256437/),%,51,202470,DB01045,Rifampicin
,16256437,encapsulation efficiency,"The SLNs were prepared by the ""emulsion solvent diffusion"" technique with an encapsulation efficiency of 51+/-5% for rifampicin, 45+/-4% for isoniazid and 41+/-4% for pyrazinamide.",Oral solid lipid nanoparticle-based antitubercular chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256437/),%,45,202471,DB01045,Rifampicin
,16256437,encapsulation efficiency,"The SLNs were prepared by the ""emulsion solvent diffusion"" technique with an encapsulation efficiency of 51+/-5% for rifampicin, 45+/-4% for isoniazid and 41+/-4% for pyrazinamide.",Oral solid lipid nanoparticle-based antitubercular chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256437/),%,41,202472,DB01045,Rifampicin
≥,32330996,area under the curve/minimum inhibitory concentration,"When rifampicin was administered with fusidic acid, the pharmacokinetic/pharmacodynamic (PK/PD) target (area under the curve/minimum inhibitory concentration ≥952) was achieved with all tested dosing regimen, except 600 mg once daily for Staphylococcus epidermidis infections.",Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32330996/),,952,203071,DB01045,Rifampicin
,18391026,oral clearance,"The typical population estimate of oral clearance was 19.2 liters x h(-1), while the volume of distribution was estimated to be 53.2 liters.","Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18391026/),[l] / [h],19.2,203427,DB01045,Rifampicin
,18391026,volume of distribution,"The typical population estimate of oral clearance was 19.2 liters x h(-1), while the volume of distribution was estimated to be 53.2 liters.","Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18391026/),l,53.2,203428,DB01045,Rifampicin
,17504177,Cl/F/kg,"Cases had a significantly higher Cl/F/kg if compared with controls (0.269 +/- 0.12 versus 0.167 + 0.05 L/h/kg, p<0.01).",Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17504177/),[l] / [h·kg],0.269,203505,DB01045,Rifampicin
,17504177,Cl/F/kg,"Cases had a significantly higher Cl/F/kg if compared with controls (0.269 +/- 0.12 versus 0.167 + 0.05 L/h/kg, p<0.01).",Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17504177/),[l] / [h·kg],0.167,203506,DB01045,Rifampicin
,2085859,t 1/2,"Important parameters were taken: t 1/2 2.39 +/- 0.66, 3.84 +/- 1.91 h; Cmax: 14.56 +/- 6.45, 9.83 +/- 2.55 micrograms/ml; vd: 0.43 +/- 0.11, 0.67 +/- 0.15L/kg; CL: 0.14 +/- 0.03, 0.13 +/- 0.06 L.h-1/kg respectively.",[Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085859/),h,2.39,203687,DB01045,Rifampicin
,2085859,t 1/2,"Important parameters were taken: t 1/2 2.39 +/- 0.66, 3.84 +/- 1.91 h; Cmax: 14.56 +/- 6.45, 9.83 +/- 2.55 micrograms/ml; vd: 0.43 +/- 0.11, 0.67 +/- 0.15L/kg; CL: 0.14 +/- 0.03, 0.13 +/- 0.06 L.h-1/kg respectively.",[Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085859/),h,3.84,203688,DB01045,Rifampicin
,2085859,Cmax,"Important parameters were taken: t 1/2 2.39 +/- 0.66, 3.84 +/- 1.91 h; Cmax: 14.56 +/- 6.45, 9.83 +/- 2.55 micrograms/ml; vd: 0.43 +/- 0.11, 0.67 +/- 0.15L/kg; CL: 0.14 +/- 0.03, 0.13 +/- 0.06 L.h-1/kg respectively.",[Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085859/),[μg] / [ml],14.56,203689,DB01045,Rifampicin
,2085859,Cmax,"Important parameters were taken: t 1/2 2.39 +/- 0.66, 3.84 +/- 1.91 h; Cmax: 14.56 +/- 6.45, 9.83 +/- 2.55 micrograms/ml; vd: 0.43 +/- 0.11, 0.67 +/- 0.15L/kg; CL: 0.14 +/- 0.03, 0.13 +/- 0.06 L.h-1/kg respectively.",[Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085859/),[μg] / [ml],9.83,203690,DB01045,Rifampicin
,2085859,vd,"Important parameters were taken: t 1/2 2.39 +/- 0.66, 3.84 +/- 1.91 h; Cmax: 14.56 +/- 6.45, 9.83 +/- 2.55 micrograms/ml; vd: 0.43 +/- 0.11, 0.67 +/- 0.15L/kg; CL: 0.14 +/- 0.03, 0.13 +/- 0.06 L.h-1/kg respectively.",[Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085859/),[l] / [kg],0.43,203691,DB01045,Rifampicin
,2085859,vd,"Important parameters were taken: t 1/2 2.39 +/- 0.66, 3.84 +/- 1.91 h; Cmax: 14.56 +/- 6.45, 9.83 +/- 2.55 micrograms/ml; vd: 0.43 +/- 0.11, 0.67 +/- 0.15L/kg; CL: 0.14 +/- 0.03, 0.13 +/- 0.06 L.h-1/kg respectively.",[Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085859/),[l] / [kg],0.67,203692,DB01045,Rifampicin
,2085859,CL,"Important parameters were taken: t 1/2 2.39 +/- 0.66, 3.84 +/- 1.91 h; Cmax: 14.56 +/- 6.45, 9.83 +/- 2.55 micrograms/ml; vd: 0.43 +/- 0.11, 0.67 +/- 0.15L/kg; CL: 0.14 +/- 0.03, 0.13 +/- 0.06 L.h-1/kg respectively.",[Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085859/),[l] / [h·kg],0.14,203693,DB01045,Rifampicin
,2085859,CL,"Important parameters were taken: t 1/2 2.39 +/- 0.66, 3.84 +/- 1.91 h; Cmax: 14.56 +/- 6.45, 9.83 +/- 2.55 micrograms/ml; vd: 0.43 +/- 0.11, 0.67 +/- 0.15L/kg; CL: 0.14 +/- 0.03, 0.13 +/- 0.06 L.h-1/kg respectively.",[Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085859/),[l] / [h·kg],0.13,203694,DB01045,Rifampicin
,25070100,50% inhibitory concentration [IC50],"In human hepatocytes, ketoconazole dose dependently inhibited the formation of N(+)-glucuronides (50% inhibitory concentration [IC50], 1.5 μM), while rifampin induced the mRNA level of UGT1A9 by 28% and the activity of UGT1A9 by 53%.",Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070100/),μM,1.5,203796,DB01045,Rifampicin
,25281400,AUC0-48,"The median (range) AUC0-48 of rifabutin was 6.91 (3.52-8.67) μg · h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19-0.46) μg/mL, the median (range) AUC0-48 of 25-O-desacetyl rifabutin was 5.73 (2.85-9.13) μg · h/mL and the median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08-0.32) μg/mL.",Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25281400/),[h·μg] / [ml],6.91,204209,DB01045,Rifampicin
,25281400,Cmax,"The median (range) AUC0-48 of rifabutin was 6.91 (3.52-8.67) μg · h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19-0.46) μg/mL, the median (range) AUC0-48 of 25-O-desacetyl rifabutin was 5.73 (2.85-9.13) μg · h/mL and the median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08-0.32) μg/mL.",Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25281400/),[μg] / [ml],0.39,204210,DB01045,Rifampicin
,25281400,AUC0-48,"The median (range) AUC0-48 of rifabutin was 6.91 (3.52-8.67) μg · h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19-0.46) μg/mL, the median (range) AUC0-48 of 25-O-desacetyl rifabutin was 5.73 (2.85-9.13) μg · h/mL and the median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08-0.32) μg/mL.",Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25281400/),[h·μg] / [ml],5.73,204211,DB01045,Rifampicin
,25281400,Cmax,"The median (range) AUC0-48 of rifabutin was 6.91 (3.52-8.67) μg · h/mL, the median (range) Cmax of rifabutin was 0.39 (0.19-0.46) μg/mL, the median (range) AUC0-48 of 25-O-desacetyl rifabutin was 5.73 (2.85-9.13) μg · h/mL and the median (range) Cmax of 25-O-desacetyl rifabutin was 0.17 (0.08-0.32) μg/mL.",Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25281400/),[μg] / [ml],0.17,204212,DB01045,Rifampicin
,9686884,recovery,Sample (1 ml plasma) preparation involved a simple solvent extraction step with a recovery of approximately 90% for both compounds.,Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9686884/),%,90,204458,DB01045,Rifampicin
,9686884,flow-rate,The flow-rate of the mobile phase was 16 microl/min and the eluate was monitored by UV detection.,Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9686884/),[μl] / [min],16,204459,DB01045,Rifampicin
,862650,elimination half-life,The average elimination half-life of hexobarbital had decreased from 624 to 262 min and that of tolbutamide from 292 to 160 min following rifampicin treatment.,Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/862650/),min,624 to 262,205510,DB01045,Rifampicin
,862650,elimination half-life,The average elimination half-life of hexobarbital had decreased from 624 to 262 min and that of tolbutamide from 292 to 160 min following rifampicin treatment.,Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/862650/),min,292 to 160,205511,DB01045,Rifampicin
,14576102,fever clearance time,"The median fever clearance time was 58.5 h, and the mean +/- standard deviation parasite clearance time was 73 +/- 24 h.",Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),h,58.5,205934,DB01045,Rifampicin
,14576102,parasite clearance time,"The median fever clearance time was 58.5 h, and the mean +/- standard deviation parasite clearance time was 73 +/- 24 h.",Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),h,73,205935,DB01045,Rifampicin
<,14576102,area under the concentration-time curve from 3 to 7 days,Patients for whom the area under the concentration-time curve from 3 to 7 days for quinine in plasma was <20 microg.,Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),μg,20,205936,DB01045,Rifampicin
,14576102,minimum parasiticidal concentration,Modeling of these data suggested an average minimum parasiticidal concentration of quinine in plasma of 3.4 microg/ml and an MIC of 0.7 microg/ml for uncomplicated falciparum malaria in Thailand.,Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),[μg] / [ml],3.4,205937,DB01045,Rifampicin
,14576102,MIC,Modeling of these data suggested an average minimum parasiticidal concentration of quinine in plasma of 3.4 microg/ml and an MIC of 0.7 microg/ml for uncomplicated falciparum malaria in Thailand.,Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576102/),[μg] / [ml],0.7,205938,DB01045,Rifampicin
,30239829,AUC0-24,The predicted AUC0-24 is reduced by 29% in patients who are fast acetylators of isoniazid and receiving efavirenz-based ART (6.73 versus 4.68 mg·h/L).,Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30239829/),[h·mg] / [l],6.73,206555,DB01045,Rifampicin
,30239829,AUC0-24,The predicted AUC0-24 is reduced by 29% in patients who are fast acetylators of isoniazid and receiving efavirenz-based ART (6.73 versus 4.68 mg·h/L).,Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30239829/),[h·mg] / [l],4.68,206556,DB01045,Rifampicin
,30239829,AUC0-24,"In slow acetylators, efavirenz-based ART had no effect on isoniazid exposure (AUC0-24 = 17.5 mg·h/L).",Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30239829/),[h·mg] / [l],17.5,206557,DB01045,Rifampicin
,23625188,t ½,Ketoconazole decreased mirabegron t ½ from 50.9 to 37.6 h suggesting that volume of distribution as well as first-pass effect decreased.,"Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23625188/),h,50.9,207683,DB01045,Rifampicin
,23625188,t ½,Ketoconazole decreased mirabegron t ½ from 50.9 to 37.6 h suggesting that volume of distribution as well as first-pass effect decreased.,"Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23625188/),h,37.6,207684,DB01045,Rifampicin
,11808861,clearance (CL),"Systemic antipyrine clearance (CL) increased from 31.8 ml/min/kg (controls) by 64% and 42% following repeated exposure to RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[ml] / [kg·min],31.8,207919,DB01045,Rifampicin
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.97,207920,DB01045,Rifampicin
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.58,207921,DB01045,Rifampicin
,11808861,F,"Estimate of F for antipyrine decreased from 0.97 in controls to 0.58 and 0.82 in animals treated with RFM and RBT, respectively.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),,0.82,207922,DB01045,Rifampicin
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],0.61,207923,DB01045,Rifampicin
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],1.36,207924,DB01045,Rifampicin
,11808861,P450,"The content of P450 (nmol/mg protein) in the liver increased from 0.61 (control) to 1.36 following RFM and 0.82 for RBT, while no significant changes were observed for the GI tract.",Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808861/),[nM] / [mg],0.82,207925,DB01045,Rifampicin
,31912537,maximum concentration [Cmax ],"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[μg] / [ml],7.4,207934,DB01045,Rifampicin
,31912537,maximum concentration [Cmax ],"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[μg] / [ml],8.3,207935,DB01045,Rifampicin
,31912537,maximum concentration [Cmax ],"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[μg] / [ml],3.6,207936,DB01045,Rifampicin
,31912537,maximum concentration [Cmax ],"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[μg] / [ml],3.5,207937,DB01045,Rifampicin
,31912537,maximum concentration [Cmax ],"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[μg] / [ml],50.1,207938,DB01045,Rifampicin
,31912537,maximum concentration [Cmax ],"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[μg] / [ml],46.8,207939,DB01045,Rifampicin
,31912537,area under the concentration-time curve from 0 to 8 hours,"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[h·mg] / [l],41.0,207940,DB01045,Rifampicin
,31912537,area under the concentration-time curve from 0 to 8 hours,"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[h·mg] / [l],43.8,207941,DB01045,Rifampicin
,31912537,area under the concentration-time curve from 0 to 8 hours,"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[h·mg] / [l],13.5,207942,DB01045,Rifampicin
,31912537,area under the concentration-time curve from 0 to 8 hours,"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[h·mg] / [l],12.4,207943,DB01045,Rifampicin
,31912537,area under the concentration-time curve from 0 to 8 hours,"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[h·mg] / [l],316.5,207944,DB01045,Rifampicin
,31912537,area under the concentration-time curve from 0 to 8 hours,"Rifampicin, isoniazid and pyrazinamide exposure was similar between hospitalized and outpatients (maximum concentration [Cmax ]: 7.4 vs 8.3 μg mL-1 , P = .223; 3.6 vs 3.5 μg mL-1 , P = .569; 50.1 vs 46.8 μg mL-1 , P = .081; area under the concentration-time curve from 0 to 8 hours: 41.0 vs 43.8 mg h L-1 , P = 0.290; 13.5 vs 12.4 mg h L-1 , P = .630; 316.5 vs 292.2 mg h L-1 , P = .164, respectively) and not lower in inpatients who died.",Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912537/),[h·mg] / [l],292.2,207945,DB01045,Rifampicin
>,31049868,maximum (peak) concentration (Cmax),"Rifampicin maximum (peak) concentration (Cmax) > 8.2 μg/mL is an independent predictor of sterilizing activity and therapeutic drug monitoring at 2, 4, and 6 h post-dose may aid in optimizing dosing to achieve the recommended rifampicin concentration of ≥ 8 µg/mL.",Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31049868/),[μg] / [ml],8.2,208026,DB01045,Rifampicin
≥,31049868,Cmax,"A higher rifampicin Cmax is required for severe forms TB such as TB meningitis, with Cmax ≥ 22 μg/mL and area under the concentration-time curve (AUC) from time zero to 6 h (AUC6) ≥ 70 μg·h/mL associated with reduced mortality.",Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31049868/),[μg] / [ml],22,208027,DB01045,Rifampicin
≥,31049868,area under the concentration-time curve (AUC) from time zero to 6 h (AUC6),"A higher rifampicin Cmax is required for severe forms TB such as TB meningitis, with Cmax ≥ 22 μg/mL and area under the concentration-time curve (AUC) from time zero to 6 h (AUC6) ≥ 70 μg·h/mL associated with reduced mortality.",Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31049868/),[h·μg] / [ml],70,208028,DB01045,Rifampicin
<,16249706,Ctrough,"In 10 patients (36%), saquinavir Ctrough was <0.05 microg/mL during tuberculosis therapy and 5 of them had virologic failure.","Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16249706/),[μg] / [ml],0.05,208207,DB01045,Rifampicin
,33229425,maximum concentrations (C max),"Median maximum concentrations (C max) in the rifampin and rifabutin arms were 2.14 and 3.35 mg/liter, while median AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively.",Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33229425/),[mg] / [l],2.14,210110,DB01045,Rifampicin
,33229425,maximum concentrations (C max),"Median maximum concentrations (C max) in the rifampin and rifabutin arms were 2.14 and 3.35 mg/liter, while median AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively.",Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33229425/),[mg] / [l],3.35,210111,DB01045,Rifampicin
,33229425,AUC0-24,"Median maximum concentrations (C max) in the rifampin and rifabutin arms were 2.14 and 3.35 mg/liter, while median AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively.",Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33229425/),[h·mg] / [l],30.1,210112,DB01045,Rifampicin
,33229425,AUC0-24,"Median maximum concentrations (C max) in the rifampin and rifabutin arms were 2.14 and 3.35 mg/liter, while median AUC0-24 values were 30.1 and 59.5 mg·h/liter, respectively.",Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33229425/),[h·mg] / [l],59.5,210113,DB01045,Rifampicin
,31900032,Passive diffusion clearance,Passive diffusion clearance in liver was experimentally determined as 0.013 mL/min/106 human hepatocytes.,Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900032/),[ml] / [106·min],0.013,210496,DB01045,Rifampicin
,31900032,intrinsic clearance,"In vitro intrinsic clearance values for pemafibrate by cytochromes P450 2C8, 2C9, and 3A4 were 54, 26, and 16 μL/min/mg protein, respectively.",Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900032/),[μl] / [mg·min],54,210497,DB01045,Rifampicin
,31900032,intrinsic clearance,"In vitro intrinsic clearance values for pemafibrate by cytochromes P450 2C8, 2C9, and 3A4 were 54, 26, and 16 μL/min/mg protein, respectively.",Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900032/),[μl] / [mg·min],26,210498,DB01045,Rifampicin
,31900032,intrinsic clearance,"In vitro intrinsic clearance values for pemafibrate by cytochromes P450 2C8, 2C9, and 3A4 were 54, 26, and 16 μL/min/mg protein, respectively.",Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900032/),[μl] / [mg·min],16,210499,DB01045,Rifampicin
,9226591,relative bioavailability,The mean relative bioavailability of nifedipine following pre-treatment with rifampicin 1200 mg was 35.8% (P < 0.0001).,The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226591/),%,35.8,210635,DB01045,Rifampicin
,9226591,elimination half life (t1/2),"The mean elimination half life (t1/2) of nifedipine decreased from 2.62 to 1.03 h (P < 0.0001); and, the total clearance (ClT) increased from 17.33 to 50.17 ml min-1 kg-1 (P < 0.0001).",The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226591/),h,2,210636,DB01045,Rifampicin
,9226591,total clearance (ClT),"The mean elimination half life (t1/2) of nifedipine decreased from 2.62 to 1.03 h (P < 0.0001); and, the total clearance (ClT) increased from 17.33 to 50.17 ml min-1 kg-1 (P < 0.0001).",The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9226591/),[ml] / [kg·min],17.33 to 50.17,210637,DB01045,Rifampicin
,29723418,apparent clearance,Doravirine apparent clearance increased from 5.9 L/h without rifabutin to 12.2 L/h when coadministered.,Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29723418/),[l] / [h],5.9,211704,DB01045,Rifampicin
,29723418,apparent clearance,Doravirine apparent clearance increased from 5.9 L/h without rifabutin to 12.2 L/h when coadministered.,Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29723418/),[l] / [h],12.2,211705,DB01045,Rifampicin
,27138546,t1/2,"The model predicted that the equilibration t1/2 and 4βHC t1/2 were 72.8 and 142 hours, respectively.",An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138546/),h,72.8,212342,DB01045,Rifampicin
,27138546,t1/2,"The model predicted that the equilibration t1/2 and 4βHC t1/2 were 72.8 and 142 hours, respectively.",An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138546/),h,142,212343,DB01045,Rifampicin
,27138546,EM50,"EM50 and Emax of rifampicin induction were 32.6 μg and 8.39-fold, respectively.",An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138546/),μg,32,212344,DB01045,Rifampicin
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],336,212367,DB01045,Rifampicin
,9433391,total area under the plasma zolpidem concentration-time curve,The total area under the plasma zolpidem concentration-time curve after administration of rifampin was 27% of that after administration of placebo (336 +/- 67 versus 1202 +/- 157 ng.hr/ml [mean value +/- SEM; p < 0.01]).,Rifampin reduces plasma concentrations and effects of zolpidem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[h·ng] / [ml],1202,212368,DB01045,Rifampicin
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],293,212369,DB01045,Rifampicin
,9433391,peak plasma concentration,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),[ng] / [ml],117,212370,DB01045,Rifampicin
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,2.5,212371,DB01045,Rifampicin
,9433391,elimination half-life,"Rifampin decreased the peak plasma concentration of zolpidem by 58%, that is, from 293 +/- 61 to 117 +/- 25 ng/ml (p < 0.01) and the elimination half-life from 2.5 +/- 0.2 to 1.6 +/- 0.1 hours (p < 0.01).",Rifampin reduces plasma concentrations and effects of zolpidem. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9433391/),h,1.6,212372,DB01045,Rifampicin
,10722501,peak concentrations,"The peak concentrations in plasma, ELF, and AC, 26.2, 3. 7, and 5.3 microg/ml, respectively, occurred at 5, 5, and 7 h after drug administration, respectively.",Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722501/),[μg] / [ml],26.2,212678,DB01045,Rifampicin
,10722501,peak concentrations,"The peak concentrations in plasma, ELF, and AC, 26.2, 3. 7, and 5.3 microg/ml, respectively, occurred at 5, 5, and 7 h after drug administration, respectively.",Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722501/),[μg] / [ml],3. 7,212679,DB01045,Rifampicin
,10722501,peak concentrations,"The peak concentrations in plasma, ELF, and AC, 26.2, 3. 7, and 5.3 microg/ml, respectively, occurred at 5, 5, and 7 h after drug administration, respectively.",Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722501/),[μg] / [ml],5.3,212680,DB01045,Rifampicin
,10722501,half-lives,"The half-lives and areas under the curve for plasma, ELF, and AC were 18.3 h and 520 microg.",Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722501/),h,18.3,212681,DB01045,Rifampicin
,10722501,areas under the curve,"The half-lives and areas under the curve for plasma, ELF, and AC were 18.3 h and 520 microg.",Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10722501/),μg,520,212682,DB01045,Rifampicin
below,16639340,Cmin,The Cmin of nevirapine fell below the therapeutic range of 3 microg/ml in 8 of 13 patients.,Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16639340/),[μg] / [ml],3,213602,DB01045,Rifampicin
,20922637,heart rate,The heart rate reflected a value of 98 beats per minute.,[Urinary bladder tuberculosis and Bacillus Calmette-Guérin instillation: reduced efficacy of bisoprolol in hypertension]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20922637/),[beats] / [min],98,214475,DB01045,Rifampicin
,7189454,area under the plasma EE versus time curve,The area under the plasma EE versus time curve increased significantly on stopping rifampicin from 1014 +/- 317 pg/ml x h (mean +/- SE) to 1747 +/- 218 pg/ml x h (p less than 0.01).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),[pg] / [h·ml],1014,214896,DB01045,Rifampicin
,7189454,area under the plasma EE versus time curve,The area under the plasma EE versus time curve increased significantly on stopping rifampicin from 1014 +/- 317 pg/ml x h (mean +/- SE) to 1747 +/- 218 pg/ml x h (p less than 0.01).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),[pg] / [h·ml],1747,214897,DB01045,Rifampicin
,7189454,terminal plasma half-life,The terminal plasma half-life increased from 2.9 +/- 0.8 h to 6.3 +/- 1.4 h (p less than 0.005).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),h,2.9,214898,DB01045,Rifampicin
,7189454,terminal plasma half-life,The terminal plasma half-life increased from 2.9 +/- 0.8 h to 6.3 +/- 1.4 h (p less than 0.005).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),h,6.3,214899,DB01045,Rifampicin
,7189454,capacity,The sex hormone binding globulin (S.H.B.G.) capacity was also reduced from 213.4 +/- 11.5 nmoles to 129.0 +/- 7.7 nmoles/1 after stopping rifampicin.,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),nmoles,213.4,214900,DB01045,Rifampicin
,7189454,capacity,The sex hormone binding globulin (S.H.B.G.) capacity was also reduced from 213.4 +/- 11.5 nmoles to 129.0 +/- 7.7 nmoles/1 after stopping rifampicin.,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),nmoles,129.0,214901,DB01045,Rifampicin
,12968988,half-life (t(1/2)),"Rifampicin decreased the mean AUC(0,7 h) of nateglinide by 24% (range 5-53%; P = 0.0009) and shortened its half-life (t(1/2)) from 1.6 to 1.3 h (P = 0.001).",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968988/),h,1.6,215471,DB01045,Rifampicin
,12968988,half-life (t(1/2)),"Rifampicin decreased the mean AUC(0,7 h) of nateglinide by 24% (range 5-53%; P = 0.0009) and shortened its half-life (t(1/2)) from 1.6 to 1.3 h (P = 0.001).",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968988/),h,1.3,215472,DB01045,Rifampicin
,12968988,t(1/2),"The AUC(0,7 h) of the M7 metabolite of nateglinide was decreased by 19% (P = 0.002) and its t(1/2) was shortened from 2.1 to 1.6 h by rifampicin (P = 0.008).",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968988/),h,2.1,215473,DB01045,Rifampicin
,12968988,t(1/2),"The AUC(0,7 h) of the M7 metabolite of nateglinide was decreased by 19% (P = 0.002) and its t(1/2) was shortened from 2.1 to 1.6 h by rifampicin (P = 0.008).",Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968988/),h,1.6,215474,DB01045,Rifampicin
,22638872,passive diffusion,"SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin.",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),[min·μl] / [10(6)cells],0.5,215573,DB01045,Rifampicin
,22638872,efflux intrinsic clearance,"SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin.",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),[min·μl] / [10(6)cells],1.2,215574,DB01045,Rifampicin
,22638872,AUC ratio,"However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10).",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),,4.4,215575,DB01045,Rifampicin
,22638872,Vs,"However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10).",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),,10,215576,DB01045,Rifampicin
,3731135,half-life,"The serum haloperidol clearance rate was accelerated in patients taking rifampicin, with a shortened half-life (4.9 h) compared with the control group (9.4 h).",Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731135/),h,4.9,215599,DB01045,Rifampicin
,3731135,half-life,"The serum haloperidol clearance rate was accelerated in patients taking rifampicin, with a shortened half-life (4.9 h) compared with the control group (9.4 h).",Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731135/),h,9.4,215600,DB01045,Rifampicin
,3309808,T1/2,"Moreover, as regard doxycycline half-life, a difference was observed between these two groups before rifampicin treatment: in one case T1/2 was of 17.9 + 6.6 hours, while in the other it was of 9.2 + 2.3 hours.",[Effects of rifampicin on the pharmacokinetics of doxycycline]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3309808/),h,17.9,215856,DB01045,Rifampicin
,3309808,T1/2,"Moreover, as regard doxycycline half-life, a difference was observed between these two groups before rifampicin treatment: in one case T1/2 was of 17.9 + 6.6 hours, while in the other it was of 9.2 + 2.3 hours.",[Effects of rifampicin on the pharmacokinetics of doxycycline]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3309808/),h,9.2,215857,DB01045,Rifampicin
,30593249,Tmax,"The pharmacokinetic parameters displayed that as compared with rifampicin alone, AUC0-t and Cmax were decreased significantly, MRT0-t slowed down significantly, Tmax doubled to 7.0 h and the bioavailability was only 31.65% in rifampicin + tannins in Galla Chinensis group.",[Effects of tannins in Galla Chinensis on pharmacokinetics of rifampicin in vivo and in vitro]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30593249/),h,7.0,215925,DB01045,Rifampicin
,30593249,bioavailability,"The pharmacokinetic parameters displayed that as compared with rifampicin alone, AUC0-t and Cmax were decreased significantly, MRT0-t slowed down significantly, Tmax doubled to 7.0 h and the bioavailability was only 31.65% in rifampicin + tannins in Galla Chinensis group.",[Effects of tannins in Galla Chinensis on pharmacokinetics of rifampicin in vivo and in vitro]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30593249/),%,31.65,215926,DB01045,Rifampicin
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,6.5,216135,DB01045,Rifampicin
,25452230,bioavailability,"After intravenous and oral administration of ibuprofen and fexofenadine (BCS class II and III), the plasma concentration and pharmacokinetic parameters were evaluated by our method and a terminal blood sampling method, with the result that both methods gave comparable results (ibuprofen: 63.8 ± 4.0% and 64.4%, fexofenadine: 6.5 ± 0.7% and 7.9%, respectively, in bioavailability).",Using improved serial blood sampling method of mice to study pharmacokinetics and drug-drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25452230/),%,7.9,216136,DB01045,Rifampicin
,8549036,area under the plasma midazolam concentration-time curve,"Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]).",Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),[min·μg] / [ml],10.2,216786,DB01045,Rifampicin
,8549036,area under the plasma midazolam concentration-time curve,"Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]).",Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),[min·μg] / [ml],0.42,216787,DB01045,Rifampicin
,8549036,maximum concentration,"Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]).",Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),[ng] / [ml],55,216788,DB01045,Rifampicin
,8549036,maximum concentration,"Rifampin pretreatment decreased the area under the plasma midazolam concentration-time curve by 96% (i.e., from 10.2 +/- 0.8 to 0.42 +/- 0.05 micrograms.min/ml [mean +/- SEM; p < 0.001]) and the maximum concentration by 94% (i.e., from 55 +/- 4 to 3.5 +/- 0.7 ng/ml [p < 0.001]).",Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),[ng] / [ml],3.5,216789,DB01045,Rifampicin
,8549036,elimination half-life,The elimination half-life of midazolam was decreased from 3.1 +/- 0.2 to 1.3 +/- 0.2 hours by rifampin (p < 0.001).,Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),h,3.1,216790,DB01045,Rifampicin
,8549036,elimination half-life,The elimination half-life of midazolam was decreased from 3.1 +/- 0.2 to 1.3 +/- 0.2 hours by rifampin (p < 0.001).,Rifampin drastically reduces plasma concentrations and effects of oral midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549036/),h,1.3,216791,DB01045,Rifampicin
,25487804,Cmax,"Children less than 5 years old had a lower median Cmax and lower exposure (area under the time-concentration curve from 0 to 8 h [AUC0-8]) of INH (Cmax, 2.5 versus 5.1 μg/ml, respectively [P=0.016]; AUC0-8, 11.1 versus 22.0 μg/ml·h, respectively [P=0.047[) and PZA (Cmax, 34.1 versus 42.3 μg/ml, respectively [P=0.055]; AUC0-8, 177.9 versus 221.7 μg/ml·h, respectively [P=0.05]) than those more than 5 years old.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [ml],2.5,216840,DB01045,Rifampicin
,25487804,Cmax,"Children less than 5 years old had a lower median Cmax and lower exposure (area under the time-concentration curve from 0 to 8 h [AUC0-8]) of INH (Cmax, 2.5 versus 5.1 μg/ml, respectively [P=0.016]; AUC0-8, 11.1 versus 22.0 μg/ml·h, respectively [P=0.047[) and PZA (Cmax, 34.1 versus 42.3 μg/ml, respectively [P=0.055]; AUC0-8, 177.9 versus 221.7 μg/ml·h, respectively [P=0.05]) than those more than 5 years old.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [ml],5.1,216841,DB01045,Rifampicin
,25487804,AUC0-8,"Children less than 5 years old had a lower median Cmax and lower exposure (area under the time-concentration curve from 0 to 8 h [AUC0-8]) of INH (Cmax, 2.5 versus 5.1 μg/ml, respectively [P=0.016]; AUC0-8, 11.1 versus 22.0 μg/ml·h, respectively [P=0.047[) and PZA (Cmax, 34.1 versus 42.3 μg/ml, respectively [P=0.055]; AUC0-8, 177.9 versus 221.7 μg/ml·h, respectively [P=0.05]) than those more than 5 years old.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [h·ml],11.1,216842,DB01045,Rifampicin
,25487804,AUC0-8,"Children less than 5 years old had a lower median Cmax and lower exposure (area under the time-concentration curve from 0 to 8 h [AUC0-8]) of INH (Cmax, 2.5 versus 5.1 μg/ml, respectively [P=0.016]; AUC0-8, 11.1 versus 22.0 μg/ml·h, respectively [P=0.047[) and PZA (Cmax, 34.1 versus 42.3 μg/ml, respectively [P=0.055]; AUC0-8, 177.9 versus 221.7 μg/ml·h, respectively [P=0.05]) than those more than 5 years old.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [h·ml],22.0,216843,DB01045,Rifampicin
,25487804,Cmax,"Children less than 5 years old had a lower median Cmax and lower exposure (area under the time-concentration curve from 0 to 8 h [AUC0-8]) of INH (Cmax, 2.5 versus 5.1 μg/ml, respectively [P=0.016]; AUC0-8, 11.1 versus 22.0 μg/ml·h, respectively [P=0.047[) and PZA (Cmax, 34.1 versus 42.3 μg/ml, respectively [P=0.055]; AUC0-8, 177.9 versus 221.7 μg/ml·h, respectively [P=0.05]) than those more than 5 years old.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [ml],34.1,216844,DB01045,Rifampicin
,25487804,Cmax,"Children less than 5 years old had a lower median Cmax and lower exposure (area under the time-concentration curve from 0 to 8 h [AUC0-8]) of INH (Cmax, 2.5 versus 5.1 μg/ml, respectively [P=0.016]; AUC0-8, 11.1 versus 22.0 μg/ml·h, respectively [P=0.047[) and PZA (Cmax, 34.1 versus 42.3 μg/ml, respectively [P=0.055]; AUC0-8, 177.9 versus 221.7 μg/ml·h, respectively [P=0.05]) than those more than 5 years old.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [ml],42.3,216845,DB01045,Rifampicin
,25487804,AUC0-8,"Children less than 5 years old had a lower median Cmax and lower exposure (area under the time-concentration curve from 0 to 8 h [AUC0-8]) of INH (Cmax, 2.5 versus 5.1 μg/ml, respectively [P=0.016]; AUC0-8, 11.1 versus 22.0 μg/ml·h, respectively [P=0.047[) and PZA (Cmax, 34.1 versus 42.3 μg/ml, respectively [P=0.055]; AUC0-8, 177.9 versus 221.7 μg/ml·h, respectively [P=0.05]) than those more than 5 years old.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [h·ml],177.9,216846,DB01045,Rifampicin
,25487804,AUC0-8,"Children less than 5 years old had a lower median Cmax and lower exposure (area under the time-concentration curve from 0 to 8 h [AUC0-8]) of INH (Cmax, 2.5 versus 5.1 μg/ml, respectively [P=0.016]; AUC0-8, 11.1 versus 22.0 μg/ml·h, respectively [P=0.047[) and PZA (Cmax, 34.1 versus 42.3 μg/ml, respectively [P=0.055]; AUC0-8, 177.9 versus 221.7 μg/ml·h, respectively [P=0.05]) than those more than 5 years old.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [h·ml],221.7,216847,DB01045,Rifampicin
,25487804,Cmax,"In children with unfavorable versus favorable outcomes, the median Cmax of RMP (1.0 versus 2.8 μg/ml, respectively; P=0.002) and PZA (31.9 versus 44.4 μg/ml, respectively; P=0.045) were significantly lower.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [ml],1.0,216848,DB01045,Rifampicin
,25487804,Cmax,"In children with unfavorable versus favorable outcomes, the median Cmax of RMP (1.0 versus 2.8 μg/ml, respectively; P=0.002) and PZA (31.9 versus 44.4 μg/ml, respectively; P=0.045) were significantly lower.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [ml],2.8,216849,DB01045,Rifampicin
,25487804,Cmax,"In children with unfavorable versus favorable outcomes, the median Cmax of RMP (1.0 versus 2.8 μg/ml, respectively; P=0.002) and PZA (31.9 versus 44.4 μg/ml, respectively; P=0.045) were significantly lower.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [ml],31.9,216850,DB01045,Rifampicin
,25487804,Cmax,"In children with unfavorable versus favorable outcomes, the median Cmax of RMP (1.0 versus 2.8 μg/ml, respectively; P=0.002) and PZA (31.9 versus 44.4 μg/ml, respectively; P=0.045) were significantly lower.",Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25487804/),[μg] / [ml],44.4,216851,DB01045,Rifampicin
,16815319,apparent clearance,"Rifampin treatment increased the apparent clearance of bupropion in Chinese subjects and white subjects combined (n = 16) from 2.6 L x h(-1) x kg(-1) (95% confidence interval [CI], 2.3-3.0 L x h(-1) x kg(-1)) after bupropion alone to 7.9 L x h(-1) x kg(-1) (95% CI, 6.8-10.1 L x h(-1) x kg(-1)) during rifampin treatment.",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[l] / [h·kg],2.6,216852,DB01045,Rifampicin
,16815319,apparent clearance,"Rifampin treatment increased the apparent clearance of bupropion in Chinese subjects and white subjects combined (n = 16) from 2.6 L x h(-1) x kg(-1) (95% confidence interval [CI], 2.3-3.0 L x h(-1) x kg(-1)) after bupropion alone to 7.9 L x h(-1) x kg(-1) (95% CI, 6.8-10.1 L x h(-1) x kg(-1)) during rifampin treatment.",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[l] / [h·kg],7.9,216853,DB01045,Rifampicin
,16815319,half-life,"Rifampin treatment decreased the half-life of bupropion from 15.9 hours (95% CI, 13.5-20.4 hours) to 8.2 hours (95% CI, 6.7-12.4 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,15.9,216854,DB01045,Rifampicin
,16815319,half-life,"Rifampin treatment decreased the half-life of bupropion from 15.9 hours (95% CI, 13.5-20.4 hours) to 8.2 hours (95% CI, 6.7-12.4 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,8.2,216855,DB01045,Rifampicin
,16815319,maximum concentration,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[ng] / [ml],395,216856,DB01045,Rifampicin
,16815319,maximum concentration,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[ng] / [ml],548,216857,DB01045,Rifampicin
,16815319,area under the concentration-time curve,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[h·μg] / [ml],14.7,216858,DB01045,Rifampicin
,16815319,area under the concentration-time curve,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),[h·μg] / [ml],8.4,216859,DB01045,Rifampicin
,16815319,elimination half-life,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,21.9,216860,DB01045,Rifampicin
,16815319,elimination half-life,"Rifampin treatment increased the hydroxybupropion maximum concentration from 395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL), decreased the area under the concentration-time curve extrapolated to infinity of hydroxybupropion from 14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL), and reduced the elimination half-life of hydroxybupropion from 21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours).",Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815319/),h,10.7,216861,DB01045,Rifampicin
,12648026,bioavailability,"Tamoxifen and toremifene have a bioavailability of approximately 100%, whereas that of raloxifene is only 2%.",Pharmacokinetics of selective estrogen receptor modulators. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648026/),%,100,217207,DB01045,Rifampicin
,12648026,bioavailability,"Tamoxifen and toremifene have a bioavailability of approximately 100%, whereas that of raloxifene is only 2%.",Pharmacokinetics of selective estrogen receptor modulators. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648026/),%,2,217208,DB01045,Rifampicin
,12648026,terminal elimination half-lives,The terminal elimination half-lives of these drugs range from 27.7 hours to 7 days.,Pharmacokinetics of selective estrogen receptor modulators. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648026/),h,27.7,217209,DB01045,Rifampicin
,12648026,terminal elimination half-lives,The terminal elimination half-lives of these drugs range from 27.7 hours to 7 days.,Pharmacokinetics of selective estrogen receptor modulators. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12648026/),d,7,217210,DB01045,Rifampicin
,973984,peak serum concentrations,"Mean peak serum concentrations of rifampicin (8.2-11.7 mug/ml) occurring 2 to 4 h after doses of 600 mg, and isoniazid (3.6-4.8 mug/ml) occurring 0.5 to 1 h after doses of 300 mg, were similar to those reported in the literature.",Serum concentrations and bioavailability of rifampicin and isoniazid in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/973984/),[μg] / [ml],8.2-11.7,217307,DB01045,Rifampicin
,973984,peak serum concentrations,"Mean peak serum concentrations of rifampicin (8.2-11.7 mug/ml) occurring 2 to 4 h after doses of 600 mg, and isoniazid (3.6-4.8 mug/ml) occurring 0.5 to 1 h after doses of 300 mg, were similar to those reported in the literature.",Serum concentrations and bioavailability of rifampicin and isoniazid in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/973984/),[μg] / [ml],3.6-4.8,217308,DB01045,Rifampicin
,30224533,area under the concentration-time curve from 0 to 24 h [AUC0-24],"A double and triple dose of oral rifampin led to 3- and 5-fold higher geometric mean total exposures in plasma in the critical early days (2 ± 1) of treatment (area under the concentration-time curve from 0 to 24 h [AUC0-24], 53.5 mg · h/liter versus 170.6 mg · h/liter and 293.5 mg · h/liter, respectively; P < 0.001), with proportional increases in cerebrospinal fluid (CSF) concentrations and without an increase in the incidence of grade 3 or 4 adverse events.","Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224533/),[h·mg] / [l],53.5,217676,DB01045,Rifampicin
,30224533,area under the concentration-time curve from 0 to 24 h [AUC0-24],"A double and triple dose of oral rifampin led to 3- and 5-fold higher geometric mean total exposures in plasma in the critical early days (2 ± 1) of treatment (area under the concentration-time curve from 0 to 24 h [AUC0-24], 53.5 mg · h/liter versus 170.6 mg · h/liter and 293.5 mg · h/liter, respectively; P < 0.001), with proportional increases in cerebrospinal fluid (CSF) concentrations and without an increase in the incidence of grade 3 or 4 adverse events.","Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224533/),[h·mg] / [l],170.6,217677,DB01045,Rifampicin
,30224533,area under the concentration-time curve from 0 to 24 h [AUC0-24],"A double and triple dose of oral rifampin led to 3- and 5-fold higher geometric mean total exposures in plasma in the critical early days (2 ± 1) of treatment (area under the concentration-time curve from 0 to 24 h [AUC0-24], 53.5 mg · h/liter versus 170.6 mg · h/liter and 293.5 mg · h/liter, respectively; P < 0.001), with proportional increases in cerebrospinal fluid (CSF) concentrations and without an increase in the incidence of grade 3 or 4 adverse events.","Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30224533/),[h·mg] / [l],293.5,217678,DB01045,Rifampicin
,3994110,overall elimination rate constants,"The overall elimination rate constants per minute were similar for the 10 mg/kg dose (0.0021 +/- 0.0004, IV; 0.0017 +/- 0.0002, IM; and 0.0023 +/- 0.0006, orally).","Rifampin in the horse: comparison of intravenous, intramuscular, and oral administrations. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994110/),,0.0021,218348,DB01045,Rifampicin
,3994110,overall elimination rate constants,"The overall elimination rate constants per minute were similar for the 10 mg/kg dose (0.0021 +/- 0.0004, IV; 0.0017 +/- 0.0002, IM; and 0.0023 +/- 0.0006, orally).","Rifampin in the horse: comparison of intravenous, intramuscular, and oral administrations. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994110/),,0.0017,218349,DB01045,Rifampicin
,3994110,overall elimination rate constants,"The overall elimination rate constants per minute were similar for the 10 mg/kg dose (0.0021 +/- 0.0004, IV; 0.0017 +/- 0.0002, IM; and 0.0023 +/- 0.0006, orally).","Rifampin in the horse: comparison of intravenous, intramuscular, and oral administrations. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994110/),,0.0023,218350,DB01045,Rifampicin
,3994110,apparent bioavailability,"The apparent bioavailability was moderate to low for IM and oral administrations (59.8% +/- 3.2% and 39.5% +/- 5.0%, respectively).","Rifampin in the horse: comparison of intravenous, intramuscular, and oral administrations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994110/),%,59.8,218351,DB01045,Rifampicin
,3994110,apparent bioavailability,"The apparent bioavailability was moderate to low for IM and oral administrations (59.8% +/- 3.2% and 39.5% +/- 5.0%, respectively).","Rifampin in the horse: comparison of intravenous, intramuscular, and oral administrations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994110/),%,39.5,218352,DB01045,Rifampicin
,3994110,absorption half-life,The rate of absorption was most rapid for oral administration with an absorption half-life of 249.7 +/- 71.6 minutes as compared with 403.5 +/- 89.7 minutes for IM administration.,"Rifampin in the horse: comparison of intravenous, intramuscular, and oral administrations. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994110/),min,249.7,218353,DB01045,Rifampicin
,3994110,absorption half-life,The rate of absorption was most rapid for oral administration with an absorption half-life of 249.7 +/- 71.6 minutes as compared with 403.5 +/- 89.7 minutes for IM administration.,"Rifampin in the horse: comparison of intravenous, intramuscular, and oral administrations. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994110/),min,403.5,218354,DB01045,Rifampicin
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.,218802,DB01045,Rifampicin
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.19,218803,DB01045,Rifampicin
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0.06,218804,DB01045,Rifampicin
,31145690,fm,"The fractions metabolized in the liver via oxidation by CYP enzymes (fm,CYP3A4 = 0.75, fm,CYP2C9 = 0.19, and fm,CYPothers = 0.06) for an initial ruxolitinib model based on in vitro data were optimized (0.43, 0.56, and 0.01, respectively) using the observed exposure changes of ruxolitinib (10 mg) with co-administered ketoconazole (200 mg).","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,0,218805,DB01045,Rifampicin
,31145690,AUC ratio,"With the optimized fm values, the predicted AUC ratio was 1.82.","Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31145690/),,1.82,218806,DB01045,Rifampicin
,3239839,half-life (t1/2[beta]),"A rapid distribution phase was followed by a slower elimination phase, with a half-life (t1/2[beta]) of 7.27 +/- 1.11 hours.","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),h,7.27,220520,DB01045,Rifampicin
,3239839,body clearance,The mean body clearance was 1.49 +/- 0.41 ml/min.,"Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),[ml] / [min],1.49,220521,DB01045,Rifampicin
,3239839,volume of distribution,"kg, and the mean volume of distribution was 932 +/- 292 ml/kg, indicating that rifampin was widely distributed in the body.","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),[ml] / [kg],932,220522,DB01045,Rifampicin
,3239839,lag period,"After intragastric administration of rifampin in aqueous suspension, a brief lag period (0.31 +/- 0.09 hour) was followed by rapid, but incomplete, absorption (t1/2[a] = 0.51 +/- 0.32 hour) and slow elimination (t1/2[d] = 11.50 +/- 1.55 hours).","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),h,0.31,220523,DB01045,Rifampicin
,3239839,t1/2[a],"After intragastric administration of rifampin in aqueous suspension, a brief lag period (0.31 +/- 0.09 hour) was followed by rapid, but incomplete, absorption (t1/2[a] = 0.51 +/- 0.32 hour) and slow elimination (t1/2[d] = 11.50 +/- 1.55 hours).","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),h,0.51,220524,DB01045,Rifampicin
,3239839,t1/2[d],"After intragastric administration of rifampin in aqueous suspension, a brief lag period (0.31 +/- 0.09 hour) was followed by rapid, but incomplete, absorption (t1/2[a] = 0.51 +/- 0.32 hour) and slow elimination (t1/2[d] = 11.50 +/- 1.55 hours).","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),h,11.50,220525,DB01045,Rifampicin
,3239839,bioavailability (fractional absorption),"The mean bioavailability (fractional absorption) of the administered dose during the first 24 hours was 53.94 +/- 18.90%, and we estimated that 70.0 +/- 23.6% of the drug would eventually be absorbed.","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),%,53.94,220526,DB01045,Rifampicin
,3239839,bioavailability (fractional absorption),"The mean bioavailability (fractional absorption) of the administered dose during the first 24 hours was 53.94 +/- 18.90%, and we estimated that 70.0 +/- 23.6% of the drug would eventually be absorbed.","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),%,70.0,220527,DB01045,Rifampicin
,3239839,peak plasma rifampin concentration,The mean peak plasma rifampin concentration was 13.25 +/- 2.70 micrograms/ml at 2.5 +/- 1.6 hours after dosing.,"Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),,13.25,220528,DB01045,Rifampicin
,3239839,concentrations,"Mean plasma rifampin concentrations at 12 and 24 hours after dosing were 6.86 +/- 1.69 micrograms/ml and 3.83 +/- 0.87 micrograms/ml, respectively.","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),[μg] / [ml],6.86,220529,DB01045,Rifampicin
,3239839,concentrations,"Mean plasma rifampin concentrations at 12 and 24 hours after dosing were 6.86 +/- 1.69 micrograms/ml and 3.83 +/- 0.87 micrograms/ml, respectively.","Pharmacokinetics, bioavailability, and in vitro antibacterial activity of rifampin in the horse. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239839/),[μg] / [ml],3.83,220530,DB01045,Rifampicin
,34332109,culture conversion rates,"Current treatment regimens of azithromycin, ethambutol and rifampicin have culture conversion rates of around 65%.",Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34332109/),%,65,221897,DB01045,Rifampicin
,30817698,apparent clearance (CL/F),"For a typical 70-kg PLWH, the apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.748 L/h and 14.6 L, respectively.",Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817698/),[l] / [h],0.748,223164,DB01045,Rifampicin
,30817698,apparent volume of distribution (V/F),"For a typical 70-kg PLWH, the apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.748 L/h and 14.6 L, respectively.",Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30817698/),l,14.6,223165,DB01045,Rifampicin
above,33070176,AUC,Isoniazid AUC above 21.78 mg·h/L or rifampicin AUC above 82.01 mg·h/L were predictive of DILI or AKI during TB treatment.,Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33070176/),[h·mg] / [l],21.78,223804,DB01045,Rifampicin
above,33070176,AUC,Isoniazid AUC above 21.78 mg·h/L or rifampicin AUC above 82.01 mg·h/L were predictive of DILI or AKI during TB treatment.,Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33070176/),[h·mg] / [l],82.01,223805,DB01045,Rifampicin
,26928044,peak serum rifampin level (C(max)),Assaying these concentrations by high-pressure liquid chromatography demonstrated a peak serum rifampin level (C(max)) of 18 μg/ml and total rifampin exposure (area under the curve from 0-6 hours [AUC(0-6)]) of 50.1 μg/ml.,Adequacy of Rifampin Absorption after Jejunostomy Tube Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26928044/),[μg] / [ml],18,224321,DB01045,Rifampicin
,26928044,area under the curve from 0-6 hours [AUC(0-6)],Assaying these concentrations by high-pressure liquid chromatography demonstrated a peak serum rifampin level (C(max)) of 18 μg/ml and total rifampin exposure (area under the curve from 0-6 hours [AUC(0-6)]) of 50.1 μg/ml.,Adequacy of Rifampin Absorption after Jejunostomy Tube Administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26928044/),[μg] / [ml],50.1,224322,DB01045,Rifampicin
,26928044,C(max),These are high compared with rifampin C(max) and AUC(0-6) values reported in patients after oral rifampin administration; C(max) tends to range between 4.0-10.5 μg/ml and AUC(0-6) 7.0-52.9 μg/ml after oral administration of 600 mg at steady state.,Adequacy of Rifampin Absorption after Jejunostomy Tube Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26928044/),[μg] / [ml],4.0-10.5,224323,DB01045,Rifampicin
,26928044,AUC(0-6),These are high compared with rifampin C(max) and AUC(0-6) values reported in patients after oral rifampin administration; C(max) tends to range between 4.0-10.5 μg/ml and AUC(0-6) 7.0-52.9 μg/ml after oral administration of 600 mg at steady state.,Adequacy of Rifampin Absorption after Jejunostomy Tube Administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26928044/),[μg] / [ml],7.0-52.9,224324,DB01045,Rifampicin
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],2.94 to,224410,DB01045,Rifampicin
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],1,224411,DB01045,Rifampicin
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],1.03 to 0.50,224412,DB01045,Rifampicin
,23750331,Cmax,"Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone.","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],3.38 to 0.45,224413,DB01045,Rifampicin
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],2.65 to 3.36,224414,DB01045,Rifampicin
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],0.66 to 1.25,224415,DB01045,Rifampicin
,23750331,Cmax,"Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%).","A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23750331/),[ng] / [ml],3.59 to 10.92,224416,DB01045,Rifampicin
>,31704214,trough concentration (Cmin),Primary endpoints were a lopinavir trough concentration (Cmin) >1.0 µg/mL and a rifampicin maximum concentration (Cmax) of 8-24 µg/mL.,Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704214/),[μg] / [ml],1.0,224429,DB01045,Rifampicin
,31704214,maximum concentration (Cmax),Primary endpoints were a lopinavir trough concentration (Cmin) >1.0 µg/mL and a rifampicin maximum concentration (Cmax) of 8-24 µg/mL.,Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704214/),[μg] / [ml],8-24,224430,DB01045,Rifampicin
,31704214,area under the concentration-time curve from 0-24 h (AUC0-24),"Secondary PK endpoints were a rifampicin area under the concentration-time curve from 0-24 h (AUC0-24) of 44-70 µg·h/mL, a lopinavir Cmax of 6-14 µg/mL and a lopinavir AUC0-12 of 56-130 µg·h/mL.",Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704214/),[h·μg] / [ml],44-70,224431,DB01045,Rifampicin
,31704214,Cmax,"Secondary PK endpoints were a rifampicin area under the concentration-time curve from 0-24 h (AUC0-24) of 44-70 µg·h/mL, a lopinavir Cmax of 6-14 µg/mL and a lopinavir AUC0-12 of 56-130 µg·h/mL.",Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704214/),[μg] / [ml],6-14,224432,DB01045,Rifampicin
,31704214,AUC0-12,"Secondary PK endpoints were a rifampicin area under the concentration-time curve from 0-24 h (AUC0-24) of 44-70 µg·h/mL, a lopinavir Cmax of 6-14 µg/mL and a lopinavir AUC0-12 of 56-130 µg·h/mL.",Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704214/),[h·μg] / [ml],56-130,224433,DB01045,Rifampicin
>,31704214,Cmin,A lopinavir Cmin of >1.0 µg/mL was achieved in a least one of the PK samplings in all nine subjects who completed treatment.,Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704214/),[μg] / [ml],1.0,224434,DB01045,Rifampicin
≥,31704214,Cmax,"Five patients achieved the primary endpoint of rifampicin Cmax (≥8 µg/mL) in at least one of the PK samplings, and five achieved the minimum rifampicin AUC0-24 (≥44 µg·h/mL).",Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704214/),[μg] / [ml],8,224435,DB01045,Rifampicin
≥,31704214,AUC0-24,"Five patients achieved the primary endpoint of rifampicin Cmax (≥8 µg/mL) in at least one of the PK samplings, and five achieved the minimum rifampicin AUC0-24 (≥44 µg·h/mL).",Evaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31704214/),[h·μg] / [ml],44,224436,DB01045,Rifampicin
,25534740,MIC,"When used alone, timcodar weakly inhibited M. tuberculosis growth in broth culture (MIC, 19 μg/ml); however, it demonstrated synergism in drug combination studies with rifampin, bedaquiline, and clofazimine but not with other anti-TB agents.",The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25534740/),[μg] / [ml],19,225521,DB01045,Rifampicin
,25534740,50% inhibitory concentration,"When M. tuberculosis was cultured in host macrophage cells, timcodar had about a 10-fold increase (50% inhibitory concentration, 1.9 μg/ml) in the growth inhibition of M. tuberculosis and demonstrated synergy with rifampin, moxifloxacin, and bedaquiline.",The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25534740/),[μg] / [ml],1.9,225522,DB01045,Rifampicin
,2285340,maximum antibiotic concentration,"When the antibiotic was administered in the 5-, 10- or 15-minute regimen in a dose of 10 mg/kg the maximum decrease in blood pressure was 44, 34 or 21% of the initial level and the maximum antibiotic concentration attained in the blood was 34.4, 27.2 or 22.6 micrograms/ml, respectively.",[Hypotension caused by intravenous infusion of rifampicin and its relation to the administration schedule]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285340/),[μg] / [ml],34.4,225820,DB01045,Rifampicin
,2285340,maximum antibiotic concentration,"When the antibiotic was administered in the 5-, 10- or 15-minute regimen in a dose of 10 mg/kg the maximum decrease in blood pressure was 44, 34 or 21% of the initial level and the maximum antibiotic concentration attained in the blood was 34.4, 27.2 or 22.6 micrograms/ml, respectively.",[Hypotension caused by intravenous infusion of rifampicin and its relation to the administration schedule]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285340/),[μg] / [ml],27.2,225821,DB01045,Rifampicin
,2285340,maximum antibiotic concentration,"When the antibiotic was administered in the 5-, 10- or 15-minute regimen in a dose of 10 mg/kg the maximum decrease in blood pressure was 44, 34 or 21% of the initial level and the maximum antibiotic concentration attained in the blood was 34.4, 27.2 or 22.6 micrograms/ml, respectively.",[Hypotension caused by intravenous infusion of rifampicin and its relation to the administration schedule]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285340/),[μg] / [ml],22.6,225822,DB01045,Rifampicin
,2285340,maximum antibiotic concentration,"With the infusion for 30 minutes, the maximum antibiotic concentration in the blood was 17.6 micrograms/ml and the blood pressure did not undergo any significant changes.",[Hypotension caused by intravenous infusion of rifampicin and its relation to the administration schedule]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285340/),[μg] / [ml],17.6,225823,DB01045,Rifampicin
,26613187,CL/F,The mean population estimate for CL/F was 23.9 (l h(-1) 70 kg(-1) ) with inter-individual variability of 46.6%.,A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26613187/),[l] / [70·h·kg],23.9,225991,DB01045,Rifampicin
,26613187,Relative bioavailability,Relative bioavailability in children was estimated at 49% lower compared to adults (100% relative bioavailability).,A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26613187/),%,49,225992,DB01045,Rifampicin
,26613187,Relative bioavailability,Relative bioavailability in children was estimated at 49% lower compared to adults (100% relative bioavailability).,A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26613187/),%,100,225993,DB01045,Rifampicin
,26613187,AUC,"In children average AUC was 13.5 mg l(-1) h, which was nearly half that was observed in adults (26.3 mg l(-1) h).",A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26613187/),[h·mg] / [l],13.5,225994,DB01045,Rifampicin
,26613187,AUC,"In children average AUC was 13.5 mg l(-1) h, which was nearly half that was observed in adults (26.3 mg l(-1) h).",A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26613187/),[h·mg] / [l],26.3,225995,DB01045,Rifampicin
,26613187,AUC,"Increasing dose to approximately 15 mg kg(-1) , increased AUC in children to an average of 22 mgl(-1) h. bringing expected exposures in children closer to those predicted for adults.",A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26613187/),[h] / [mgl],22,225996,DB01045,Rifampicin
under,27250739,peak rifampin concentration (Cmax),"In the derivation study, a urine colorimetric assay value of 4.0 × 10(-2) Abs, using a timed void 4 h after dosing, demonstrated a sensitivity of 92 % and specificity of 60 % to detect a peak rifampin concentration (Cmax) under 8 mg/L, with an area under the ROC curve of 0.92.",Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27250739/),[mg] / [l],8,226197,DB01045,Rifampicin
,27250739,Cmax,"We observed similar test characteristics for a target Cmax target of 6.6 mg/L, and a target area under the drug concentration-versus-time curve (AUC0-8) target of 24.1 mg•hour/L.",Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27250739/),[mg] / [l],6.6,226198,DB01045,Rifampicin
,27250739,area under the drug concentration-versus-time curve (AUC0-8),"We observed similar test characteristics for a target Cmax target of 6.6 mg/L, and a target area under the drug concentration-versus-time curve (AUC0-8) target of 24.1 mg•hour/L.",Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27250739/),[h·mg] / [l],24.1,226199,DB01045,Rifampicin
,29718390,time to positivity,The 90% prediction interval for the predicted median day 7 increase in time to positivity for 50 mg/kg rifampicin was 7.25-10.3 days.,Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29718390/),d,7.25-10.3,226355,DB01045,Rifampicin
,22028201,area under the curve (AUC(0-24)),The median values of the area under the curve (AUC(0-24)) of rifampicin increased by 39% at T1 (15.69 μg · h/mL; P = 0.01) and by 83% at T2 (20.65 μg · h/mL; P = 0.001) compared with T0 (11.28 μg · h/mL).,Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028201/),[h·μg] / [ml],15.69,226463,DB01045,Rifampicin
,22028201,area under the curve (AUC(0-24)),The median values of the area under the curve (AUC(0-24)) of rifampicin increased by 39% at T1 (15.69 μg · h/mL; P = 0.01) and by 83% at T2 (20.65 μg · h/mL; P = 0.001) compared with T0 (11.28 μg · h/mL).,Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028201/),[h·μg] / [ml],20.65,226464,DB01045,Rifampicin
,22028201,area under the curve (AUC(0-24)),The median values of the area under the curve (AUC(0-24)) of rifampicin increased by 39% at T1 (15.69 μg · h/mL; P = 0.01) and by 83% at T2 (20.65 μg · h/mL; P = 0.001) compared with T0 (11.28 μg · h/mL).,Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028201/),[h·μg] / [ml],11.28,226465,DB01045,Rifampicin
,22028201,C(max),Similar variations were observed for the median C(max) at T0 (2.24 μg/mL) compared with T2 (2.83 μg/mL; P = 0.003).,Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028201/),[μg] / [ml],2.24,226466,DB01045,Rifampicin
,22028201,C(max),Similar variations were observed for the median C(max) at T0 (2.24 μg/mL) compared with T2 (2.83 μg/mL; P = 0.003).,Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028201/),[μg] / [ml],2.83,226467,DB01045,Rifampicin
>,22028201,C(max),"However, none of the subjects had C(max) levels >8 μg/mL at either T0 or T2.",Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028201/),[μg] / [ml],8,226468,DB01045,Rifampicin
,30559132,volume of distribution,"The volume of distribution (217 liters) was greater than that of extracellular fluid, which suggests distribution beyond the central compartment.",Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30559132/),l,217,226567,DB01045,Rifampicin
,6473487,volume of distribution,From these data one obtains for the volume of distribution a value of 48.1 +/- 17.2 liters and for the serum disappearance rate the value of 0.212 +/- 0.070 h-1 in adult subjects.,Pharmacokinetic study on intravenous rifampicin in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473487/),l,48.1,226626,DB01045,Rifampicin
,6473487,serum disappearance rate,From these data one obtains for the volume of distribution a value of 48.1 +/- 17.2 liters and for the serum disappearance rate the value of 0.212 +/- 0.070 h-1 in adult subjects.,Pharmacokinetic study on intravenous rifampicin in man. ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473487/),1/[h],0.212,226627,DB01045,Rifampicin
,31871093,clearance,"Allometric scaling of clearance (typical value, 8.88 liters/h), the volume of distribution (typical value, 21.4 liters), and maturation of clearance and absorption improved the model fit.",Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871093/),[l] / [h],8.88,227465,DB01045,Rifampicin
,31871093,volume of distribution,"Allometric scaling of clearance (typical value, 8.88 liters/h), the volume of distribution (typical value, 21.4 liters), and maturation of clearance and absorption improved the model fit.",Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31871093/),l,21.4,227466,DB01045,Rifampicin
,12531776,area under the concentration-time curve for 12 hours after the dose [AUC(0-12)],"In multivariate analyses that were adjusted for severity of disease, low plasma concentrations of isoniazid were associated with failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentration-time curve for 12 hours after the dose [AUC(0-12)] was 36 microg x hour/ml in failure/relapse versus 56 microg x hour/ml in control cases p = 0.005), but not with twice-weekly isoniazid/rifampin.",Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12531776/),[h·μg] / [ml],36,228046,DB01045,Rifampicin
,12531776,area under the concentration-time curve for 12 hours after the dose [AUC(0-12)],"In multivariate analyses that were adjusted for severity of disease, low plasma concentrations of isoniazid were associated with failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentration-time curve for 12 hours after the dose [AUC(0-12)] was 36 microg x hour/ml in failure/relapse versus 56 microg x hour/ml in control cases p = 0.005), but not with twice-weekly isoniazid/rifampin.",Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12531776/),[h·μg] / [ml],56,228047,DB01045,Rifampicin
,601547,MIC,In all the gastrectomized and control patients a serum level well above the MIC for M. tuberculosis (0.2-0.5 microgram/ml) was achieved irrespective of whether rifampicin was administered after the meal or during fasting.,Absorption of rifampicin in gastrectomized patients. Effect of meals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/601547/),,0.2-0.5,229056,DB01045,Rifampicin
>,25313213,Cmax,A rifampin Cmax of >8.2 mg/liter and a pyrazinamide AUC/MIC of >11.3 were key predictors of the β-slope and interacted positively to increase the β-slope.,Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25313213/),[mg] / [l],8.2,229204,DB01045,Rifampicin
>,25313213,AUC/MIC,A rifampin Cmax of >8.2 mg/liter and a pyrazinamide AUC/MIC of >11.3 were key predictors of the β-slope and interacted positively to increase the β-slope.,Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25313213/),,11.3,229205,DB01045,Rifampicin
<,25313213,AUC,"In patients with a rifampin AUC of <35.4 mg · h/liter, an increase in the pyrazinamide AUC/MIC and/or ethambutol Cmax/MIC increased the β-slope, while increasing isoniazid Cmax decreased it, suggesting isoniazid antagonism.",Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25313213/),[h·mg] / [l],35.4,229206,DB01045,Rifampicin
,19620331,maximum concentration of drug in serum (Cmax),"INH at 6.25 mg/kg of body weight produced a maximum concentration of drug in serum (Cmax) value of 4 microg/ml and an area under the concentration-time curve from 0 to 24 h (AUC(0-24)) value of 4.9 microg x h/ml, the former being close to the Cmax value observed after the standard 5-mg/kg dose in humans.",Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620331/),[μg] / [ml],4,229350,DB01045,Rifampicin
,19620331,area under the concentration-time curve from 0 to 24 h (AUC(0-24)),"INH at 6.25 mg/kg of body weight produced a maximum concentration of drug in serum (Cmax) value of 4 microg/ml and an area under the concentration-time curve from 0 to 24 h (AUC(0-24)) value of 4.9 microg x h/ml, the former being close to the Cmax value observed after the standard 5-mg/kg dose in humans.",Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620331/),[h·μg] / [ml],4.9,229351,DB01045,Rifampicin
,19620331,Cmax,"INH at 25 mg/kg produced a Cmax value of 22 microg/ml and an AUC(0-24) value of 29 microg x h/ml, the latter being close to the AUC observed after a 5-mg/kg dose of INH in humans with the slow acetylation phenotype.",Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620331/),[μg] / [ml],22,229352,DB01045,Rifampicin
,19620331,AUC(0-24),"INH at 25 mg/kg produced a Cmax value of 22 microg/ml and an AUC(0-24) value of 29 microg x h/ml, the latter being close to the AUC observed after a 5-mg/kg dose of INH in humans with the slow acetylation phenotype.",Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620331/),[h·μg] / [ml],29,229353,DB01045,Rifampicin
,15034704,C(max),The median C(max) was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml.,Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15034704/),[ng] / [ml],35,229421,DB01045,Rifampicin
,15034704,C(max),The median C(max) was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml.,Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15034704/),[ng] / [ml],7.5,229422,DB01045,Rifampicin
above,30496458,peak concentration,These negative interactions disappeared if rifampicin peak concentration was above 7 mg/L.,"Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496458/),[mg] / [l],7,229627,DB01045,Rifampicin
,29243231,Ki,Estimated rifampicin in vivo unbound OATP Ki (0.13 μM) using CPI data was 2-fold lower relative to rosuvastatin.,Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29243231/),μM,0.13,230892,DB01045,Rifampicin
,23806476,Cmax,"After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [ml],39.7,231032,DB01045,Rifampicin
,23806476,AUC,"After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],108,231033,DB01045,Rifampicin
,23806476,AUC,"After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [ml],43.6,231034,DB01045,Rifampicin
,23806476,AUC,"After an oral dose of 0.875 mg predicted Cmax and AUC were 39.7 (95% CI:37.0-42.7)ng/mL and 108 (95% CI: 96.9-120)ng/mLh, respectively, which is in line with observed values of 43.6 (95% CI: 37.7-49.5)ng/mL and 133 (95% CI: 107-159)ng/mLh.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],133,231035,DB01045,Rifampicin
,23806476,Cmax,"For a 1.75 mg oral dose, the predicted and observed values were 82.5 (95% CI:76.6-88.9)ng/mL vs 91.1 (95% CI: 67.9-115.9) for Cmax and 224 (95% CI: 202-248) vs 324 (95% CI: 197-451)ng/mLh for AUC, respectively.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],91.1,231036,DB01045,Rifampicin
,23806476,AUC,"For a 1.75 mg oral dose, the predicted and observed values were 82.5 (95% CI:76.6-88.9)ng/mL vs 91.1 (95% CI: 67.9-115.9) for Cmax and 224 (95% CI: 202-248) vs 324 (95% CI: 197-451)ng/mLh for AUC, respectively.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],224,231037,DB01045,Rifampicin
,23806476,AUC,"For a 1.75 mg oral dose, the predicted and observed values were 82.5 (95% CI:76.6-88.9)ng/mL vs 91.1 (95% CI: 67.9-115.9) for Cmax and 224 (95% CI: 202-248) vs 324 (95% CI: 197-451)ng/mLh for AUC, respectively.",Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23806476/),[ng] / [mlh],324,231038,DB01045,Rifampicin
,1424418,clearances,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [h·kg],0.30,231598,DB01045,Rifampicin
,1424418,clearances,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [h·kg],0.55,231599,DB01045,Rifampicin
,1424418,volume of distribution at steady state,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [kg],1.31,231600,DB01045,Rifampicin
,1424418,volume of distribution at steady state,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [kg],1.68,231601,DB01045,Rifampicin
,1424418,bioavailabilities,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),%,27,231602,DB01045,Rifampicin
,1424418,bioavailabilities,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),%,33,231603,DB01045,Rifampicin
,1424418,phase clearances,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [h·kg],0.42,231604,DB01045,Rifampicin
,1424418,phase clearances,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [h·kg],0.79,231605,DB01045,Rifampicin
,1424418,volume of distribution at steady state,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [kg],1.36,231606,DB01045,Rifampicin
,1424418,volume of distribution at steady state,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [kg],1.35,231607,DB01045,Rifampicin
,1424418,bioavailabilities,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),%,10,231608,DB01045,Rifampicin
,1424418,bioavailabilities,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),%,9,231609,DB01045,Rifampicin
,9923817,tmax,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),h,0.7 to 0.8,231686,DB01045,Rifampicin
,9923817,CLr,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),[ml] / [kg·min],2.0 to 2.6,231687,DB01045,Rifampicin
,9923817,t1/2,"Small differences were found in mean tmax (0.7 to 0.8 h), CLr (2.0 to 2.6 ml/min per kg), and t1/2 (7.4 to 8.8 h) for hydrodolasetron between treatment periods.",Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923817/),h,7.4 to 8.8,231688,DB01045,Rifampicin
,9765852,MIC,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,10.3,232497,DB01045,Rifampicin
,9765852,MIC,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28.0,232498,DB01045,Rifampicin
,9765852,MIC,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,2,232499,DB01045,Rifampicin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,14.7,232500,DB01045,Rifampicin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,17.7,232501,DB01045,Rifampicin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28.0,232502,DB01045,Rifampicin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,62.0,232503,DB01045,Rifampicin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,71,232504,DB01045,Rifampicin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,2,232505,DB01045,Rifampicin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,15.0,232506,DB01045,Rifampicin
,9765852,MIC x 4,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28,232507,DB01045,Rifampicin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28.0,232508,DB01045,Rifampicin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,62.0,232509,DB01045,Rifampicin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,71,232510,DB01045,Rifampicin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,2,232511,DB01045,Rifampicin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,15.0,232512,DB01045,Rifampicin
,9765852,MIC x 8,"Our results underlined two distinct patterns concerning PAE: pattern I included drugs for which PAE (in hours) was dose-dependent and varied (for MIC, MIC x 4 and MIC x 8 concentrations) for amikacin (10.3 +/- 1.7, 14.7 +/- 1.9 and 17.7 +/- 4.1), rifampin (28.0 +/- 7.6, 62.0 +/- 18.5 and 71.0 +/- 3.2) and clarithromycin (2.6 +/- 1.0, 15.0 +/- 4.0 and 22.0 +/- 4.0), whereas pattern II included drugs with a stable PAE, relatively independent of the drug concentrations: sparfloxacin (11.0 +/- 2.5, 12.3 +/- 6.4 and 13.0 +/- 2.1) and clofazimine (26.0 +/- 2.8, 28.8 +/- 2.5 and 27.3 +/- 1.3).","Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9765852/),,28,232513,DB01045,Rifampicin
,25887748,Cmax,"The median (IQR) Cmax of isoniazid increased significantly from 0.6 (0.3,1.2) μg/mL to 3.4 (1.8, 5.0) μg/mL with increase in the dose.","Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25887748/),[μg] / [ml],0.6,233000,DB01045,Rifampicin
,25887748,Cmax,"The median (IQR) Cmax of isoniazid increased significantly from 0.6 (0.3,1.2) μg/mL to 3.4 (1.8, 5.0) μg/mL with increase in the dose.","Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25887748/),[μg] / [ml],3.4,233001,DB01045,Rifampicin
,25887748,Cmax,"Plasma rifampicin concentrations increased only marginally on increasing the dose [median (IQR) Cmax: 10.4 (7.2, 13.9) μg/mL vs. 12.0 (6.1, 24.3) μg/mL, p=0.08].","Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25887748/),[μg] / [ml],10.4,233002,DB01045,Rifampicin
,25887748,Cmax,"Plasma rifampicin concentrations increased only marginally on increasing the dose [median (IQR) Cmax: 10.4 (7.2, 13.9) μg/mL vs. 12.0 (6.1, 24.3) μg/mL, p=0.08].","Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25887748/),[μg] / [ml],12.0,233003,DB01045,Rifampicin
,30500116,maximum M2 concentrations (Cmax ),"In the rifabutin group maximum M2 concentrations (Cmax ) increased significantly (P < .001) from 47.59 to 79.53 ng/mL, and clearance slowed slightly (P = .01).",Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500116/),[ng] / [ml],47.59,233337,DB01045,Rifampicin
,30500116,maximum M2 concentrations (Cmax ),"In the rifabutin group maximum M2 concentrations (Cmax ) increased significantly (P < .001) from 47.59 to 79.53 ng/mL, and clearance slowed slightly (P = .01).",Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500116/),[ng] / [ml],79.53,233338,DB01045,Rifampicin
,30500116,Cmax,"In rifampin recipients M2 Cmax doubled (48.44 to 101.52 ng/mL), but M2 clearance and time to Cmax significantly (P < .001) increased, and AUC0-∞ and mean residence time significantly decreased (P < .001).",Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500116/),[ng] / [ml],48.44 to 101.52,233339,DB01045,Rifampicin
,10634135,AUC,"Ketoconazole and rifampin pretreatment significantly changed AUC values of ALP (mean AUC values in microg/l h: ALP = 242.2, ALP + ketoconazole = 426.2, ALP + rifampin = 28.4, ANOVA F = 17.7, P < 0.001).",Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10634135/),[μg] / [h·l],242,233774,DB01045,Rifampicin
,10634135,AUC,"Ketoconazole and rifampin pretreatment significantly changed AUC values of ALP (mean AUC values in microg/l h: ALP = 242.2, ALP + ketoconazole = 426.2, ALP + rifampin = 28.4, ANOVA F = 17.7, P < 0.001).",Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10634135/),[μg] / [h·l],42,233775,DB01045,Rifampicin
,23837923,area under the concentration-time curve over 12 h (AUC(0-12 h),"Exposure to clarithromycin when combined with rifampicin was very low [area under the concentration-time curve over 12 h (AUC(0-12 h), geometric mean 2.6 h·mg/L, range 1.6-3.2 h·mg/L; peak concentration in plasma (C(max)), geometric mean 0.3 mg/L, range 0.1-0.7 mg/L].",Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23837923/),[h·mg] / [l],2.6,234788,DB01045,Rifampicin
,23837923,peak concentration in plasma (C(max)),"Exposure to clarithromycin when combined with rifampicin was very low [area under the concentration-time curve over 12 h (AUC(0-12 h), geometric mean 2.6 h·mg/L, range 1.6-3.2 h·mg/L; peak concentration in plasma (C(max)), geometric mean 0.3 mg/L, range 0.1-0.7 mg/L].",Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23837923/),[mg] / [l],0.3,234789,DB01045,Rifampicin
,28862186,concentrations,"The geometric mean two-hour concentrations with food and under fasting conditions were 2.2 and 5.5 μg/ml for RMP (P<0.001), 3.9 and 11.3 μg/ml for INH (P<0.001), and 18.0 and 28.2 μg/ml for PZA (P<0.001), respectively.",Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28862186/),[μg] / [ml],2.2,234900,DB01045,Rifampicin
,28862186,concentrations,"The geometric mean two-hour concentrations with food and under fasting conditions were 2.2 and 5.5 μg/ml for RMP (P<0.001), 3.9 and 11.3 μg/ml for INH (P<0.001), and 18.0 and 28.2 μg/ml for PZA (P<0.001), respectively.",Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28862186/),[μg] / [ml],5.5,234901,DB01045,Rifampicin
,28862186,concentrations,"The geometric mean two-hour concentrations with food and under fasting conditions were 2.2 and 5.5 μg/ml for RMP (P<0.001), 3.9 and 11.3 μg/ml for INH (P<0.001), and 18.0 and 28.2 μg/ml for PZA (P<0.001), respectively.",Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28862186/),[μg] / [ml],3.9,234902,DB01045,Rifampicin
,28862186,concentrations,"The geometric mean two-hour concentrations with food and under fasting conditions were 2.2 and 5.5 μg/ml for RMP (P<0.001), 3.9 and 11.3 μg/ml for INH (P<0.001), and 18.0 and 28.2 μg/ml for PZA (P<0.001), respectively.",Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28862186/),[μg] / [ml],11.3,234903,DB01045,Rifampicin
,28862186,concentrations,"The geometric mean two-hour concentrations with food and under fasting conditions were 2.2 and 5.5 μg/ml for RMP (P<0.001), 3.9 and 11.3 μg/ml for INH (P<0.001), and 18.0 and 28.2 μg/ml for PZA (P<0.001), respectively.",Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28862186/),[μg] / [ml],18.0,234904,DB01045,Rifampicin
,28862186,concentrations,"The geometric mean two-hour concentrations with food and under fasting conditions were 2.2 and 5.5 μg/ml for RMP (P<0.001), 3.9 and 11.3 μg/ml for INH (P<0.001), and 18.0 and 28.2 μg/ml for PZA (P<0.001), respectively.",Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28862186/),[μg] / [ml],28.2,234905,DB01045,Rifampicin
,16390353,elimination half-life (t(1/2)),Rifampicin decreased the mean total area under the plasma concentration-time curve (AUC(0-infinity)) of pioglitazone by 54% (range 20-66%; P = 0.0007; 95% confidence interval -78 to -30%) and shortened its dominant elimination half-life (t(1/2)) from 4.9 to 2.3 h (P = 0.0002).,Effect of rifampicin on the pharmacokinetics of pioglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390353/),h,4.9,235492,DB01045,Rifampicin
,16390353,elimination half-life (t(1/2)),Rifampicin decreased the mean total area under the plasma concentration-time curve (AUC(0-infinity)) of pioglitazone by 54% (range 20-66%; P = 0.0007; 95% confidence interval -78 to -30%) and shortened its dominant elimination half-life (t(1/2)) from 4.9 to 2.3 h (P = 0.0002).,Effect of rifampicin on the pharmacokinetics of pioglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16390353/),h,2.3,235493,DB01045,Rifampicin
,22126409,Bioavailability,"Bioavailability was 42% and 45% higher for evening doses compared with morning doses for lopinavir and ritonavir, respectively, while oral clearance of both drugs was 33% lower overnight.",Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126409/),%,42,236105,DB01045,Rifampicin
,22126409,Bioavailability,"Bioavailability was 42% and 45% higher for evening doses compared with morning doses for lopinavir and ritonavir, respectively, while oral clearance of both drugs was 33% lower overnight.",Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126409/),%,45,236106,DB01045,Rifampicin
>,22126409,trough concentrations,"Simulations predicted that 99.5% of our patients receiving doubled doses of lopinavir/ritonavir achieve morning trough concentrations of lopinavir > 1 mg l(-1) during rifampicin co-administration, and 95% of those weighing less than 50 kg achieve this target already with 600/150 mg doses of lopinavir/ritonavir.",Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126409/),[mg] / [l],1,236107,DB01045,Rifampicin
,2792166,half-life,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.7,237637,DB01045,Rifampicin
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[l] / [kg],0.514,237638,DB01045,Rifampicin
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.5,237639,DB01045,Rifampicin
,2792166,volume of distribution,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[l] / [kg],0.519,237640,DB01045,Rifampicin
,2792166,total clearance,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.63,237641,DB01045,Rifampicin
,2792166,total clearance,"None of theophylline half-life (9.7 h), volume of distribution (0.514 l.kg-1) and total clearance (0.63 ml.min-1.kg-1) after pretreatment differed from the respective control value of 9.5 h, 0.519 l.kg-1 and 0.65 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.65,237642,DB01045,Rifampicin
,2792166,half-life,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,9.6,237643,DB01045,Rifampicin
,2792166,half-life,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,5.5,237644,DB01045,Rifampicin
,2792166,total clearance,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],0.64,237645,DB01045,Rifampicin
,2792166,total clearance,The control half-life of the bronchodilator (9.6 h) was reduced to 5.5 h and its total clearance (0.64 ml.min-1.kg-1) increased to 1.22 ml.min-1.kg-1.,Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],1.22,237646,DB01045,Rifampicin
,2792166,half-life,"In these 6 volunteers, intake of diltiazem (240 mg daily), concurrently with rifampicin for a week, significantly elevated theophylline half-life to 6.2 h as well as reduced its clearance to 1.03 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),h,6.2,237647,DB01045,Rifampicin
,2792166,clearance,"In these 6 volunteers, intake of diltiazem (240 mg daily), concurrently with rifampicin for a week, significantly elevated theophylline half-life to 6.2 h as well as reduced its clearance to 1.03 ml.min-1.kg-1.",Attenuation of rifampicin-induced theophylline metabolism by diltiazem/rifampicin coadministration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792166/),[ml] / [kg·min],1.03,237648,DB01045,Rifampicin
,6967586,peak serum concentrations,Mean peak serum concentrations of from 9 to 11.5 microgram/ml were observed one hour after a 10-mg/kg dose and the average half-life was 2.9 hours.,Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6967586/),[μg] / [ml],9 to 11.5,238193,DB01045,Rifampicin
,6967586,half-life,Mean peak serum concentrations of from 9 to 11.5 microgram/ml were observed one hour after a 10-mg/kg dose and the average half-life was 2.9 hours.,Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6967586/),h,2.9,238194,DB01045,Rifampicin
greater,17167747,Overall extraction recovery,Overall extraction recovery of hydroxybupropion enantiomers and the internal standard phenacetin from plasma was greater than 80% and reproducible over the concentration range of 12.5-500 ng/ml for each enantiomer.,Stereoselective analysis of hydroxybupropion and application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17167747/),%,80,238584,DB01045,Rifampicin
,12621387,elimination,"During rifampin, intestinal digoxin elimination was 0.80 +/- 0.59 (P =.383).",P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621387/),,0.80,239516,DB01045,Rifampicin
,9812178,t1/2 beta,The clinically relevant t1/2 beta is about 3 to 5 hours.,Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),h,3 to 5,239662,DB01045,Rifampicin
,9812178,apparent oral clearance,"The pharmacokinetics of ritonavir are relatively linear after multiple doses, with apparent oral clearance averaging 7 to 9 L/h.",Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812178/),[l] / [h],7 to 9,239663,DB01045,Rifampicin
,7780091,bioavailability,The bioavailability of isoniazid and rifampicin was decreased by food in a high percentage (33-56%) of patients.,"Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7780091/),%,33-56,239961,DB01045,Rifampicin
,28363192,size,"The range of size and entrapment efficiency of prepared nanoparticles was estimated from 124.1±0.2 to 402.3±2.8nm and 72.00±0.1%, respectively.",Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363192/),nm,124.1,239988,DB01045,Rifampicin
,28363192,size,"The range of size and entrapment efficiency of prepared nanoparticles was estimated from 124.1±0.2 to 402.3±2.8nm and 72.00±0.1%, respectively.",Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363192/),nm,402.3,239989,DB01045,Rifampicin
,28363192,entrapment efficiency,"The range of size and entrapment efficiency of prepared nanoparticles was estimated from 124.1±0.2 to 402.3±2.8nm and 72.00±0.1%, respectively.",Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363192/),nm,402.3,239990,DB01045,Rifampicin
,28363192,entrapment efficiency,"The range of size and entrapment efficiency of prepared nanoparticles was estimated from 124.1±0.2 to 402.3±2.8nm and 72.00±0.1%, respectively.",Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28363192/),%,72.00,239991,DB01045,Rifampicin
,24242939,aerodynamic diameters,"The antibiotic powders, with and without leucine, had similar median aerodynamic diameters of 2.58 ± 0.08 μm and 2.51 ± 0.06 μm, with a relatively high fine particle fraction of 55.5 ± 1.9% and 63.6 ± 2.0%, respectively.",A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242939/),μm,2.58,241021,DB01045,Rifampicin
,24242939,aerodynamic diameters,"The antibiotic powders, with and without leucine, had similar median aerodynamic diameters of 2.58 ± 0.08 μm and 2.51 ± 0.06 μm, with a relatively high fine particle fraction of 55.5 ± 1.9% and 63.6 ± 2.0%, respectively.",A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242939/),μm,2.51,241022,DB01045,Rifampicin
,24242939,fine,"The antibiotic powders, with and without leucine, had similar median aerodynamic diameters of 2.58 ± 0.08 μm and 2.51 ± 0.06 μm, with a relatively high fine particle fraction of 55.5 ± 1.9% and 63.6 ± 2.0%, respectively.",A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24242939/),%,55.5,241023,DB01045,Rifampicin
,25100135,clearance,This correlated with an increased clearance with rifampin (39.6-59.8 L/h) and a decreased clearance with ketoconazole (20.3-12.0 L/h).,"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25100135/),[l] / [h],39.6-59.8,241286,DB01045,Rifampicin
,25100135,clearance,This correlated with an increased clearance with rifampin (39.6-59.8 L/h) and a decreased clearance with ketoconazole (20.3-12.0 L/h).,"Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25100135/),[l] / [h],20.3-12.0,241287,DB01045,Rifampicin
,10677836,retention times,"The assay produces sharp peaks with retention times of 6.2 and 15 min for rifampin and diazepam, respectively.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),min,6.2,241328,DB01045,Rifampicin
,10677836,retention times,"The assay produces sharp peaks with retention times of 6.2 and 15 min for rifampin and diazepam, respectively.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),min,15,241329,DB01045,Rifampicin
,10677836,detection limits,"The detection limits for rifampin were 0.5 microgram/mL for plasma, 0.015 microgram/mL for BAL supernatants, and 0.03 microgram/mL for AC suspensions.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),[μg] / [ml],0.5,241330,DB01045,Rifampicin
,10677836,detection limits,"The detection limits for rifampin were 0.5 microgram/mL for plasma, 0.015 microgram/mL for BAL supernatants, and 0.03 microgram/mL for AC suspensions.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),[μg] / [ml],0.015,241331,DB01045,Rifampicin
,10677836,detection limits,"The detection limits for rifampin were 0.5 microgram/mL for plasma, 0.015 microgram/mL for BAL supernatants, and 0.03 microgram/mL for AC suspensions.","Liquid chromatographic determination of rifampin in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10677836/),[μg] / [ml],0.03,241332,DB01045,Rifampicin
,11477883,Cmax,"The Cmax of INH, RFP and OFLX in serum were 10.87 +/- 7.09 micrograms/ml, 9.98 +/- 3.53 micrograms/ml, and 5.29 +/- 0.72 micrograms/ml, while the Cmax of INH, RFP and OFLX in cold abscesses were 2.84 +/- 1.63 micrograms/ml, 0.57 +/- 0.26 microgram/ml and 3.19 +/- 1.29 micrograms/ml respectively.",[Comparison of three antituberculous drugs in serum and cold abscesses of patients with spinal tuberculosis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477883/),[μg] / [ml],10.87,241846,DB01045,Rifampicin
,11477883,Cmax,"The Cmax of INH, RFP and OFLX in serum were 10.87 +/- 7.09 micrograms/ml, 9.98 +/- 3.53 micrograms/ml, and 5.29 +/- 0.72 micrograms/ml, while the Cmax of INH, RFP and OFLX in cold abscesses were 2.84 +/- 1.63 micrograms/ml, 0.57 +/- 0.26 microgram/ml and 3.19 +/- 1.29 micrograms/ml respectively.",[Comparison of three antituberculous drugs in serum and cold abscesses of patients with spinal tuberculosis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477883/),[μg] / [ml],9.98,241847,DB01045,Rifampicin
,11477883,Cmax,"The Cmax of INH, RFP and OFLX in serum were 10.87 +/- 7.09 micrograms/ml, 9.98 +/- 3.53 micrograms/ml, and 5.29 +/- 0.72 micrograms/ml, while the Cmax of INH, RFP and OFLX in cold abscesses were 2.84 +/- 1.63 micrograms/ml, 0.57 +/- 0.26 microgram/ml and 3.19 +/- 1.29 micrograms/ml respectively.",[Comparison of three antituberculous drugs in serum and cold abscesses of patients with spinal tuberculosis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477883/),[μg] / [ml],5.29,241848,DB01045,Rifampicin
,11477883,Cmax,"The Cmax of INH, RFP and OFLX in serum were 10.87 +/- 7.09 micrograms/ml, 9.98 +/- 3.53 micrograms/ml, and 5.29 +/- 0.72 micrograms/ml, while the Cmax of INH, RFP and OFLX in cold abscesses were 2.84 +/- 1.63 micrograms/ml, 0.57 +/- 0.26 microgram/ml and 3.19 +/- 1.29 micrograms/ml respectively.",[Comparison of three antituberculous drugs in serum and cold abscesses of patients with spinal tuberculosis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477883/),[μg] / [ml],2.84,241849,DB01045,Rifampicin
,11477883,Cmax,"The Cmax of INH, RFP and OFLX in serum were 10.87 +/- 7.09 micrograms/ml, 9.98 +/- 3.53 micrograms/ml, and 5.29 +/- 0.72 micrograms/ml, while the Cmax of INH, RFP and OFLX in cold abscesses were 2.84 +/- 1.63 micrograms/ml, 0.57 +/- 0.26 microgram/ml and 3.19 +/- 1.29 micrograms/ml respectively.",[Comparison of three antituberculous drugs in serum and cold abscesses of patients with spinal tuberculosis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477883/),[μg] / [ml],0.57,241850,DB01045,Rifampicin
,11477883,Cmax,"The Cmax of INH, RFP and OFLX in serum were 10.87 +/- 7.09 micrograms/ml, 9.98 +/- 3.53 micrograms/ml, and 5.29 +/- 0.72 micrograms/ml, while the Cmax of INH, RFP and OFLX in cold abscesses were 2.84 +/- 1.63 micrograms/ml, 0.57 +/- 0.26 microgram/ml and 3.19 +/- 1.29 micrograms/ml respectively.",[Comparison of three antituberculous drugs in serum and cold abscesses of patients with spinal tuberculosis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11477883/),[μg] / [ml],3.19,241851,DB01045,Rifampicin
,25860000,Peak RMP concentration (Cmax),Peak RMP concentration (Cmax) attained was 6.24 μg/ml (range 5.44-7.61) at time to Cmax of 3.5 h (range 3-4).,"Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25860000/),[μg] / [ml],6.24,242284,DB01045,Rifampicin
,25860000,time to Cmax,Peak RMP concentration (Cmax) attained was 6.24 μg/ml (range 5.44-7.61) at time to Cmax of 3.5 h (range 3-4).,"Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25860000/),h,3.5,242285,DB01045,Rifampicin
<,25860000,Cmax,"RMP Cmax was <8 μg/ml in all patients, a level considered too low for therapeutic efficacy.","Rifampicin pharmacokinetics in children under the Revised National Tuberculosis Control Programme, India, 2009. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25860000/),[μg] / [ml],8,242286,DB01045,Rifampicin
,26902373,solubility,"Lipospheres exhibited amorphous, smooth spherical morphology with a significant increase (p < 0.001) in solubility of SDRPL (2:1), 350.9 ± 23 versus 105.1 ± 12 μg/ml and SDRPL (1:1) 306.4 ± 20 versus 105.1 ± 12 μg/ml in comparison to rifampicin (RMP).",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),[μg] / [ml],350.9,242293,DB01045,Rifampicin
,26902373,solubility,"Lipospheres exhibited amorphous, smooth spherical morphology with a significant increase (p < 0.001) in solubility of SDRPL (2:1), 350.9 ± 23 versus 105.1 ± 12 μg/ml and SDRPL (1:1) 306.4 ± 20 versus 105.1 ± 12 μg/ml in comparison to rifampicin (RMP).",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),[μg] / [ml],105.1,242294,DB01045,Rifampicin
,26902373,solubility,"Lipospheres exhibited amorphous, smooth spherical morphology with a significant increase (p < 0.001) in solubility of SDRPL (2:1), 350.9 ± 23 versus 105.1 ± 12 μg/ml and SDRPL (1:1) 306.4 ± 20 versus 105.1 ± 12 μg/ml in comparison to rifampicin (RMP).",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),[μg] / [ml],306.4,242295,DB01045,Rifampicin
,26902373,peak plasma concentration,"Lipospheres exhibited higher peak plasma concentration (109.92 ± 25 versus 54.31 ± 18 μg/ml), faster T max (two versus four hours), and enhanced area under the curve (AUC0-∞) (406.92 ± 18 versus 147.72 ± 15 μg h/L) in comparison to pure RMP.",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),[μg] / [ml],109.92,242296,DB01045,Rifampicin
,26902373,peak plasma concentration,"Lipospheres exhibited higher peak plasma concentration (109.92 ± 25 versus 54.31 ± 18 μg/ml), faster T max (two versus four hours), and enhanced area under the curve (AUC0-∞) (406.92 ± 18 versus 147.72 ± 15 μg h/L) in comparison to pure RMP.",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),[μg] / [ml],54.31,242297,DB01045,Rifampicin
,26902373,T max,"Lipospheres exhibited higher peak plasma concentration (109.92 ± 25 versus 54.31 ± 18 μg/ml), faster T max (two versus four hours), and enhanced area under the curve (AUC0-∞) (406.92 ± 18 versus 147.72 ± 15 μg h/L) in comparison to pure RMP.",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),h,two,242298,DB01045,Rifampicin
,26902373,T max,"Lipospheres exhibited higher peak plasma concentration (109.92 ± 25 versus 54.31 ± 18 μg/ml), faster T max (two versus four hours), and enhanced area under the curve (AUC0-∞) (406.92 ± 18 versus 147.72 ± 15 μg h/L) in comparison to pure RMP.",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),h,four,242299,DB01045,Rifampicin
,26902373,area under the curve (AUC0-∞),"Lipospheres exhibited higher peak plasma concentration (109.92 ± 25 versus 54.31 ± 18 μg/ml), faster T max (two versus four hours), and enhanced area under the curve (AUC0-∞) (406.92 ± 18 versus 147.72 ± 15 μg h/L) in comparison to pure RMP.",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),[h·μg] / [l],406.92,242300,DB01045,Rifampicin
,26902373,area under the curve (AUC0-∞),"Lipospheres exhibited higher peak plasma concentration (109.92 ± 25 versus 54.31 ± 18 μg/ml), faster T max (two versus four hours), and enhanced area under the curve (AUC0-∞) (406.92 ± 18 versus 147.72 ± 15 μg h/L) in comparison to pure RMP.",In Vitro-In Vivo Evaluation of Novel Co-spray Dried Rifampicin Phospholipid Lipospheres for Oral Delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26902373/),[h·μg] / [l],147.72,242301,DB01045,Rifampicin
,26810651,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[μg] / [ml],2.9,242302,DB01045,Rifampicin
,26810651,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[μg] / [ml],7.9,242303,DB01045,Rifampicin
,26810651,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[μg] / [ml],41.9,242304,DB01045,Rifampicin
,26810651,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[μg] / [ml],1.3,242305,DB01045,Rifampicin
,26810651,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[μg] / [ml],8 to 24,242306,DB01045,Rifampicin
,26810651,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[μg] / [ml],3 to 6,242307,DB01045,Rifampicin
,26810651,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[μg] / [ml],20 to 50,242308,DB01045,Rifampicin
,26810651,maximum plasma concentrations (Cmax),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[μg] / [ml],2 to 6,242309,DB01045,Rifampicin
,26810651,areas under the concentration-time curves from 0 to 8 h (AUC0-8),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[h·μg] / [ml],12.1,242310,DB01045,Rifampicin
,26810651,areas under the concentration-time curves from 0 to 8 h (AUC0-8),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[h·μg] / [ml],24.7,242311,DB01045,Rifampicin
,26810651,areas under the concentration-time curves from 0 to 8 h (AUC0-8),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[h·μg] / [ml],239.4,242312,DB01045,Rifampicin
,26810651,areas under the concentration-time curves from 0 to 8 h (AUC0-8),"The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 μg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 μg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 μg · h/ml, respectively.","Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26810651/),[h·μg] / [ml],5.1,242313,DB01045,Rifampicin
,22300396,clearance,"The model included a mixture of two subpopulations with different typical values of clearance, namely fast (3.12 l h(-1)) and slow metabolizers (1.45 l h(-1)), with 17% probability of belonging to the latter.",Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300396/),[l] / [h],3.12,242715,DB01045,Rifampicin
,22300396,clearance,"The model included a mixture of two subpopulations with different typical values of clearance, namely fast (3.12 l h(-1)) and slow metabolizers (1.45 l h(-1)), with 17% probability of belonging to the latter.",Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300396/),[l] / [h],1.45,242716,DB01045,Rifampicin
,22300396,absorption mean transit time,"Absorption displayed large between-occasion variability, and food slowed the absorption mean transit time from 0.6 to 2.5 h.",Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300396/),h,0.6,242717,DB01045,Rifampicin
,22300396,absorption mean transit time,"Absorption displayed large between-occasion variability, and food slowed the absorption mean transit time from 0.6 to 2.5 h.",Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300396/),h,2.5,242718,DB01045,Rifampicin
,2037709,AUC,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),[h·μg] / [ml],160.5,243153,DB01045,Rifampicin
,2037709,AUC,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),[h·μg] / [ml],124,243154,DB01045,Rifampicin
,2037709,AUC,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),[h·μg] / [ml],152,243155,DB01045,Rifampicin
,2037709,AUC,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),[h·μg] / [ml],152.8,243156,DB01045,Rifampicin
,2037709,Kel,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),1/[h],.0211,243157,DB01045,Rifampicin
,2037709,Kel,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),1/[h],.0264,243158,DB01045,Rifampicin
,2037709,Kel,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),1/[h],.0219,243159,DB01045,Rifampicin
,2037709,Kel,"On days 1 and 22, respectively, the AUC (micrograms.hr/mL) (mean +/- SD) was 160.5 +/- 19.5 and 124 +/- 22.2 in group I, 152 +/- 25 and 152.8 +/- 33.9 in group II; the Kel (hr-1) was .0211 +/- .0030 and .0264 +/- .0040 in group I, .0219 +/- .0036 and .0216 +/- .0053 in group II.",Induction of fluconazole metabolism by rifampin: in vivo study in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037709/),1/[h],.0216,243160,DB01045,Rifampicin
,14534520,elimination half-life,Rifampin decreased the mean area under the plasma concentration-time curve for gliclazide by 70% (P <.001) and the mean elimination half-life from 9.5 to 3.3 hours (P <.05).,Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534520/),h,9.5,243244,DB01045,Rifampicin
,14534520,elimination half-life,Rifampin decreased the mean area under the plasma concentration-time curve for gliclazide by 70% (P <.001) and the mean elimination half-life from 9.5 to 3.3 hours (P <.05).,Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534520/),h,3.3,243245,DB01045,Rifampicin
,22923869,Percent recoveries,"Percent recoveries for rifampicin at high, middle and low quality control samples was obtained 55.15, 48.65 and 49.62%, respectively and for internal standard was 60.22%.",Development and validation of liquid chromatography-mass spectrometry method for the estimation of rifampicin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22923869/),%,55.15,244005,DB01045,Rifampicin
,22923869,Percent recoveries,"Percent recoveries for rifampicin at high, middle and low quality control samples was obtained 55.15, 48.65 and 49.62%, respectively and for internal standard was 60.22%.",Development and validation of liquid chromatography-mass spectrometry method for the estimation of rifampicin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22923869/),%,48.65,244006,DB01045,Rifampicin
,22923869,Percent recoveries,"Percent recoveries for rifampicin at high, middle and low quality control samples was obtained 55.15, 48.65 and 49.62%, respectively and for internal standard was 60.22%.",Development and validation of liquid chromatography-mass spectrometry method for the estimation of rifampicin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22923869/),%,49.62,244007,DB01045,Rifampicin
,22923869,Percent recoveries,"Percent recoveries for rifampicin at high, middle and low quality control samples was obtained 55.15, 48.65 and 49.62%, respectively and for internal standard was 60.22%.",Development and validation of liquid chromatography-mass spectrometry method for the estimation of rifampicin in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22923869/),%,60.22,244008,DB01045,Rifampicin
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],3.0 to 6.0,244163,DB01045,Rifampicin
,19347334,maximum concentration in plasma (C(max),"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.4 to 13.4,244164,DB01045,Rifampicin
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],38.2 to 88.3,244165,DB01045,Rifampicin
,19347334,area under the plasma concentration time curve (AUC,"Compared with fesoterodine alone, coadministration of fesoterodine with ketoconazole resulted in increases in mean 5-HMT maximum concentration in plasma (C(max); from 3.0 to 6.0 ng/mL in EMs and from 6.4 to 13.4 ng/mL in PMs) and mean area under the plasma concentration time curve (AUC; from 38.2 to 88.3 ng h/mL in EMs and 88.3 to 217.2 ng h/mL in PMs).",Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],88.3 to 217.2,244166,DB01045,Rifampicin
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],5.2 to 1.5,244167,DB01045,Rifampicin
,19347334,C(max),Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[ng] / [ml],6.8 to 1.9,244168,DB01045,Rifampicin
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],62.4 to 14.4,244169,DB01045,Rifampicin
,19347334,AUC,Coadministration of festerodine with rifampicin resulted in decreases in mean 5-HMT C(max) (from 5.2 to 1.5 ng/mL in EMs and from 6.8 to 1.9 ng/mL in PMs) and mean AUC (from 62.4 to 14.4 ng h/mL in EMs and from 87.8 to 19.6 ng h/mL in PMs).,Evaluation of drug-drug interactions with fesoterodine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19347334/),[h·ng] / [ml],87.8 to 19.6,244170,DB01045,Rifampicin
,8758480,Cmax,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[ng] / [ml],113.0,244925,DB01045,Rifampicin
,8758480,Cmax,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[ng] / [ml],6.2,244926,DB01045,Rifampicin
,8758480,AUC,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[h·ng] / [ml],1652.7,244927,DB01045,Rifampicin
,8758480,AUC,"The coadministration of rifampin resulted in a 18 fold decrease of the Cmax of itraconazole [from 113.0 (SD: 17.2) to 6.2 ng/ml (SD: 3.9)], and in a 22 fold decrease of the AUC [from 1652.7 (SD: 297.7) to 75.6 ng.h/ml (SD: 30.01)].",[Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8758480/),[h·ng] / [ml],75.6,244928,DB01045,Rifampicin
,6508979,elimination half-life,After rifampicin treatment the elimination half-life of antipyrine had decreased in all patients from 12.9 +/- 5.0 to 8.8 +/- 2.0 h (P less than 0.05).,Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),h,12.9,245332,DB01045,Rifampicin
,6508979,elimination half-life,After rifampicin treatment the elimination half-life of antipyrine had decreased in all patients from 12.9 +/- 5.0 to 8.8 +/- 2.0 h (P less than 0.05).,Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),h,8.8,245333,DB01045,Rifampicin
,6508979,clearance,"Antipyrine clearance had increased from 2.2 +/- 0.9 to 2.9 +/- 0.7 l/h (P less than 0.05), while no change in apparent volume of distribution was observed.",Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),[l] / [h],2.2,245334,DB01045,Rifampicin
,6508979,clearance,"Antipyrine clearance had increased from 2.2 +/- 0.9 to 2.9 +/- 0.7 l/h (P less than 0.05), while no change in apparent volume of distribution was observed.",Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),[l] / [h],2.9,245335,DB01045,Rifampicin
,6508979,rate of formation,The increase in antipyrine clearance was primarily due to a selective increase in the rate of formation of norantipyrine by 80% from 6.9 +/- 3.4 to 12.4 +/- 3.4 ml/min.,Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),[ml] / [min],6.9,245336,DB01045,Rifampicin
,6508979,rate of formation,The increase in antipyrine clearance was primarily due to a selective increase in the rate of formation of norantipyrine by 80% from 6.9 +/- 3.4 to 12.4 +/- 3.4 ml/min.,Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508979/),[ml] / [min],12.4,245337,DB01045,Rifampicin
,22139693,t(1/2),"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),h,4.83 to 7.75,245672,DB01045,Rifampicin
,22139693,t(1/2),"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),h,6.42,245673,DB01045,Rifampicin
,22139693,t(1/2),"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),h,7.46,245674,DB01045,Rifampicin
,22139693,total body clearance,"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),[l] / [h·kg],0.46 to 0.26,245675,DB01045,Rifampicin
,22139693,total body clearance,"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),[l] / [h·kg],0.28,245676,DB01045,Rifampicin
,22139693,total body clearance,"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),[l] / [h·kg],0.24,245677,DB01045,Rifampicin
,10460103,Cmax,"Both fasting conditions produced similar results: a mean INH Cmax of 5.53 +/- 2.92 microg/ml, Tmax of 1.02 +/- 1.10 hours, and AUC0-infinity of 20.16 +/- 12.45 microg x hr/ml.","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[μg] / [ml],5.53,246003,DB01045,Rifampicin
,10460103,Tmax,"Both fasting conditions produced similar results: a mean INH Cmax of 5.53 +/- 2.92 microg/ml, Tmax of 1.02 +/- 1.10 hours, and AUC0-infinity of 20.16 +/- 12.45 microg x hr/ml.","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),h,1.02,246004,DB01045,Rifampicin
,10460103,AUC0-infinity,"Both fasting conditions produced similar results: a mean INH Cmax of 5.53 +/- 2.92 microg/ml, Tmax of 1.02 +/- 1.10 hours, and AUC0-infinity of 20.16 +/- 12.45 microg x hr/ml.","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[h·μg] / [ml],20.16,246005,DB01045,Rifampicin
,10460103,Cmax,"Antacids did not alter these parameters significantly (Cmax of 5.62 +/- 2.53 microg/ml, Tmax of 0.71 +/- 0.56 hours, and AUC0-infinity of 20.27 +/- 11.39 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[μg] / [ml],5.62,246006,DB01045,Rifampicin
,10460103,Tmax,"Antacids did not alter these parameters significantly (Cmax of 5.62 +/- 2.53 microg/ml, Tmax of 0.71 +/- 0.56 hours, and AUC0-infinity of 20.27 +/- 11.39 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),h,0.71,246007,DB01045,Rifampicin
,10460103,AUC0-infinity,"Antacids did not alter these parameters significantly (Cmax of 5.62 +/- 2.53 microg/ml, Tmax of 0.71 +/- 0.56 hours, and AUC0-infinity of 20.27 +/- 11.39 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[h·μg] / [ml],20.27,246008,DB01045,Rifampicin
,10460103,Cmax,"In contrast, the high-fat meal recommended by the Food and Drug Administration reduced INH Cmax by 51% (2.73 +/- 1.70 microg/ml), nearly doubled Tmax (1.93 +/- 1.61 hours), and reduced AUC0-infinity by 12% (17.72 +/- 10.32 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[μg] / [ml],2.73,246009,DB01045,Rifampicin
,10460103,Tmax,"In contrast, the high-fat meal recommended by the Food and Drug Administration reduced INH Cmax by 51% (2.73 +/- 1.70 microg/ml), nearly doubled Tmax (1.93 +/- 1.61 hours), and reduced AUC0-infinity by 12% (17.72 +/- 10.32 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),h,1.93,246010,DB01045,Rifampicin
,10460103,AUC0-infinity,"In contrast, the high-fat meal recommended by the Food and Drug Administration reduced INH Cmax by 51% (2.73 +/- 1.70 microg/ml), nearly doubled Tmax (1.93 +/- 1.61 hours), and reduced AUC0-infinity by 12% (17.72 +/- 10.32 microg x hr/ml).","Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460103/),[h·μg] / [ml],17.72,246011,DB01045,Rifampicin
,25096076,rate constant,"The rate constant of 4β-hydroxycholesterol formation [mean (95% CI)] just before completion of TB treatment [efavirenz/rifampicin co-treatment, 7.40 × 10(-7) h(-1) (5.5 × 10(-7)-1.0 × 10(-6))] was significantly higher than that calculated 8 weeks after completion [efavirenz alone, 4.50 × 10(-7) h(-1) (4.40 × 10(-7)-4.52 × 10(-7))].",Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25096076/),1/[h],7.40 × 10(-7),246179,DB01045,Rifampicin
,25096076,rate constant,"The rate constant of 4β-hydroxycholesterol formation [mean (95% CI)] just before completion of TB treatment [efavirenz/rifampicin co-treatment, 7.40 × 10(-7) h(-1) (5.5 × 10(-7)-1.0 × 10(-6))] was significantly higher than that calculated 8 weeks after completion [efavirenz alone, 4.50 × 10(-7) h(-1) (4.40 × 10(-7)-4.52 × 10(-7))].",Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25096076/),,5,246180,DB01045,Rifampicin
,25096076,rate constant,"The rate constant of 4β-hydroxycholesterol formation [mean (95% CI)] just before completion of TB treatment [efavirenz/rifampicin co-treatment, 7.40 × 10(-7) h(-1) (5.5 × 10(-7)-1.0 × 10(-6))] was significantly higher than that calculated 8 weeks after completion [efavirenz alone, 4.50 × 10(-7) h(-1) (4.40 × 10(-7)-4.52 × 10(-7))].",Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25096076/),,1,246181,DB01045,Rifampicin
,25096076,rate constant,"The rate constant of 4β-hydroxycholesterol formation [mean (95% CI)] just before completion of TB treatment [efavirenz/rifampicin co-treatment, 7.40 × 10(-7) h(-1) (5.5 × 10(-7)-1.0 × 10(-6))] was significantly higher than that calculated 8 weeks after completion [efavirenz alone, 4.50 × 10(-7) h(-1) (4.40 × 10(-7)-4.52 × 10(-7))].",Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25096076/),1/[h],4.50 × 10(-7),246182,DB01045,Rifampicin
,25096076,rate constant,"The rate constant of 4β-hydroxycholesterol formation [mean (95% CI)] just before completion of TB treatment [efavirenz/rifampicin co-treatment, 7.40 × 10(-7) h(-1) (5.5 × 10(-7)-1.0 × 10(-6))] was significantly higher than that calculated 8 weeks after completion [efavirenz alone, 4.50 × 10(-7) h(-1) (4.40 × 10(-7)-4.52 × 10(-7))].",Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25096076/),,4.40 ×,246183,DB01045,Rifampicin
,25096076,rate constant,"The rate constant of 4β-hydroxycholesterol formation [mean (95% CI)] just before completion of TB treatment [efavirenz/rifampicin co-treatment, 7.40 × 10(-7) h(-1) (5.5 × 10(-7)-1.0 × 10(-6))] was significantly higher than that calculated 8 weeks after completion [efavirenz alone, 4.50 × 10(-7) h(-1) (4.40 × 10(-7)-4.52 × 10(-7))].",Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25096076/),,4.52 ×,246184,DB01045,Rifampicin
,26518065,plasma clearance,"Extended dialysis removed a considerable amount of both EMB and RIF, with a dialyser plasma clearance ranging between 37 and 95 ml/min for EMB and between 39 and 53 ml/min for RIF.",Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518065/),[ml] / [min],37 and 95,246302,DB01045,Rifampicin
,26518065,plasma clearance,"Extended dialysis removed a considerable amount of both EMB and RIF, with a dialyser plasma clearance ranging between 37 and 95 ml/min for EMB and between 39 and 53 ml/min for RIF.",Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518065/),[ml] / [min],39 and 53,246303,DB01045,Rifampicin
,26518065,peak level,"The EMB peak level (3h after a 2-h infusion) using a dose of 1000 mg/day on the first day of treatment was 2.3mg/l, which is in the low therapeutic range (2-5mg/l).",Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518065/),[mg] / [l],2.3,246304,DB01045,Rifampicin
,33542056,area under the plasma concentration-time curve from time 0 to 12 h (AUC0-24 h),"There was a more than proportional increase in the rifampicin geometric mean area under the plasma concentration-time curve from time 0 to 12 h (AUC0-24 h) for 50 mg·kg-1 compared with 40 mg·kg-1; 571 (range 320-995) versus 387 (range 201-847) mg·L-1·h, while peak exposures saw proportional increases.",Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33542056/),[h·mg] / [l],571,246651,DB01045,Rifampicin
,33542056,area under the plasma concentration-time curve from time 0 to 12 h (AUC0-24 h),"There was a more than proportional increase in the rifampicin geometric mean area under the plasma concentration-time curve from time 0 to 12 h (AUC0-24 h) for 50 mg·kg-1 compared with 40 mg·kg-1; 571 (range 320-995) versus 387 (range 201-847) mg·L-1·h, while peak exposures saw proportional increases.",Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33542056/),[h·mg] / [l],387,246652,DB01045,Rifampicin
,33542056,Protein-unbound exposure,Protein-unbound exposure after 50 mg·kg-1 (11% (range 8-17%)) was comparable with lower rifampicin doses.,Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33542056/),%,11,246653,DB01045,Rifampicin
,31269277,steady state AUC0-24h,The suggested exposure target for Bayesian dose optimisation was a steady state AUC0-24h of 181-214 h × mg/L.,Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269277/),[h·mg] / [l],181-214,246796,DB01045,Rifampicin
,31269277,MICs,The observed MICs ranged from 0.016-0.125 mg/L (mode: 0.064 mg/L).,Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269277/),[mg] / [l],0.016-0.125,246797,DB01045,Rifampicin
,31269277,MICs,The observed MICs ranged from 0.016-0.125 mg/L (mode: 0.064 mg/L).,Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31269277/),[mg] / [l],0.064,246798,DB01045,Rifampicin
,32816738,MIC,The median pretreatment MIC was 16 mg/liter.,Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816738/),[mg] / [l],16,247341,DB01045,Rifampicin
≤,32816738,MICs,"Simulations showed that with daily doses of terizidone (750 mg and 1,000 mg for patients weighing ≤45 kg and >45 kg, respectively), the probability of maintaining the plasma cycloserine concentration above the MIC for more than 30% of the dosing interval (30% T >MIC) (which is associated with a 1.0-log10-CFU/ml kill in vitro) exceeded 90% at MIC values of ≤16 mg/liter, but the proportion of patients achieving 100% T >MIC (which is associated with the prevention of resistance) was more than 90% only at MICs of ≤8 mg/liter.",Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816738/),[mg] / [l],8,247342,DB01045,Rifampicin
≤,32816738,MICs,"Based on a target derived in vitro, the WHO-recommended doses of terizidone are effective for cycloserine MICs of ≤8 mg/liter, and higher doses are required to prevent the development of resistance.",Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32816738/),[mg] / [l],8,247343,DB01045,Rifampicin
,6391781,elimination half-life,"The effect of renal impairment is relatively unimportant for the excretion of isoniazid, rifampicin and para-aminosalicylic acid, but the elimination half-life of streptomycin increases to 100 hours when the blood urea nitrogen level is greater than 100mg/100ml, and ototoxicity is strikingly more frequent.",Clinical pharmacokinetics of the antituberculosis drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6391781/),h,100,247974,DB01045,Rifampicin
up to,6391781,elimination half-life,"Of the data concerning age-related effects, most notable are the prolonged elimination half-life of isoniazid in neonates (up to 19.8 hours), and the lower peak serum concentrations of rifampicin in children of one-third to one-tenth those of adults following a similar dose on a weight basis.",Clinical pharmacokinetics of the antituberculosis drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6391781/),h,19.8,247975,DB01045,Rifampicin
,3752982,half-lives,"The half-lives of novobiocin and rifampin when administered alone were 5.85 +/- 1.20 and 1.46 +/- 0.30 h, respectively; when administered in combination, the half-lives were 2.66 +/- 0.65 and 1.43 +/- 0.29 h, respectively.",Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752982/),h,5.85,248130,DB01045,Rifampicin
,3752982,half-lives,"The half-lives of novobiocin and rifampin when administered alone were 5.85 +/- 1.20 and 1.46 +/- 0.30 h, respectively; when administered in combination, the half-lives were 2.66 +/- 0.65 and 1.43 +/- 0.29 h, respectively.",Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752982/),h,1.46,248131,DB01045,Rifampicin
,3752982,half-lives,"The half-lives of novobiocin and rifampin when administered alone were 5.85 +/- 1.20 and 1.46 +/- 0.30 h, respectively; when administered in combination, the half-lives were 2.66 +/- 0.65 and 1.43 +/- 0.29 h, respectively.",Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752982/),h,2.66,248132,DB01045,Rifampicin
,3752982,half-lives,"The half-lives of novobiocin and rifampin when administered alone were 5.85 +/- 1.20 and 1.46 +/- 0.30 h, respectively; when administered in combination, the half-lives were 2.66 +/- 0.65 and 1.43 +/- 0.29 h, respectively.",Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752982/),h,1.43,248133,DB01045,Rifampicin
,28193650,half-maximal [50%] inhibitory concentration [IC50],RTV was more effective in lowering 10 μM RIF-induced elevations in DRV CLint.app. (half-maximal [50%] inhibitory concentration [IC50] = 0.025 μM) than COBI (IC50 = 0.223 μM).,Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193650/),μM,0.025,248175,DB01045,Rifampicin
,28193650,IC50,RTV was more effective in lowering 10 μM RIF-induced elevations in DRV CLint.app. (half-maximal [50%] inhibitory concentration [IC50] = 0.025 μM) than COBI (IC50 = 0.223 μM).,Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28193650/),μM,0.223,248176,DB01045,Rifampicin
,32103956,permeation flux,"The OCNE-1T gel exhibited higher permeation flux (51.32 ± 0.5 µg/cm2 hr), permeation coefficient (2.566 ± 0.08 cm/hr), drug deposition (994.404 µg/cm2), and enhancement ratio (7.16) than those of the OCNE-1 nanoemulsion or drug solution.",Novel Approach for Transdermal Delivery of Rifampicin to Induce Synergistic Antimycobacterial Effects Against Cutaneous and Systemic Tuberculosis Using a Cationic Nanoemulsion Gel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32103956/),[μg] / [cm2·h],51.32,248329,DB01045,Rifampicin
,32103956,permeation coefficient,"The OCNE-1T gel exhibited higher permeation flux (51.32 ± 0.5 µg/cm2 hr), permeation coefficient (2.566 ± 0.08 cm/hr), drug deposition (994.404 µg/cm2), and enhancement ratio (7.16) than those of the OCNE-1 nanoemulsion or drug solution.",Novel Approach for Transdermal Delivery of Rifampicin to Induce Synergistic Antimycobacterial Effects Against Cutaneous and Systemic Tuberculosis Using a Cationic Nanoemulsion Gel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32103956/),[cm] / [h],2.566,248330,DB01045,Rifampicin
,32103956,drug deposition,"The OCNE-1T gel exhibited higher permeation flux (51.32 ± 0.5 µg/cm2 hr), permeation coefficient (2.566 ± 0.08 cm/hr), drug deposition (994.404 µg/cm2), and enhancement ratio (7.16) than those of the OCNE-1 nanoemulsion or drug solution.",Novel Approach for Transdermal Delivery of Rifampicin to Induce Synergistic Antimycobacterial Effects Against Cutaneous and Systemic Tuberculosis Using a Cationic Nanoemulsion Gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32103956/),[μg] / [cm2],994.404,248331,DB01045,Rifampicin
,32103956,enhancement ratio,"The OCNE-1T gel exhibited higher permeation flux (51.32 ± 0.5 µg/cm2 hr), permeation coefficient (2.566 ± 0.08 cm/hr), drug deposition (994.404 µg/cm2), and enhancement ratio (7.16) than those of the OCNE-1 nanoemulsion or drug solution.",Novel Approach for Transdermal Delivery of Rifampicin to Induce Synergistic Antimycobacterial Effects Against Cutaneous and Systemic Tuberculosis Using a Cationic Nanoemulsion Gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32103956/),,7.16,248332,DB01045,Rifampicin
,3740826,systemic absorption,The absolute extent of rifampicin systemic absorption following oral administration to the rats was 60 to 85 per cent.,[Modelling of rifampicin pharmacokinetics in experimental animals administered the drug intravenously and internally]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740826/),%,60 to 85,248454,DB01045,Rifampicin
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),,98.,248833,DB01045,Rifampicin
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,53.1,248834,DB01045,Rifampicin
,32458378,total radioactivity recovered,"In the human mass balance study, mean total radioactivity recovered was 98.3% of the dose administered (53.1% and 45.2% excreted via urine and feces, respectively).","Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32458378/),%,45.2,248835,DB01045,Rifampicin
,21429802,2 h,It is noteworthy that many adult patients receiving currently recommended RMP dosages also do not reach the often recommended RMP 2 h serum concentration of 8 μg/mL.,The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21429802/),[μg] / [ml],8,249090,DB01045,Rifampicin
,21429802,serum concentration,It is noteworthy that many adult patients receiving currently recommended RMP dosages also do not reach the often recommended RMP 2 h serum concentration of 8 μg/mL.,The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21429802/),[μg] / [ml],8,249091,DB01045,Rifampicin
,8894514,oral clearance,"In contrast, oral clearance of nifedipine increased from 1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p < 0.01) and bioavailability decreased from 41.2 +/- 5.4% to 5.3 +/- 2.7% (p < 0.001).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),[l] / [min],1.5,249747,DB01045,Rifampicin
,8894514,oral clearance,"In contrast, oral clearance of nifedipine increased from 1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p < 0.01) and bioavailability decreased from 41.2 +/- 5.4% to 5.3 +/- 2.7% (p < 0.001).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),[l] / [min],20.9,249748,DB01045,Rifampicin
,8894514,bioavailability,"In contrast, oral clearance of nifedipine increased from 1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p < 0.01) and bioavailability decreased from 41.2 +/- 5.4% to 5.3 +/- 2.7% (p < 0.001).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,41.2,249749,DB01045,Rifampicin
,8894514,bioavailability,"In contrast, oral clearance of nifedipine increased from 1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p < 0.01) and bioavailability decreased from 41.2 +/- 5.4% to 5.3 +/- 2.7% (p < 0.001).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,5.3,249750,DB01045,Rifampicin
,8894514,hepatic extraction,"Although hepatic extraction of nifedipine was not significantly altered during induction (47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns), the calculated extraction of nifedipine in gut wall mucosa increased from 21.8 +/- 13.3% to 75.8 +/- 28.2% (p < 0.05).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,47.4,249751,DB01045,Rifampicin
,8894514,hepatic extraction,"Although hepatic extraction of nifedipine was not significantly altered during induction (47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns), the calculated extraction of nifedipine in gut wall mucosa increased from 21.8 +/- 13.3% to 75.8 +/- 28.2% (p < 0.05).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,67.4,249752,DB01045,Rifampicin
,8894514,extraction,"Although hepatic extraction of nifedipine was not significantly altered during induction (47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns), the calculated extraction of nifedipine in gut wall mucosa increased from 21.8 +/- 13.3% to 75.8 +/- 28.2% (p < 0.05).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,21.8,249753,DB01045,Rifampicin
,8894514,extraction,"Although hepatic extraction of nifedipine was not significantly altered during induction (47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns), the calculated extraction of nifedipine in gut wall mucosa increased from 21.8 +/- 13.3% to 75.8 +/- 28.2% (p < 0.05).",The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894514/),%,75.8,249754,DB01045,Rifampicin
,26808255,Absolute bioavailability,"Absolute bioavailability of CLA was reduced from ∼40% to below 5% after comedication of RIF in both schedules of administration, and Tmax occurred ∼2-3 h earlier.",Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808255/),%,∼40,249902,DB01045,Rifampicin
below,26808255,Absolute bioavailability,"Absolute bioavailability of CLA was reduced from ∼40% to below 5% after comedication of RIF in both schedules of administration, and Tmax occurred ∼2-3 h earlier.",Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26808255/),%,5,249903,DB01045,Rifampicin
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,323,250135,DB01045,Rifampicin
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,357,250136,DB01045,Rifampicin
,7363932,half-life of,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),min,344,250137,DB01045,Rifampicin
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],3.41,250138,DB01045,Rifampicin
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],4.08,250139,DB01045,Rifampicin
,7363932,clearances,"The half-life of a latter phase was 323 +/- 84 min in the healthy group, 357 +/- 151 min in the patients with intrahepatic cholestasis and 344 +/- 115 min in the group with biliary obstruction; the clearances were 3.41 +/- 0.90, 4.08 +/- 1.95 and 3.81 +/- 1.97 ml x min-1 x kg-1, respectively.",Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7363932/),[ml] / [kg·min],3.81,250140,DB01045,Rifampicin
,21047828,minimum effective concentration (MEC),A minimum effective concentration (MEC) of 3000 ng/mL was used to interpret nevirapine concentrations 12 h after dosing (C(12)).,Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21047828/),[ng] / [ml],3000,250730,DB01045,Rifampicin
,21047828,C(12),"day 7 geometric mean nevirapine C(12) [90% confidence interval (CI)] was 1504 (1127-2115) ng/mL and 3148 (2451-4687) ng/mL in the NVP200 and NVP400 arms, respectively (P < 0.01).",Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21047828/),[ng] / [ml],1504,250731,DB01045,Rifampicin
,21047828,C(12),"day 7 geometric mean nevirapine C(12) [90% confidence interval (CI)] was 1504 (1127-2115) ng/mL and 3148 (2451-4687) ng/mL in the NVP200 and NVP400 arms, respectively (P < 0.01).",Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21047828/),[ng] / [ml],3148,250732,DB01045,Rifampicin
,21047828,area under the curve (AUC(0-12)),"On Day 7, geometric mean area under the curve (AUC(0-12)) was lower in the NVP200 arm, 25 223 (90% CI, 21 978-29 695) ng·h/mL versus 43 195 (35 607-57 035) ng·h/mL in the NVP400 arm (P < 0.01).",Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21047828/),[h·ng] / [ml],25 223,250733,DB01045,Rifampicin
,21047828,area under the curve (AUC(0-12)),"On Day 7, geometric mean area under the curve (AUC(0-12)) was lower in the NVP200 arm, 25 223 (90% CI, 21 978-29 695) ng·h/mL versus 43 195 (35 607-57 035) ng·h/mL in the NVP400 arm (P < 0.01).",Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21047828/),[h·ng] / [ml],43 195,250734,DB01045,Rifampicin
,21047828,AUC(0-12),"Similarly, on Day 14, nevirapine AUC(0-12) was lower in the NVP200 arm 23 668 (18 253-32 218) ng·h/mL versus the NVP400 arm 44 918 (36 264-62 769) ng·h/mL (P = 0.03).",Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21047828/),[h·ng] / [ml],23 668,250735,DB01045,Rifampicin
,21047828,AUC(0-12),"Similarly, on Day 14, nevirapine AUC(0-12) was lower in the NVP200 arm 23 668 (18 253-32 218) ng·h/mL versus the NVP400 arm 44 918 (36 264-62 769) ng·h/mL (P = 0.03).",Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21047828/),[h·ng] / [ml],44 918,250736,DB01045,Rifampicin
,28881378,CL/F,"These changes were primarily because of the effect of rifampin on the elimination parameters of istradefylline; mean CL/F was increased from 4.0 to 20.6 L/h, and mean t1/2 was reduced from 94.8 to 31.5 hours.",Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28881378/),[l] / [h],4.0 to 20.6,251841,DB01045,Rifampicin
,28881378,t1/2,"These changes were primarily because of the effect of rifampin on the elimination parameters of istradefylline; mean CL/F was increased from 4.0 to 20.6 L/h, and mean t1/2 was reduced from 94.8 to 31.5 hours.",Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28881378/),h,94.8 to 31.5,251842,DB01045,Rifampicin
,17495878,AUC(0-infinity),"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[h·ng] / [ml],107.9,252431,DB01045,Rifampicin
,17495878,AUC(0-infinity),"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[h·ng] / [ml],175.3,252432,DB01045,Rifampicin
,17495878,Cl/F/kg,"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[l] / [h·kg],1.26,252433,DB01045,Rifampicin
,17495878,Cl/F/kg,"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[l] / [h·kg],0.81,252434,DB01045,Rifampicin
,17495878,T(1/2),"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),h,2.01,252435,DB01045,Rifampicin
,17495878,T(1/2),"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),h,3.15,252436,DB01045,Rifampicin
,17495878,Cmax,"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[ng] / [ml],50.6,252437,DB01045,Rifampicin
,17495878,Cmax,"Comparisons of pre- and post-supplementation MDZ pharmacokinetic parameters revealed significant inhibition of CYP3A by goldenseal (AUC(0-infinity), 107.9+/-43.3 vs 175.3+/-74.8 ng x h/ml; Cl/F/kg, 1.26+/-0.59 vs 0.81+/-0.45 l/h/kg; T(1/2), 2.01+/-0.42 vs 3.15+/-1.12 h; Cmax, 50.6+/-26.9 vs 71.2+/-50.5 ng/ml).","Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495878/),[ng] / [ml],71.2,252438,DB01045,Rifampicin
,9925057,maximal serum concentration (Cmax),"Both fasting conditions produced similar results: a mean RIF maximal serum concentration (Cmax) of 10.54+/-3.18 microg/mL, the time at which it occurred (Tmax) of 2.42+/-1.32 h, and the area under the curve from time zero to infinity (AUC0-infinity) of 57.15+/-13.41 microg x h/mL.","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[μg] / [ml],10.54,252957,DB01045,Rifampicin
,9925057,time at which it occurred (Tmax),"Both fasting conditions produced similar results: a mean RIF maximal serum concentration (Cmax) of 10.54+/-3.18 microg/mL, the time at which it occurred (Tmax) of 2.42+/-1.32 h, and the area under the curve from time zero to infinity (AUC0-infinity) of 57.15+/-13.41 microg x h/mL.","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),h,2.42,252958,DB01045,Rifampicin
,9925057,area under the curve from time zero to infinity (AUC0-infinity),"Both fasting conditions produced similar results: a mean RIF maximal serum concentration (Cmax) of 10.54+/-3.18 microg/mL, the time at which it occurred (Tmax) of 2.42+/-1.32 h, and the area under the curve from time zero to infinity (AUC0-infinity) of 57.15+/-13.41 microg x h/mL.","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[h·μg] / [ml],57.15,252959,DB01045,Rifampicin
,9925057,Cmax,"Antacids did not alter these parameters (Cmax of 10.89+/-5.22 microg/mL, Tmax of 2.36+/-1.28 h, and AUC0-infinity of 58.37+/-18.49 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[μg] / [ml],10.89,252960,DB01045,Rifampicin
,9925057,Tmax,"Antacids did not alter these parameters (Cmax of 10.89+/-5.22 microg/mL, Tmax of 2.36+/-1.28 h, and AUC0-infinity of 58.37+/-18.49 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),h,2.36,252961,DB01045,Rifampicin
,9925057,AUC0-infinity,"Antacids did not alter these parameters (Cmax of 10.89+/-5.22 microg/mL, Tmax of 2.36+/-1.28 h, and AUC0-infinity of 58.37+/-18.49 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[h·μg] / [ml],58.37,252962,DB01045,Rifampicin
,9925057,Cmax,"In contrast, the Food and Drug Administration high-fat meal reduced RIF Cmax by 36% (7.27+/-2.29 microg/mL), nearly doubled Tmax (4.43+/-1.09 h), but reduced AUC0-infinity by only 6% (55.20+/-14.48 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[μg] / [ml],7.27,252963,DB01045,Rifampicin
,9925057,Tmax,"In contrast, the Food and Drug Administration high-fat meal reduced RIF Cmax by 36% (7.27+/-2.29 microg/mL), nearly doubled Tmax (4.43+/-1.09 h), but reduced AUC0-infinity by only 6% (55.20+/-14.48 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),h,4.43,252964,DB01045,Rifampicin
,9925057,AUC0-infinity,"In contrast, the Food and Drug Administration high-fat meal reduced RIF Cmax by 36% (7.27+/-2.29 microg/mL), nearly doubled Tmax (4.43+/-1.09 h), but reduced AUC0-infinity by only 6% (55.20+/-14.48 microg x h/mL).","Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9925057/),[h·μg] / [ml],55.20,252965,DB01045,Rifampicin
,29341245,terminal elimination phase half-life,"Coadministration of a single 20-mg dose of avatrombopag with fluconazole at steady-state resulted in 2.16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19.7 h to 39.9 h) and led to a clinically significant increase in maximum platelet count (1.66-fold).",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,19.7,253568,DB01045,Rifampicin
,29341245,terminal elimination phase half-life,"Coadministration of a single 20-mg dose of avatrombopag with fluconazole at steady-state resulted in 2.16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19.7 h to 39.9 h) and led to a clinically significant increase in maximum platelet count (1.66-fold).",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,39.9,253569,DB01045,Rifampicin
,29341245,terminal elimination phase half-life,"Coadministration of rifampicin caused a 0.5-fold decrease in AUC and shortened terminal elimination phase half-life (from 20.3 h to 9.84 h), but has no impact on maximum platelet count.",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,20.3,253570,DB01045,Rifampicin
,29341245,terminal elimination phase half-life,"Coadministration of rifampicin caused a 0.5-fold decrease in AUC and shortened terminal elimination phase half-life (from 20.3 h to 9.84 h), but has no impact on maximum platelet count.",Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29341245/),h,9.84,253571,DB01045,Rifampicin
,25813936,clearance (CL),"After i.v. administration of 1 mg/kg cobimetinib to wild-type [(WT) FVB], Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice, clearance (CL) (26-35 ml/min/kg) was similar in the CYP3A4 transgenic and WT mice.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),[ml] / [kg·min],26-35,253713,DB01045,Rifampicin
,25813936,area under the curve (AUC),"After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1.35, 3.39, 1.04, and 0.701 μM⋅h, respectively.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),h·μM,1.35,253714,DB01045,Rifampicin
,25813936,area under the curve (AUC),"After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1.35, 3.39, 1.04, and 0.701 μM⋅h, respectively.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),h·μM,3.39,253715,DB01045,Rifampicin
,25813936,area under the curve (AUC),"After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1.35, 3.39, 1.04, and 0.701 μM⋅h, respectively.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),h·μM,1.04,253716,DB01045,Rifampicin
,25813936,area under the curve (AUC),"After oral administration of 5 mg/kg cobimetinib, the area under the curve (AUC) values of cobimetinib in WT, Cyp3a(-/-)Tg-3A4Hep, Cyp3a(-/-)Tg-3A4Int, or Cyp3a(-/-)Tg-3A4Hep/Int mice were 1.35, 3.39, 1.04, and 0.701 μM⋅h, respectively.","Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25813936/),h·μM,0.701,253717,DB01045,Rifampicin
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,8.6,253862,DB01045,Rifampicin
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,10.7,253863,DB01045,Rifampicin
,15726657,AUC,"Metabolite formation was enhanced by rifampicin, but not by UDCA (e.g., AUC(16alpha-hydroxyprednisolone)/AUC(budesonide) in patients: baseline, 8.6 +/- 3.9; UDCA, 10.7 +/- 7.1; rifampicin, 527.0 +/- 248.7).",No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726657/),,527.0,253864,DB01045,Rifampicin
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.04,254724,DB01045,Rifampicin
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.19,254725,DB01045,Rifampicin
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.06,254726,DB01045,Rifampicin
,18519719,MICs,"The minocycline MICs for these four strains were 0.04 mg/liter, 0.19 mg/liter, 0.06 mg/liter, and 0.75 mg/liter.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.75,254727,DB01045,Rifampicin
<,18519719,MICs,"Minocycline alone produced a 1.5- to 2.0-log(10)-unit reduction in viable count for the strains with MICs of <0.2 mg/liter, while the addition of rifampin increased the ABE for these strains (P < 0.05).",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),[mg] / [l],0.2,254728,DB01045,Rifampicin
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,33.9,254729,DB01045,Rifampicin
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,75.9,254730,DB01045,Rifampicin
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,"1,350",254731,DB01045,Rifampicin
,18519719,AUC/MIC ratios,"Free area under the concentration-time curve (AUC)/MIC was best related to AUBKC or d24 using a sigmoid maximal effect (Emax) model with r(2) of 0.92 and 0.87, respectively, and the AUC/MIC ratios for no change and -1-log-unit, -2-log-unit, and -3-log-unit drop at 24 h were 33.9, 75.9, 1,350, and >2,000, respectively.",Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18519719/),,"2,000",254732,DB01045,Rifampicin
,25633891,clearance,The clearance of all drugs except rifampicin in sodium chloride 0.9% was comparable (mean 1.76 ± 0.11 l/h).,Anti-infective drugs during continuous hemodialysis - using the bench to learn what to do at the bedside. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25633891/),[l] / [h],1.76,255173,DB01045,Rifampicin
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],95,256281,DB01045,Rifampicin
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],110.4,256282,DB01045,Rifampicin
,18691987,AUC(0-infinity),The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ml·ng] / [h],115.3,256283,DB01045,Rifampicin
,18691987,C(max),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ng] / [ml],18.5,256284,DB01045,Rifampicin
,18691987,C(max),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),[ng] / [ml],16.5,256285,DB01045,Rifampicin
,18691987,t(1/2),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h,12.8,256286,DB01045,Rifampicin
,18691987,t(1/2),There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h,13.3,256287,DB01045,Rifampicin
,18691987,oral clearance,The oral clearance of rosuvastatin was not significantly affected by rifampicin pretreatment either (0.4 [0.3] vs 0.3 [0.2] L . h; P = 0.072).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h·l,0.4,256288,DB01045,Rifampicin
,18691987,oral clearance,The oral clearance of rosuvastatin was not significantly affected by rifampicin pretreatment either (0.4 [0.3] vs 0.3 [0.2] L . h; P = 0.072).,"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18691987/),h·l,0.3,256289,DB01045,Rifampicin
,26467592,Cmax,"Neither the peak concentration (Cmax) nor the 24 h area under the curve (AUC24) differed significantly between the two groups (Group 1, Cmax median 3.9 [range 1.9-4.5] mg/l; AUC24 29.1 [10-47.4] mg·h/l and Group 2, Cmax 4.1 [2-6.4] mg/l; AUC24 36.5 [14.6-54.2] mg·h/l).",Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467592/),[mg] / [l],3.9,256414,DB01045,Rifampicin
,26467592,AUC24,"Neither the peak concentration (Cmax) nor the 24 h area under the curve (AUC24) differed significantly between the two groups (Group 1, Cmax median 3.9 [range 1.9-4.5] mg/l; AUC24 29.1 [10-47.4] mg·h/l and Group 2, Cmax 4.1 [2-6.4] mg/l; AUC24 36.5 [14.6-54.2] mg·h/l).",Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467592/),[h·mg] / [l],29.1,256415,DB01045,Rifampicin
,26467592,Cmax,"Neither the peak concentration (Cmax) nor the 24 h area under the curve (AUC24) differed significantly between the two groups (Group 1, Cmax median 3.9 [range 1.9-4.5] mg/l; AUC24 29.1 [10-47.4] mg·h/l and Group 2, Cmax 4.1 [2-6.4] mg/l; AUC24 36.5 [14.6-54.2] mg·h/l).",Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467592/),[mg] / [l],4.1,256416,DB01045,Rifampicin
,26467592,AUC24,"Neither the peak concentration (Cmax) nor the 24 h area under the curve (AUC24) differed significantly between the two groups (Group 1, Cmax median 3.9 [range 1.9-4.5] mg/l; AUC24 29.1 [10-47.4] mg·h/l and Group 2, Cmax 4.1 [2-6.4] mg/l; AUC24 36.5 [14.6-54.2] mg·h/l).",Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26467592/),[h·mg] / [l],36.5,256417,DB01045,Rifampicin
,11760222,plasma clearance (CL),"Results showed that repeated exposure of rifabutin, relative to control, caused a 16% increase in the plasma clearance (CL) of ciprofloxacin after i.v. dosing (4.19 vs. 4.87 L/h/kg).",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[l] / [h·kg],4.19,256851,DB01045,Rifampicin
,11760222,plasma clearance (CL),"Results showed that repeated exposure of rifabutin, relative to control, caused a 16% increase in the plasma clearance (CL) of ciprofloxacin after i.v. dosing (4.19 vs. 4.87 L/h/kg).",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[l] / [h·kg],4.87,256852,DB01045,Rifampicin
,11760222,elimination half-life (T1/2),Estimates of elimination half-life (T1/2) were not affected by rifabutin (control: 0.81 vs. rifabutin pretreated: 1.18 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.81,256853,DB01045,Rifampicin
,11760222,elimination half-life (T1/2),Estimates of elimination half-life (T1/2) were not affected by rifabutin (control: 0.81 vs. rifabutin pretreated: 1.18 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,1.18,256854,DB01045,Rifampicin
,11760222,maximal plasma concentration (Cmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[μg] / [ml],1.34,256855,DB01045,Rifampicin
,11760222,maximal plasma concentration (Cmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),[μg] / [ml],0.91,256856,DB01045,Rifampicin
,11760222,time to Cmax (Tmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.17,256857,DB01045,Rifampicin
,11760222,time to Cmax (Tmax,The data obtained after oral dosing showed that repeated rifabutin dosing caused a significant reduction in the maximal plasma concentration (Cmax: 1.34 vs. 0.91 microg/mL) and a longer time to Cmax (Tmax: 0.17 vs. 0.33 h).,Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,0.33,256858,DB01045,Rifampicin
,11760222,T1/2,"With or without rifabutin pretreatment, the T1/2 estimates of ciprofloxacin for p.o. dosing were similar (2.37-2.58 h) and were approximately twice as long as those obtained after i.v. dosing.",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),h,2.37-2.58,256859,DB01045,Rifampicin
,11760222,oral bioavailability (F),"Since the changes in systemic exposure as a result of rifabutin pretreatment were similar after i.v. and p.o. dosing, the oral bioavailability (F) of ciprofloxacin remained unaffected by rifabutin at approximately 38%.",Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11760222/),%,38,256860,DB01045,Rifampicin
,30853987,total run time,"The proposed method is the fastest method published by now, both in terms of sample preparation (approximately one minute per sample) and chromatographic analysis (total run time 2.4 min).",Fast and Simple LC-MS/MS Method for Rifampicin Quantification in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30853987/),min,2.4,258152,DB01045,Rifampicin
,30853987,recovery,The method showed almost complete recovery (92%) and absence of any significant matrix effect as demonstrated by uniform responses from QC samples prepared in blood plasma from 6 volunteers (RSD <5%).,Fast and Simple LC-MS/MS Method for Rifampicin Quantification in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30853987/),,92,258153,DB01045,Rifampicin
,1282174,bioavailability,"Thus, it easily enters the systemic blood flow, resulting in almost complete bioavailability (75-100%).",Pharmacokinetic profile of nicorandil in humans: an overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),%,75-100,258555,DB01045,Rifampicin
,1282174,Cmax,"On average, the Cmax then is approximately 300 ng/ml, which is achieved rapidly within 30 min after drug intake.",Pharmacokinetic profile of nicorandil in humans: an overview. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[ng] / [ml],300,258556,DB01045,Rifampicin
,1282174,apparent volume of distribution,"After oral (and i.v.) administration of the drug, the apparent volume of distribution is approximately 1.0 L/kg body weight.",Pharmacokinetic profile of nicorandil in humans: an overview. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[l] / [body·kg·weight],1.0,258557,DB01045,Rifampicin
,1282174,apparent elimination half-life,"The apparent elimination half-life is short (approximately 1 h), and total body clearance is close to 1.15 L/min, which is lower than the liver blood flow.",Pharmacokinetic profile of nicorandil in humans: an overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),h,1,258558,DB01045,Rifampicin
,1282174,total body clearance,"The apparent elimination half-life is short (approximately 1 h), and total body clearance is close to 1.15 L/min, which is lower than the liver blood flow.",Pharmacokinetic profile of nicorandil in humans: an overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282174/),[l] / [min],1.15,258559,DB01045,Rifampicin
,23716052,maximum concentration [C(max)],"Three combination regimens achieving clinically relevant concentrations (constant colistin concentration of 0.5, 2, or 5 mg/liter and a rifampin maximum concentration [C(max)] of 5 mg/liter every 24 hours; half-life, 3 h) were investigated.",Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716052/),[mg] / [l],5,259762,DB01045,Rifampicin
,23716052,half-life,"Three combination regimens achieving clinically relevant concentrations (constant colistin concentration of 0.5, 2, or 5 mg/liter and a rifampin maximum concentration [C(max)] of 5 mg/liter every 24 hours; half-life, 3 h) were investigated.",Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23716052/),h,3,259763,DB01045,Rifampicin
,9239804,PKa's,Rifampicin is a zwitterion with PKa's of 1.7 and 7.9.,Plasma and saliva concentrations of rifampicin in man after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9239804/),,1.7,260068,DB01045,Rifampicin
,9239804,PKa's,Rifampicin is a zwitterion with PKa's of 1.7 and 7.9.,Plasma and saliva concentrations of rifampicin in man after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9239804/),,7.9,260069,DB01045,Rifampicin
,9239804,saliva-plasma concentration ratios,The saliva-plasma concentration ratios calculated on the basis of the PKa of 1.7 was 1.6346.,Plasma and saliva concentrations of rifampicin in man after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9239804/),,1.6346,260070,DB01045,Rifampicin
,28833380,clearance (CL),"For the median subject, not taking interacting drugs, estimates for clearance (CL) and central volume of distribution (V2) for selumetinib in the final joint model were 12.7 l h-1 and 35.6 l, respectively.",Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833380/),[l] / [h],12.7,260345,DB01045,Rifampicin
,28833380,central volume of distribution (V2),"For the median subject, not taking interacting drugs, estimates for clearance (CL) and central volume of distribution (V2) for selumetinib in the final joint model were 12.7 l h-1 and 35.6 l, respectively.",Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833380/),l,35.6,260346,DB01045,Rifampicin
greater,10582879,MIC,Its MIC for MAI in broth was greater than 100 microg/ml.,Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582879/),[μg] / [ml],100,260466,DB01045,Rifampicin
,10582879,MIC,"Surprisingly, its MIC for MAI growing in human U937 monocytoid cells was much lower, 5 microg/ml.",Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582879/),[μg] / [ml],5,260467,DB01045,Rifampicin
,10582879,elimination half-life,Pharmacokinetic analysis revealed that the copolymer had an elimination half-life of 60 h and suggested dosing regimens that might produce therapeutic concentrations in tissue.,Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582879/),h,60,260468,DB01045,Rifampicin
,31504342,clearance,The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls.,Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31504342/),[l] / [week],19 681,261371,DB01045,Rifampicin
,31504342,clearance,The median clearance of MPA was 19 681 L/week compared with 12 118 L/week for historical controls.,Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31504342/),[l] / [week],12 118,261372,DB01045,Rifampicin
,16905688,area under the time-concentration curve (AUC),"Results from hepatocyte concentration-time course studies showed that compared with uninduced control (26.9 +/- 1.3 microM . min/mg), digoxin area under the time-concentration curve (AUC) in induced cells when no RIF is present decreased significantly (13.7 +/- 0.9 microM . min/mg; p < 0.01), suggesting induction of Cyp3a.",Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16905688/),[min·μM] / [mg],13.7,262187,DB01045,Rifampicin
,16905688,AUC,"However, digoxin AUC for induced cells in the presence of RIF (27.3 +/- 0.9 microM . min/mg) matched the control.",Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16905688/),[min·μM] / [mg],27.3,262188,DB01045,Rifampicin
,16905688,clearance,"Rat pharmacokinetic studies showed that compared with digoxin clearance in uninduced controls (7.08 +/- 1.57 ml/min/kg), digoxin clearance in induced rats increased 2-fold (15.6 +/- 3.7 ml/min/kg; p < 0.001), but when RIF was coadministered in the induced rats, digoxin clearance (7.14 +/- 1.24 ml/min/kg) overlapped with control.",Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16905688/),[ml] / [kg·min],7.08,262189,DB01045,Rifampicin
,16905688,clearance,"Rat pharmacokinetic studies showed that compared with digoxin clearance in uninduced controls (7.08 +/- 1.57 ml/min/kg), digoxin clearance in induced rats increased 2-fold (15.6 +/- 3.7 ml/min/kg; p < 0.001), but when RIF was coadministered in the induced rats, digoxin clearance (7.14 +/- 1.24 ml/min/kg) overlapped with control.",Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16905688/),[ml] / [kg·min],15.6,262190,DB01045,Rifampicin
,16905688,clearance,"Rat pharmacokinetic studies showed that compared with digoxin clearance in uninduced controls (7.08 +/- 1.57 ml/min/kg), digoxin clearance in induced rats increased 2-fold (15.6 +/- 3.7 ml/min/kg; p < 0.001), but when RIF was coadministered in the induced rats, digoxin clearance (7.14 +/- 1.24 ml/min/kg) overlapped with control.",Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16905688/),[ml] / [kg·min],7.14,262191,DB01045,Rifampicin
,23817346,saliva to plasma ratio,The mean saliva to plasma ratio of RIF concentration was approximately 0.15.,Effect of ofloxacin and norfloxacin on rifampicin pharmacokinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23817346/),,0.15,262548,DB01045,Rifampicin
,31651031,total exposure (AUC0-24),"A trend was shown for 25% lower total exposure (AUC0-24) to rifampicin among diabetics versus non-diabetics (29.9 versus 39.9 mg·h/L, P=0.052).",Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31651031/),[h·mg] / [l],29.9,262668,DB01045,Rifampicin
,31651031,total exposure (AUC0-24),"A trend was shown for 25% lower total exposure (AUC0-24) to rifampicin among diabetics versus non-diabetics (29.9 versus 39.9 mg·h/L, P=0.052).",Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31651031/),[h·mg] / [l],39.9,262669,DB01045,Rifampicin
,31651031,AUC0-24,"The AUC0-24 and peak concentration (Cmax) of isoniazid were also lower in diabetic TB patients (5.4 versus 10.6 mg·h/L, P=0.015 and 1.6 versus 2.8 mg/L, P=0.013).",Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31651031/),[h·mg] / [l],5.4,262670,DB01045,Rifampicin
,31651031,AUC0-24,"The AUC0-24 and peak concentration (Cmax) of isoniazid were also lower in diabetic TB patients (5.4 versus 10.6 mg·h/L, P=0.015 and 1.6 versus 2.8 mg/L, P=0.013).",Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31651031/),[h·mg] / [l],10.6,262671,DB01045,Rifampicin
,31651031,peak concentration (Cmax),"The AUC0-24 and peak concentration (Cmax) of isoniazid were also lower in diabetic TB patients (5.4 versus 10.6 mg·h/L, P=0.015 and 1.6 versus 2.8 mg/L, P=0.013).",Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31651031/),[mg] / [l],1.6,262672,DB01045,Rifampicin
,31651031,peak concentration (Cmax),"The AUC0-24 and peak concentration (Cmax) of isoniazid were also lower in diabetic TB patients (5.4 versus 10.6 mg·h/L, P=0.015 and 1.6 versus 2.8 mg/L, P=0.013).",Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31651031/),[mg] / [l],2.8,262673,DB01045,Rifampicin
,30124844,Chigh,"After 2 weeks of treatment, the median Chigh values for rifampicin, isoniazid, pyrazinamide and ethambutol were 10.0, 5.3, 41.1 and 3.3 mg/L respectively.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),[mg] / [l],10.0,262904,DB01045,Rifampicin
,30124844,Chigh,"After 2 weeks of treatment, the median Chigh values for rifampicin, isoniazid, pyrazinamide and ethambutol were 10.0, 5.3, 41.1 and 3.3 mg/L respectively.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),[mg] / [l],5.3,262905,DB01045,Rifampicin
,30124844,Chigh,"After 2 weeks of treatment, the median Chigh values for rifampicin, isoniazid, pyrazinamide and ethambutol were 10.0, 5.3, 41.1 and 3.3 mg/L respectively.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),[mg] / [l],41.1,262906,DB01045,Rifampicin
,30124844,Chigh,"After 2 weeks of treatment, the median Chigh values for rifampicin, isoniazid, pyrazinamide and ethambutol were 10.0, 5.3, 41.1 and 3.3 mg/L respectively.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),[mg] / [l],3.3,262907,DB01045,Rifampicin
,30124844,Chigh/MIC,"The median Chigh/MIC values for rifampicin, isoniazid, pyrazinamide and ethambutol were 164, 128, 1.3 and 2.5, respectively, whereas the AUC0-6/MIC was 636 (range 156-2759) for rifampicin and 351 (range 72-895) for isoniazid.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),,164,262908,DB01045,Rifampicin
,30124844,Chigh/MIC,"The median Chigh/MIC values for rifampicin, isoniazid, pyrazinamide and ethambutol were 164, 128, 1.3 and 2.5, respectively, whereas the AUC0-6/MIC was 636 (range 156-2759) for rifampicin and 351 (range 72-895) for isoniazid.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),,128,262909,DB01045,Rifampicin
,30124844,Chigh/MIC,"The median Chigh/MIC values for rifampicin, isoniazid, pyrazinamide and ethambutol were 164, 128, 1.3 and 2.5, respectively, whereas the AUC0-6/MIC was 636 (range 156-2759) for rifampicin and 351 (range 72-895) for isoniazid.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),,1.3,262910,DB01045,Rifampicin
,30124844,Chigh/MIC,"The median Chigh/MIC values for rifampicin, isoniazid, pyrazinamide and ethambutol were 164, 128, 1.3 and 2.5, respectively, whereas the AUC0-6/MIC was 636 (range 156-2759) for rifampicin and 351 (range 72-895) for isoniazid.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),,2.5,262911,DB01045,Rifampicin
,30124844,AUC0-6/MIC,"The median Chigh/MIC values for rifampicin, isoniazid, pyrazinamide and ethambutol were 164, 128, 1.3 and 2.5, respectively, whereas the AUC0-6/MIC was 636 (range 156-2759) for rifampicin and 351 (range 72-895) for isoniazid.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),,636,262912,DB01045,Rifampicin
,30124844,AUC0-6/MIC,"The median Chigh/MIC values for rifampicin, isoniazid, pyrazinamide and ethambutol were 164, 128, 1.3 and 2.5, respectively, whereas the AUC0-6/MIC was 636 (range 156-2759) for rifampicin and 351 (range 72-895) for isoniazid.",Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30124844/),,351,262913,DB01045,Rifampicin
,32235864,EC50,"The EC50 of alflutinib-induced CYP3A4 mRNA expression was 0.25 μM, which was similar to that of rifampin.","Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32235864/),μM,0.25,263150,DB01045,Rifampicin
,29488303,area under the plasma concentration-time curve from time zero to infinity (AUCinf ),"When dosed alone, glasdegib geometric mean (% coefficient of variation) area under the plasma concentration-time curve from time zero to infinity (AUCinf ) was 8145 ng × h ml-1 (23%) and maximum observed concentration (Cmax ) was 703.2 ng ml-1 (19%).",Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488303/),[h·ng] / [ml],8145,263526,DB01045,Rifampicin
,29488303,maximum observed concentration (Cmax ),"When dosed alone, glasdegib geometric mean (% coefficient of variation) area under the plasma concentration-time curve from time zero to infinity (AUCinf ) was 8145 ng × h ml-1 (23%) and maximum observed concentration (Cmax ) was 703.2 ng ml-1 (19%).",Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488303/),[ng] / [ml],703.2,263527,DB01045,Rifampicin
,29488303,terminal half-life,"Mean terminal half-life decreased from 13.39 to 5.11 hours, geometric mean apparent oral clearance increased from 12.27 to 41.38 l h-1 , whereas median time to Cmax remained similar (1.50 vs.",Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488303/),h,13.39 to 5.11,263528,DB01045,Rifampicin
,29488303,apparent oral clearance,"Mean terminal half-life decreased from 13.39 to 5.11 hours, geometric mean apparent oral clearance increased from 12.27 to 41.38 l h-1 , whereas median time to Cmax remained similar (1.50 vs.",Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488303/),[l] / [h],12.27 to 41.38,263529,DB01045,Rifampicin
,29488303,time to Cmax,"Mean terminal half-life decreased from 13.39 to 5.11 hours, geometric mean apparent oral clearance increased from 12.27 to 41.38 l h-1 , whereas median time to Cmax remained similar (1.50 vs.",Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29488303/),,1.50,263530,DB01045,Rifampicin
,1302435,T1/2,"The T1/2 of AcHz was shortened by Rif (control group 3.3 h, Rif-pretreated group 1.4 h) after i.v. injection of AcHz 10 mg.kg-1 to rats and the results showed that AcHz was converted to its active metabolites quickly by increasing the oxidative elimination rate of AcHz, which is related to the higher incidence of liver necrosis caused by Iso and Rif in combination.",Effects of rifampicin on pharmacokinetics of isoniazid and its metabolite acetylhydrazine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302435/),h,3.3,263729,DB01045,Rifampicin
,1302435,T1/2,"The T1/2 of AcHz was shortened by Rif (control group 3.3 h, Rif-pretreated group 1.4 h) after i.v. injection of AcHz 10 mg.kg-1 to rats and the results showed that AcHz was converted to its active metabolites quickly by increasing the oxidative elimination rate of AcHz, which is related to the higher incidence of liver necrosis caused by Iso and Rif in combination.",Effects of rifampicin on pharmacokinetics of isoniazid and its metabolite acetylhydrazine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1302435/),h,1.4,263730,DB01045,Rifampicin
,17038881,peak,"Rifampicin peak and trough plasma concentrations were 4.66 +/- 1.47 mg/L and 0.21 +/- 0.20 mg/L, respectively, after a dose of 8.5 +/- 2.1 (mean +/- SD) mg/kg per day.",Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038881/),[mg] / [l],4.66,263904,DB01045,Rifampicin
,17038881,trough plasma concentrations,"Rifampicin peak and trough plasma concentrations were 4.66 +/- 1.47 mg/L and 0.21 +/- 0.20 mg/L, respectively, after a dose of 8.5 +/- 2.1 (mean +/- SD) mg/kg per day.",Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038881/),[mg] / [l],0.21,263905,DB01045,Rifampicin
,17038881,First-order elimination constant,"First-order elimination constant, volume of distribution corrected for weight, total body clearance corrected for weight (CL/W), and elimination half-life were 0.16 +/- 0.06 h(-1), 1.84 +/- 0.59 L/kg, 0.28 +/- 0.11 Lkg(-1) h(-1), and 4.9 +/- 1.7 h, respectively.",Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038881/),1/[h],0.16,263906,DB01045,Rifampicin
,17038881,total body clearance corrected for weight (CL/W),"First-order elimination constant, volume of distribution corrected for weight, total body clearance corrected for weight (CL/W), and elimination half-life were 0.16 +/- 0.06 h(-1), 1.84 +/- 0.59 L/kg, 0.28 +/- 0.11 Lkg(-1) h(-1), and 4.9 +/- 1.7 h, respectively.",Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038881/),[l] / [kg],1.84,263907,DB01045,Rifampicin
,17038881,elimination half-life,"First-order elimination constant, volume of distribution corrected for weight, total body clearance corrected for weight (CL/W), and elimination half-life were 0.16 +/- 0.06 h(-1), 1.84 +/- 0.59 L/kg, 0.28 +/- 0.11 Lkg(-1) h(-1), and 4.9 +/- 1.7 h, respectively.",Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038881/),h,4.9,263908,DB01045,Rifampicin
,24479349,maximal drug,"After oral administration to rats, the maximal drug observed in plasma one hour after was 0.5 and 4.2 mkg/ml for free rifampicin for rifampicin in phospholipids-oleate nanoparticles, respectively.",[Drug delivery system on the base of phospholipid nanoparticles for rifampicin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479349/),[mkg] / [ml],0.5,264044,DB01045,Rifampicin
,24479349,maximal drug,"After oral administration to rats, the maximal drug observed in plasma one hour after was 0.5 and 4.2 mkg/ml for free rifampicin for rifampicin in phospholipids-oleate nanoparticles, respectively.",[Drug delivery system on the base of phospholipid nanoparticles for rifampicin]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24479349/),[mkg] / [ml],4.2,264045,DB01045,Rifampicin
,15371985,elimination half-life (t 1/2 ),The elimination half-life (t 1/2 ) of rosiglitazone was prolonged from 3.8 to 4.8 hours ( P =.0013).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,3.8,264185,DB01045,Rifampicin
,15371985,elimination half-life (t 1/2 ),The elimination half-life (t 1/2 ) of rosiglitazone was prolonged from 3.8 to 4.8 hours ( P =.0013).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,4.8,264186,DB01045,Rifampicin
,15371985,t 1/2,The t 1/2 of rosiglitazone was shortened from 3.8 to 1.9 hours ( P <.0001).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,3.8,264187,DB01045,Rifampicin
,15371985,t 1/2,The t 1/2 of rosiglitazone was shortened from 3.8 to 1.9 hours ( P <.0001).,Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371985/),h,1.9,264188,DB01045,Rifampicin
,31119275,apparent clearance (CL/F),"Typical dolutegravir apparent clearance (CL/F) was 0.93 L/h with 32% between-subject variability, the apparent volume of distribution was 20.2 L and the absorption rate constant was fixed to 2.24 h-1.",Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119275/),[l] / [h],0.93,264437,DB01045,Rifampicin
,31119275,apparent volume of distribution,"Typical dolutegravir apparent clearance (CL/F) was 0.93 L/h with 32% between-subject variability, the apparent volume of distribution was 20.2 L and the absorption rate constant was fixed to 2.24 h-1.",Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119275/),l,20.2,264438,DB01045,Rifampicin
,31119275,absorption rate constant,"Typical dolutegravir apparent clearance (CL/F) was 0.93 L/h with 32% between-subject variability, the apparent volume of distribution was 20.2 L and the absorption rate constant was fixed to 2.24 h-1.",Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31119275/),1/[h],2.24,264439,DB01045,Rifampicin
,27118859,bioavailability,The bioavailability of orally administered enrofloxacin was decreased from 72.5% to 24.8% by rifampicin.,Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27118859/),%,72.5,265228,DB01045,Rifampicin
,27118859,bioavailability,The bioavailability of orally administered enrofloxacin was decreased from 72.5% to 24.8% by rifampicin.,Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27118859/),%,24.8,265229,DB01045,Rifampicin
,24498115,maximum serum drug concentration (Cmax),Pharmacokinetic analysis of ND-09759 determined that at a dosage of 30 mg/kg mouse body weight (PO) gave a maximum serum drug concentration (Cmax) of 2.9 µg/ml and a half-life of 20.1 h.,"Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498115/),[μg] / [ml],2.9,265724,DB01045,Rifampicin
,24498115,half-life,Pharmacokinetic analysis of ND-09759 determined that at a dosage of 30 mg/kg mouse body weight (PO) gave a maximum serum drug concentration (Cmax) of 2.9 µg/ml and a half-life of 20.1 h.,"Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498115/),h,20.1,265725,DB01045,Rifampicin
<,34432364,area under the concentration-time curve ratio [AUCR],"Simulations of untested scenarios revealed an absence of drug-drug interaction (DDI) risk between remibrutinib and the weak CYP3A4 inhibitor fluvoxamine (area under the concentration-time curve ratio [AUCR] <1.25), and a moderate effect with the CYP3A4 inhibitor erythromycin (AUCR: 2.71).",Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432364/),,1.25,265863,DB01045,Rifampicin
,34432364,AUCR,"Simulations of untested scenarios revealed an absence of drug-drug interaction (DDI) risk between remibrutinib and the weak CYP3A4 inhibitor fluvoxamine (area under the concentration-time curve ratio [AUCR] <1.25), and a moderate effect with the CYP3A4 inhibitor erythromycin (AUCR: 2.71).",Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432364/),,2.71,265864,DB01045,Rifampicin
,34432364,Oral bioavailability,Oral bioavailability of remibrutinib was 34%.,Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34432364/),%,34,265865,DB01045,Rifampicin
,17352770,trough plasma level,"In all three cases, more than 50% of the time the atazanavir level was below the minimum recommended trough plasma level (150 ng/mL according to current pharmacokinetic guidelines) to inhibit HIV wild-type replication.",Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17352770/),[ng] / [ml],150,266304,DB01045,Rifampicin
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.78,266363,DB01045,Rifampicin
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.74,266364,DB01045,Rifampicin
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.52,266365,DB01045,Rifampicin
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.40,266366,DB01045,Rifampicin
,19369937,total apparent clearances (Cl/F),"Mean total apparent clearances (Cl/F) in the genotype groups CYP2C9*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 before rifampin were 0.78, 0.74, 0.52, 0.40, and 0.13 l/h, respectively.",Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19369937/),[l] / [h],0.13,266367,DB01045,Rifampicin
,28559276,Ka,"EFV concentration data were well described by a two-compartment model with first-order absorption (Ka ) and absorption lag time (Alag) (Ka = 0.2 h-1; Alag = 0.83 h; central compartment clearance [CLc/F] for CYP2B6*1/*1 = 18 liters/h, for CYP2B6*1/*6 = 14 liters/h, and for CYP2B6*6/*6 = 8.6 liters/h) and PBMCs as a peripheral compartment.","Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559276/),1/[h],0.2,266990,DB01045,Rifampicin
,28559276,Alag,"EFV concentration data were well described by a two-compartment model with first-order absorption (Ka ) and absorption lag time (Alag) (Ka = 0.2 h-1; Alag = 0.83 h; central compartment clearance [CLc/F] for CYP2B6*1/*1 = 18 liters/h, for CYP2B6*1/*6 = 14 liters/h, and for CYP2B6*6/*6 = 8.6 liters/h) and PBMCs as a peripheral compartment.","Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559276/),h,0.83,266991,DB01045,Rifampicin
,28559276,central compartment clearance [CLc/F],"EFV concentration data were well described by a two-compartment model with first-order absorption (Ka ) and absorption lag time (Alag) (Ka = 0.2 h-1; Alag = 0.83 h; central compartment clearance [CLc/F] for CYP2B6*1/*1 = 18 liters/h, for CYP2B6*1/*6 = 14 liters/h, and for CYP2B6*6/*6 = 8.6 liters/h) and PBMCs as a peripheral compartment.","Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559276/),[l] / [h],18,266992,DB01045,Rifampicin
,28559276,central compartment clearance [CLc/F],"EFV concentration data were well described by a two-compartment model with first-order absorption (Ka ) and absorption lag time (Alag) (Ka = 0.2 h-1; Alag = 0.83 h; central compartment clearance [CLc/F] for CYP2B6*1/*1 = 18 liters/h, for CYP2B6*1/*6 = 14 liters/h, and for CYP2B6*6/*6 = 8.6 liters/h) and PBMCs as a peripheral compartment.","Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559276/),[l] / [h],14,266993,DB01045,Rifampicin
,28559276,central compartment clearance [CLc/F],"EFV concentration data were well described by a two-compartment model with first-order absorption (Ka ) and absorption lag time (Alag) (Ka = 0.2 h-1; Alag = 0.83 h; central compartment clearance [CLc/F] for CYP2B6*1/*1 = 18 liters/h, for CYP2B6*1/*6 = 14 liters/h, and for CYP2B6*6/*6 = 8.6 liters/h) and PBMCs as a peripheral compartment.","Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559276/),[l] / [h],8.6,266994,DB01045,Rifampicin
,28559276,CLp/F,"EFV transfer from plasma to PBMCs was first order (CLp/F = 32 liters/h), followed by capacity-limited return (Vmax = 4,400 ng/ml/h; Km = 710 ng/ml).","Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559276/),[l] / [h],32,266995,DB01045,Rifampicin
,28559276,Vmax,"EFV transfer from plasma to PBMCs was first order (CLp/F = 32 liters/h), followed by capacity-limited return (Vmax = 4,400 ng/ml/h; Km = 710 ng/ml).","Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559276/),[ng] / [h·ml],"4,400",266996,DB01045,Rifampicin
,28559276,Km,"EFV transfer from plasma to PBMCs was first order (CLp/F = 32 liters/h), followed by capacity-limited return (Vmax = 4,400 ng/ml/h; Km = 710 ng/ml).","Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28559276/),[ng] / [ml],710,266997,DB01045,Rifampicin
,28827417,area under the concentration-versus-time curve up to 24 h after the dose,"Geometric mean total exposures (area under the concentration-versus-time curve up to 24 h after the dose) were 24.6, 50.8, and 76.1 mg · h/liter in the 600-mg, 900-mg, and 1,200-mg groups, respectively, reflecting a nonlinear increase in exposure with the dose (P < 0.001).","Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827417/),[h·mg] / [l],24.6,267778,DB01045,Rifampicin
,28827417,area under the concentration-versus-time curve up to 24 h after the dose,"Geometric mean total exposures (area under the concentration-versus-time curve up to 24 h after the dose) were 24.6, 50.8, and 76.1 mg · h/liter in the 600-mg, 900-mg, and 1,200-mg groups, respectively, reflecting a nonlinear increase in exposure with the dose (P < 0.001).","Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827417/),[h·mg] / [l],50.8,267779,DB01045,Rifampicin
,28827417,area under the concentration-versus-time curve up to 24 h after the dose,"Geometric mean total exposures (area under the concentration-versus-time curve up to 24 h after the dose) were 24.6, 50.8, and 76.1 mg · h/liter in the 600-mg, 900-mg, and 1,200-mg groups, respectively, reflecting a nonlinear increase in exposure with the dose (P < 0.001).","Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28827417/),[h·mg] / [l],76.1,267780,DB01045,Rifampicin
,19898996,Drug,"Drug retention times were 10.00 +/- 0.25, 2.00 +/- 0.25, 3.50 +/- 0.25, 11.50 +/- 0.25, and 12.50 +/- 0.25 min for daptomycin, amikacin, gentamicin, rifampicin, and quinoxaline, respectively.","Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898996/),min,10.00,268928,DB01045,Rifampicin
,19898996,retention times,"Drug retention times were 10.00 +/- 0.25, 2.00 +/- 0.25, 3.50 +/- 0.25, 11.50 +/- 0.25, and 12.50 +/- 0.25 min for daptomycin, amikacin, gentamicin, rifampicin, and quinoxaline, respectively.","Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898996/),min,10.00,268929,DB01045,Rifampicin
,19898996,retention times,"Drug retention times were 10.00 +/- 0.25, 2.00 +/- 0.25, 3.50 +/- 0.25, 11.50 +/- 0.25, and 12.50 +/- 0.25 min for daptomycin, amikacin, gentamicin, rifampicin, and quinoxaline, respectively.","Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898996/),min,2.00,268930,DB01045,Rifampicin
,19898996,retention times,"Drug retention times were 10.00 +/- 0.25, 2.00 +/- 0.25, 3.50 +/- 0.25, 11.50 +/- 0.25, and 12.50 +/- 0.25 min for daptomycin, amikacin, gentamicin, rifampicin, and quinoxaline, respectively.","Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898996/),min,3.50,268931,DB01045,Rifampicin
,19898996,retention times,"Drug retention times were 10.00 +/- 0.25, 2.00 +/- 0.25, 3.50 +/- 0.25, 11.50 +/- 0.25, and 12.50 +/- 0.25 min for daptomycin, amikacin, gentamicin, rifampicin, and quinoxaline, respectively.","Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898996/),min,11.50,268932,DB01045,Rifampicin
,19898996,retention times,"Drug retention times were 10.00 +/- 0.25, 2.00 +/- 0.25, 3.50 +/- 0.25, 11.50 +/- 0.25, and 12.50 +/- 0.25 min for daptomycin, amikacin, gentamicin, rifampicin, and quinoxaline, respectively.","Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898996/),min,12.50,268933,DB01045,Rifampicin
,15260105,half-lives,"Following a single iv administration of liposomal drugs, the latter were found to exhibit sustained therapeutic levels in plasma for 96-168 hr with half-lives of 24-70 hr, mean residence time (MRT) of 35-81 hr and organ drug levels up to day 7.",Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260105/),h,24-70,269336,DB01045,Rifampicin
,15260105,mean residence time (MRT),"Following a single iv administration of liposomal drugs, the latter were found to exhibit sustained therapeutic levels in plasma for 96-168 hr with half-lives of 24-70 hr, mean residence time (MRT) of 35-81 hr and organ drug levels up to day 7.",Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15260105/),h,35-81,269337,DB01045,Rifampicin
,8527275,clearance (CL/F),The mean (+/- s.d.) clearance (CL/F) of quinine coadministered with rifampicin (0.87 +/- 0.35 1 h-1 kg-1) was significantly greater than that of quinine alone (0.14 +/- 0.05 1 h-1 kg-1).,Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),[1] / [h·kg],0.87,269358,DB01045,Rifampicin
,8527275,clearance (CL/F),The mean (+/- s.d.) clearance (CL/F) of quinine coadministered with rifampicin (0.87 +/- 0.35 1 h-1 kg-1) was significantly greater than that of quinine alone (0.14 +/- 0.05 1 h-1 kg-1).,Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),[1] / [h·kg],0.14,269359,DB01045,Rifampicin
,8527275,unbound clearance (CLu/F),"The unbound clearance (CLu/F) of quinine, which reflects the activity of the drug-metabolizing enzymes, was considerably greater (6.9-fold) in subjects when rifampicin was coadministered with quinine than that of quinine alone (6.9 +/- 3.6 vs 1.0 +/- 0.5 1 h-1 kg-1; the 95% C.I. for the mean difference was 3.3 to 8.5).",Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),[1] / [h·kg],6.9,269360,DB01045,Rifampicin
,8527275,unbound clearance (CLu/F),"The unbound clearance (CLu/F) of quinine, which reflects the activity of the drug-metabolizing enzymes, was considerably greater (6.9-fold) in subjects when rifampicin was coadministered with quinine than that of quinine alone (6.9 +/- 3.6 vs 1.0 +/- 0.5 1 h-1 kg-1; the 95% C.I. for the mean difference was 3.3 to 8.5).",Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),[1] / [h·kg],1.0,269361,DB01045,Rifampicin
,8527275,elimination half-life,The mean elimination half-life of quinine when coadministered with rifampicin (5.5 +/- 3.0 h) was significantly shorter than when quinine was given alone (11.1 +/- 3.0 h; the 95% C.I. for the mean difference was -8.6 to -2.6).,Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),h,5.5,269362,DB01045,Rifampicin
,8527275,elimination half-life,The mean elimination half-life of quinine when coadministered with rifampicin (5.5 +/- 3.0 h) was significantly shorter than when quinine was given alone (11.1 +/- 3.0 h; the 95% C.I. for the mean difference was -8.6 to -2.6).,Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527275/),h,11.1,269363,DB01045,Rifampicin
∼5,30862625,high-affinity,"MVC showed significant active uptake and biliary excretion in sandwich-cultured human hepatocytes, and biphasic organic anion transporting polypeptide (OATP)1B1-mediated uptake kinetics in transfected cells (high-affinity K m ∼5 µM).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),,µ,270037,DB01045,Rifampicin
∼5,30862625,K m,"MVC showed significant active uptake and biliary excretion in sandwich-cultured human hepatocytes, and biphasic organic anion transporting polypeptide (OATP)1B1-mediated uptake kinetics in transfected cells (high-affinity K m ∼5 µM).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),,µ,270038,DB01045,Rifampicin
,30862625,"inactivation constant, K I","TVR inhibited OATP1B1-mediated MVC transport in vitro, and also exhibited CYP3A time-dependent inhibition in human hepatocytes (inactivation constant, K I = 2.24 µM, and maximum inactivation rate constant, k inact = 0.0112 minute-1).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),μM,2.24,270039,DB01045,Rifampicin
,30862625,"maximum inactivation rate constant, k inact","TVR inhibited OATP1B1-mediated MVC transport in vitro, and also exhibited CYP3A time-dependent inhibition in human hepatocytes (inactivation constant, K I = 2.24 µM, and maximum inactivation rate constant, k inact = 0.0112 minute-1).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),1/[min],0.0112,270040,DB01045,Rifampicin
,30397233,clearance,"The estimated typical efavirenz clearance in the HIV only subjects with the CYP2B6*1/*1 genotype was 23.6 L/h/70 kg, while it was 38% and 69% lower in subjects with the CYP2B6*1/*6 and *6/*6 genotypes, respectively.",Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30397233/),[l] / [70·h·kg],23.6,270653,DB01045,Rifampicin
,24486870,oral clearances,"For a 2-year-old child weighing 12.5 kg, the estimated typical oral clearances of rifampicin and pyrazinamide were 8.15 and 1.08 L/h, respectively.","Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486870/),[l] / [h],8.15,271971,DB01045,Rifampicin
,24486870,oral clearances,"For a 2-year-old child weighing 12.5 kg, the estimated typical oral clearances of rifampicin and pyrazinamide were 8.15 and 1.08 L/h, respectively.","Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486870/),[l] / [h],1.08,271972,DB01045,Rifampicin
,24486870,oral clearance,"Isoniazid typical oral clearance (adjusted for bioavailability) was predicted to be 4.44, 11.6 and 14.6 L/h for slow, intermediate and fast acetylators, respectively.","Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486870/),[l] / [h],4.44,271973,DB01045,Rifampicin
,24486870,oral clearance,"Isoniazid typical oral clearance (adjusted for bioavailability) was predicted to be 4.44, 11.6 and 14.6 L/h for slow, intermediate and fast acetylators, respectively.","Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486870/),[l] / [h],11.6,271974,DB01045,Rifampicin
,24486870,oral clearance,"Isoniazid typical oral clearance (adjusted for bioavailability) was predicted to be 4.44, 11.6 and 14.6 L/h for slow, intermediate and fast acetylators, respectively.","Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486870/),[l] / [h],14.6,271975,DB01045,Rifampicin
<,24200269,Peak RBT concentration,"Peak RBT concentration was below the lower therapeutic limit (<0.3 μg/ml) in seven patients, while 10 patients had trough concentrations below the minimal inhibitory concentration against Mycobacterium tuberculosis (0.06 μg/ml), suggesting that the RBT dosage may be inadequate.",Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24200269/),[μg] / [ml],0.3,272406,DB01045,Rifampicin
,24200269,minimal inhibitory concentration,"Peak RBT concentration was below the lower therapeutic limit (<0.3 μg/ml) in seven patients, while 10 patients had trough concentrations below the minimal inhibitory concentration against Mycobacterium tuberculosis (0.06 μg/ml), suggesting that the RBT dosage may be inadequate.",Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24200269/),[μg] / [ml],0.06,272407,DB01045,Rifampicin
,24741485,bioavailability indices C max,The bioavailability indices C max of rifampicin increased from 4.57 ± 0.19 to 5.95 ± 0.19 (P = 0.000) and AUC increased from 40.11 ± 1.69 to 53.01 ± 1.88 (P = 0.000).,"Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,4.57,272436,DB01045,Rifampicin
,24741485,bioavailability indices C max,The bioavailability indices C max of rifampicin increased from 4.57 ± 0.19 to 5.95 ± 0.19 (P = 0.000) and AUC increased from 40.11 ± 1.69 to 53.01 ± 1.88 (P = 0.000).,"Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,5.95,272437,DB01045,Rifampicin
,24741485,AUC,The bioavailability indices C max of rifampicin increased from 4.57 ± 0.19 to 5.95 ± 0.19 (P = 0.000) and AUC increased from 40.11 ± 1.69 to 53.01 ± 1.88 (P = 0.000).,"Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,40.11,272438,DB01045,Rifampicin
,24741485,AUC,The bioavailability indices C max of rifampicin increased from 4.57 ± 0.19 to 5.95 ± 0.19 (P = 0.000) and AUC increased from 40.11 ± 1.69 to 53.01 ± 1.88 (P = 0.000).,"Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,53.01,272439,DB01045,Rifampicin
,24741485,C max,"Similarly, C max of isoniazid increased from 2.66 ± 0.16 to 3.62 ± 0.16 (P = 0.000) and AUC from 17.72 ± 0.78 to 22.87 ± 0.94 (P = 0.000).","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,2.66,272440,DB01045,Rifampicin
,24741485,C max,"Similarly, C max of isoniazid increased from 2.66 ± 0.16 to 3.62 ± 0.16 (P = 0.000) and AUC from 17.72 ± 0.78 to 22.87 ± 0.94 (P = 0.000).","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,3.62,272441,DB01045,Rifampicin
,24741485,AUC,"Similarly, C max of isoniazid increased from 2.66 ± 0.16 to 3.62 ± 0.16 (P = 0.000) and AUC from 17.72 ± 0.78 to 22.87 ± 0.94 (P = 0.000).","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,17.72,272442,DB01045,Rifampicin
,24741485,AUC,"Similarly, C max of isoniazid increased from 2.66 ± 0.16 to 3.62 ± 0.16 (P = 0.000) and AUC from 17.72 ± 0.78 to 22.87 ± 0.94 (P = 0.000).","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,22.87,272443,DB01045,Rifampicin
,24741485,bioavailability,"The bioavailability indices of pyrazinamide also revealed an increase in C max from 18.81 ± 0.79 to 25.06 ± 1.14 (P = 0.000) and AUC from 107.65 ± 4.42 to 137.71 ± 5.92 (P = 0.000), respectively.","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,18.81,272444,DB01045,Rifampicin
,24741485,bioavailability,"The bioavailability indices of pyrazinamide also revealed an increase in C max from 18.81 ± 0.79 to 25.06 ± 1.14 (P = 0.000) and AUC from 107.65 ± 4.42 to 137.71 ± 5.92 (P = 0.000), respectively.","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,25.06,272445,DB01045,Rifampicin
,24741485,C max,"The bioavailability indices of pyrazinamide also revealed an increase in C max from 18.81 ± 0.79 to 25.06 ± 1.14 (P = 0.000) and AUC from 107.65 ± 4.42 to 137.71 ± 5.92 (P = 0.000), respectively.","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,18.81,272446,DB01045,Rifampicin
,24741485,C max,"The bioavailability indices of pyrazinamide also revealed an increase in C max from 18.81 ± 0.79 to 25.06 ± 1.14 (P = 0.000) and AUC from 107.65 ± 4.42 to 137.71 ± 5.92 (P = 0.000), respectively.","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,25.06,272447,DB01045,Rifampicin
,24741485,AUC,"The bioavailability indices of pyrazinamide also revealed an increase in C max from 18.81 ± 0.79 to 25.06 ± 1.14 (P = 0.000) and AUC from 107.65 ± 4.42 to 137.71 ± 5.92 (P = 0.000), respectively.","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,107.65,272448,DB01045,Rifampicin
,24741485,AUC,"The bioavailability indices of pyrazinamide also revealed an increase in C max from 18.81 ± 0.79 to 25.06 ± 1.14 (P = 0.000) and AUC from 107.65 ± 4.42 to 137.71 ± 5.92 (P = 0.000), respectively.","Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: A study in healthy human volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741485/),,137.71,272449,DB01045,Rifampicin
,10417493,AUC ratios,"Over the three periods AMT plasma levels were <18 ng ml-1 (n=6) and <40 ng ml-1 (n=2), and molar AMT/zidovudine AUC ratios ranged from 1.7% to 4.5%.",Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417493/),%,1.7,272831,DB01045,Rifampicin
,10417493,AUC ratios,"Over the three periods AMT plasma levels were <18 ng ml-1 (n=6) and <40 ng ml-1 (n=2), and molar AMT/zidovudine AUC ratios ranged from 1.7% to 4.5%.",Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417493/),%,4.5,272832,DB01045,Rifampicin
,10223773,peak plasma concentration,Rifampin decreased the peak plasma concentration of oral ondansetron by about 50% (from 27.2+/-3.0 to 13.8+/-1.5 ng/mL [mean +/- SEM]; P < .001]) and the elimination half-life (t1/2) by 38% (P < .01).,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),[ng] / [ml],27.2,273326,DB01045,Rifampicin
,10223773,peak plasma concentration,Rifampin decreased the peak plasma concentration of oral ondansetron by about 50% (from 27.2+/-3.0 to 13.8+/-1.5 ng/mL [mean +/- SEM]; P < .001]) and the elimination half-life (t1/2) by 38% (P < .01).,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),[ng] / [ml],13.8,273327,DB01045,Rifampicin
,10223773,bioavailability,The bioavailability of oral ondansetron was reduced from 60% to 40% (P < .01) by rifampin.,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),%,60,273328,DB01045,Rifampicin
,10223773,bioavailability,The bioavailability of oral ondansetron was reduced from 60% to 40% (P < .01) by rifampin.,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),%,40,273329,DB01045,Rifampicin
,10223773,clearance,The clearance of intravenous ondansetron was increased 83% (from 440+/-38.4 to 805+/-44.6 mL/min [P < .001]) by rifampin.,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),[ml] / [min],440,273330,DB01045,Rifampicin
,10223773,clearance,The clearance of intravenous ondansetron was increased 83% (from 440+/-38.4 to 805+/-44.6 mL/min [P < .001]) by rifampin.,The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223773/),[ml] / [min],805,273331,DB01045,Rifampicin
,1687853,plasma half-life (t1/2),3. The plasma half-life (t1/2) of RIF increased significantly from 1.92 +/- 0.57 h to 2.31 +/- 0.134 h after CTZ treatment.,Drug interaction between rifampicin and cotrimoxazole in patients with tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687853/),h,1.92,274098,DB01045,Rifampicin
,1687853,plasma half-life (t1/2),3. The plasma half-life (t1/2) of RIF increased significantly from 1.92 +/- 0.57 h to 2.31 +/- 0.134 h after CTZ treatment.,Drug interaction between rifampicin and cotrimoxazole in patients with tuberculosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687853/),h,2.31,274099,DB01045,Rifampicin
